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Abstract 
Although global gene microarray studies have demonstrated the molecular 
heterogeneity of breast cancer (BC) and provided potential for clinical 
applications, the molecular subclassification of luminallER-positive tumours, 
which is the largest class of BC, remains unclear. Characterisation of 
." luminallER-positive subtypes could have important implications in clinical 
decision-making and patient management. 
The patient study cohort is derived from a consecutive series of approximately 
1902 cases of primary operable invasive breast carcinoma obtained from the 
Nottingham Tenovus Primary Breast Carcinoma Series, with patients 
presenting between 1986 and 1998. This is a well-characterized series of 
primary breast carcinoma that has been treated in a uniform way and 
previously used to study a wide range of proteins. Using gene microarray 
experiments in 128 frozen invasive BC derived from this series 47 293 gene , , 
transcripts were analysed using a number of different bio-statistical models to 
identify a transcript signature for luminallER-positive BC, from which 
candidate genes were selected and that can be used to characterise ER-positive 
breast cancer. In addition, other biomarkers with strong relevance in ER-
positive breast cancer were studied because the evidence strongly suggests an 
important role in the biology and molecular classification of ER-positive breast 
cancer. The selection criteria was based on published literature concentrating 
mainly on ER related pathways including ER coregulators (CARMI, PELPI), 
cellular proliferation (p27. TK 1, cyclin B 1), apoptosis (Bcl2). AktIPIK3 
I 
pathway (FOX03a), gene expression profiling (FOXAl, XBPl, TFFl) and 
endocrine resistance (CD71). 
Immunohistochemistry and high throughput tissue micro array technology were 
used to study the protein expression of 16 biomarkers with strong relevance to 
ER pathways in a well characterised consecutive series of invasive BC 
(n=1902) in addition to anther 9 markers that were available from the database 
of the breast cancer research group, University of Nottingham. The data were 
analysed using different clustering methods including K-means and 
Partitioning around Medoids. Kaplan Meier plots with Log-rank test (LR) were 
used to model clinical outcome. 
A transcript signature for ER positive BC was identified including RERG, 
GATA3 and other genes by a supervised classification analysis using IO-fold 
external cross-validation of the gene microarray data. Immunohistochemical 
validation studies confirmed their association with ER positive BC. 
Through a consensus approach using different clustering techniques applied to 
protein expression data 25 markers, three biological clusters (patient 
subclasses) in ER positive breast cancer showing significant difference in 
clinical outcome (LR= 28.185 & p<O.OOI) have been identified. Importantly, 
the poor prognosis cluster was significantly characterised by high tumour grade 
and frequent development of distant metastasis. 
In conclusion, our results emphasised the heterogeneity of luminallER-positive 
BC. Molecular profiling of breast cancer using protein biomarkers on TMAs 
can sub-classify ER-positive tumours into clinically and biologically relevant 
subgroups. 
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1.1 Introduction 
Breast cancer is a major cause of death among middle-aged women and some 
patients develop relapses despite advances in therapeutic methods. Currently, 
pathological diagnosis and classification of human neoplasia is based on the 
pathological features, immunophenotyping and other techniques for 
distinguishing tumour types. The combination of pathological classification 
and clinical criteria are mainly used to differentiate distinct subclasses in 
clinical practice that differ in prognosis. However, there is still marked 
differences in the clinical behaviour of cancers within this current tumour 
classification, which makes the prediction of response to treatment and clinical 
outcomes more difficult. So, breast cancer has to be defined by genetic 
biomarkers to improve the therapeutic methods and patients follow-up (Ahr et 
al., 2001). Most breast cancers are derived from the epithelial cells lining the 
ducts and lobules. 
1.1.1 Terminal duct lobular unit (TDLU) 
The functional unit of the breast is a complex structure that is composed of two 
major parts: the terminal duct-lobular unit and the large duct system. 
The TDLU is formed by the alveoli and the terminal ductule of a lobule and 
represents the secretory part of the gland. It connects with the subsegmental 
duct, which in tum leads to a segmental duct and lastly to a collecting duct 
which empties into the nipple. The TDLU is recognized because of its lobular 
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arrangement and the presence of a myxoid-appearing connective tissue 
(Cunha, 1994). 
After puberty, this structure forms the major hormone sensitive areas of the 
mammary epithelium. It also appears to be the site of origin for most mammary 
cancers. This suggests that it contains the major proliferative stem cell 
populations that are most sensitive to the effects of somatic cell mutation. 
Normal breast ducts contain at least three types of epithelial cells: luminal 
(glandular) cells, basal/myoepithelial cells, and stem cells (Fig 1.1). Many 
theories have been proposed to describe the lining cells and the presence of 
stem or progenitor cells which give rise to the main lineages, luminal/glandular 
and myoepithelial. 
Luminal 
Progenitor 
Myoepithelial 
Basement 
membra no 
Figure 1.1: Cells ofthe mammary acini 
(Birnbaum et aI. , 2004) 
~ ~
Stroma 
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1.1.2 Concepts of progenitor cells 
(A) Stem cells and progenitors are found in the basal or suprabasal position in 
the acini, in between myoepithelial and luminal layers. Self-renewing 
pluripotent stem cells enter into a bipotant CKS/6+ progenitor stage and give 
rise to two main lineages via committed progenitor stages, luminal/glandular 
CK8118+ and myoepithelial-restricted CK 14+ and smooth muscle actin 
(SMA)+. New markers are needed to identify the criteria of the different cell 
types (Birnbaum et ai. , 2004) (Fig 1.2). 
Quiescent Prol"''''''_ 
Slem cell slem cell 
Basal 
blpolenl 
progenitor 
CK:5I6. 
... 
Figure 1.2: The concept of progenitor cell 
(Birnbaum et ai. , 2004) 
Cornmi1led 
progenlto r 
CKMi+. CKBl1S+ 
... 
... 
Oudal klmma l eel 
CKSI1S" 
Comma1ed Myoepttheial ce4 
progenlor CK1<4", SMA. 
CK516+. CS< 14", SMA .. 
(B) The concept of progenitor cell is useful to understand nonnal physiological 
regeneration and cellular mechanisms of lactation and involution. Under the 
effects of hormones produced in pregnancy and lactation, luminal cells 
differentiate to CKS/18+ secretory cells. In the resting breast, the lobules 
display cells from progenitors (CK5+) to intermediate glandular (CK5+, 
CKS/18+) and glandular cells (CKS/18+) (Boecker and Buerger, 2003) 
(Horwitzt et a!., 2008) (Fig 1.3,4). 
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P regnancy. 
Hormonal 
s t imula tio n s 
R estin g b reast 
Termina l duct 
1'.-1a ture dlftaren tlated Jobute 
CK5-. CI(8/ 1/'+ 
'-Au ItIpllc;a bon of 
CKS .... progenitor eells 
Alveolar lum inal cell 
CK8/18 ... . CQse In + 
Figure 1.3: Another concept of progenitor cell 
(Birnbaum et aI. , 2004) 
Breast cancer 
Ck 5 positive 
Breast cancer 
Ck 5 negative 
\ 5-10% ~ -~ ~ , 
-;.y 
--
_on_c:;-- @;) 
Int.....-.,y 
rnyoep" ... II-' ceO 
t 90% 
,_ .... ' 1 
,-" \ \,J.J 0--
-
Figure 1.4: A cell biology concept model 
(Boeker et aI., 2002) 
myoepithelial cell 
A cell biology concept based on CKS progenitor cells (yellow) give rise to both 
glandular cells (CKS/1S/19; green) and myoepithelial cells (SMA; red) via 
intermediary cells, which co-express CkSI6 with the lineage-specific marker 
(either CKSIlSI19 or SMA) (Bocker et aI., 2002). 
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1.1.2.1 How do lining cells give rise to cancer? 
(A) The stochastic model 
This model suggests that tumour arises from any cell , despite its stage of 
differentiation, after a genetic alteration that triggers the transformation; the 
tumour cell acquires a self-renewing capability without losing its original 
criteria (Birnbaum et ai. , 2004) (Fig 1.5). 
Luminal cell 
Stochastic model 
Luminal-derived 
tumors, ER+, GATA3+ 
Basal-derived tumors, ER-, ERBB2+ 
Proliferative 
stem cell Progenitor ... 
Myoepithelial cell 
Figure 1.5: The stochastic model (Birnbaum et ai. , 2004) 
(B) The hierarchy or stem cell model. 
Myoepilhelial-derived 
tumors (rare) 
This model suggests that transformation occurs In a stem cell , or in a 
progenitor cell, and expansion proceeds to usual maturation until various 
stages, depending on the genomic alterations (Birnbaum et aI., 2004). 
The biology of the tumour could partially reflect the biology of the originally 
initiated normal epithelial cell stopping the evolution to the developmental 
stage of the epithelial cell at the time of initiation (Olsson, 2000). 
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1.1.3 Breast Carcinoma 
1.1.3.1 Incidence 
About 44,100 cases of breast cancer are diagnosed in the UK each year and 
more than a million women are diagnosed with breast cancer annually 
worldwide. In 2007, the numbers of new cases of breast cancer in the UK 
increased to 45,695 cases. (Cancer research UK, UK Breast Cancer statistics) 
1.1.3.2 Risk factors 
Many risk factors have been described for breast cancer development. The 
most important are discussed. 
A. Hereditary predisposition and family history of breast cancer 
Mutations in the breast cancer susceptibility genes, BRCAI and BRCA2, 
account for the majority of familial breast cancer (Ford et aI., 1998). Women 
carrying this mutation show 50-80% increased incidence of developing breast 
cancer. A woman with one affected first degree relative has two times the risk 
of breast cancer in comparison to a woman with no family history of the 
~ ~
disease (Clamp et aI., 2002). 
B. Hormone replacement therapy (HRT) 
Hormonal replacement therapy (HRT) increases the risk of breast cancer. The 
risk increases with the use of combined oestrogen and progestin regimen in 
comparison to the use of oestrogen alone (Schairer et aI., 2000). 
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c. Diet, alcohol consumption and smoking 
Fat intake, particularly animal fat, may cause a slight increase in breast cancer 
risk (Bingham et aI., 2003). There is a significant association between alcohol 
intake and breast cancer (Key et aI., 2001). Although alcohol and tobacco 
smoking are closely related social habits, there is no direct association between 
tobacco and breast cancer (Key et aI., 2001). 
D. Radiation exposure 
Ionizing radiation is a well known risk factor for breast cancer. Moderate to 
high-dose radiotherapy is known to increase the risk of breast cancer. The 
effect of radiation on the breast is related to age at exposure, the younger the 
woman is exposed the greater the risk of developing cancer (Berrington de 
Gonzalez and Darby, 2004). 
E. Benign breast diseases 
The term benign breast disease describes all non-malignant breast conditions. It 
includes diseases associated with an increased risk of breast cancer and others 
that have no increase in risk. 
Relative risk for invasive carcinoma associated with benign lesions in a 
prior breast biopsy (Fitzgibbons et aI., 1998) 
No increased risk 
Adenosis, other than sclerosing adenosis 
Duct ectasia 
Fibroadenoma lacking complex features 
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Fibrosis 
Mastitis 
Hyperplasia without atypia 
Cysts, gross or microscopic 
Simple apocrine metaplasia without associated hyperplasia or 
adenosis 
Squamous metaplasia 
Slightly increased risk (1.5-2.0) 
Complex fibroadenoma 
Moderate or florid hyperplasia without atypia 
Sclerosing adenosis 
Solitary papilloma without atypical hyperplasia 
Moderately increased risk (4.0-5.0) 
Atypical ductal hyperplasia 
Atypical lobular hyperplasia 
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1.1.4 Molecular classification of breast cancer 
Wilson and Dering (Wilson and Dering, 2004) proposed that the oestrogen 
receptor (ER) and the HER-2 gene are central classifiers of breast cancer, the 
contribution of cell type has emerged as a dominant feature in gene expression 
profiles that segregate primary human breast cancers (Fig 1.6). For example, 
ER-negative tumours expressing basal markers exhibit a poor clinical outcome 
whereas ER-positive luminal cancers are associated with a favourable 
prognosis and characterized by low frequency of p53 mutation, less 
lymphocytic infiltration, luminal cytokeratins expression and GA TA3 
expression. 
1 
basaVsupra-basal 
precursor 
I 
1 
ER 
negative 
BRCA1 
mutant 
MgUgnoo! p/I9no!Ypo· 
high Ir8quency p53 mun.on 
h 1 ~ ~ lymphocytic Inlil!rtlton 
high r u : : I ~ r r grad<> 
"" .... cylokom'n .. xpr .... llion 
P-C«Iherin oxp .... aIon 
Ilminal 
precursor 
I 
I I 1 
lOR ER ER HER-2 
strong moderate _ak Amplified 
positive positive positive 
MgUmgn! p/l9!lO!ypo. 
low I ~ n c y y p53 mutation 
I .... lymphocytic Inlilration 
luminal cylokemfn ... prosslon 
GATA3. ~ F 3 . > c p p ... Mion 
Figure 1.6: Cell-type origin model for classification of human breast cancers 
(Wilson and Dering, 2004) 
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Based on the expression of EpCAM and CD49f, Lim and colleagues suggested 
a novel phenotype of breast cancer subtypes. Lim and co-workers found that 
EpCAM was predominantly expressed on luminal cells, whereas high CD49f 
expression marked basal cells. 
The CD49f hi-EpCAM- subpopulation expressed the basal lineage markers 
p63, CK14 and vimentin but did not express the oestrogen receptor or 
progesterone receptor. In contrast, the CD49f- EpCAM+ and CD49f+EpCAM+ 
subsets expressed luminal lineage markers including CK8 and CK18, CK 19, 
GA T A3 and MUC I (Lim et ai., 2009) (Fig 1.7). 
For many years, ER, PgR and HER2 were extensively used for breast cancer 
classification but what could be inferred from this study that novels biomarkers 
could be used in this purpose. 
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Figure 1.7: Model of the cell of origin classification of human breast cancers 
(Lim et ai. , 2009) 
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1.1.4.1 Molecular classification of breast cancer using gene 
microarrays 
The recently developed micro array technologies have created new possibilities 
to identify gene expression profiles and have provided a better view of the 
biological processes involved in tumour fonnation. The identification of cancer 
subclasses with direct clinical impact has been established, based on gene 
expression patterns derived from eDNA microarrays or high-throughput 
reverse transcriptase-polymerase chain reaction (RT-PCR) techniques (van't 
Veer et aI., 2002). 
The advances in microarray analysis have been used to explore gene expression 
in breast tissue on a genome-wide scale, and have shown that different 
biological subtypes of breast cancer are accompanied by differences in gene 
expression. With eDNA mieroarrays, the relative expression levels of 
thousands of genes within a specific tissue sample can be measured at the same 
time (Jeffrey et aI., 2002). These analyses have provided interesting 
classifications of breast tumours. Perou and colleagues established the first 
molecular portraits of breast tumours by using DNA microarrays, which allow 
mRNA expression levels of thousands of genes to be measured in a single 
assay (Perou et aI., 2000). Commercially available arrays from a number of 
sources have been used in 'single-colour' hybridizations to measure gene 
expression. Also, complex cDNA probes labelled with fluorescent dyes are 
made by perfonning reverse transcription on the complex mix of mRNAs 
isolated from a tumour specimen. In contrast to single-colour methods, most 
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spotted DNA microarray methods consist of a two-colour hybridization method 
in order to measure gene expression in multiple samples. A mixture of red 
(Cy5-labelled) cDNA from a test sample and green (Cy3-labelled) cDNA from 
a known reference sample is hybridized to each cDNA microarray. The relative 
level of expression for each gene on the array in comparison between multiple 
samples (e.g. tumour versus normal, or multiple tumours) can be determined by 
comparing the fluorescent intensity for that gene. 
Molecular analysis of breast cancer is used to characterize the breast cancer 
and has been useful to discover a direct communication between tumour 
genotype and phenotype and to identify new cancer subtypes and molecular 
pathways (Reis and Lakhani, 2003). Molecular subgroups may be needed in 
order to develop the most accurate prediction of treatment response. 
To overcome the inherent subjectivity involved in histopathology, a few well-
defined molecular biomarkers have been introduced in more recent times to aid 
tumour classification (Reis-Filho et aI., 2005). For instance, hormone receptors 
(HR) including oestrogen (ER) and progesterone (PR) receptors are used to 
classify BC into HR-positive and negative categories. In addition, assessment 
of HER2 status has been used to classify BC into HER2 positive and negative 
groups (Dowsett et aI., 2000). Currently, HR (ER and PR) and HER2 remain 
the only molecular targets in routine clinical use in BC management. 
Moreover, ER status ofBC is used in determining the postoperative therapeutic 
strategies regarding use of adjuvant hormonal therapy. ER-positive tumours 
comprise the majority of breast cancers, accounting for up to 70% of all cases 
and are generally expected to show good response to hormonal therapy and are 
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associated with better clinical outcome (Murphy and Watson, 2002). It is 
recognised that most ER-positive tumours have characteristic morphological 
features: they are frequently of low histological grade displaying glandular 
differentiation, low degree of nuclear pleomorphism, low mitotic activity, and 
include most of the good prognostic special histological types (e.g. tubular, 
invasive cribriform, mucinous and lobular types) in comparison to ER negative 
tumours (Putti et aI., 2005). Fig 1.8 shows the diversity of BC with respect to 
ER expression and illustrates the morphological heterogeneity of this disease. 
Although ER protein expression is a predictor of hormonal treatment response, 
its effectiveness is impaired because of the existence of a proportion of ER-
positive cancers that do not respond to hormonal treatment (Osborne, 1998). 
Furthermore, it is documented that a proportion of ER-negative tumours 
respond to hormonal therapy (Esserman et aI., 2005). This demonstrates that 
ER-positivity per se defines a heterogeneous group of tumours with respect to 
their clinical behaviour and biology. 
Improved understanding of the molecular features of ER positive BC and 
identifying the key oncogenes and tumour suppressor genes involved in 
defining this molecular heterogeneity could lead to better prediction of tumour 
behaviour and treatment response (Albertson, 2003, Nessling et aI., 2005). 
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1.1.4.2 Identification of the ER-positive luminal-like class of 
breast cancer 
The gene expression microarray studies have provided an alternative view of 
the complex biological processes involved in tumour development, creating 
new methods for identifying distinct molecular tumour classes based on gene 
expression profiles (van't Veer et aI. , 2002). Importantly, these studies have 
shown that ER is the main differentiating marker of molecular signature 
classification, supporting the fact that breast cancer is heterogeneous and that 
ER-positive and negative breast carcinomas are biologically separate entities 
(Gruvberger et aI. , 2001 , Sorlie et aI. , 2001). 
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1.1.4.3 The heterogeneity of ER-positive/luminal-like breast 
cancer 
(A) Understanding the heterogeneity of ER-positive/luminal-like Be by 
GEP studies 
Perou and colleagues were the first to study global gene-expression patterns of 
BC and demonstrated the existence of distinct molecular classes. Their 
classification was derived from gene expression data from 40 breast tumours 
including 1 fibroadenoma, 36 invasive ductal cancers, 2 lobular cancers and 1 
ductal in situ carcinoma and three normal breast samples (twenty tumours were 
sampled twice). A total of 1753 genes were selected which showed significant 
expression variation between samples from different tumours. Data was 
subsequently analysed using hierarchical clustering producing a dendogram 
with two main branches. One branch, called the 'luminal-like' class, was 
characterised by the expression of ER and other markers of normal luminal 
glandular epithelial cells of the breast (ER-responsive genes, luminal 
cytokeratins (CKs) and other luminal associated markers). The other branch, 
which was mainly ER-negative, was subdivided into three distinct clusters 
termed 'basal-like' (characterized by HR-negativity and basal CKs positivity), 
'HER2-positive', and 'normal-like' class, which showed a gene expression 
pattern similar to that of normal breast with relatively high expression of genes 
characterising fat cells and .other mesenchymal cell types but decreased 
expression of luminal epithelial cell genes (Perou et aI., 2000). 
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Initially, although Perou and colleagues recognised the importance of ER and 
ER-related genes as key markers in the molecular clustering and classification 
of BC, they did not attempt to subclassify this large ER-positive luminal-like 
class of tumours. This followed in a subsequent study of 78 cases and seven 
non-malignant breast samples where the gene list was modified to 456 cDNA 
clones, with the identification of three luminal-like subgroups: Luminal A, 
Luminal B, and Luminal C (Sorlie et aI., 2001). The latter subclass was 
distinguished from the other luminal subclasses by high expression of a novel 
gene set including transferrin receptor (CD71), MYB, nucleolar protein p40, 
SQLE, GGH and others. In a third study by the same investigators, a modified 
intrinsic gene list of 534 genes was used and resulted in only two luminal-like 
subclasses being observed: Luminal A and B. Interestingly, some of the genes 
that previously clustered in the Luminal C subclass were clustered in the 
Luminal B subclass and Basal-like class (Sorlie et aI., 2003). 
Importantly, characterisation of luminal-like cancer varies between studies. 
Some of the variance between different studies can be explained by the 
identification and use of different intrinsic gene sets for cluster analysis, 
leading to the view that a standard intrinsic gene set should be adopted to 
minimise discordant results (Andre and Pusztai, 2006). In this respect, Hu and 
colleagues evaluated a novel 1300 intrinsic gene set, sharing 108 genes in 
common with that of Sorlie's intrinsic set, on an independent combined dataset 
consisting of 315 breast samples (311 tumours and 4 normal breast samples) 
(Hu et aI., 2006). The combined dataset from 315 breast samples was created 
by combining the gene array data from Sorlie et al. (2001 and 2003; cDNA 
17 
Chapter 1 
microarrays), van't Veer et al. (2002; oligo-microarrays) and Sotiriou et al. 
(2003; cDNA microarray) . Genes common to all three microarray data sets 
(2800 genes) were identified and Distance Weighted Discrimination (DWD) 
was used to fuse the datasets together; DWD compensates for systematic bias 
between different datasets (Benito et aI., 2004). The authors found that 306 of 
the 1300 intrinsic genes were present in the combined dataset and when 
analysed by hierarchical clustering, two main luminal-like subclasses were 
identified corresponding to the previously defined Luminal A and Luminal B 
in addition to HER2-positive, basal-like, and normal-like tumour groups 
identified in the earlier studies (Fig 1.9). 
Figure 1.9: Dendogram of the molecular breast cancer subtypes 
(Hu et aI., 2006) 
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Most subsequent studies supported the existence of at least two luminal-like 
subclasses (A & B). Luminal A tumours are characterised by high expression 
of luminal epithelial CKs and other luminal associated markers including 
oestrogen receptor 1 (ESRI), and genes associated with ER function such as 
LIVI, hepatocyte nuclear factor 3 alpha (FOXAI), X-box binding protein 1 
(XBP1) and OATA-binding protein 3 (OATA3) (Sotiriou et al., 2003). 
Whereas the Luminal B group is characterized by low to moderate expression 
of the Luminal A genes mentioned above, but is further distinguished by high 
expression of additional genes, mainly related to proliferation such as v-MYB, 
OOH, LAPTMB4, NSEPI and CCNEI (Sorlie et al., 2001). 
Molecular pathways within the luminal gene cluster have been identified using 
PANTHERTM Protein Classification System (www.pantherdb.org) (Sorlie et 
aI., 2006). For Luminal A the most common represented biological pathways 
included steroid hormone signalling (e.g. CRABP2, AR, and ESRI) and fatty 
acid metabolism (e.g. PODS, ACOX2, PTE2B, CROT, IVD, DECR2, 
FLJ20920, SLC27 A2, ELOVL5, and MCCC2). Using an alternative tool, 
PathArt™ pathways, revealed that the most common pathway enriched in the 
Luminal A subclass is ER signalling. The other represented pathways included 
retinoic acid signalling pathway, nucleotide excision repair pathway, IL6 
pathway and EOF signalling pathway (Sorlie et aI., 2006). Another group have 
profiled a series of 138 tumour comprising 80 Luminal A and 58 basal cancers 
using whole-genome DNA microarrays and identified 5621 genes differentially 
expressed between the two subclasses. Luminal A tumours overexpressed 
genes involved mainly in fatty acid metabolism, TGFJ3 signalling, and 
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oestrogen receptor (ER) signalling (Bertucci et aI., 2009). To the best of our 
knowledge, there is no published data concerning the Luminal B subclass 
pathways. In addition, there is no evidence supporting or refuting the 
progression of Luminal A into the Luminal B subclass. 
Improved understanding of the biology of the luminal-like class of BC IS 
clearly required and should translate into more effective methods of diagnosis 
and management. Despite the fact that these observations demonstrate that the 
luminal-like class of breast cancers exhibits ER related pathway activity and is 
ER-positive, it is widely recognised that it comprises a large and heterogeneous 
group of Be which cannot consistently be subclassified into biologically and 
clinically distinct subgroups. This has raised the following question: Are there 
alternative approaches which could help to provide a solution? 
Some investigators have applied gene expression profiling technology to ER-
positive tumours alone in an attempt to identify distinct molecular and 
biological subclasses. Oh and co-workers have developed a gene expression 
signature for outcome prediction of ER-positive Be patients (Dh et aI., 2006). 
The authors used the ER-positive MCF-7 Be cell line treated with 17P-
estradiol and a hierarchical clustering method to identify oestrogen-regulated 
genes. Subsequently, the gene set identified in MCF-7 cells was used to 
subclassify a training set of 65 breast tumours into two groups with significant 
clinical outcome differences. Subsequently, the investigators validated this 
gene expression predictor of outcome on three independent published data sets 
and found that the good prognosis group had significantly better outcome than 
the poor prognosis group and were characterised by high expression of 
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GATA3, XBPl, and PR which are all known ER related genes. The poor 
prognosis group was characterised by high expression of cell proliferation and 
anti-apoptosis genes and increased expression of a cluster of oestrogen-related 
genes that included CTPS, E2F6, and F ANCA, demonstrating the 
heterogeneity and the biological and clinical importance of ER and ER related 
genes even within the ER-positive tumours. 
In another approach, some researchers used a gene expression grade index 
(GGI), which defines the tumour histologic grade on the basis of their gene 
expression characteristics to assign a grade index to ER-positive BC in an 
attempt to refine their molecular classification (Loi et aI., 2007). The authors 
have assigned ER-positive BC to either high or low GGI subgroups and 
compared these with the molecular classification of ER-positive tumours. The 
two subclasses were associated with a distinct clinical outcome in both 
tamoxifen-treated and untreated patients. The authors concluded that the use of 
genomic grade can identify two different ER-positive molecular subgroups in 
multiple data sets. They identified 97 genes associated with histologic grade; 
many of these genes were highly expressed in the luminal-like ER-positive 
cluster like ESRl, XBPl, FOXAI and GATA3. In Tamoxifen-only treated 
populations of more than 650 patients, GGI appeared to be a strong predictor of 
clinical outcome, indicating the prognostic importance of proliferation genes in 
ER-positive subgroups, as previously reported by others (lvshina et aI., 2006, 
Dai et aI., 2005). These prognostic classes as defined by genomic grade were 
an improvement over standard stratification by quantitative ER expression 
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levels, which correlate well to immunohistochemical protein values (Sotiriou et 
aI.,2006) 
Other authors identified distinct biological and clinical subgroups within the 
ER-positive BC using standard histopathological data and hierarchical 
clustering analysis (Webster et aI., 2008). 
(B) Understanding the heterogeneity of ER-positive I luminal-like BC 
by genomic DNA profiling 
Genomic analysis has been used in the characterization of breast lesions to 
investigate the relationship between their genotypic and phenotypic 
characteristics and for providing new prognostic parameters (Reis and Lakhani, 
2003). 
The identification of genome copy number abnormalities (CNAs) has been 
used for finding important chromosomal loci for gene identification and more 
specific characterisation of ER-positive BC. Bergamaschi and colleagues 
applied array comparative genomic hybridisation (aCGH) to 89 invasive breast 
cancers with locally advanced disease that were previously classified by 
expression arrays to determine whether different gene expression subclasses 
were associated with distinct CNAs (Bergamaschi et aI., 2006) . The authors 
found Luminal A group tumours were associated with gain at lq12-q41 and 
16p12-p13 whereas Luminal B tumours exhibited more frequent loss at 3q12, 
gain at 8qll-q24 and 20q13, and high-level amplification at 7p22, 8ql1-24, 
19q 13, and 20q 13. High level amplifications were more prevalent in Luminal 
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B tumours compared to Luminal A suggesting that distinct mechanisms of 
genomic alterations might be behind their pathogenesis. 
Chin and colleagues explored the roles of CNAs in BC by identifying 
associations between recurrent CNAs, gene expression, and clinical outcome in 
a set of aggressively treated early stage breast tumours. Their study showed 
that the recurrent CNAs differed between tumour subclasses defined by their 
gene expression, and the prognostic subclassification of patients can be 
improved by determining both expression and the associated copy number 
changes (Chin et aI., 2006). 
Using high resolution aCGH analysis with BAC clones, Han and colleagues 
investigated genomic alterations in ER-positive breast cancers showing tumour 
recurrence within 5 years. The investigators reported loss of I1p15.5, Ilp15.4, 
Ip36.33, Ilq13.I, and llpll in the recurrence group (Han et aI., 2006). 
The concept of relating genomic and gene expression data to identify 
subgroups ofBC was further explored (Wang et aI., 2004). In this study, loss of 
heterozygosity (LOH) was determined by single nucleotide polymorphism 
(SNP) arrays. LOH on lp and 16q occurred in a subclass ofER positive breast 
cancers. The authors used 672 gene probes that showed highest variation of 
expression across samples in clustering and identified two large clusters named 
'cluster I' and 'cluster II'; cluster II was characterized by ER positivity and 
further subdivided into 2 clusters (A and B). They found distinct LOH patterns 
in two chromosomal regions which are more associated with the ER-positive 
cancers, 1 p34 and 16q23-24, being affected frequently in cluster II. Allelic 
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imbalance at 16q23-24 and 1 p34 was common in cluster liB; loss at 16q 
occurred in 88% of lIB tumours compared to only 50% of lIA tumours. 
Furthennore, loss of 1 p34 was seen in 50% of lIB tumours, but not in any of 
cluster lIA tumours (Wang et al., 2004). 
In summary, the genomic studies of ER positive breast cancers support the 
existence of common characteristics within the luminal-like class. Importantly 
in future studies it will be necessary to interrogate these findings to assist 
discovery of new candidate genes with relevance to the biology of ER-positive 
BC, the causes behind resistance to therapy, and new candidate biomarkers 
useful in prognosis and prediction. For example, gain on 8q is more frequent in 
Luminal B subclass tumours and is known to harbour the MYC oncogene. 
MYC plays a key role in promoting cell proliferation (Adhikary and Eilers, 
2005) and this association may explain the higher proliferation rates of 
Luminal B tumours and their resistance to tamoxifen in some cases compared 
to the good prognosis luminal subgroup (Bergamaschi et al., 2006). Further 
genomic studies are needed to understand the relevance of alterations in 
chromosome 16 and chromosome one in ER-positive BC. 
(C) Understanding the heterogeneity luminal-like BC by 
immunohistochemical (IHC) identification 
In 2005, Abd EI-Rehim and colleagues applied semi-quantitative 
morphometric IHC to tissue microarray (TMA) sections of a large series of 
invasive BC (1076 tumours) using a panel of 25 tumour relevant biomarkers. 
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The IHC results were analyzed using hierarchical clustering and artificial 
neural network (ANN) methods, comparable to the GEP studies described 
above, to categorize cases into groups and to examine the biomarkers 
responsible for driving group membership. Two luminal groups (termed group 
1 and group 2) were identified, characterised by the expression of oestrogen 
receptor, luminal CKs, MUel, absence of basal epithelial phenotype 
characteristics and lack of HER2 protein overexpression. Group 1 showed 
relatively stronger combined expression of HER3 and HER4 compared to 
group 2. In addition, the mean expression of BRCAI protein was lower in 
group 1 than in group 2 (Abd EI-Rehim et aI., 2005). 
To date there is no internationally accepted single definition for luminal-like 
cancers although the majority of these cancers appear to have lower grade or 
more differentiated morphological features and are ER-positive. As a 
consequence, ER positivity has been used as the most important feature for a 
tumour to be classified as luminal-like. In their attempt to define basal-like 
tumours, Nielsen and co-workers classified all HER2 positive tumours in the 
HER2 subclass and of the remaining cases, ER-positive tumours were 
considered as luminal-like (Nielsen et aI., 2004). Other investigators 
recognised the important association between lack of HER2 amplification and 
ER expression in determining a good prognosis associated with Luminal A 
tumours (Carey et aI., 2006). The authors identified five tumour subclasses, 
Luminal A (ER-positive and/or PgR-positive and HER2-negative), Luminal B 
(ER positive and/or PgR-positive and HER2-positive), basal-like (ER-negative, 
PR-negative, HER2-negative, and CK5/6-positive, and/or HERI-positive), 
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HER2-positive (ER-negative, PgR-negative, and HER2-positive), and 
unclassified (negative for all 5 markers) subclasses. Recently, Hugh and 
colleagues used the proliferation marker Ki67 expression in defining the 
luminal-like tumours in addition to ER, PgR, and HER2. Luminal A was 
defined as (ER-positive and/or PR-positive and not HER2-positive or Ki67 
high) while Luminal B was defined as (ER-positive and/or PgR-positive and 
either HER2-positive and/or Ki67 high) (Hugh et aI., 2009). The importance of 
Ki67 in defining the poor prognosis variant luminal form has been studied by 
many authors in distinguishing it from the good prognosis subclass (Cheang et 
aI.,2009). 
Regarding HER2 expression, although GEP studies have shown that some 
luminal-like tumours express HER2 and some authors include HER2 positivity 
as a feature of Luminal B tumours, others argue against that and include 
HER2-positive tumours, regardless of the expression of ER, with the HER2-
positive subgroup (Bhargava and Dabbs, 2008). Supporting this, ER-positive 
HER2 positive tumours are candidates to receive specific systemic therapy 
targeting HER2 overexpression and so differ in management from ER-positive 
HER2 negative tumours. Furthermore, the amplified HER2 positive cases have 
similar genetic changes regardless of their ER status (Marchio et aI., 2008). 
In some instances the molecular class of an individual case contradicts its 
immunophenotypic characteristics. Rouzier and colleagues found that only 
80% of the HER2+ molecular class had HER2 gene amplification by in situ 
hybridization analysis and 5% of basal-like tumours were ER-positive (Rouzier 
et aI., 2005). In other studies, 12% of luminal-like tumours as defined by 
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expression arrays were reported to be ER-negative by IHC (Sotiriou et aI., 
2003) and ER IHC expression is reported to be found in 5-45% of basal-like 
cancers and 20-30% of HER2 positive cancers as defined by expression arrays 
(Sotiriou et aI., 2003, Calza et aI., 2006). The discordance between molecular 
and immunophenotypic criteria of BC can be partially explained by differences 
in methods used including the use of different monoclonal and polyclonal 
antibodies or different intrinsic gene sets in protein and gene expression 
studies, respectively. This wide disagreement about the definition of the 
luminal-like cancer indicates a need for additional protein markers to be used 
to identify the major tumour subgroups using IHC provided that they are 
clearly associated with prognosis and distinct biological pathways. 
(D) Additional clinical and biological features of ER-positive I luminal-
like classes 
There are no specific morphological features that can identify these breast 
tumours apart from ER positivity and low histological grade and even using 
such criteria, there are notable exceptions as a small percentage (9%) of 
luminal-like tumours defined by molecular characteristics are of high grade 
(Livasy et aI., 2006). In the Carolina Breast Cancer Study, luminal breast 
cancers represented approximately two thirds of the cases with a number of 
important observations relating to the ER-positive group being made. Young 
African American women showed a low frequency of Luminal A subclass in 
comparison to the basal-like subgroup, possibly accounting for the poor 
outcome in this group of patients (Carey et aI., 2006). Ihemelandu and co-
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workers showed that the Luminal A subclass was more common (50%) in 
comparison to the Luminal B (14%) subgroup in premenopausal African 
American women. However, when stratified by age, results showed that in the 
group below 35 years of age, Luminal A and Luminal B were less frequent 
(Ihemelandu et aI., 2007). 
The expression of the anti-apoptosis Bcl-2 gene was found to be overexpressed 
in Luminal A compared to Luminal B cancer. As might be expected, TP53 
mutation was more frequent in the basal-like subclass compared to good 
prognosis luminal-like subclasses (Ihemelandu et aI., 2007, Sorlie et aI., 2001). 
Hoadley and colleagues suggested that the high expression of genes associated 
with the HER family pathway can predict outcome differences in ER-positive 
and tamoxifen-treated patients and demonstrated that the difference between 
Luminal A and Luminal B groups is partially due to the activation of this 
important pathway in Luminal B tumours. In their study, the Luminal A 
subclass showed low expression of the genes in the HER pathway with the 
exception of HER4. In contrast, the Luminal B tumours showed moderate to 
high expression of the EGFR-associated genes, high H-RAS and MEK2 
expression (Hoadley et aI., 2007). 
Badve and Nakshatri proposed a model of hormonal network between ER, 
FOXAI and GATA3 with predictive and prognostic signature for ER-positive 
breast cancers (Badve and Nakshatri, 2009). Other studies have confirmed the 
relation between ER and its downstream transcription through FOXA 1 (Badve 
et aI., 2007). 
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The luminal-like subclasses have a good prognosis but within this group of 
patients, Luminal Band C have been described as having a worse prognosis in 
comparison to the pure Luminal A cancers (Sorlie et aI., 2001). The reasons for 
this difference in prognosis are still unknown but a possible explanation relates 
to ER function and signalling differences between Luminal A and Luminal B 
cancers, which could be attributed to the influence of additional transcription 
factors, coactivators, and corepressors that modulate ER activity. In addition, 
overexpression of proliferation and cell cycle genes in BC is well recognised to 
be associated with poor outcome suggesting that these genes may contribute to 
the Luminal B subgroup's poorer prognosis. Also, it has been proposed that 
abnormal apoptosis function, DNA damage response and PI3K1Akt pathways 
may be additional factors influencing prognosis (Bertucci et aI., 2009). 
Supporting this concept, Dai and colleagues reported a cell proliferation 
signature as the key marker of poor outcome in a population of young women 
below 55 years whose breast cancers had high expression of ER for their age 
(Dai et aI., 2005). 
(E) Therapeutic implications of ER-positive I luminal-like classes 
Recently, gene signatures derived from microarray studies have also been 
reported to predict outcome in women with ER-positive breast cancers after 
tamoxifen treatment better than the traditional pathological factors (Klijn et aI., 
2005). Jansen and co-workers identified 81 genes that predicted response to 
tamoxifen using a set of 46 tumours from ER-positive women with advanced 
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disease on cDNA microarray. They further refined the signature to 44 genes 
and validated it on a set of 66 tumours. It predicted the response to tamoxifen 
treatment in 27 out of 35 cases with disease progression. Interestingly, pathway 
analysis of these genes showed that they were mainly involved in oestrogen 
function and apoptosis which support the view that prognostic heterogeneity 
within ER-positive tumours in respect of resistance to hormonal therapy and 
outcome might be related to abnormal apoptosis function (Jansen et aI., 2005). 
The performance of this signature was confirmed using 44K oligomicroarray 
platform on a set of 69 independent patient tumours series treated with 
tamoxifen and the profile included 78 genes (Kok et aI., 2009). Other authors 
have developed a molecular signature of 36 genes for detection of a subgroup 
of patients who did not respond to tamoxifen treatment that correctly classified 
78% of patients with relapse. Among this prognostic signature, many genes are 
related to DNA replication and proliferation such as TKl, CCNB2, CDC2 and 
AURKB (Chanrion et aI., 2008). 
Previous studies indicated that Luminal A tumours can be treated effectively 
with hormonal therapy, while Luminal B tumours are more resistant and may 
benefit from combined endocrine treatment and chemotherapy (Hugh et aI., 
2009). 
Goldhirsch and colleagues reported two categories of ER-positive BC based on 
their response to endocrine therapy, those that are highly endocrine responsive 
expressing high level of both ER and PgR, and those that are incompletely 
endocrine responsive expressing low levels of eitherlboth receptors. A third 
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group called endocrine non-responSIve was reported in tumours having 
negative expression for ER and PgR. (Goldhirsch et aI., 2007). Comparing 
these finding to the recent molecular subclasses and their response to different 
types of adjuvant therapy, the highly endocrine responsive category being 
characterised by high ER expression seems similar to Luminal A, while 
incompletely endocrine responsive appears closer to Luminal B in term of their 
ER status and response to adjuvant therapy discussed above. 
Generally, ER-positive BC is resistant to chemotherapy (Rouzier et aI., 2005) 
and there is a need to develop prognostic assays to predict chemo-response in 
ER-positive tumours. Subsequently, an assay based on polymerase chain 
reaction (PCR) has been developed using a signature of sixteen genes and five 
reference genes for prediction of recurrence in tamoxifen treated ER-positive 
lymph node negative patients producing the 'Recurrence Score' (RS) or the 21-
gene Oncotype Dx (TM) (Paik et aI., 2004). Patients with a low RS were 
mostly found not to benefit from adjuvant chemotherapy, whereas those with 
high RS had a high rate of pathological response after chemotherapy (Paik et 
aI., 2004). The low RS group of patients are probably Luminal A because 
these cases are strongly ER-positive characterised by low tumour grade and 
low proliferative activity and expected to respond to hormonal therapy better 
than the high RS group which are characterised by high proliferation (Hugh et 
aI., 2009). The highly proliferative cancers may respond better and show 
improved survival after chemotherapy (Levack et aI., 1999). It is also important 
to mention that patients with low RS responded well to tamoxifen alone and no 
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significant survival differences were found if they had given chemotherapy in 
addition to endocrine therapy (Paik et al., 2004). 
Estimation of cell proliferation pathways could have significant clinical benefit 
in predicting behaviour and subclassification of the luminal-like subclasses, 
and their potential for response to systemic therapy. There remains a need for 
further identification of additional biomarkers by their relationship to 
biological pathways, outcome or therapeutic implications to improve the 
classification and clinical management of luminal-like BC especially the non-
Luminal A subtypes. 
The biological and behavioural criteria should be studied in depth for better 
characterisation ofER-positive breast cancer with respect to prognosis, biology 
and response to therapy. Subsequently, more research efforts are needed to 
study the characteristic features of these molecular subclasses and their 
reliability in diagnosis and prognosis of breast cancers. 
1.1.5 Estrogen receptor alpha (ESR1) 
Oestrogen receptor alpha (ESRl) is a dominant regulator of breast cancer 
aetiology and progression and the main discriminator marker of molecular 
classification (Schiff et aI., 2005). 
1.1.5.1 Structure 
ER consists of multiple domains which include a DNA-binding domain (DBD) 
found in the core of the protein and two major transcriptional activation 
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function (AF) domains: Ligand-independent AF -1 and the ligand-dependent 
AF-2 , found in the ER amino- and carboxyl-termini, respectively (Fig 1:10). 
-t 
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Figure 1.10: Structure of ER alpha. 
(Schiff et aI. , 2005) 
1.1.5.2 Function 
(A) Genomic function 
ligand Binding Domain 
Transcriptional 
Activation 
(ligand-dependent) 
ER is the key member in the aetiology, pathogenesis and progression of breast 
cancer. Many genetic and histological studies have confirmed this role. ER is a 
nuclear protein and shares a common structural and functional organization 
with all other nuclear receptors. It acts as a ligand-dependent transcription 
factor and regulates the expression of a variety of genes. Many of these genes 
promote breast cancer proliferation like the insulin-like growth factor 1 
receptor (IGFR) and the cell cycle regulator cyclin Dl(Nemere et aI. , 2003). 
Others are proteins involved in tumour progression including factors involved 
in tumour invasiveness and metastasis or in the activation of tumour stromal 
components such as the angiogenic vascular endothelial growth factor (Klinge, 
2001). 
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(B) Nongenomic function 
Oestrogen and other steroid hormones, in addition to their role as direct 
modulators of gene transcription mediated by their classic nuclear receptors, 
can also perform rapid stimulatory effects on a variety of signal transduction 
pathways (Nemere et aI., 2003). The significance of non genomic ER activity in 
mediating oestrogen signalling to promote cell proliferation and survival in 
breast cancer cells has also been documented. A large number of studies using 
biochemical, immunohistochemical and genetic methods have further proved 
the existence and function of ER in breast tumours cells (Levin, 2002). 
Several mechanisms by which ER interacts with components of signalling 
complexes and triggers their responses have been proposed. ER, in response to 
oestrogen, can directly and indirectly interact with several growth factors and 
tyrosine kinase receptors such as HER2 and IGFR and thereby activate their 
kinase/phosphorylation cascades. ER also directly associates with key signal 
transduction adaptors and kinases. Kinase cascade signalling induced by 
nongenomic ER activity can phosphorylate and activate various components of 
the ER pathway as well as other components of the transcriptional machinery 
such as ERK and PI3 kinase (Kelly and Levin, 2001), resulting in potentiation 
of nuclear ER transcriptional function (Sun et aI., 2001). 
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1.2 AIM OF WORK 
This thesis has several aims: 
1) Identification of putative biomarkers for better characterisation of the 
ER-positive luminal-like subclass using gene expression analysis, novel 
bioinformatic approaches, conventional statistical methods and a 
literature search which could be used in prognosis and phenotypic 
characterisation ofER-positive luminal-like breast cancer. 
2) Investigation of selected ER related genes on the basis of their 
biological function and their potential ability to distinguish different 
prognostic subclasses within the luminal-like group. 
3) Validation of selected biomarkers using high throughput proteomic 
tissue microarrays (TMAs) and immunohistochemistry applied to a well 
characterised clinical patient series with long term follow-up. 
4) Identification of ER-positive subgroups using a consensus of clustering 
algorithms applied to protein expression data of selected biomarkers. 
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2 General Material and Methods 
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2.1 Material and Methods 
2.1.1 Study group 
The breast cancer samples for this study derived from a consecutive series of 
1,942 cases of primary operable invasive breast carcinoma obtained from the 
Nottingham Tenovus Primary Breast Carcinoma Series (Table 2.1). 
In previous studies, these patients have been immunohistochemically 
characterized using a range of markers of tumour-biological interest; the data 
has been correlated with survival outcome and prognosis. Previously, tissues 
from approximately 1942 paraffin processed breast tumours were used to 
prepare tissue microarrays (TMA) comprising wax blocks containing 150 cores 
of tissue (Abd EI-Rehim et al., 2005). Briefly, formalin fixed paraffin 
embedded (FFPE) TMAs were prepared from the cases of primary operable 
(stage I and II) breast carcinoma of patients aged <70 years with tumours of 
less than 5 cm in diameter presented consecutively to the Nottingham Breast 
Unit between 1986 to 1998. This well-characterized resource contains patients' 
clinical and pathological data including patients' age, histologic tumour type 
(Ellis et al., 1992), primary tumour size, lymph node status, mitotic count and 
histologic grade, vascular invasion (VI) (Pinder et al., 1994), Nottingham 
Prognostic Index (Galea et al., 1992), development of recurrence, and distant 
metastases (DM). Survival data including survival time and disease-free 
interval (DFI) were maintained on a prospective basis. Breast cancer specific 
survival (BCSS) was defined as the time (in months) from the date of the 
primary surgical treatment to the time of death from (or with active) breast 
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cancer. DFI was defined as the interval (in months) from the date of the 
primary surgical treatment to the first locoregional or distant metastasis 
(DMFI). 
The available data, slides and blocks were used to: 
1- Identification of the oestrogen receptor positive cases in the whole 
series. Correlations and statistical analysis of the data available on the 
previously studied biomarkers. 
2- Construction of a new TMAs senes (n=I,902). TMAs allow large 
populations of patients' tumours to be rapidly screened to detect overall 
protein expression in large patient groups, thereby overcoming the 
weakness of IHC results when using smaller cohorts. 
Patients' characteristics of Nottingham primary invasive breast carcinoma 
series are summarised in (Table 2.1). 
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Table 2.1: Patient characteristics of Nottingham invasive breast carcinoma 
senes 
Variable Number Cases (%) 
Tumour type 1961 
No Special Type 1089 (56) 
Lobular 219(11) 
Mixed NST and special !)'pe 443 (22) 
Other 210(11) 
Tumour 2rade 1940 
I 367 (19) 
2 648 (33) 
3 925 (48) 
Tumour size (cm) 1943 
<2 1033 (53) 
2-5 864 (45) 
>5 46 (2) 
Nodal status 1938 
Negative 1233 (64) 
Positive (1-3 nodes) 549 (28) 
Positive (>3 nodes) 156 (8) 
Nottingham prognostic index 1934 
Good prognosis group 618 (32) 
Moderate prognosis group_ 994 (51) 
Poor prognosis group 322 (17) 
Oestro2en receptor status 1812 
Positive 1268 (70) 
Negative 544 (30) 
2.1.1.1 The Nottingham histologic grading system 
The Nottingham combined histological grading system (Elston-Ellis 
modification of Scarff-Bloom-Richardson grading system) is the commonly 
used system in grading 0 f breast cancer (Elston and Ellis, 1991 ). The 
parameters measured are the extent of tubular formation; the extent of nuclear 
pleomorphism, and mitotic rate. Each of the three elements is assigned a score 
on a scale of 1 to 3, and the final grade is determined from the sum of the 
scores. Histological grade is traditionally expressed in three categories: score 3 
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to 5, well differentiated (grade 1); scores 6 to 7, intermediate (grade 2); and 
scores 8 to 9, poorly differentiated (grade 3). 
2.1.1.2 Nottingham prognostic index (NPI) 
NPI is widely used in the UK and was developed for the prognostic 
management of breast cancer by using multivariate analysis to determine the 
most important prognostic factors. It includes 3 factors; tumour histologic 
grade (1-3 using the Nottingham Grading System), lymph node (LN) stage (1-
3; I=LN negative, 2=1-3 positive nodes and 3= more than 3 positive nodes) 
and primary tumour size (O.2x size in cm). NPI is then categorized into 3 
groups: the good prognostic group (score ~ 3 . 4 ) , , the moderate group (>3.4 -
5.4) and the poor prognostic group (score> 5.4). 
2.1.2 Patient management 
Patient management was based on the Nottingham Prognostic Index (NPI) 
score and ER status. The treatment protocol during this time was based on a 
previous publication (Bianco et aI., 1988). Patients within the good prognostic 
NPI group ( ~ 3 . 4 ) ) did not receive adjuvant systemic therapy. Honnonal therapy 
(Tamoxifen ± Zoladex if premenopausal) was given to patients with ER-
positive tumours and NPI scores of >3.4. Pre-menopausal patients with 
moderate and poor prognostic NPI groups were given chemotherapy 
(Cyclophosphamide, Methotrexate, and 5-Flourouracil). ER-positive 
postmenopausal patients with moderate or poor NPI were offered hormonal 
therapy, while ER negative patients received eMF if fit to receive these 
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cytotoxic agents with no concurrent diseases that were considered as potential 
contraindication to the use of chemotherapy. 
2.1.3 Gene expression studies 
The study population used was derived from the Nottingham Tenovus Primary 
Breast Carcinoma Series of women aged 70 years or less, who presented with 
stage I and II primary operable invasive breast carcinomas. 
Total RNA was extracted from a total of 128 frozen breast cancers retrieved 
from Nottingham Hospitals NHS Trust Tumour Bank between 1986 and 1992 
in collaboration with Cambridge University (Cambridge dataset). RNA 
integrity and DNA contamination were analysed using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Total RNA was 
biotin-labelled using the Illumina TotalPrep RNA Amplification kit (Ambion, 
Austin, TX, USA) according to manufacturer's instructions. Biotin-labelled 
cRNA (l.5 Jig) was used for each hybridisation on Sentrix Human-6 
BeadChips (IlIum ina, San Diego, CA, USA) in accordance with the 
manufacturer's protocol. Illumina gene expression data containing 47,293 
transcripts were analysed and summarised in the Illumina Bead Studio 
software. Analyses of the probe level data were done using the bead array 
Bioconductor package. The expression data are available at the EBI website 
(http://www.ebi.ac.uklmiamexpress/) with the accession number E-TABM-
576. Transcript expression profiling has been previously described (Chin et at, 
2007, Naderi et at, 2006). 
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2.1.3.1 Histopathological characterisation of the Cambridge 
dataset 
Seventy five percent of patients were postmenopausal, 68.8% were LN stage 1 
(no lymph node involvement) and 40.6% were tumour grade 2. During the 
follow-up period 24.2% developed metastatic disease and 34.4% developed 
tumour recurrence. Forty four percent of tumours were ductal with no special 
types. Sixty five percent of patients were positive for oestrogen receptor alpha 
expression (Table 2.2). 
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Table 2.2: Patient characteristics of Cambridge dataset 
Variable Frequency Percentage 
Menopause 
Premenopausal 94 75.2 
Postmenopausal 31 24.8 
Tumour grade 
1 33 25.8 
2 52 40.6 
3 43 33.6 
Lymph node stage 
1 88 68.8 
2 28 21.9 
3 12 9.4 
Death 
Alive 81 63.3 
Due to breast cancer 33 23.8 
Due to other causes 14 11 
Distant metastasis 
No 97 75.8 
Yes 31 24.2 
Tumour recurrence 
No 84 65.6 
Yes 44 34.4 
Tumour type 
Ductal NOS 57 44.5 
Others 71 55.5 
ER status 
Positive 84 65.6 
Negative 44 34.3 
2.1.4 Gene selection for protein expression studies 
One of the aims of this study was to identify a set of specific genes whose 
expression best identify prognostic subgroups of luminal ER positive tumours. 
Candidate genes were selected from three sources including: 
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2.1.4.1 Literature search 
A literature search was perfonned for genes with strong relevance in ER-
positive breast cancer, or has been the subject of recently published studies and 
strongly suggests an important role in the biology and molecular classification 
of ER-positive breast cancer. The selection criteria was based on the published 
literature concentrating mainly on ER related pathways such as ER 
coregulators, cellular proliferation, apoptosis, AktlPIK3 pathway and endocrine 
resistance. 
2.1.4.2 Bioinformatical analysis of the gene microarray data 
(A)Ensemble classification and cross-validation analysis 
A cross-validation analysis was used in combination with an ensemble sample 
classification in order to obtain a robust ranking of genes that are differentially 
expressed between the luminal ER-positive (n=84) cases and the non-luminal 
cases (all other cases) (n=44) in Cambridge gene microarray data. For this 
purpose, the 128 patient samples were first partitioned randomly into 10 sub-
groups of approximately equal size. For each possible combination of 9 sub-
groups differentially expressed genes were selected independently with the 
"Empirical Bayes moderated t-statistic" (Smyth, 2004) and used to train a 
machine learning model, while the remaining sub-group was left out as the test 
set (a procedure known as "external cross-validation"). To classify the samples 
in these remaining test set groups, the prediction results of four algorithms 
(Support Vector Machine, Random Forest, kNN and Prediction Analysis for 
Microarrays) (Tibshirani et aI., 2002) were combined to a majority-vote 
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ensemble classifier. In order to rank the genes based on the cross-validation 
results, their frequency of occurrence in the list of significantly differentially 
expressed genes (p-value < 0.05) across different cross-validation cycles was 
recorded, and genes received higher scores the more often they had been 
selected (expressed as a z-score significance measure). RERG and GAT A3 
belonged to the top-ranked genes which were selected in each of the 10 cross-
validation cycles. Subsequently they were included in the study. 
(B) Artificial neural networks (ANN) analysis 
ANNs are a form of artificial intelligence inspired by learning in human 
neuronal systems and have been shown to be capable of modelling complex 
systems with high predictive accuracies on several large scale datasets (Ball et 
aI.,2002). 
We have used the immunohistochemically identified ER-positive cases to 
develop an ANN model to identify novel genes associated with ER-positive 
status. Our aim was to identify; using a novel prediction method (ANN), a set 
of genes that show significant association with ER expression (high expression 
vs. low expression) and to validate the genes using protein expression. To 
study this, the ER-positive cases (84 tumours) were categorized according to 
the level of ER expression into high and low expression using the median of 
the H-score values (H-score 140). RERG gene was found to be associated with 
the high ER expression and was included in the study. 
The ANN model used a supervised learning approach with multi-layer 
perceptron architecture and a sigmoidal transfer function, where weights were 
updated by a back propagation algorithm as previously described (Lancashire 
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et aI., 2010). Data consisted of 84 samples each with 47,293 corresponding 
variables specifying the Log 10 expression ratio of each transcript. 
Prior to ANN training, the data were randomly divided into three subsets: 60% 
for training, 20% for testing (to assess model performance during the training 
process) and 20% for validation (to independently test the model on data 
completely blind to the model). This process of random sample cross-
validation enabled the generation of confidence intervals for the predictions on 
a separate blind dataset, and therefore avoided over-fitting of the data. The 
intensity of each gene was used as an individual input in an ANN model, 
creating n individual models, where n was the number of transcripts on the 
array (47,293). These n models were then split into three subsets (described 
above) and trained. This random resampling and training process was repeated 
50 times to generate predictions and associated error values for each sample 
with respect to the validation (blind) data. Inputs were ranked in ascending 
order based on predictive error, and the gene that performed with the lowest 
error was selected for further training. Next, each of the remaining genes was 
sequentially added to the previous best gene, and was used in combination in a 
model, creating n - 1 models each containing two genes as inputs. Training 
was repeated and performance evaluated. The model with the highest 
modelling performance was again selected and the process repeated creating 
n - 2 models each containing three inputs. This process was repeated until no 
significant gain was evident from the addition of further inputs. This resulted in 
a final model containing those transcripts that most accurately classified the 
patients according to ER status. 
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Initially we had gene expression data on 112 cases, and we firstly used the 
definition of luminal cancers [ER (+), HER2 (-), CKS/6(-) and CK14 (-)] in 
another ANN model to identify the cases with this luminal immunophenotype. 
Five cases were omitted from the analysis due to missing data. Fifty luminal 
cases were identified using this definition. The luminal versus non-luminal data 
was used to divide the gene expression data of the cases into two groups, 
luminal and non-luminal cases to identify genes that can characterise this 
luminal phenotype. These data has been bioinfomatically analysed using the 
ANN analysis in collaboration with Dr Graham Ball from Nottingham Trent 
University. AGTRI was found to be significantly associated with this luminal 
phenotype and was selected for further study. 
(C)Identification of genes with variable expression within the ER-positive 
cases 
The gene microarray data were analysed to identify the genes with greatest 
intensity variation in the ER-positive cohort in Cambridge dataset by 
calculating the mean of the normalised expression values and their standard 
deviations (500 genes) and these genes were used in genes' selection. BEXI 
and TFF3 were selected using this approach (Table 2.3). 
2.1.4.1 Collaboration with the Tenovus group 
Gene lists were provided from our Tenovus group collaborators, University of 
Cardiff. Tenovus group has Affymetrix (HG-UI33A chip) gene expression 
data for ER (+) MCF7 breast cell lines treated with/without ER antagonists. 
CD71 was chosen as a result of this collaboration because of its association 
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with ER-positive endocrine resistant cell lines. The additional methods that 
have been included in CD71 study including cell culture and growth studies 
will be discussed in the relevant chapter. 
All together, 16 genes from these different sources were selected and grouped 
in four major groups for discussion purposes. The other remaining biomarkers 
including (ER, PgR, HER2, MIlll, pS3, EGFR, C-MYC, CKI8, and CKS/6) 
have been studied previously with the breast cancer research group. The data 
from these additional markers was used for statistical analysis and correlation 
studies with the other selected biomarkers and in the clustering algorithms. The 
genes selected from the previously mentioned methods were summarised in 
(Fig 2.1). 
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Table 2.3: The first 40 genes that showed the highest variable expression in the 
ER-positive cohort in Cambridge dataset 
Gene Mean normalised 
expression values SO 
SCGBID2 9.483224206 2.379469 
LOCI 18430 7.95417379 2.285829 
SCGB2A2 10.01130869 2.043923 
LTF 8.54435204 2.039819 
TFFI 9.17543 7669 2.013808 
CPBI 6.971 236321 2.011 272 
PIP 9. 189106121 1.986287 
HLA-DQAI 7. 159601507 1.810792 
CLECSFI 6.62 148258 1.720225 
HLA-OQAI 8.082224755 1.708589 
HLA-ORB3 7.876714799 1.705458 
SlOOP 7.484085096 1.675328 
CLIC6 7.756489436 1.630974 
HLA-ORB5 8.328738367 1.591707 
LOC374572 10.52884356 1.571225 
CYP4Z1 7.574942319 1.566103 
HLA-ORBI 6.647622139 1.553243 
REXI 6.81501 2397 1.522082 
hmm26383 8.237634375 1.492765 
B7-H4 8.062896149 1.49053 
CALML5 6.708645698 1.488676 
FABP4 8.811597417 1.486944 
IGJ 8.915041805 1.470825 
NATI 8.793049646 1.459964 
SCGB2AI 7.451528134 1.430942 
TFF3 7.699783357 1.401232 
LOC388978 8.372983703 1.389522 
TeNt 6.749026392 1.376035 
Hs.183902 8.609720389 1.371672 
ALOH3B2 8.303825863 1.369684 
hmm28274 8.606773066 1.357618 
OHRS2 6.952377114 1.354725 
MUCI 8.773726712 1.339532 
hmm28273 9.063794915 1.33537 
EEFIA2 7.6426 18826 1.326032 
HLA-ORB4 8.993471537 1.324762 
CEACAM6 7.007334103 1.319888 
COLIIAI 8.599856281 1.305509 
OCO 6.179133363 1.30549 
APOO 9.369169441 1.299178 
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Figure 2.1: Biomarkers selected for inclusion in the study 
The genes grouped according to phenotypic associations, potential therapeutic 
implications or their related biological pathways 
For the other markers used in the study, the cutoffs were chosen according to 
the previously published studies of the breast cancer research group (Abd El-
Rehim et a!. , 2005, Rakha et a!. , 2009). The sources, dilutions, pretreatment of 
the antibodies used are summarised in (Table 2.4). 
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Table 2.4: List of antibodies used in the study 
Antibody supplier Cat number/eione Dilution 
FOXAI Abeam Ab4086812F83 1:2000 
THI Abcam Ab 17829 1:2000 
CD71 Abcam Ab495 17/ IOF II 1:30 
PELPI Novus N13 100-1749 1:100 
CA RMI Novus N13 100-1817 1:300 
BcI-2 Dako M0887/124 1:100 
BEX I Abeam Ab69032 1:3500 
TKI Abeam Ab57757 5 5 I g g m l l
AGTR I Abeam Ab939 1 ( IEI0- IA9) 1:100 
XBP I NOVIIS NB I 00-8086 1 0 . 5 ~ g g m l l
Cyelin BI Abeam Ab72 0 . 3 3 I g g m l l
TFFJ Abeam Ab57752 3 ~ ~ g g m l l
FOXOJa Cell Signalling 9467 1:50 
RERG Proteintech 10687- I-A P 1:20 
p27 Oako SX53G8 1:40 
GATAJ Santa Cruz sc-268/11G3-3 1 1:80 
EI{ Oako IDS 1:80 
PgR Oako PgR636 1:100 
AR Biogenex F39.4.1 1:30 
E-cadherin Zymed II ECO- I 1:100 
P-cadhcrin BO 56 1:200 
C-Myc Abeam Ab32/9A I0 1:100 
pSJ Novocastra 007 1:50 
Ki67 Oako MIB I 1:100 
EG FR Novocastra EGFR. 1I 3 1:10 
II ER2 Oako cerbB-2 1:250 
BRCAI Oncogene Res MS II O 1:150 
PIKJCA Sigma HPA009985 1:50 
CK I4 Novocastra LL002 1:100 
CKS/6 Boehringer 0 5116 134 1:100 
CK7/8 BO CAM5.2 1:2 
CK I8 Oako OCIO 1:50 
CK I9 Oako OCK 108 1:100 
*Hscore 
**Cytoplasmic intensity 
***N/C nuclear and cytoplasmic localisation 
****Hercep test guidelines (Dako, Cambridge, UK) 
Pretreatment Cut-off 
Microwave 10' 
Microwave 100' 
Microwave 5' 
No 5, 170' 
Microwave 30,150' 
Microwave 10% 
Microwave 100' 
Microwave 8% 
No 30,100' 
Microwave 0, I ,2,3*' 
Microwave 0% 
Microwave 90' 
Microwave N/C'" 
Microwave 0,1,2" 
Microwave 10% 
Microwave 60' 
Microwave 10% 
Microwave 10% 
Microwave 10% 
Microwave 100 
Microwave 5% 
Microwave 0, 1.2.3" 
Microwave 10% 
Microwave 10% 
Microwave 10% 
No 0.1.2,3···· 
Microwave 5% 
Microwave 100' 
Microwave 10% 
Microwave 10% 
Microwave 50' 
Microwave 50' 
Microwave 50' 
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2.1.5 Tissue microarrays (TMAs) construction 
To speed up the analysis of a large number of breast cancers, a high throughput 
TMA approach was used. 2,000 haematoxylin and eosin stained slides of breast 
cancer were reviewed for the construction of TMAs. 1,902 cases of paraffin 
processed breast tumours were used to prepare new tissue microarray blocks, 
each comprising 150 cores (0.6 mm) of tissue. All the available blocks were 
marked, in some cases more than one block per cases. Two peripheral tumour 
core blocks and one central tumour core block were constructed from the 
whole series in 13 batches (39 TMAs block in total). The new TMA set was 
used to study the protein expression of the selected candidate genes. The F oxa 1 
study was conducted using the old TMAs blocks while other studies were 
performed using the new TMAs. Only the versions of the peripheral cores were 
selected (invading edge) to avoid the use of central cores which might show 
areas of necrosis. 
Figure 2.2: The manual arrayer used for TMA construction 
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Construction 
1) Preparation ofsamples to be arrayed 
A representative FFPE block from each patient's tumour sample (donor) was 
retrieved from the archives, selected for the presence of tumour and adequate 
thickness ideally 3-4mm. To ensure the presence of invasive tumour tissue a 
three micron section was cut from each block and stained with haematoxylin 
and eosin (by Dr Claire Paish) (n=1902). If the block contained tumour, it was 
then marked on the slide for representative area of the tumour suitable for array 
sampling. In cases the tumour block did not contain sufficient tumour, we 
retrieved alternative archive blocks for the patient and repeated the process to 
ensure that as many patients' samples as possible represented on the new 
TMAs of Nottingham series. 
2) Preparation of the recipient array block 
5-10 mm deep moulds were used to generate recipient blocks. Once all donor 
blocks were marked, and the recipient block had been prepared, construction of 
the tissue array was commenced. 
3) Construction process 
1- The blocks were designed to accommodate 150 samples, using a 3x50 
sub-array format. 
2- The construction was done usmg a preClSlon instrument (Beecher 
Instruments, Inc. San Prairie, USA) according to the manufacturer's 
datasheet (Fig 2.2). Archival blocks dating back 20--40 years are 
usually adequate for the construction if they have been fixed in 4% 
buffered formalin (Kallioniemi et al., 2001). 
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3- The array construction involved making a hole in the recipient TMA 
block, acquiring a cylindrical core sample from the donor tissue block 
and depositing this core into the TMA block. 
4- Core tissue biopsies (diameter 0.6 mm; height 3-4 mm) were taken 
from hundreds of different donor paraffin-embedded tumour blocks and 
precisely arrayed into a new recipient paraffin block (45 x 20 mm) 
using the custom-made precision instrument. Samples spaced 1.25 apart 
and the 50 sub-array spaced 5 mm apart. 
5- Kidney cores were used for block orientation. 
3) Preparing the array block 
The surface was smoothed and levelled by incubating the array block in 37°C 
for 10-15 minutes. This warms the paraffin wax thereby promoting adherence 
of the tissue cores to the walls of the holes in the array block and makes the 
wax flexible to handle. After the block has warmed, a clean glass microscope 
slide was used to apply even pressure on the top of the array block and to push 
all tissue cores level with the top surface of the array. Using a microtome, 4-5 
Jlm sections were cut from the TMA blocks to generate TMA slides for 
molecular analyses. 
2.1.6 Validation of antibodies 
We have selected our antibody panel according to the availability of 
commercially validated antibodies. For confirmation we have applied further 
validation steps on selected antibodies using WB and peptide blocking. 
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2.1.6.1 Western blotting (WB) 
WB was performed on breast cancer cell lysates of the human breast cancer 
cell line MCF -7 to confirm the specificity of the FOX03a antibody used in 
immunohistochemistry. 
Method 
The cell culture experiment was conducted with my colleague Mohamed 
Ahmed including the western blot experiment using the MCF7 eelllysate. 
MCF-7 cells were obtained from the American Type Culture Collection 
(Rockville, MO, USA) and cultured in RPMI 1640 medium in T75 flasks 
supplemented with 10% foetal calf serum (FCS), penicillin (100 IU/ml) and 
streptomycin (100 Ilg/ ml). The sub-confluent cells were washed with PBS, 
then 30111 of protease inhibitors (Sigma Aldrich) were added to 470111 of ice-
cold lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCI, 1 % TritonX-lOO, 0.5% 
sodium deoxycholate, 1 mM EOTA, 0.1 % SOS). Western blotting was done on 
the cell lysates to confirm the specificity of the antibody used in 
immunohistochemistry. Lysates (20J..lg) were added to 4X SDS loading buffer 
with 5% p-mercaptoethanol (Sigma Aldrich, UK) and denatured by heating at 
100°C for 10 minutes prior to loading then added for 5 minutes into ice. 
Samples were subjected to Sodium Oodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SOS-PAGE) using a 10% resolving polyacrylamide gel and 
transferred onto a Hybond-P PVDF membrane (Amersham Bioscience, 
Buckinghamshire, UK). After blocking with 5% milk powder 0.1 % TPBS 
(Tween20 in PBS solution) for 60 minutes, the membrane was then incubated 
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with 1:1000 dilution of the FOX03a rabbit polyclonal Antibody (9467) at 4°C 
overnight. The membrane was washed with 0.1 % PBS/Tween20 3 times for 5 
minutes each then incubated for 1 hour at room temperature with a horseradish 
peroxidase-linked secondary antibody (Sigma Aldrich) (1: 4000, anti-rabbit) 
diluted with 5% milk powder PBS containing 0.1 % Tween20. After further 3 
washes, the membrane was visualized by enhanced chemiluminescence 
reagents (Amersham Bioscience, Buckinghamshire, UK). The monoclonal 
A n t i - ~ - a c t i n n antibody (Sigma Aldrich) in a dilution of 1 :2000 against the 
Ubiquitous ~ - a c t i n n protein was used. 
2.1.6.2 Peptide blocking 
It is recommended procedure for confirming the specific reactivity of an 
antibody. In this protocol, the antibody is incubated with the immunizing 
peptide that has been used to raise the antibody. The antibody that is bound to 
the blocking peptide will be no longer available to bind to the peptide antigen 
in the cell. In comparing the staining from the blocked antibody versus the 
antibody alone, specific staining should be absent or significantly reduced from 
the immunostaining performed with the neutralized antibody. 
This protocol can be used to prepare "blocked" antibody for use in either 
western blotting or immunohistochemistry. 
After determination of the optimal concentration of antibody that consistently 
gives a positive result. Using that concentration, we determined how much 
antibody needed for two experiments. In the first tube, labelled Blocked, the 
blocking peptide was added to a final concentration of 10 times of the 
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antibody. In the second tube, labelled Control, an equivalent amount of diluent 
was added. Both tubes were incubated, with agitation, at room temperature for 
30 minutes. The tubes were centrifuged for 15 min at 4°c, and then the staining 
protocol on the two identical samples, using the blocked antibody for one and 
the control for the other was performed and the staining was observed. PELP 1 
antibody was evaluated using this method. 
2.1.6.3 Controls 
To ensure the correct tissue preparation and staining of the used antibodies, 
tumours and tissues with known staining patterns were used as positive 
immunostaining controls and were processed by the same method used to stain 
the tumour sections and IMAs. Negative controls were obtained by omitting 
the primary antibodies and were used to evaluate non-specific binding of the 
secondary antibody to the tissues and to ensure specific detection of the antigen 
by the primary antibody. 
2.1.7 Immunohistochemistry and optimization ofthe antibodies 
To determine the optimal staining conditions for each antibody used, full 
sections and TMAs were used for staining using different antibody 
concentrations and antigen retrieval methods with different pH and incubation 
times. Data sheets with each antibody suggested a dilution range for 
optimisation experiments. If the staining using the suggested dilution was 
found too intense or weak, further dilutions were used in subsequent 
experiments to achieve the optimal dilution. 
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Immunohistochemical staining of the sections was perfonned using either a 
DAKO TechMate immunostainer to ensure the consistency between various 
immunohistochemistry runs or the manual method if the staining requires an 
overnight incubation with the primary antibody. A set of full face sections for 
each of the selected biomarkers was stained to assess the staining distribution 
and to assess its suitability for TMAs. 
2.1.7.1 Automatic immunostainer 
An indirect labelled streptavidin avidin biotin technique (LSAB©) technique 
with Diaminobenzidine (DAB) chromogen was perfonned using a 
DakoCytomation Techmate 500 Plus (DakoCytomation, Cambridge, UK) 
automatic immunostainer. IHC was perfonned on sections of fonnalin-fixed 
paraffin embedded tissue (4f..lm). Prior to staining, the sections were melted on 
a hotplate for 10 minutes (60°C), dewaxed in two changes of xylene for 10 
minutes each, rehydrated in 3 changes of alcohol for 1 minute each. Sections 
were pre-treated with microwave antigen retrieval (when needed) using O.OIM 
citrate buffer or EDT A accordingly for 23 minutes at 700w. Then, sections 
were transferred to the immunostainer and the staining was carried out using 
Dako LSAB iC kit (DakoCytomation, Cambridge, UK). Slides were incubated in 
buffer 1 (ChemMate) which contains goat serum for 20 minutes and in H202 
for 10 minutes to block the endogenous peroxidase. Sections were incubated in 
the primary antibody for 1 hour followed by incubation in the biotinylated 
secondary antibody for 30 minutes and HRP horseradish peroxidase 
streptavidin for 30 minutes. Then, the slides were incubated in DAB for 10 
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minutes. Slides were washed by buffer 2 and buffer 3 included in the kit 
between the steps. The sections were counterstained in haematoxylin for 2 
minutes, rinsed in tap water, dehydrated in alcohol, cleared in xylene and 
mounted by DPX. 
2.1.7.2 Manual immunostaining 
Manual staining methods was used for the RERG study according to the 
optimisation process; different antibody concentrations and incubation times 
were tested. Overnight incubation deemed the most optimal method. After 
microwave antigen retrieval in citrate buffer pH 6, the TMAs sections and 
control sections were put in a humidity chamber followed by blocking of 
endogenous peroxidase by applying hydrogen peroxide in methanol for 10 min. 
The TMA slides were then incubated in primary antibody at 4°C overnight. The 
immunohistochemical detection of RERG was carried out using a labelled 
steptavidin biotin technique LSAB@ in accordance with the manufacturer's 
instructions (DakoCytomation, Cambridge, UK). The slides were incubated 
with the biotinylated secondary antibody for 30 min, followed by HRP-
Streptavidin for another 30 min. Tris buffer saline (TBS) were used for 
washing between steps (3x2 minutes with stirrer). For visualisation of the 
reaction, the slides were incubated in freshly prepared peroxidase substrate 
solution (DAB) diluted 1 :50 for 10 min. 
After application of DAB, the slides were washed in runmng tap water, 
counterstained in haematoxylin, dehydrated in alcohols, cleared in xylene and 
coverslipped using DPX mounting medium. Negative controls were performed 
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by omitting the primary antibody while positive control BC sections were used 
in each run. 
2.1.8 Assessment of protein expression using immunohistochemistry 
Sections were examined by light microscope. Positive and negative controls 
were examined to confirm the appropriate staining. Only the invasive tumour 
component was evaluated and scored for the intensity and percentage of 
positive cells accordingly. The distribution of staining was assessed both in 
whole sections of malignant breast carcinoma and in tissue microarray sections. 
As the distribution of staining was homogenous in the full section, only one 
tumour core was stained from each tumour, as previous studies have validated 
the use of one core to study the expression of tumour markers even for those 
that have a heterogeneous distribution (Camp et aI., 2000). GAT A3 and XBP 1 
were scored using high resolution digital images (NanoZoomer; Hamamatsu 
Photonics, Welwyn Garden City, UK), at x20 magnification, using a web-
based interface (Distiller; Slidepath Ltd, Dublin, Ireland). 
H-score (histochemical score) scoring system has been successfully used for 
TMAs evaluation (Abd El-Rehim et aI., 2005). The H-score includes an 
assessment of both the intensity of staining and the percentage of stained cells. 
For the intensity, a score of 0, 1, 2 and 3 was used and the percentage of 
positive cells at each intensity was subjectively estimated. The final score is in 
the range of 0-300 derived from of multiplying the intensity by the percentage. 
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2.1.9 Statistical analysis 
Statistical analysis was performed using SPSS statistical software (SPSS Inc., 
Chicago. IL, USA). Association between the immunoreactivity and different 
clinicopathological parameters was evaluated either by Fisher's exact test or 
chi-squared test. For multiple testing of biomarkers and clinicopathological 
associations. a conservative p-value of <0.01 was considered to reflect a 
significance and all were 2-sided. Survival curves were calculated by the 
Kaplan-Meier method with log rank test to assess significance. Multivariate 
Cox regression analysis was used to evaluate any independent prognostic effect 
of the variables on patients' survival with 95% confidence interval and p value 
of <0.05 was considered. 
All factors were used as dichotomous covariates in the statistical analysis with 
the exception of age. tumour grade. tumour types. lymph node stage. vascular 
invasion and NPI which were analysed as more than 2 groups. 
2.1.9.1 Categorisation of continuous data 
1- We used the median of the continuous data when it is abnormally distributed 
and the mean if the data is normally distributed. 
2- X-tile bioinformatic tool. (Camp et aI., 2004) developed the graphical 
method, X-tile plot. to demonstrate the presence of meaningful tumour 
subpopulations and show· the robustness of the relationship between a 
biomarker and outcome by construction of a two dimensional projection of 
every possible subpopulation. For further validation of the chosen cut-off point, 
the X-tile program randomly divides the total patient cohort into two separate 
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training and validation sets ranked by patient follow up time. Statistical 
significance is tested by validating the obtained cut points to the validation set 
(Camp et aI., 2004). The approach used was similar to that used by others 
within the group for existing biomarkers. Where the cut-off was not known, it 
was determined using the more recently published x-tile technique and 
compared with the median H-score. The median cut-off value was obtained 
using the frequency statistics according to the one that produced distinct 
categorisation and significance with measures of clinical outcome. In the early 
phases of this research project, we used the median value for stratification of 
patients' biomarker results with regard to relationships with prognostic and 
patient outcome variables. This method has been standard practice in the 
literature. During the project, x-tile software became available which provides 
a more sophisticated approach to determination of clinically relevant biomarker 
cut points and was therefore adopted for all subsequent studies. Retrospective 
use of x-tile was not appropriate as these early studies had been already 
published using median value stratification. 
3-Frequancy distribution histograms were initially used for visualisation of the 
distribution and for discovery of obvious cutoff points. The histogram is a 
descriptive figure of frequencies, displayed as adjacent rectangles. Each 
rectangle is elevated over a certain interval, with an area equal to the frequency 
of the observations in the interval. 
62 
Chapter 2 
2.1.10 Ethical approval 
This study was approved by the Nottingham Research Ethics Committee 2 
under the title "Development of a molecular genetics classification of breast 
cancer", 
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3 Study of selected candidate luminal markers and their role 
in breast cancer prognosis with emphasis on ER-positive 
luminal-like subtype 
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3.1 Introduction 
The recently developed microarray technologies have created new possibilities 
to identify gene expression profiles and have provided a better view of the 
involved biological processes. As previously discussed, Perou and colleagues 
established the first molecular portraits of breast tumours by using DNA 
microarrays, which allow mRNA expression levels of thousands of genes to be 
measured in a single assay (Perou et aI., 2000). They distinguished two main 
classes of tumours, one with the characteristics of basal (and/or myoepithelial) 
cells, the other of luminal cells. The basal tumours expressed CK5 and CK 17 
mRNAs, while the luminal phenotype was based on the expression of CK8118, 
and the oestrogen receptor (ER). Subsequent analyses refined this two-class 
model and several subclasses of luminal-like (Luminal A, Luminal B and C) 
tumours were further characterized (Sorlie et aI., 2001) then the concept of 
luminal C became less evident with most of the authors suggesting that luminal 
breast cancer is better divided into A and B groups (van't Veer et aI., 2002, 
Sorlie et aI., 2003) 
Luminal A tumours show high expreSSIOn of oestrogen-regulated and 
associated genes especially XBP 1, GAT A3 and FOXA 1 while, Luminal B 
tumours, although still ER positive, expressed lower levels of the genes 
associated with the ER cluster and also expressed some genes that had 
previously clustered with some of the HER2 overexpressing and basal tumours. 
Luminal B tumours in contrast to the Luminal A ER-positive subtype, 
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produced transcripts encoding the myeloblastosis viral oncogene homologue 
MYB, gamma-glutamyl hydrolase (GGH), and other enzymes involved in cell 
signalling and sterol biosynthesis that differentiate them from the better 
survival group. 
In summary, these gene expression array experiments suggest that the luminal-
like class of breast cancer is characterised by ER positivity but IS 
heterogeneous with respect to the expression of other genes. While it IS 
recognised that the major luminal-like subclasses differ in terms of prognosis, 
it can be inferred from the subsequent studies that other genes are responsible 
for the precise positioning of an individual within the spectrum of luminal-like 
breast cancer (Sorlie et aI., 2003). Importantly, characterisation ofluminal-like 
cancer varies between studies and a consensus of definition is lacking. It is 
widely recognised that there is a need for identification of new biomarkers that 
can be used to characterise the ER-positive luminal cancer. 
In this chapter we discussed the expression of some candidate luminal genes by 
IHC and TMAs based method using a large series of patient with long term 
follow-up. 
The selection of biomarkers was based on our bioinformatic analysis of the 
gene microarray data using the conventional statistical cross validation analysis 
and ANNs that identified RERG, GATA3, BEXI and TFF3. TFFl, FOXAI 
and XBPI were selected for further studies due to their potential role in 
subclassification of breast cancer and as potential makers of the luminal 
subclass. 
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3.2 FOXA1 
3.2.1 Introduction 
The forkhead-box Al (FOXAI) gene is a member of the fox family of 
transcription factors, which is expressed in the breast, liver, pancreas, bladder, 
prostate, colon and lung and can bind to the promoters of more than 100 genes 
associated with metabolic processes including regulation of cell signalling and 
the cell cycle (Lin et aI., 2002). It is involved in the pathogenesis of many 
cancers including lung, oesophageal and prostate cancer (Wolf et aI., 2007). In 
breast cancer however, the role of FOXAI appears more controversial. 
Previous studies have shown that FOXA I can act either as a growth stimulator 
or repressor. As a stimulator, it functions as a pioneer factor that binds to 
chromatinized DNA, opens the chromatin and enhances binding of oestrogen 
receptor-alpha (ERa) to its target genes (Laganiere et aI., 2005). Down-
regulation of FOXAI by RNA interference significantly suppressed 
proliferation of HER2-negative and FOXAI-positive breast cancer cell lines 
(Yamaguchi et aI., 2008). Emphasising its importance, FOXA 1 is required for 
the expression of 50% of ER-regulated genes (Carroll and Brown, 2006, 
Holmqvist et aI., 2005, Laganiere et aI., 2005). As a repressor, it has been 
shown that FOXAI overexpression can block metastatic progression by 
influencing expression of the BRCAI associated cell cycle inhibitor, p27, and 
promoting E-cadherin expression. This suggests that FOXA 1 plays important 
roles in the upregulation of genes that reduce the growth and motility of breast 
cancer cells (Williamson et aI., 2006, Liu et aI., 2005). 
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Importantly, recent global gene expression studies of breast cancer revealed 
that high FOXAI mRNA expression is often found in association with ER 
positivity, and frequently present in a subset of ER-positive tumours that have 
favourable outcome. Therefore, FOXA 1 expression appears to have potential 
relevance in sub classification of luminallER-positive tumours into subgroups 
with different biologic behaviour and prognosis. 
3.2.2 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed usmg the streptavidin-biotin complex method usmg 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
(General Material and Methods Chapter). To unmask the antigens, the sections 
were microwaved in citrate buffer pH 6 for 23 minutes. 
Mouse monoclonal antibody to FOXAI (clone 2F83, ab40868; Abeam, 
Cambridge, UK) that was raised against the recombinant full length human 
FOXA I protein was optimized at a working dilution of 1 :2000 using full-face 
sections and TMAs of breast cancer. 
H-score was used for immunohistochemical staining assessment. The cutoff 
point was assigned by using the median ofH-score values (H-score ~ 1 0 ) . .
3.2.3 FOXAI immunohistochemical results 
After excluding the uninformative TMA cores from the study, 696 tumours 
were available. The median age of the patients was 54 years (range 27-70). 
Sixty seven percent of patients had large tumours greater than or equal to 1.5 
cm in size. Twenty one percent of the tumours were grade 1 and 31 % showed 
good NPI. Twenty eight percent of the patients had metastatic disease and 29% 
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had tumour recurrence. Fifty six percent of the tumours were ductal with no 
special type. The FOXA 1 staining pattern was nuclear with no evidence of 
cytoplasmic and membranous staining (Fig 3.1). 
The expression was detected in the nuclei of the malignant cells as well as in 
some luminal ductal epithelial cells of the entrapped normal tissues in the 
cores. 
3.2.3.1 Correlation between FOXAI expression and other 
clinicopathological variables 
FOXA 1 nuclear expression was associated with smaller primary tumour size, 
lower grade tumours, lower mitotic count (p<O.OOI) and with the good NPI 
group. It also showed an association with histologic tumour type with frequent 
expression in invasive lobular and tubular carcinomas and decreased 
expression in medullary carcinomas (p<O.OOI). No associations were found 
between FOXAI protein expression and patients' age, lymph node stage, 
vascular invasion, development of recurrences or distant metastasis (Table 
3.1). 
3.2.3.2 Correlation between FOXAI expression and other 
biomarkers 
There were positive associations between FOXAI expression and ERa, PgR, 
AR and BRCAI. In contrast, we found inverse associations between FOXAI 
expression and basal CKs expression (CKS/6; p=O.003) and P-cadherin 
(p=O.002). No associations were found between FOXAI and p53, HER2 or 
EGFR expression (Table 3.2). 
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When the analysis was repeated only on the cohort of ER-positive (luminal-
like) patients, FOXA 1 expression retained its significant association with 
smaller tumour size (Tables 3.3&3.4). 
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Figure 3.1: FOXA 1 protein expression in breast cancer 
TMA cores of (A) lobular (x I 00), (8) Grade 2 ductal (x 200) and (C) Grade 3 
ductal carCInoma (x 1 00), USIng immunohistochemistry. (D) Grade 3 ductal 
carcinoma with negative FOXA 1 expression (x 1 00). 
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Table 3.1: Relation of FOXA 1 expressIon to other cl inicopathological 
variables in the whole series 
Va ria ble Tota l Nega tive Pos itive 
, 
p- va lue FO XA I FO XA I 1.-
Age 
<40 40 19 2 1 
40-50 200 97 103 2.822 0.420 
5 1-60 246 III 135 
>60 2 10 85 125 
T umour Size 
< 1.5 em 230 150 80 14.755 <0.00 1 
> 1.5 em 460 23 1 229 
LN Stage 
I (Negative) 46 1 20 1 260 1.1 33 0.568 2( 1-3 LN) 158 75 83 
3(>3 LN) 72 35 37 
Grade 
I 148 50 98 38 .209 <0.00 1 
2 2 16 74 142 
3 325 187 138 
NPI 
Poor 96 53 43 38.5 15 <0.00 1 
Moderate 377 198 179 
Good 2 16 60 156 
OM 
No 496 2 14 282 2.647 0. 100 
Pos itive 194 97 97 
Recurrence 
No 403 175 228 0.979 0.320 
Positive 288 136 152 
VI 
No 271 125 146 1.501 0.470 
Probable 328 14 1 187 
Definite 82 4 1 4 1 
Mitotic counts 
I 2 18 69 149 30.797 <0.00 1 
2 125 5 1 74 
3 309 172 137 
Tumour type 
Ducta llNST 382 198 184 
Lobular 62 17 45 
Tubular and 163 56 107 33.724 <0.00 1 Tubular mixed 
Medullary 2 1 16 5 
Other spec ial types 14 6 8 
Mixed 40 15 25 
*Includes MUCOId, InVaSIVe cnbrIform and InvaSive papillary carCInoma, ** 
Include ductallNST mixed with lobular or special type 
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Table 3.2: Relation of the FOXA I expression to other biomarkers in the whole 
senes 
Va ria ble Tota l Nega tive Positive 'C p-va lue FO XA I FO XA I 
ERa 
Negative 213 141 72 54.677 <0.00 1 Positive 435 154 28 1 
AR 
Negative 245 151 94 42 .192 <0.00 1 
Posi ti ve 359 125 234 
PgR 
Negative 302 178 124 35.965 <0.00 1 
Positive 340 120 220 
BRCA I 
Negative 73 47 26 8.540 0.003 
Positive 425 195 230 
H ER2 
Negati ve 440 205 235 0.008 0.928 
Positive 89 41 48 
pS3 
Negat ive 383 III 494 2.7 15 0.090 
Positive 133 26 159 
EGFR 
Negati ve 418 194 224 0.697 0.400 
Positive 106 54 52 
C KS/6 
Negative 523 224 299 8.987 0.003 
Positive 150 85 65 
CKI4 
Negative 524 23 1 293 6.080 0.01 
Pos iti ve 132 74 58 
CKIS 
Negative 348 177 171 5.121 0.024 
Pos itive 237 98 139 
CKI9 
Negative 399 11 2 155 3.087 0.08 
Positive 267 195 204 
CK7/S 
Negative 352 184 168 11 .894 <0.001 
Positive 318 123 195 
E-cadherin 
Negative 280 143 137 5.283 0.022 
Positive 360 151 209 
P-cadherin 
Negative 185 73 11 2 9.624 0.002 
Positive 312 168 144 
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Table 3.3: Relation of FOXA 1 expressIOn to other clinicopathological 
variables in the ER-positive cohort 
Variable Total Negative Positive 
-l p- value FOXAI FOXAI 
Age 
<40 17 4 13 
40-50 109 36 73 1.782 0.619 
51-60 158 60 98 
>60 151 54 97 
Tumour Size 
< 1.5 em 167 46 12 1 7.318 0.007 
> 1.5 em 268 108 160 
LN Stage 
I (Negative) 288 93 195 4.16\ 0.1 25 2( 1-3 LN) 104 45 59 
3(>3 LN) 42 16 26 
Grade 
I 125 40 85 5.261 0.072 
2 176 56 120 
3 134 58 76 
NPI 
Poor 48 22 26 14.29 1 0.001 
Moderate 205 86 119 
Good 182 46 136 
OM 
No 322 109 2 13 1.51 0.219 
Positive 109 44 65 
Recurrence 
No 266 94 \72 0.008 0.93 
Positive 165 59 106 
VI 
No 17 1 58 11 3 4.386 0.112 Probable 211 72 139 
Definite 44 22 22 
Mitosis 
I 187 57 130 4.124 0.127 
2 92 32 60 
3 54 76 130 
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Table 3.4: Relation of FOXA 1 expressIOn to other biomarkers In the ER-
positive cohort 
Va riable Tota l Nega tive Positive 'l p-va lue 
FOXA I FOXA I 
AR 
Negative 104 45 59 4.315 0.038 
Positive 297 95 202 
PgR 
Negative 11 6 52 64 5.804 0.0 16 
Positive 307 99 208 
HER2 
Negative 297 108 189 0.0 15 0.902 
Posi tive 34 12 22 
pS3 
Negat ive 343 129 24 1 1.827 0. 177 
Positive 75 22 53 
EGFR 
N e ~ g a t i v e e 300 11 5 185 0.045 0.832 
Posit ive 57 21 36 
C KS/6 
Negat ive 373 134 239 0.2 14 0.644 
Positive 55 18 37 
CKI4 
Negative 362 130 232 0.053 0.818 
Positive 56 21 35 
CKIS 
Negati ve 192 65 127 0.964 0.326 
Posi tive 194 75 11 9 
CKI9 
Negative 220 74 146 0.809 0.368 
Positi ve 209 130 79 
CK7/S 
Negati ve 175 60 11 5 0.124 0.724 
Positive 256 92 164 
E-cadherin 
Negative 176 72 104 3.343 0.06 
Positive 245 79 166 
P-cadherin 
Negative 156 54 102 3.005 0.08 
Positive 180 79 101 
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3.2.3.3 Correlation between FOXAI expression and patient 
outcome 
In the whole patient series, an association between loss of FOXA 1 expression 
and shorter breast cancer specific survival (BCSS) was found (Log Rank (LR) 
=6.987, p=0.008). However, multivariate Cox hazard analysis including 
tumour size, histologic grade, lymph node stage and FOXA 1 expression 
showed that FOXA 1 expression was not an independent predictor of survival 
(Hazard ratio (HR)=0.891,p=OA18) (Table 3.5). Interestingly, in a model that 
included only FOXAI and ERa expression, FOXAI did not retain independent 
significance in contrast to ERa which did. No association between FOXA 1 
expression and disease free interval (DFI) was found (LR= 1.687, p =0.194). 
In the ER-positive group, no association between FOXAI expression and 
outcome was found (Fig 3.2A&B). In the group of patients who had not 
received hormonal therapy, FOXA 1 expression was associated with more 
favourable BCSS (LR =0.5.49, P =0.01). 
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Figure 3.2: Kaplan Meier plots ofFOXAI protein expression 
(A) Kaplan Meier plot of FOXA 1 protein expression and BCSS in the ER 
positive cohort. (B) Kaplan Meier analysis of FOXAI protein expression 
and disease free interval in ER positive cohort. 
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Table 3.5: Cox proportional hazards analysis for predictors of breast cancer 
specific survival in the whole series 
Variable P value HR 95%CI 
Lower Upper 
FOXAI expression 0.418 0.891 0.674 1.178 
Lymph node stage <0.001 1.802 1.505 2.159 
Tumour grade <0.001 2.024 1.611 2.545 
Tumour size 0.038 1.481 1.022 2.146 
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3.3 RERG 
3.3.1 Introduction 
The Ras-related, oestrogen-regulated growth inhibitor (RERG) was initially 
identified as one of the genes that characterise luminal tumours and its 
expression was decreased in the aggressive ER-negative subtypes (Finlin et aI., 
2001). RERG is a GTP-binding protein with intrinsic GTPase activity (Finlin et 
aI., 2001). RERG mRNA expression was found to be induced rapidly in MCF-
7 cells stimulated by estradiol and repressed by tamoxifen treatment (Finlin et 
aI., 2001). 
The suggested heterogeneity of ER-positive tumours has prompted the need to 
identify candidate biomarkers to refine their subclassification particularly with 
respect to their behaviour. Subsequently, in this study we have analysed 47,293 
gene transcripts in 128 invasive breast carcinomas using different biostatistical 
models to identify genes that is strongly associated with ER-positive/luminal 
tumours and that can be used to stratify them into clinically relevant subgroups. 
3.3.2 Material and Methods 
3.3.2.1 Gene expression study 
The study population used was derived from the Nottingham Tenovus Primary 
Breast Carcinoma Series of women aged 70 years or less, who presented with 
stage I and II primary operable invasive breast carcinomas. 
79 
Chapter 3 
Total RNA was extracted from a series of frozen breast cancers retrieved from 
Nottingham Hospitals NHS Trust Tumour Bank between 1986 and 1992 as 
described in the General Material and Methods chapter. 
Bioinformatics analysis (1): Artificial neural network model 
We identified the ER-positive cases (n=84) by immunohistochemistry in our 
patient cohort (n=128) and applied an artificial neural network (ANN) model 
for sample classification to the gene expression data comprising 47,293 inputs 
for each sample. The output node was coded as 0 if a case was low ER 
expression (the median H-score<140; n = 42), and 1 if high ER expression (ll 
score> 140; n = 42). Each gene was considered singly as an input to the 
model. More precisely, the data was analysed using multi-layer perceptron 
architecture with a sigmoidal transfer function, where weights were updated by 
a back propagation algorithm as previously described in general material and 
methods chapter. Inputs were ranked in ascending order based on the predictive 
error. 
Bioinformatics analysis (2): Ensemble classification and cross-validation 
analysis 
In a second bioinformatics analysis step, we sought to obtain a robust ranking 
of genes that are differentially expressed between the ER-positive (n=84) cases 
and the ER negative non-luminal cases (all other cases) and have high 
predictive power, by applying an ensemble sample classification method (see 
General Material and Methods chapter). 
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3.3.2.2 Immunohistochemistry 
The RERG specific rabbit polyclonal antibody (Purified rabbit anti-human 
RERG polyclonal antibody, 10687-I-AP, Proteintech Group, Chicago, IL, 
USA) was optimized at a working dilution of 1 :20 using randomly selected 
full-face sections of breast cancer tissue to assess the staining distribution. The 
detailed method is described in the general material and methods chapter. 
Negative controls were performed by omitting the primary antibody while 
positive control of known BC sections was used in each run. 
3.3.3 Results 
3.3.3.1 Novel genes associated with ER-positive status using 
Artificial Neural Network 
High ER expression is associated with good prognosis when compared to low 
ER expression. Our aim was to identify; using a novel prediction method 
(ANN), a set of genes that can associate with high ER expression and to 
validated the genes using protein expression. To study this, ER-positive cases 
(84 tumours) were categorized according to the level ofER expression into high 
and low expression using the median of the H-score value (H-score 140). 
The ranking order of the ANN results was based on predictive error for the 
unseen cohort in the Monte Carlo Cross validation with the lowest being higher 
in the ranking order. Table 3.6 illustrates top transcripts according to ER status 
ranked by predictive error. 
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In this study ESR1, the gene for ER, was ranked as the most important gene 
for ER membership and this was used a proof for the validation of the model. 
3.3.3.2 Novel genes associated with ER-positive luminal phenotype 
using the ensemble cross- validation analysis 
The RERG-gene was selected among the significantly differentially expressed 
genes in every cycle of a leave-one-out external cross-validation analysis. The 
prediction models obtained from this procedure distinguished the luminal from 
the non-luminal samples with an average accuracy of 88.3% (sensitivity: 
95.2%, specificity: 75.0%). Very similar results were obtained in a 10-fold 
cross-validation analysis, which was conducted for further verification 
(average accuracy: 89%, sensitivity: 95.2%, specificity: 77.3%). Table 3.7 lists 
the 30 genes which were identified as being differentially expressed in ER-
positive luminal and non-luminal samples. These were identified using both in 
a leave-one-out and a lO-fold cross-validation analysis, i.e. using different 
subsets of samples, and they were always selected as significantly differentially 
expressed in each cycle of the analysis 
Figure 3.3 shows a heat map displaying the microarray expression values of 30 
genes (rows) in 128 breast cancer samples (columns) using different colour 
codes (red = high expression, green = low expression). The 30 rows correspond 
to the 30 top-ranked genes from the cross-validation analysis, grouped 
according to the results of an average linkage hierarchical clustering using the 
Euclidean distance metric of the 30 gene expression vectors (see the 
dendogram on the left in Figure 3.3). The 128 columns in this figure represent 
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the microarray samples, grouped into non-luminal samples (left) and ER-
positive samples (right). Figure 3.4A shows a box plot of RERG gene 
(mRNA) expression (normalised expression value) in ER-positive versus non-
luminal samples with higher expression in ER-positive cohort, while Figure 
3.48 shows a box plot of RERG gene (mRNA) expression (normalised 
expression value) in different tumour grades which shows that the expression 
of RERG mRNA is higher in low grade tumours. 
RERG was therefore selected for further study using a protein expression assay 
to assess the biological and prognostic significance of its protein expression in 
large breast cancer patient cohort as well as in the ER-positive subgroup. 
Table 3.6: A gene rank of ER expression status 
(Summary of step 1 of the ANN approach- 10 genes shown) 
Gene Selection Error 
ESRI 0.403422327 
RERG 0.438626499 
AMNI 0.441492448 
ZNF271 0.445580899 
PCOHA5 0.446326207 
PRKAR2B 0.447933195 
TCEALI 0.448787999 
CTBP2 0.449052205 
LOB3 0.449750785 
ODIT4 0.451080472 
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Table 3.7: A gene list of 30 genes to differentiate between luminal-like ( R-
positive) and non-luminal cases (ER-) using cross-validation analysis ranked 
by z-score 
Gene identifier z-score Gene 
GI_ 4503602-S 5.7 ESR I 
G 1 14249703-S 5.7 RERG 
GI 9951924-S 5.7 CA I2 
GI_37551139-S 5.7 C6orfll5 
GI_34452698-S 5.7 ACTR3 
GI_22779933-S 5.7 WDRI9 
GI_38455428-S 5.7 AGR3 
GI_38146007-A 5.7 TIC 8 
G 1_ 40788002-S 5.7 PSME4 
GI_4503928-S 5.7 GATA3 
GI_22748948-S 5.7 IGFIR 
G 1_29 126237-S 5.7 BTF3 
GI_37552339-S 5.7 KDM4B 
GI_34304343-A 5.7 PSATI 
GI_29728071 -S 5.7 TBCID9 
GI_34147362-S 5 CHACI 
GI_ 4885496-S 4.2 MYB 
GI_7706686-S 4.2 EVL 
GI_31341936-S 3.5 Clorf64 
GI_21614543-S 2.7 S100A8 
GI_ 40255152-S 2.7 KCTD6 
GI_2 1614495-S 2 VAV3 
GI_ 4502846-S 2 CIRBP 
GI_30581 1 15-S 1.2 SOXll 
GI_22035691-A 1.2 GFRAI 
GU6507967-S 0.49 KCNKI5 
GI_32698779-S 0.49 CMYA5 
GU8152766-S 0.49 SYTL4 
GU 0835186-S 0.49 SOD2 
GI_37595559-S 0.49 DNALII 
84 
Chapter 3 
CoiorKty 
Heat map· AL hierarchical clustering 
·2 0 1 
Row Z·Scoce 
non-kJninal luninal 
\',11)11 
\YllI 
Mette 
CtIAL/1 
!1M 
hO«ll 
GtAAI 
(!tACt 
ISAII 
SOIII 
O/IM, 
pgf. 
IoC1R! 
SOOl 
C6anll 
SlID.\! 
YA1'3 
1M 
lIQ 
IlIIR 
!'!Me 
f',\ 
TD:IOI 
-~ ~
CAll 
/oClIl 
Ct.'" 
IIfl 
ClAIAl 
Figure 3.3: A heatmap created to visualise the differential expression of the 30 
top-ranked genes identified by the cross validation analysis 
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3.3.4 Expression of RERG protein in breast cancer using 
immunohistochemistry 
Evaluation of RERG protein expression in breast cancer showed that the 
immunoreactivity was localised to the cytoplasm of invasive tumour cells (Fig 
3.5) and was strongly expressed in the luminal cells in the normal breast acini. 
Of the whole patient series, 1,140 informative cases for RERG expression were 
available for assessment. 
RERG cytoplasmic expression was scored as negative (no staining) in 28% of 
cases, low (weak staining hardly visible at low magnification) in 45.6% of 
cases or high (strong staining easily visible at low magnification) in 26.4% of 
cases. When the expression was studied in relation to BeSS, we found no 
difference in patients' outcome between those with negative and low 
expression of RERG protein and therefore we combined them into one group 
of negative/low RERG expression. 
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Figure 3.5: RERG expression in breast cancer 
TMA core of grade 2 invasive breast cancer with strong RERG cytoplasmic 
expression. (A) Lower magnification (x200) (B) Higher magnification (x400) 
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3.3.4.1 Correlation between RERG protein expression and other 
clinicopathological variables 
In the whole patient series, we found that high RERG protein expression was 
positively associated with low tumour grade (p=O.002), low mitotic counts 
(p=O.006) and good NPI (p=O.006). It was associated with tumours that were 
less likely to develop DM (p=O.OOI) or tumour recurrence (p=O.003). No 
associations were found between RERG and other clinicopathological variables 
included in this study (Table 3.8). 
In the ER-positive luminal cohort, RERG expreSSIon showed similar 
associations in relation to tumour size, NPI, DM and recurrence (Table 3.9). 
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Table 3.8: Relation of RERG immunostaining to other clinicopathological 
variables in the whole series 
Variable Low High 'l p value 
Age 4.870 0.182 
<40 70(79.5) 18(20.5) 
40-50 25 1(76.1) 7 ~ { 2 2 . 9 1 1
5 1-60 277(73.3) 101(26.7) 
>60 24 1(70.1) 103(29.9) 
Size 4.604 0.032 
~ c m m 406(70.9l 167(29.1) 
>2 cm 432(76.5) I 33{23.51 
LN Stage 1.334 0.513 
I (Negative) 497(72.6) 188(27.4) 
2( 1-3 LN) 261 (74.6) 89(25·41 
3(>3 LN) 79(77.5) 23(22.5) 
Grade 12.4 19 0.002 
I 127(66.8) 63(33.2) 
2 260(70.3) 11 0(29.7) 
3 45 1{781 127(22) 
NPI 10.330 0.006 
Good 212(67.3) 103(32.7) 
Moderate 470(75 1571251 
Poor 157(79.3) 4 1(20.7) 
OM 11.948 0.001 
No 565(70.9) 232(29.1) 
Positive 266(80.9) 6 ~ ( I I 9.1) 
Recurrence 8.642 0.003 
No 474(70.6) I 97(29.4} 
Positive 348(78.6) 95(21.4) 
Tumour type 4.783 0.443 
DuctallNST 498(75) 166(25) 
Lobular 94(72·91 35127.1) 
Tubular and Tubular mixed 163(70.6) 68(29.4) 
Medullary 25(83.3) 5( 16.7) 
Other special types* 12(75} 4{25) 
Mixed** 47(67. 1) 23(32.9) 
Mitosis 10.274 0.006 
I 268(68.7) 122(31 .3) 
2 144(73.5) 52i26·51 
3 407(78. 1) 114(21.9) 
Menopause 6.1 16 0.0 16 
Premenopausal 34 1(77.7) 98(22.3) 
Postmenopausal 498{7 I) 20K29l 
*Includes MUCOid, invaSive cnbnforrn and invaSIve papIllary carCinoma, ** 
Include ductallNST mixed with lobular or special type 
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Table 3.9: Relation of RERG immunostaining to other clinicopatho logical 
variables in the ER-positive cohort 
Va riab le Low High -l p va lu e 
Age 1.875 0.599 
<40 3 1 (70.5) 13(29.5) 
40-50 160(73.4) 58(26.6) 
5 1-60 187(72.2) 72(27.8) 
>60 177(68.1) 83(3 1.9) 
Size 5.335 0.02 1 
<2 em 288(67.6) I 38(32.4} 
>2 em 266(75. 1) 88(24.9) 
LN Stage 2.044 0.360 
I (Negative) 325(69.1) 145(30.5) 
2( 1-3LN) 182(73.4) 66(26.6) 
3(>3 LN) 46(75.4) 15(24.6) 
Grade 5.379 0.068 
I I I 1(65.7) 58(34.3) 
2 227(69.8) 98(30.2) 
3 2 16(75.5) 70(24.5) 
NPI 7.3 13 0.026 
Good 185(65 .8) 96(34.2) 
Moderate 285(72.7) 107(27.3) 
Poor 85(78.7) 23(2 1.3) 
OM 9.537 0.002 
No 382(68.2) 178(3 1.8) 
Positive 170(79.4) 44(20.6) 
Recurrence 7.189 0.007 
No 32 1(67.9) 152(32. 1) 
Positive 226(76.9) 68(23. 1) 
Tumour type 3.30 I 0.654 
DuetalfNST 272(70.6) 113(29.4) 
Lobular 90(76.9) 27(23. 1) 
Tubular and Tubular mixed 142(70) 6 1 (30) 
Medullary 3(75) 1(25) 
Other special types 9(75) 3(25) 
Mixed 39(65) 2 1 (35) 
Mitosis 3.223 0.200 
I 238(68.6) 109(3 1.4) 
2 11 6(72) 45(28) 
3 186(75.3) 6 1(24.7) 
Menopa use 2.984 0.084 
Premenopausal 203(74.9) 68(25. 1) 
Postmenopausal 352(69) 158(3 1 ) 
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3.3.4.2 Correlation between RERG protein expression and other 
biomarkers 
In the whole patient series, RERG protein expression was found to be 
positively associated with markers of luminal differentiation such as CKl9 
CKl8 (p=O.OOI), CK7/8(p=O.002), p27 (p=O.005), E-cadherin (p=O.OOI), ER 
(p=O.OOI) and androgen receptor (AR) (p<O.OOI). 
In contrast, RERG expression was inversely associated with MIB 1 (p=O.005) 
(Table 3.10). 
In the ER-positive cohort, RERG expression retained similar associations. No 
significant associations were found between RERG and other biomarkers 
included in the study. 
a 
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Table 3.10: Relation of RERG immunostaining to other biomarkers In the 
whole series 
Variable Nega tive RERG I'ositive REItG X' p-valuc 
C KS/6 
Negative 688(737) 245(263) 0.003 0.954 
Positive 125(73.5) 45(26.5) 
C KI4 
Nl:gative 7 11 (73 .8) 253(26.2) 0.290 0.590 
Positive 92(76) 29(24) 
C KI8 
Negative 11 8(849) 2 1 (15.1) 10.823 0.00 1 
Positive 647(7 1.7) 256(28.3) 
C KI9 
Negative 90(82.6) 19( 17.4) 4.829 0.028 
Positi ve 726(72.8) 27 1(27.2) 
CK718 
Nezative 17( 100) 0(0) 6.128 0.0 13 
Positive 800(73.4) 290(26.6) 
Ell 
Negative 249(80.8) 59( 19.2) 10.938 0.00 1 
Positive 555(7 1.1 ) 226(28.9) 
PgR 
Negative 384(74) 122(26) 0.026 0.872 
Positive 449(73.6) 16 1(26.4) 
AR 
N ~ ~ l l v e e 300(82.9) 62( 17.1) 23.6 14 <0.00 1 
Positive 469(69) 2 11 (3 1) 
pS3 
Negative 571 (71. 7) 225(28.3) 3.839 0.050 
Positive 223(77.7) 64(22.3) 
BRCAI 
Negative 11 4(82) 25( 18) 5.163 0.023 
Positive 586(72.9) 2 18(27.1) 
BcI-2 
N ~ a a i i e e 268(77.5) 78(22.5) 2.280 0. 13 1 
Weak 385(72.9) 143(27. 1) 
MIB I 
Low 172(67.7) 82(32.3) 7.9 15 0.005 
High 488(76.9) 147(23.1) 
P-cadherin 
Negative 32 1 (71.7) 127(28.3) 2.60 1 0.107 
Positive 382(76.2) 11 9(23 .8) 
E-cad herin 
Negati ve 332(79.6) 85(20.4) 11.370 0.00 1 
Positive 473(70.4) 199(29.6) 
FOXAI 
Negative 344(78.9) 92(2 1.1) 8.082 0.004 
Positive 272(70.3) 11 5(29.7) 
HElt2 
Negative 711 (73 .8) 253(26.2) 0.243 0.622 
Positive 103(75 .7) 33(24.3) 
EGFR 
Negative 596(75 .3) 196(24.7) 5.524 0.019 
Positive 132(67) 65(33) 
p27 
Negative 3 17(79.1) 84(20.9) 7.7 11 0.005 
Positive 264(70.4) 111 (29.6) 
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3.3.4.3 Correlation between RERG protein expression and patient 
outcome 
(A) Univariate analysis 
Breast cancer patients with strong RERG expression showed a significantly 
longer BeSS (LR=12.267, p<O.OOI) and longer DMFI (LR=7.472, p=O.006). 
The association with longer BeSS was also confinned in the group of patients 
that did not receive systemic therapy (n=397) (LR=6.467,p=O.Ol). 
In ER-positive group, patients with strong RERG expression also showed a 
significantly longer BeSS (LR=9.887, p=O.002) (Fig 3.6A) and longer DMFI 
(LR=7.205, p=O.007) (Fig 3.6B). 
In the ER-positive tamoxifen-only treated patients, high RERG expression 
indicated better response to tamoxifen monotherapy (LR =4.553, p=O.033). 
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(B) Multivariate analysis 
Multivariate analyses including well-established prognostic variables showed 
that RERG expression was an independent prognostic marker for longer BeSS 
in the whole series (Hazard ratio (HR) =0.573, P =0.001 , 95% CI =0.411-
0.799) and in ER+ luminal-like cohort (HR =0.555, P =0.006, 95% CI =0.364-
0.846) (Table 3.11). 
Table 3.11: COX model for predictors of BeSS in the whole patient series and 
in the ER-positive subgroup 
Whole series ER-positive cohort 
Variable p value IIR 9S% C I P value IIR 9S%CI 
Lower Upper Lower Upper 
RERG expression 0.00 1 0.573 0.4 11 0.799 0.006 0.555 0.364 0.846 
Endocrine therapy 0.020 0.670 0.478 0.938 0.126 0.713 0.463 1.1 00 
given 
Chemotherapy given 0.00 1 0.508 0.338 0.762 0.Q28 0.52 1 0.292 0.93 1 
Tumour size (>2cm) <0.00 1 1.95 1 1.472 2.585 <0.00 1 2.083 1.464 2.963 
I <0.00 1 I 
Tumour stage I <0.001 
Tumour stage 2 <O.OOt 1.814 1.34 1 2.454 0.004 1.769 1.20 1 2.606 
Tumour stage 3 <0.001 4.604 3.204 6.6 17 <0.00 1 3.948 2.388 6.526 
I <0.00 1 I 
Tumour grade 1 <0.00 1 
Tumour grade 2 0.011 1.982 1.174 3.348 0.02 1 1.955 1.107 3.454 
Tumour orade 3 <0.00 1 4.175 2.495 6.985 <0.00 1 4.487 2.483 8.107 
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3.4 GATA3 
3.4.1 Introduction 
Recent gene expression studies identified GA TA3 as a marker of Luminal A 
breast cancer subtype (Sorlie et al., 2001). It has been documented that GAT A3 
is an essential regulator of mammary morphogenesis and luminal 
differentiation and normally expressed at high levels in association with ER in 
luminal epithelial cells (Asselin-Labat et al., 2007). Functionally, GAT A3 is an 
important factor that accompanies the undiffentiated breast cells on their 
development to form luminal epithelial cells (Asselin-Labat et al., 2007, 
Kouros-Mehr et aI., 2006). Due to its strong relation to ER, GAT A3 is 
involved in growth control and the maintenance of the differentiated state in 
epithelial cells in ER-positive breast tumours (Usary et aI., 2004). 
The GA TA family consists of six members (GAT A 1-6) that can be separated 
into two groups based on their expression patterns and sites. GAT AI, GAT A2 
and GAT A3 are expressed in hematopoietic cell lineages and are essential for 
differentiation, proliferation of hematopoietic stem cells, and the development 
of T lymphocytes (Ko and Engel, 1993). GATA4, GATA5, and GATA6 are 
expressed mainly in the cardiovascular system, liver, lung, pancreas, and 
intestine (Abba et al., 2006). 
The importance of GAT A3 as a possible candidate luminal marker is due to its 
involvement in a positive cross-regulatory cycle with the ER gene, where each 
one is required for the transcription of the other gene (Dydensborg et al., 2009). 
The role of GAT A3 in oestrogen signalling requires this direct positive 
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regulation of the expression of the ER alpha gene itself by GAT A3 which 
binds to two cis-regulatory elements located within the ER alpha gene, and this 
is required for RNA polymerase II recruitment to ER alpha promoters 
(Dydensborg et aI., 2009). 
GAT A3 could contribute to the transcriptional upregulation of MUC 1 gene 
expression in some breast carcinomas with luminal phenotype (Abba et aI., 
2006). Moreover, GATA3, in addition to ER, is linked to FOXAI and the three 
genes form a network that can influence the biology of ER-positive luminal-
like breast cancer (Badve and Nakshatri, 2009). 
Previous studies have shown an important role of GAT A3 in inhibiting the 
development of metastatic breast cancer by regulating key genes involved in 
metastatic breast tumour progression to the lung including IDlI-3, KRTHB1, 
LY6E and RARRES3 (Dydensborg et aI., 2009). 
In addition to its biological role in ER-positive breast cancer, GAT A3 has been 
previously suggested as a marker of hormone therapy response (Fang et aI., 
2009). Testing the ER-positive breast cancer for GAT A3 usmg 
immunohistochemistry might improve the prediction of hormone therapy 
response (Parikh et aI., 2005). 
Our analysis of the gene expression data of 128 frozen breast cancer cases has 
also confirmed its strong relation to the ER-positive luminal phenotype. For 
this reason, we have studied its protein expression in a cohort of well 
characterised series of breast cancer to validate our findings and to assess its 
role in the phenotypic characterisation ofER-positive breast cancer. 
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3.4.2 Material and Methods 
3.4.2.1 Gene expression study 
The study population used was derived from the Nottingham Tenovus Primary 
Breast Carcinoma Series of women aged 70 years or less, who presented with 
stage I and II primary operable invasive breast carcinomas. 
Total RNA was extracted from a series of 128 frozen breast cancers retrieved 
from Nottingham Hospitals NHS Trust Tumour Bank between 1986 and 1992 
as described in the General Material and Methods chapter. 
Bioinformatics analysis: Ensemble classification and cross-validation 
analysis 
GAT A3 gene was identified as being differentially expressed between ER-
positive and ER negative cases by applying an ensemble sample classification 
method to the gene microarray data (see General Material and Methods 
chapter). 
3.4.2.2 GAT A3 protein expression study 
Breast cancer tissue microarrays were prepared and immunohistochemical 
staining of the sections was performed according to the Streptavidin-Biotin 
complex using as described in the general material and methods. GAT A3 
(HG3-31) mouse monoclonal antibody raised against human recombinant 
GATA3 (Santa Cruz Biotechnology, Inc., CA, USA) was used at an optimised 
working dilution of 1 :80. To unmask the antigens, the sections were 
microwaved in Tris EDT A buffer pH 8.5 for 20 minutes. 
99 
Chapter 3 
Negative controls were obtained by omitting the primary antibody. Breast 
cancers sections were used as positive controls. 
The xtile program was used to categorise the cases into high and low 
expression ( ~ 6 0 0 H-score). 
3.4.3 GA TA3 expression results 
3.4.3.1 Identification of GATA3 gene as a candidate luminal 
marker 
Novel genes associated with ER-positive luminal phenotype using the 
ensemble cross- validation analysis 
The GAT A3 gene was selected among the significantly differentially expressed 
genes in every cycle of a leave-one-out external cross-validation analysis. The 
prediction models obtained from this procedure distinguished the luminal from 
the non-luminal samples with an average accuracy of 88.3% (sensitivity: 
95.2%, specificity: 75.0%). 
Very similar results were obtained in a 10-fold cross-validation analysis, which 
was conducted for further verification (average accuracy: 89%, sensitivity: 
95.2%, specificity: 77.3%). Table 3.7 shows the 30 genes identified. GATA3 
gene expression was significantly associated with luminal cases (p<O.OOI) (Fig 
3.7). 
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Figure 3.7: Boxplot of GATA3 
gene normalised expression 
values in luminal and non-luminal 
samples 
3.4.3.2 GA T A3 immunohistochemical results 
Evaluation ofGATA3 protein expression in invasive breast cancer showed that 
the immunoreactivity was localised to the nuclei of invasive tumour cells with 
homogenous distribution (Fig 3.8) and was strongly expressed in the nuclei of 
luminal cells of normal breast acini. Of the whole series, 1,045 informative 
cases for GAT A3 expression were available for assessment. In the whole 
series, 25% of cases were positive for GATA3 protein expression and 33.3% of 
cases were positive in ER-positive cohort. About 98% of GA TA3 positive 
cases were also ER positive. 
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Figure 3.8: GATA3 expression in breast cancer 
(A) Strong nuclear expression in grade 2 ductal carcinoma (x 100) 
(B) Negative expression in grade 3 invasive ductal carcinoma (x 1 00) 
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3.4.3.3 Correlation between GAT A3 expression and other 
clinicopathological variables 
In the whole series, high GAT A3 expression was positively associated with 
tumours of small size (p=O.002), low tumour grade (p<O.OO I), low mitotic 
counts (p<O.OOI), and good NPI group (p<O.OOI). GATA3 expression was 
associated with tumours that were less likely to develop DM (p=O.004) and 
showed a high expression in tubular and tubular mixed tumour types. In 
contrast, the expression was completely negative in medullary cancer 
(p<O.OOI) (Table 3.12). 
In the ER -positive luminal cohort, GA T A3 expression showed similar 
significant associations with tumour grade (p<O.OOI), NPI (p<O.OOI), DM 
(p=O.023), and mitosis (p<O.OOI) (Table 3.13). 
3.4.3.1 Correlation between GATA3 and other biomarkers 
In the whole patient series, GAT A3 expression was positively associated with 
markers of good prognosis and luminal differentiation including ER (p<O.OO I), 
PgR (p<O.OOI), luminal CKs, E-cadherin, and the ER-related gene FOXAI 
(p<O.OOI), androgen receptor (AR) (p<O.OOl), p27 (p<O.OOl) and Bcl-2. In 
contrast, GAT A3 expression was inversely associated with the expression of 
basal CKs, Ki67 (MIBl) (p<O.OOI), p53 (p<O.OOI) and HER2 (Table 3.14). 
In the ER-positive luminal-like group, GATA3 expression showed significant 
positive associations with PgR, p27 and FOXAI. In contrast, it was inversely 
associated with MIBI expression (Table 3.15). 
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Table 3.12: Relation of GA TA3 expressIon to other clinicopathological 
variables in the whole series 
GA T A3 expression 
Low High Tota l 
X
2 Variable p-va lue 
Patients' age 2.4 11 0.492 
<40 62(76.5) 19(23.5) 81 
40-50 220(73. 1) 81 (26.9) 301 
51-60 266(78.2) 74(2 1.8) 340 
>60 240(75) 80(25) 320 
Tumour size 10.039 0.002 
< 1.5cm 36 1 (71.2) 1 4 4 2 8 . 8 ) ) 507 
> 1.5 cm 423(79.7) 108{20.3) 53 1 
Lymph node stage 3.656 0. 161 
I (Negative) 467(73.5) 168(26.5) 635 
2( 1-3 LN) 240(78.2) 67(2 1.8) 307 
3(>3 LN) 77(80.2) 19(19.8) 96 
Tumour Grade 118.2 <0.001 
I 97(60.2) 64(39.8) 16 1 
2 194(59.9) 13Q{40. 1l 324 
3 493(89.2) 60(10.8) 553 
NP I 64.783 <0.001 
Good 160(58.4) 114(41.6) 274 
Moderate 467(79.7) 119(20.3) 586 
Poor 158(88.3) 2 1(11.7) 179 
DM 8.329 0.004 
No 5 17(72.9) 192{27.J'} 709 
Positive 264(8 1.2) 6 1( 18.8) 325 
Recurrence 2.825 0.107 
No 424(73.4) 154(26.6) 578 
Positive 346(77.9) 98(22.1) 444 
VI 11 .673 0.003 
No 4 17(74. 1) 146(25.9) 563 
Probable 85(67.5) 4 1 (32.5) 126 
Definite 28 1(8 1.4) 64(18.6) 345 
Histologic tumour type 6 1.832 <0.00 1 
DuctalfNST 520(82.3) 11 2( 17.7) 632 
Lobular 53(58.9) 3K4 1. 1l 90 
Tubular and Tubular 127(64.5) 70(35.5) 197 
mixed 
Medullary 28(100) QeOl 28 
Other special types* 8(47. 1 ) 9(52.9) 17 
Mixed** 40(67.8) 19{32.21 59 
Mitosis 118.3 <0.00 1 
I 183(57.2) 137(42.8) 320 
2 137(7 1) 5 ~ 2 ~ ~ 193 
3 445(90.1) 49(9.9) 494 
*Includes Mucoid, invasive cribriform and invasive papIllary carcinoma, ** 
Include ductallNST mixed with lobular or special type 
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Table 3.13: Relation of GAT A3 expression to other biomarkers in the ER-
positive cohort 
GA T A3 expression 
Variable Low High Tota l X2 p-value 
Patients' a2e 10.816 .01 30 
<40 2 1(52.5) 19(47.5) 40 
40-50 108(60) 72(40) 180 
51-60 150(69.4) 66(30.6) 2 16 
>60 173(71.8) 68(28.2) 68 
Tumour size 2.234 0.142 
< 1.5 em 228(64 128(36) 356 
> 1.5 em 223(69.5) 98(30.5) 32 1 
Lymph node sta2e 5.034 0.081 
I (Negative) 258(63.2) 150(36.8J 408 
2( 1-3 LN) 153(7 1.8) 60(28.2) 213 
3(>3 LN) 38(70.4) 16(29.6) 54 
Tumour Grade 35.505 <0.001 
I 84(6 1.3) 53(38.7) 137 
2 158(56.6) 12 1(43.4) 276 
3 209(80. 1) 52( 19.9) 26 1 
NPI 18.393 <0.001 
Good 134(57.5) 99(42.5) 233 
Moderate 24 1(68.9) 109(31. 1 ) 350 
Poor 77(8 1.1 ) 18(18.9) 95 
OM 5.386 0.023 
No 309(64. 1) 173(35.9) 482 
Positive 14 1(73.4) 5 1(26.6) 192 
Recurrence 1.601 0.2 13 
No 254(64.6) 139(35.4) 393 
Positive 192(69.3) 85{30.7) 277 
VI 8.274 0.0 16 
No 229(64. U 128(35.9) 357 
Probable 56(59.6) 38(40.4) 94 
Definite 166(73.8) 59(26.2) 225 
Histolo2ie tumour type 12.869 0.045 
DuctallNST 256(7 1.1 ) 104(28.9) 360 
Lobular 48(61.5) 30(38.5) 78 
Tubular and Tubular 106(62.7) 63(37.3) 169 
mixed 
Medullary 4( 100) 0(0) 4 
Other special types 4(36.4) 7(63.6) /I 
Mixed 3 1(62) 19(38) 50 
Mitosis 34.955 <0.00 1 
I 156(55.7) 124(44.3) 280 
2 103(66.51 52(33.5) 155 
3 180(80.7) 43(19.3) 223 
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Table 3.14: Relation of GA TA3 expression to other biomarkers in the whole 
senes 
GATA3 expression 
Variable Low Hi2h Total "l p-value 
CKS/6 18.776 <0.001 
N ~ a t i v e e 60 1(72.9) 223(27.1) 824 
Positive 158(88.3) 21 (11.7) 179 
CKI4 8.11 3 0.003 
Negative 647(74.6) 220(25.4) 867 
Positive 107(86.3) 17( 13 .7) 124 
CKI8 37.064 <0.001 
Negative 140(95.9) 6(4.1) 146 
Positive 570(72 .5) 2 16(27.5) 786 
CKI9 12.205 <0.001 
Negative 100(89.3) 12(10.7) 11 2 
Positive 663(74.3) 229(25.7) 892 
ER 110.5 <0.001 
Negative 294(97.7) 7(2.3) 30 1 
Positive 452(66.7) 226(33.3) 678 
P2R 69.659 <0.001 
Negative 394(88.3) 52(11.7) 446 
Positive 348(65.4) 184(34.6) 532 
AR 63.081 <0.00 1 
Negative 328(90. 1) 36(9.9) 364 
Positive 383(67.4) 185(32.6) 568 
p53 18.495 <0.001 
Negative 499(72.4) 190(27.6) 689 
Positive 248(85.2) 43( 14.8) 291 
MIBI 22.539 <0.001 
low 134(62.3) 81(37.7) 2 15 
High 475(78.8) 128(21.2) 603 
P-cadherin 24.698 <0.001 
Negative 256(68. 1) 124(31.9) 389 
Positive 379(82.8) 79(17.2) 458 
E-cadherin 5.690 <0.001 
Negative 293(80.7) 70(19.3) 363 
Positive 459(74) 161(26) 620 
HER2 14.457 <0.001 
Negative 635(74.4) 219(25.6) 845 
Positive 128(88.9) 16( 1l.1 ) 144 
p27 33.667 <0.001 
Negative 32 1(87.7) 45( 12.3) 366 
Positive 243(70) 104(30) 347 
EGFR 4. 194 0.041 
Negative 527(74.5) 180(25.5) 707 
Positive 141(82) 31( 18) 172 
8C\-2 47. 111 <0.001 
Negative 276(89) 34( 11) 3 10 
Positive 3 15(67.7) 151(32.4) 466 
FOXAI 67.218 <0.001 
Negative 356(89.9) 40( 10. 1) 396 
Positive 2 18(64.9) 118135 .1) 336 
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Table 3.15: Relation of GAT A3 expression to other biomarkers in the ER-
positive cohort 
GATA3 exoression 
Low High Total 
Variable i o-value 
CKS/6 0. 142 0.756 
Negative 4 11 (66.6) 206(33.4) 6 17 
Positive 32(64) 18(36) 50 
CK I4 0.0 17 1.000 
Negative 409(67) 20 1(33) 6 10 
Positive 36(67.9) 17(32. 1) 53 
CK I8 3.701 0.07 1 
Negati ve 25(83.3) 5( 16.7) 30 
Positi ve 404(66.4) 204(33.6) 608 
CK I9 0.843 0.398 
Negative 30(73.2) 11 (26.8) 4 1 
Positi ve 419(66.2) 2 14(33.8) 633 
P ~ R R 4.154 0.046 
Negative 12 1 (72.9) 45(27. 1 ) 166 
Positive 322(64.3) 179(35.7) 50 1 
AR 10.888 0.001 
Negative 12 1(78. 1 ) 34(21.9) 155 
Positi ve 308(63.8) 175(36.2) 483 
p53 0.012 1.000 
Negati ve 363(67) 179(33) 542 
Positive 83(67.5) 40(32.5) 123 
MIDI 9. 138 0.003 
Low 98(56.3) 76(43 .7) 174 
High 258(69.5) 11 3(30.5) 371 
P-cadherin 0.241 0.654 
Negative 228(65.7) 11 9(34.3) 347 
Positive 157(67.7) 75(32.3) 323 
E-cadherin 3.504 0.068 
Negative 163(71.8) 64(28.2) 227 
Positive 283(64.6) 155(35.4 ) 438 
HER2 4.856 0.030 
Negative 396(66) 204(34) 600 
Positive 48(80) 12(20) 60 
027 6.720 0.0 11 
Nt:&ative 143(78.6) 39(21.4 ) 182 
Positive 191(67.5) 92(32.5 ) 283 
EGFR 0.044 0.902 
Negative 344(66.7) 172(33.3) 516 
Positive 59(67.7) 28(32.2) 87 
Bcl-2 6.373 0.0 14 
Negative 92(76.7) 28(23.3) 120 
Positive 256(64.3) 142(35.7) 398 
FOXAI 30.6 12 <0.00 1 
Negative 181(82.6) 38( 17.4) 2 19 
Positive 157(59.5) 107(40.5) 264 
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3.4.3.2 Correlation between GAT A3 expression and patient 
outcome 
(A) Univariate analysis 
Breast cancer patients with strong GAT A3 expression showed a signi ticantly 
longer BCSS (LR=16.329,p<O.OOl) (Fig 3.9A) and longer DMFI (LR= 13.067, 
p<O.OO I) (Fig 3.98). 
Similar associations were found in the ER-positive luminal group in terms of 
BCSS (LR= 10.149, p=O.OOl; Fig 3.10A) and DMFI (LR=7.153 , p=0.007; Fig 
3.108). 
1. A 1. B 
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Figure 3.9: Kaplan Meier plots of GAT A3 expression in the whole series 
in relation to (A) BCSS and (B) DMFI 
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Figure 3.10: Kaplan Meier plots of GATA3 expressIon In ER-positive 
luminal-like cohort in relation to (A) BCSS and (B) DMFI 
According to systemic therapy groups 
The association with longer BCSS was also confirmed in the group of patients 
that did not receive systemic therapy (n=352) (LR= 13.498, p<O.OOl) (Fig 
3.11). In ER-positive tamoxifen-only treated patients, high GATA3 expression 
indicated a trend of better response to tamoxifen monotherapy (LR=2.546, 
p =O.lll). 
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Figure 3.11: Kaplan Meier plot of GATA3 expression in untreated patient 
group in relation to BCSS 
(B) Multivariate analysis 
Bess 
Multivariate Cox regression analyses including tumour size, tumour grade, 
lymph node stage and systemic therapy groups showed that GAT A3 expression 
was an independent prognostic marker for longer BCSS in the whole series 
(HR=0.665, p=0.030, 95% C[ =0.459-0.762) and with border-line significance 
in the ER-positive luminal-like cohort (HR =0.666, p=0.056, 95% CI =0.439-
1.010) (Table 3.16). 
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T able 3.16: COX analysis model of GATA3 protein expression, tumour grade, 
LN stage, tumour size and adjuvant therapies in the ER-positive cohort 
Variable p value HR 95 % CI 
Lower Upper 
GA T A3 expression 0.056 0.666 0.439 1.010 
Endocrine Therapy 0.120 0.697 0.443 1.099 
Chemotherapy 0.2 13 0.695 0.392 1.233 
Tumour size <0.001 2.272 1.562 3.304 
Tumour stage (2) vs. (1) <0.001 2.246 1.484 3.400 
Tumour stage (3) vs. (1) <0.001 3.407 1.980 5.864 
Tumour grade (2) vs. (1) 0.037 1.883 1.037 3.4 18 
Tumour grade(3) vs. (1) <0.001 3.436 1.820 6.485 
DMFI 
Multivariate Cox regressIOn analysis including the same well-established 
prognostic variables as above showed that GATA3 expression was an 
independent prognostic marker for longer DMFI in the whole seri es 
(HR=0.682, p=0.028, 95% CI =0.484-0.960) but not in the ER-positive 
luminal-like cohort (HR =0.715 , p =0.085 , 95% CI =0.488-1.047). 
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3.5 XBPI 
3.5.1 Introduction 
Human X box-binding protein 1 (XBP-I) was originally identified as a protein 
binding to the cis-acting X box which presents in the promoter regions of target 
genes (Lacroix and Leclercq, 2004). Gene expression profiling of breast cancer 
tissue has previously shown an association between ER and XBP-l expression 
because of its association with Luminal A breast cancer (Sorlie et aI., 2001). 
XBPI is stimulated by endoplasmic reticulum stress as part of the unfolded 
protein response (UPR). UPR is a cellular stress response related to the 
endoplasmic reticulum. If the stress is weak, this pathway acts in a protective 
manner, while if the stress is strong, it will induce apoptosis. Over-expression 
of the UPR may also be clinically important because it reduces the effect of 
certain types of chemotherapy, such as doxorubicin (Scriven et aI., 2009). 
XBP-l is a key transcriptional regulator of the UPR that activates genes 
involved in protein folding, secretion, and degradation to restore endoplasmic 
reticulum function (Hetz et aI., 2008, Yoshida et aI., 2001). 
Romero-Ramirez and co-workers studied the effect of hypoxia on XBPI in 
vitro using mouse embryonic fibroblasts. They showed that hypoxia could 
increase XBPI at the transcriptional level and activated splicing of its mRNA, 
resulting in increased levels of XBP 1 protein. After exposure to hypoxia, the 
XBP I-deficient cells showed increased apoptosis while loss of XBP 1 
significantly inhibited tumour growth due to a reduced capacity of the tumour 
cells to survive in a hypoxic microenvironment. They concluded that, XBPI is 
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an essential survival factor for hypoxic stress and tumour growth which could 
be targeted therapeutically to eliminate hypoxia and inhibit tumour 
proliferation (Romero-Ramirez et al., 2004). 
The unfolded protein response as regulated by XBPI and GRP78 was 
associated with a more favourable course of the disease of acute myeloid 
leukaemia (Schardt et aI., 2009). 
The oestrogenic stimulation was sufficient to induce downstream regulators of 
UPR activation such as XBP 1 (Rzymski and Harris, 2007) and this may 
explain why XBP I is identified as a Luminal A marker in the gene expression 
studies (Sorlie et aI., 2001). Previously, oestrogen stimulation has also induced 
XBPI overexpression on western blotting analysis study (Scriven et aI., 2009). 
In another study, the XBPI mRNA expression in ER-positive breast cancers 
was 2.7 fold as much as that in ER negative breast cancers (Bertucci et aI., 
2000). 
Since the XBPI mRNA expresslOn pattern is correlated with ER and 
upregulated in the luminal subset of breast cancers (West et aI., 2001, Sorlie et 
aI., 2001), it may play an important role in luminal ER breast cancer growth 
and represent a new target for therapeutic intervention. 
Because of the importance of ER signalling in the regulation of breast cancer 
development and progression, the potential role of XBPI in the ER-positive 
breast cancer biology and subclassification was investigated 
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3.5.2 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining and 
optimization was performed using the streptavidin-biotin complex method 
using DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
(general material and methods chapter). To unmask the antigens, the sections 
were microwaved in Tris EDTA buffer pH 8.5 for 23 minutes. Rabbit 
polyclonal XBP 1 antibody (NB 1 00-80861, Novus Biologicals Inc .• Littleton, 
CO, USA) was optimized at a working dilution of 0 . 5 ~ / m l l using full-face 
sections and TMAs to assess the staining distribution. 
Negative controls were performed by omitting the pnmary antibody and 
substitution with diluent. Positive breast cancer cases were used as positive 
controls. Scoring was performed using a web-based interface (Distiller; 
Slidepath Ltd, Dublin, Ireland) using the intensity of the cytoplasmic staining. 
For the intensity, a score of 0, 1,2 and 3 was used. 
3.5.3 XBPI immunohistochemical results 
XBP 1 was detected in the cytoplasm of the malignant breast cancer cells. 
After excluding the uninformative TMA cores from the study, 1111 tumours 
were available for XBPI assessment. In the whole series, 10.3% of cases were 
negative for XBPI protein expression, 38% showed weak expression, 36.9% 
showed moderate expression and 14.8% had a strong expression. In the ER-
positive cohort (n=760), 9.1 % of tumours were negative, 39.2% showed weak 
expression, 36.7% showed moderate expression and 15% were strongly 
positive (Fig 3.12A&B). Patients with strong XBPI expression showed a 
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shorter survival In companson to other groups in the ER-posit ive cohort, 
subsequently, the data was categorised into two groups of strong expression 
versus the others. 
Figure 3.12: XBPI strong cytoplasmic expression in grade 2 ductal cancer 
A) Low magnification (xIOO) B) High magnification (x200) 
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3.5.3.1 Correlation between XBPI expression and other 
clinicopathological variables 
In the whole series, XBPI expression was associated with younger age 
(p=O.002) and premenopausal status (p<O.OOl) as summarised in (Table 3.17). 
In the ER-positive cohort, strong XBPI expression was associated with 
younger age, premenopausal status, development of distant metastasis (DM) 
(p=O.OOI) and tumour recurrence (Table 3.18). 
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Table 3.17: Relation ofXBPl expression to other clinicopathological variables 
in the whole series 
XBP I expression 
Variable Low High Tota l 
-t p-value 
Patients' age 15.284 0.002 
<40 63(84) 12( 161 75 
40-50 253(79.3) 66(20.7) 3 19 
51-60 3 12(86.2) 50JD.8) 362 
>60 3 19(89.9) 36( 10.1) 355 
Tumour size 2.987 0.087 
< 1.5 em 3 19(87.9) 44(12.1 ) 363 
> 1.5 em 628(84) 120( 16) 748 
Lymph node stage 5.087 0.079 
I (Negative) 584(86.6) 90{l3.4) 674 
2( 1-3 LN) 276(84.4) 5 1 ( 15.6) 327 
3(>3 LN) 84(78.5) 23 (21.5) 107 
Tumour Grade 3.055 0.2 17 
I 158(85.5) 27(14.6) 185 
2 327(87.7) 46(12.3) 373 
3 46 1(83.5) 9 1( 16.5) 552 
NPI 5.725 0.057 
Good 273(88.1) 3?.(11.91 3 10 
Moderate 524(85.3) 90(14.7) 614 
Poor 150(80.2) 37( 19.8} 187 
OM 3.629 0.063 
No 662(86.9) I OO( 13. 1) 762 
Positive 278(82.5) 59( 17.5) 337 
Recurrence 4.236 0.046 
No 546(87.2) 80(12 .8) 626 
Positive 384(82.8) 80( 17.21 464 
VI 5.010 0.082 
No 533(86) 8?.(14) 620 
Probable 115(89.8) 13{10.2) 128 
Definite 296(82.2) 64(17.8) 360 
Histologic tumour 7.768 0. 169 
type 
DuctallNST 544(84.1) I 03( 15.9) 647 
Lobular 111(92.5) 9(7.51 120 
Tubular and Tubular 199(86.5) 3 1( 13.5) 130 
mixed 
Medullary 25(80.6) 6( 19·41 3 1 
Other special types 13(76.5) 4(23 .5) 17 
Mixed 55(83.3) 11 ( 16.71 66 
Mitosis 5.196 0.074 
I 332(88. 1) 45(1 1.9) 377 
2 167(87.4) 24(12.6) 19 1 
3 4 19(83) 86(17) 505 
Menopausa l status 14.728 <0.001 
Premenopausal 336(80) 84(20) 420 
Postmenopausal 611(88.4) 80( 11 .6) 69 1 
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Table 3.18: Relation of XBP 1 expression to other biomarkers In the ER-
positive cohort of patient 
XBPI expression 
Low High Total 
-I Variable p-value 
Patients' age 12.976 0.005 
<40 25(75 .8) 8(24 .2) 33 
40-50 162(78.6) 44(2 1.4) 206 
51-60 162(87.2) 32( 12.8) 250 
>60 24 1(88.9) 30( 11.1 ) 27 1 
Tumour size 3.147 0.089 
< 1.5 em 237(88.1 ) 32( I 1.9) 269 
> 1.5 cm 409(83.3) 82(16.7) 49 1 
Lymph node stage 4.836 0.089 
I (Negative) 394(86.4) 62(13 .6) 456 
2JI -3 LN) 203(84.6) 37( 15.4) 240 
3(>3 LN) 47(75 .8) 15(24.2) 62 
Tumour Grade 3.078 0.2 15 
I 139(85.3) 24( 14.7) 163 
2 287(87.2) 42( 12.8) 329 
3 220(82. 1) 48( 17.9) 268 
NPI 3.946 0. 139 
Poor 239(87.9) 33( 12. 1) 272 
Moderate 323(84.3) 60(15.7) 383 
Good 84(80) 2 1(20) 105 
DM 11 .4 12 0.00 1 
No 473(87.9) 65(12. 1) 538 
Positive 169 (78.2) 47(21.8) 2 16 
Recurrence 13.474 <0.001 
No 393(88.9) 49( 11.1 ) 442 
Positive 243(79.2) 64(20.8) 307 
VI 3.907 0. 142 
No 354(86.1) 57( 13.9) 4 11 
Probable 93(88.6) 12( 11.4) 105 
Definite 197(81.4) 45( 18.6) 242 
Histologic type 8. 180 0. 147 
DuetalfNST 3 11(83.4) 62(16.6) 373 
Lobular 100(9 1.7) 9(8.3) 109 
Tubular 173{86. 1) 28(13.9) 20 1 
Medullary 4( 100) 0(0) 4 
Other special types 10(7 1.4) 4(28.6) 14 
Mixed 48(8 1.4) II (18.6) 18.6 
Mitosis 4.673 0.097 
I 295(88.1 ) 40( 11 .9) 335 
2 134(85.4) 23( 14.6) 157 
3 195(8 1.6) 44( 18.4) 239 
Menopausal status 14.860 <0.00 1 
Premenopausal 198(78) 56(22) 254 
Postmenopausal 448(88.5) 58( 11 .5) 506 
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3.5.3.2 Correlation between XBPI expression and other 
biomarkers 
In the whole series, XBPI was associated with the expression of C-MYC, and 
p53 (p<O.OOI). The tables summarise the correlations. We did not find 
significant correlation between XBPI and ER or luminal CKs (Table 3.19). 
In the ER-positive luminal-like cohort, XBPI was associated with the 
expression of p53 (p<O.OO 1) (Table 3.20). 
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Table 3.19: Relation of XBPI expression to other biomarkers in the whole 
series of breast cancer patients 
XBPI Expression 
Variable Low High Total X2 p-value 
CKS/6 
Negative 766(85 .5) 130(14.5) 896 0.244 0.647 
Positive 153(84.1 ) 29(15.9) 182 
CK14 
Negative 780(84.9) 139(15.1) 919 0.298 0.698 
Positive 117(86.7) 18(13 .3) 135 
CK18 
Negative 109(82.6) 23(17.4) 132 0.9 19 0.355 
Positive 734(85.7) 122(14.3) 856 
CK19 
Negative 82(87.2) 12(12.8) 94 0.335 0.650 
Positive 834(85) 147(15) 981 
ER 
Negative 250(85) 44(15) 294 0.001 1.000 
Positive 646(85) 114(15) 760 
PgR 
Negative 399(85.4) 68(14.6) 467 0.070 0.861 
Positive 493(84.9) 88(15 . 1) 581 
p§3 
Negative 678(87.7) 95( 12.3) 773 14.497 <0.001 
Positive 220(78.3) 61 (21.7) 281 
AR 
Negative 309(84) 59(16) 368 1.000 0.352 
Positive 541(86.3) 86(13 .7) 627 
MIDI 
Low 212(86.5) 33(13 .5) 245 1.162 0.299 
High 514(83.6) 101(16.4) 615 
P-cadherin 
Negative 339(84.5) 62(15.5) 40 1 0.116 0.777 
Positive 414(85.4) 71(14.6) 585 
E-cadherin 
Negative 359(87. 1) 53( 12.9) 412 1.562 0.244 
Positive 539(84.4) 100(15.6) 639 
HER2 
Negative 790(85.5) 134(14.5) 924 0.049 0.797 
Positive 117(84.8) 21(15.2) 138 
C-MYC 
Negative 117(92.9) 9(7.1) 126 
Low 294(89.4) 35( 10.6) 329 37.95 1 <0.001 
Moderate 287(84.9 51(15.1) 51 
High 118(70.7) 49(29.3) 167 
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Table 3.20: Relation of XBP1 expressIon to other biomarkers In the ER-
positive cohort 
XBPI Expression 
Variable Low High Tota l 
-i p-value 
CKS/6 
Negative 588(84.8) 105( 15.2) 693 0.235 0.844 
Positive 48(87.3) 7(12.7) 55 
CKt4 
Negative 574(84.8) I 03( 15 .2) 677 0.355 0.700 
Positive 50(87.7) 7(12 .3) 57 
CK I8 
Negative 25(89.3) 3( 10.7) 28 0.36 1 0.785 
Positive 581 (85.2) 101 (14.8) 682 
CK I9 
Negative 33(91.7} 3(8.3) 36 1.284 0.34 1 
Positive 607(84.8) 109(15.2) 716 
PgR 
Negative 164(86.8) 25( 13.2) 189 0.605 0.481 
Positive 472(84.4) 87( 15.6) 559 
AR 
Negative 146(86.4) 23( 13 .6) 169 0.11 4 0.802 
Positive 460(85.3) 79(14.7) 539 
pS3 
Negative 538(87.6) 76(1 2.4) 614 15.754 <0.001 
Positive 10 I (74.3) 35(25.7) 136 
MIB I 
Low 175(85.8) 29( 14.2) 204 0.416 0.552 
High 325(83.8) 63(16.2) 388 
P-cadherin 
Negative 310(84.5) 57(15.5) 367 0.366 0.576 
Positive 237(86.2) 38(13.8) 275 
E-cadherin 
Negative 249(87.4) 36( 12.6) 285 1.52 1 0.243 
Positive 39 1 (84.1) 74( 15.9) 465 
H ER2 
Negative 587(85.7) 98(14.3) 685 2.989 0. 119 
Positive 44(77.2) 13(22.8) 57 
C-MYC 
Negative 75(91.5) 7(8.5) 82 
Low 197(87.9) 27( 12.1) 224 9.960 0.019 
Moderate 206(84.4) 38(15.6) 244 
Strong 79(76.7) 96(14.7) 103 
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3.5.3.3 Correlation between XBPI express ion and patient outcome 
In whole series, XBPI strong cytoplasmic expression was not assoc iated with 
patients ' survival. In the ER-positive cohort, XBPI strong cytoplasmic 
intensi ty was associated with shorter breast cancer spec ific survival (BCSS) 
(p=O.0 12) (Fig 3.13A) and shorter di stant metastasis free interval (DMFI) 
(p=O.008) (Fig 3.13B). In ER-positive cohort, mul tivari ate analysis of XBPI 
expression, tumour size, tumour grade and lymph node stage showed that 
XBP I was not an independent prognostic fac tor in relation to BCSS 
(HR= 1.277, p=O.186, 95%CI=O.889-1.835) and DMFI (HR= 1.26 1, p=O.181, 
95%CI=O.898-1.772) 
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Figure 3.13: Kaplan Meier plots of XBPI protein expression in ER-positive 
luminal-like cohort in relation to (A) BCSS (B) DMFI 
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3.6 TFFI 
3.6.1 Introduction 
Trefoil factor-l (TFF1), also known as pS2, belongs to the family ofTFFs that 
share a characteristic three loop structure named trefoil or P domain. The 
human TFFI protein is predominantly expressed in the surface epithelial cells 
of the gastric mucosa and usually increases during mucosal inflammation. 
Functionally, TFFI is a secreted protein that stabilizes the mucous gel 
overlying the gastrointestinal mucosa to provide a physical barrier against 
various irritating agents (Ioachim et aI., 2003). 
TFF 1 protein expression is induced by oestrogen through oestrogen receptors 
(ER), and is known to be inhibited by antiestrogen in the MCF-7 breast cancer 
cell line. TFFI has been reported to be correlated with hormonal status. Its 
value, either at the protein level or at mRNA level, has been the subject of 
many studies with variable results (Ribieras et aI., 1998). The most commonly 
used methods for measurmg expression of this protein are 
immunohistochemical staining on paraffin-embedded tumour sections and 
radioimmunoassay on breast tumour (loachim et aI., 2003). West and 
colleagues reported that this gene characterizes the Luminal A subclass of 
breast cancer (West et aI., 2001). 
Although it is associated with ER-positive status, a recent study by has 
suggested a potential oncogenic role ofTFFl (Amiry et aI., 2009). 
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3.6.2 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed usmg the streptavidin-biotin complex method usmg 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
(general material and methods chapter). To unmask the antigens, the sections 
were microwaved in citrate buffer pH 6 for 23 minutes. 
Mouse monoclonal TFFI antibody (Ab17829, Abeam, UK) was optimized at a 
working dilution of 1 :2000 using full-face sections and TMAs of breast cancer 
tissue and normal stomach to assess the heterogeneity and staining distribution. 
Negative controls were performed by omitting the primary antibody and 
substitution with diluent. Stomach tissue sections were used as positive 
controls. The median value of the H-score values (II score ~ 1 0 0 ) ) was used to 
categorize the data. 
3.6.3 TFFI immunohistochemical results 
Of the whole series, 1056 cores were available for assessment. The pattern of 
expression was cytoplasmic (Fig 3.14). 
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, 
Figure 3.14: TFFI expression in breast cancer 
Grade 2 ductal carcinoma with positive TFF I cytoplasmic expression (x 1 00) 
3.6.3.1 Correlation between TFFI expression and other 
clinicopathological variables 
The relationship with cytoplasmic expression of the TFFI and the vanous 
clinicopathological parameters showed a significant negative correlation with 
the tumour grade being more positive in low grade tumours (p<0.001). 
Non-significant correlations were found between TFFI expression and the 
other pathological parameters including age, tumour size, lymph node stage, 
distant metastasis and local recurrence. 
No associations were found between TFF I protein expression and the other 
clinicopathological variables in the ER-positive cohort (Table 3.21). 
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3.6.3.1 Correlation between TFFI expression and other 
biomarkers 
In the whole patient series, we found significant positive associations between 
TFF 1 protein expression and ER, PgR, CK 18 and CK 19 expression, but not 
with other biomarkers (Table 3.22). Theses associations were not found in the 
ER-positive cohort. 
3.6.3.1 Correlation between TFFI expression and patient outcome 
In the whole series, no significant association between TFFI expression and 
Bess (LR=1.101 , p=O.294) was found (Fig 3.15). In the ER-positive patient 
cohort, we also found no significant association between TFF 1 expression and 
Bess (LR=0.469, p=0.493) (Fig 3.16) or DMFI (LR=2.422, p=O.120). 
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Table 3.21: Relation of TFFI immunostaining to other clinicopathological 
variables in the ER-positive cohort 
TFFI expression 
Variable Negative Positive Total -I p-value 
Patients' age 4.083 0.253 
<40 17(47.2) 19(52.8) 36 
40-50 79(39.9) 119(60.1) 198 
51-60 109(46.8) 124(53 .2) 233 
>60 11 5«49.4) I 18(50.6) 233 
Tumour size 0.006 0.940 
$2 em 168(45.8) 199(54.2) 367 
>2 cm 15 I (45.5) 18IJ54.5) 332 
Lymph node stage 0.195 0.907 
I[Negative) 194(46.3) 225(53.7) 419 
2( 1-3 LN) 98(44.5) 122(55.5) 220 
3(>3 LN) 26(44.8) 32(55.2) 58 
Tumour Grade 5.706 0.058 
I 73(44.2) 92(55.8) 165 
2 I 15(41.2) 164(58.8) 279 
3 13 1(51.4) 124(48 .6) 255 
NPI 0.497 0.780 
Poor 50(48.5) 53(51.5) 103 
Moderate 158(45.8) 187(54.2) 345 
Good 112(44.4) 140(55.6) 252 
OM 2.406 0.13 1 
No 235(47.8) 257(52.2) 492 
Positive 83(41.3) 118(58.7) 201 
Recurrence 2.944 0.089 
No 192(48.1) 207(51 .9) 399 
Positive 120(41.5) 169(58.5) 289 
VI 1.880 0.39 1 
No 171)43.6) 22 1(56.4) 392 
Probable 42(47.2) 47(52.8) 89 
Definite 106(49.3) 109(50.7) 2 15 
Histologic tumour type 5.183 0.52 1 
DuctallNST 167(48.8) 175(51.2) 342 
Lobular 37(42.5) 50(57.5) 87 
Tubular and Tubular 81 (42.2) 111(57.8) 192 
mixed 
Medullary 1(20) 4(80) 5 
Other special t}'pes· 8(53.31 7(46.7) 15 
Mixed·· 25(46.3) 29(53 .7) 54 
Mitosis 2.7 16 0.257 
I 126(42.6) 170(57.4) 296 
2 73(50) 73(50) 146 
3 109(48) 118(52) 227 
Menopausal status 1.022 0.34 1 
Premenopausal 107(43.1) 141(56.9) 248 
Postmenopausal 2 13(47.1) 239(52.9) 452 
*Includes Mucoid, invasive cribriform and invasive papillary carcinoma, ** 
Include ductallNST mixed with lobular or special type 
127 
Chapter 3 
Table 3.22 : Relation of the TFF l expression to other biomarkers in the whole 
series 
TFFI express ion 
Variable Negative Positive Total 
, 
"f.: p-va lue 
CKS/6 0.002 1.000 
Negati ve 409(49.8) 4 12(50.2) 82 1 
Positive 93(50) 93(50) 186 
CKt4 1.545 0.243 
N ~ ~ t t v e e 429(50.4) 422(49.6) 85 1 
Pos itive 65(44.8) 80(55 .2) 145 
CKI8 9.790 0.002 
Negati ve 84(64.1 ) 47(35 .9) 13 1 
Positive 387(49.4) 397(50.6) 784 
CKI9 6.773 0.0 10 
Negati ve 55(62.5) 33(37.5) 88 
Positive 439(48) 476(52) 9 15 
ER 15.749 <0.001 
Negative 164(59.9) 110(40.1) 274 
Positive 320(45.7) 380(54.3) 700 
PgR 7.287 0.008 
N ~ ~ t t v e e 240(54.5) 200(45 .5) 440 
Positive 242(45.8) 286(54.2) 528 
AR 4.360 0.043 
Negati ve 195(54.8) 161(45 .2) 356 
Positive 273(47.7) 299(52.3) 572 
pS3 1.944 0.1 70 
N ~ ~ t i i e e 346(4 8.6) 366(5 1.4) 7 12 
Positive 140(53 .6) 12 1(46.4) 26 1 
BRCAt 3.264 0.072 
N N a t i i e e 79(59.4) 54(40.6) 133 
Weak 338(50.8) 327(49.2) 665 
MIBI 0.163 0.696 
Low 117(50.9) 11 3(49.1 ) 230 
High 277(49.3) 285(50.7) 562 
P-cadherin 4.91 3 0.058 
Negative 202(56.7) 154(43.3) 356 
Positive 220(48.9) 23Q(5 1.1 ) 450 
E-cadherin 1.206 0.295 
Negative 205(52.3) 187(47.7) 392 
Positive 282(48.7) 297(5 1.3) 579 
HER2 0.3 83 0.58 1 
Negative 428(50.3) 423(49.7) 85 1 
Positive 65(47.4) (52.6) 137 
EGFR 0.509 0.485 
Negative 357(52.5) 323(47.5) 680 
Positive 80(49.4) 82(50.6) 162 
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Figure 3.15: Kaplan Meier plot of TFF I expression in relation to BC S in the 
whole series 
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Figure 3.16: Kaplan Meier plot ofTFFl expression in relation to BCSS in the 
ER-positive cohort 
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TFF3 
3.6.4 Introduction 
Trefoil factors (TFFlIpS2, TFF2/SP and TFF3/ITF) are soluble peptides with 
trefoil domain(s) and C-terminal dimerization domain involved in protection 
and healing of the human gastrointestinal tract (May and Westley, 1997). In 
particular, TFF3 plays a key role in mucosal protection, and also in mucosal 
repair after injury. They have effects on cell motility and spreading in vitro 
(Poulsom et aI., 1997). Previous studies have demonstrated that oestradiol 
treatment increased TFF3 expression up to ten-fold in the oestrogen-responsive 
breast cancer cell lines, confirming that TFF3 is regulated by oestrogen in 
breast cancer cells (May and Westley, 1997). 
TFF3 may affect the metastatic potential of tumour cells (May and Westley, 
1997) mediated by interaction with E-cadherin, f3-catenin, and associated 
proteins (Efstathiou et aI., 1998). In vivo animal study has shown that both 
endogenous and constitutive expression of TFF3 correlates with an aggressive 
phenotype (Yio et aI., 2005). 
Blocking the expression of TFF3 inhibited the growth of gastric cancer cells 
and enhanced the response to chemotherapy (Chan et aI., 2005). 
In breast cancer, TFF3 is expressed by breast cancer cell lines and tumours, 
and the expression level was reported to be higher in ER-positive cells (May 
and Westley, 1997). This was confirmed recently in gene expression studies 
which have repeatedly reported TFF3 as a gene that characterises the Luminal 
A subtype. Our analysis of the Cambridge gene expression data has 
demonstrated that IFF3 gene shows a wide variation in the normalised 
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expression intensity values within the ER positive group implying an important 
role in the phenotypic characterisation of the ER-positive breast cancer. 
The value of TFF3 protein as a prognostic biomarker in defining breast cancer 
phenotypes remains undetermined especially in ER-positive sUbtype. 
3.6.5 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed usmg the streptavidin-biotin complex method usmg 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
(general material and methods chapter). To unmask the antigens, the sections 
were microwaved in citrate buffer pH 6 for 23 minutes. Mouse monoclonal 
TFF3 antibody (Ab57752, Abeam, UK) was optimised at a working dilution of 
3 J.lg/ml. Negative controls were performed by omitting the primary antibody 
and substitution with diluent. The H-score (histochemical score) was used for 
assessment. The cutoff point was assigned by using the median of II-score 
values (H-score ~ 9 0 ) . .
3.6.6 TFF3 immunohistochemical results 
The expression of TFF3 was detected in the cytoplasm of the malignant cells 
(Fig 3.17A&B) with decreased expression in the normal acini. After excluding 
the uninformative TMA cores from the study, 1020 tumours were available for 
assessment. In the whole series, 52% of cases were TFF3 positive while in the 
ER-positive cohort, 62% of cases were TFF3 positive. 
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A 
Figure 3.17: TFF3 expression in breast cancer 
(A) TMA core of grade 2 ductal carcinoma with strong TFF3 expressIon 
(x 1 00). (B) TMA core of grade 2 ductal carcinoma with strong TFF3 
expression (x200). 
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3.6.6.1 Correlation between TFF3 expression and the other 
clinicopathological variables 
In the whole series, high TFF3 expression was associated with low grade 
tumours, good NPI group, low mitotic counts, DM and VI (Table 3.23). In ER-
positive cohort, TFF3 expression retained its association with DM (p=O.007) 
(Table 3.25). 
3.6.6.1 Correlation between TFF3 expression and the other 
biomarkers 
On studying the correlation with other biomarkers in the whole series, our 
results showed that TFF3 was inversely associated with basal cytokeratins, p53 
and EGFR expression. In contrast, TFF3 was positively associated with ER, 
PgR, AR, HER2, and Bcl-2 expression (Table 3.24). In ER-positive cohort, 
TFF3 expression retained its association with HER2 expression (p=O.OOI) 
(Table 3.26). 
3.6.6.1 Correlation between TFF3 expression and patient outcome 
In the whole patient series, TFF3 was not significantly related to patient 
outcome. In the ER-positive cohort, patients with positive TFF3 expression 
showed shorter BCSS (LR=5.895,p=O.OI5) (Fig 3.18) and DMFI (LR=6.174, 
p=O.013) (Fig 3.19). Multivariate Cox regression analysis including tumour 
size, tumour grade and lymph node stage revealed that TFF3 was not an 
independent prognostic marker of BCSS (HR= 1.452, p=O.061, 95%CI=O.986-
1.854) or DMFI (HR=1.340,p=O.053, 95%CI=O.996-1.804). 
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Table 3.23: Relation ofTFF3 expression to other clin icopathological variables 
in the whole series 
TFF3 expression 
Negative Positive Tota l 
'l Va riable p-va lue 
Pa tients' age 4.528 0.2 10 
<40 44(55 .7) 35(44.3) 79 
40-50 139(47.3) 155(52.7) 294 
5 1-60 159(49.8) 160(50.2) 3 19 
>60 144(43.9) 184(56. 1 ) 328 
T umour size 1.898 0. 175 
< 1.5 cm 139(44.4) 174(55.6) 3 13 
> 1.5 cm 347(49. 1) 360(50.9) 707 
Lymph node stage 2.826 0.243 
I (Negative) 297(48.3) 3 18(51.7) 6 15 
2( 1-3 LN) 150(48.7) 158(51.3) 308 
3(>3 LN) 37(39.4) 57(60.6) 94 
Tumour Grade 27.492 <0.00 1 
I 70(42.4) 95(57.6) 165 
2 125(3 7.9) 205(62. 1) 330 
3 29 1(55.5) 233(44.5) 524 
NPI 12.577 0.002 
Good 104(38.7) 165(61.3) 269 
Moderate 299(5 1.7) 279(48.3) 578 
Poor 83(48) 90(52) 173 
DM 7.042 0.008 
No 388(50.5) 33 1(49.5) 669 
Positive 144(4 1.7) 201 (58.3) 345 
Recurrence 6.702 0.011 
No 282(5 1) 27 1(49) 553 
Positive 193(42.8) 258(57.2) 45 1 
VI 9.560 0.008 
No 294(52. 1) 270(47.9) 564 
Probable 52(42.3) 7 1(57.7) 123 
Definite 140(42.4) 190(57.6) 330 
Histologic tumour type 46. 120 <0.001 
DuctalfNST 3 11(50.8) 301 (49.2) 6 12 
Lobular 3 1 (32.3) 65(67.7) 96 
Tubular and Tubular mixed 93(44.7) 11 5(55.3) 208 
Medullary 28(90.3) 3(9.7) 3 1 
Other special types 8(53.3) 7(46.7) 15 
Mixed 15(25.9) 43(74. 1) 58 
Mitosis 28.587 <0.001 
I 133(4 1) 19 1(59) 324 
2 68(3 8.2) 110(61.8) 178 
3 273(57) 206(43) 479 
Menopausal status 1.425 0.247 
Premenopausal 197(50) 197(50) 394 
Postmenopausal 2 8 9 ( ( 6 . ~ ~ 337J53 .8) 626 
* 
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Table 3.24: Relation of TFF3 expression to other biomarkers in the whole 
series 
T FF3 expression 
Va riable Nega tive Positive Tota l .. l p-va lue 
CKS/6 
Negative 35 1(43. 1) 463(56.9) 8 14 36.44 1 <0.00 1 
Positive 120(68.2) 56(3 1.8) 176 
CKt 4 
Negative 380(45.5) 455(54.5) 835 9.473 0.002 
Positive 78(60) 52(40) 130 
CKt8 
Ne_gative 106(84. 1) 20( 15.9) 126 80.452 <0.00 1 
Positive 320(4 1. 1) 458(58.9) 778 
CKt9 
Negative 63(72.4) 24(27.6) 87 23.6 12 <0.00 1 
Positive 409(45.2) 493(54.8) 899 
ER 
Negative 197(7 1.1 ) 80(28.9) 277 86.762 <0.00 1 
Positive 262(38) 427(62) 689 
~ R R
Negative 252(58.5) 179(4 1.5) 43 1 37.947 <0.00 1 
Posi ti ve 205(38 .5) 327(6 1.5) 532 
AR 
Negative 2 11 (59.6) 143(40.4) 354 32.956 <0.00 1 
Positive 223(40.1) 333(59.9) 556 
J!53 
Negative 3 11 (44.6) 387(55.4) 698 9.752 0.002 
Positive 15 1(55 .7) 120(44.3) 27 1 
Bcl-2 
Negative 185(58) \ 34{42} 3 19 2 1.299 <0.00 1 
Positive 202(4 1.4) 286(58. 488 
MIBt 
Low 89(42.2) 12 1(57.6) 2 10 1.876 0. \95 
High 273(47.9) 297(52. 1) 570 
P-cadherin 
Negative 136(36.9) 233(63. 1) 369 25.56 1 <0.001 
Positive 24 1(54.6) 200(45.4) 44 1 
E-cadherin 
Negati ve 192(50.9) \85(49.\ ) 377 2.807 0.099 
Positive 267(45.4) 23 I{54.6) 588 
HER2 
Negative 428(50.4) 42 1(49.6) 849 2 1.783 <0.001 
Positive 37(28.5) 93(71.5) 130 
EGFR 
Negative 292(43.3) 383(56.7) 675 15.871 <0.001 
Positive 102(60.4) 67(39.6) 169 
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Table 3.25: Relation of TFF3 expression to other clinicopathological variables 
in the ER-positive cohort 
TFF3 expression 
Variable Negative Positive Total -i p-value 
Patients' age 3.0 16 0.3 89 
<40 12(33.3) 24(66.7) 36 
40-50 64(433.7) 126(66.3) 190 
51-60 89(41.4) 126(58.6) 2 15 
>60 97(39.1) 151(60.9) 248 
Tumour size 0.020 0.934 
< 1.5 em 87(37.7) 144(62.3) 23 1 
> 1.5 em 175(38.2) 283(61.8) 458 
Lymph node stage 3.844 0. 146 
I(Negative) 154(37.7) 254(62.3) 408 
2( 1-3 LN) 91(41) 131(59) 222 
3(>3 LN) 15(26.8) 41(73.2) 56 
Tumour Grade 0.533 0.766 
I 59(40.7) 86(59.3) 145 
2 107(37.3) 180(62.7) 287 
.., 96(37.5) 160(62.5) 265 .> 
NPI 0.282 0.868 
Good 35(35.7) 63(64.3) 98 
Moderate 328(38.7) 219(48.3) 357 
Poor 89(48) 145(52) 234 
DM 7.289 0.007 
No 192(41.5) 27 1(58.5) 463 
Positive 69 (30.8) 155(69.2) 224 
Recurrence 4.144 0.042 
No 156(41.4) 221(58.6) 377 
Positive 103(33.8) 202(66.2) 305 
VI 4.685 0.096 
No 154(41.4) 218(58.6) 372 
Probable 38(38.4) 6 1(61.6) 99 
Definite 70(32.4) 146(67.6) 2 16 
Histologic tumour type 8.593 0.126 
DuctallNST 136(38.3) 2 19(61. 7) 355 
Lobular 29(32.6) 60(67.4) 89 
Tubular and Tubular 93(42.8) 103(57.2) 180 
mixed 
Medullary 3(75) 1(25) 4 
Other special types · 4(40) 6(60) 10 
Mixed·· 13(25 .5) 38 (74.5) 51 
Mitosis 1.468 0.480 
1 115(40.1) 172(59.9) 287 
2 49(34.3) 94(65.7) 143 
3 90(39.5) 138(60.5) 228 
Menopa usal sta tus 1.800 0.187 
Premenopausal 82(34.6) 155(65.4) 237 
Postmenopausa l 180(39.8) 272(60.2) 452 
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Table 3.26: Relation of TFF3 expression to other biomarkers in ER-positive 
cohort 
TFF3 Exp ress ion 
Variable Negative Positive Total "I: p-va lue 
CKS/6 
Negative 240(38.3) 387(61.7) 627 0.178 0.765 
Positive 18(35.3) 33(64.7) 51 
CK l 4 
Negative 233(38.3) 357(6 1.7) 608 1.180 0.3 11 
Positive 17(30.9) 38(69.1) 55 
CK l8 
Negative 10(35.7) 18(64.3) 28 0.023 1.000 
Positive 228(37. 1) 386(62.9) 6 14 
CK19 
Negative 14(41.2) 20(58 .8) 34 0.156 0.719 
Positive 245(37.8) 403(62.2) 648 
PgR 
Negative 61(36.3) 107(63.7) 168 0. 184 0.668 
Positive 195(38.2) 316(6 1.8) 51 1 
AR 
Negative 57(35.6) 103(64.4) 160 0.397 0.572 
Positive 184(38.4) 295(6 1.6) 479 
pS3 
Negative 2 13(38.3) 343(6 1.7) 556 0.022 0.919 
Positive 47(37.6) 78(62.4) 125 
Bcl-2 
Negative 43(32 .8) 188(67.2) 131 1.874 0.181 
Weak 165(39.5) 253(60.5) 4 18 
MlBl 
Low 71(40.7) 105(59.7) 176 0.922 0.343 
High 128(36.1) 227(63.9) 355 
P-cadherin 
Negative 11 7(34.9) 2 18(65 .1) 335 0.303 0.600 
Positive 9 1(37. 1) 154(62.9) 245 
E-cadherin 
Negative 98(38.1 ) 159(61.9) 257 0.00 1 1.000 
Positive 162(38.2) 262{61 .8) 424 
HER2 
Negative 247(39.8) 374(60.2) 62 1 10.770 0.00 1 
Positive 9(17) 44(83) 53 
EGFR 
Negative 188(35.9) 336(64.1) 524 0.660 0.464 
Positive 34(40.5) 50(59.5) 84 
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Figure 3.18: Kaplan Meier plot ofTFF3 expression in relation to BCSS in the 
ER-positive cohort 
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Figure 3.19: Kaplan Meier plot ofTFF3 expression in relation to DMFI in the 
ER-positive cohort 
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3.7 BEXI 
3.7.1 Introduction 
BEXl (brain expressed X-linked gene) maps on the Xq22 in humans (Brown 
and Kay, 1999). It belongs to a family of genes, including BEX1, NGFRAPl 
(BEX3), BEXLI (BEX4), and, NGFRAPILI (BEX5). Both BEXI and 
NGFRAPI interact with p75NTR and modulate nerve growth factor (NGF) 
signalling through nuclear factor-kappa B (NF-kappa B) to regulate cell cycle, 
apoptosis, and differentiation in neural tissues (Naderi et aI., 2007). 
BEXl is a signalling adapter molecule involved in p75NTR (the neurotrophin 
receptor) INGFR signalling. In the central nervous system, it has been 
suggested that it inhibits the neuronal differentiation in response to nerve 
growth factor (NGF) (Vilar et aI., 2006, Naderi et aI., 2007, Foltz et at., 2006). 
Genome-wide analysis of epigenetic silencing identified BEXI as a candidate 
tumour suppressor genes in malignant glioma (Foltz et aI., 2006). 
In breast cancer, Naderi and colleagues identified a novel subtype of oestrogen 
receptor positive breast cancers with improved outcome after tamoxifen 
treatment and characterized by overexpression of the BEX2 and its homologue 
BEXl (Naderi et at., 2007). 
Our analysis of the gene expression data has shown that BEXl shows a wide 
variation in the normalised expression intensity values within the ER positive 
group implying an important role in the biology of the ER-positive breast 
cancer. Available studies in the literature regarding BEX 1 are minimal and 
largely unexplored in breast cancer. 
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3.7.2 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed usmg the streptavidin-biotin complex method usmg 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
(general material and methods chapter). To unmask the antigens, the sections 
were microwaved in citrate buffer pH 6 for 23 minutes. Rabbit polyclonal 
BEXI antibody (Ab69032, Abeam, UK) was optimised at a working dilution 
of 1 :3500. Negative controls were performed by omitting the primary antibody 
and substitution with diluent. Breast carcinoma sections were used as positive 
controls. The H-score (histochemical score) was used for assessment. Using x-
tile program, H-score of 100 was selected as the optimal cutoff point for data 
categorisation. 
3.7.3 BEXI expression results 
The pattern of staining in breast carcinoma was cytoplasmic (Fig 3.20), with 
increased expression in the normal breast acini. After excluding the 
uninformative TMA cores from the study, 1,106 tumours were available for 
assessment. 
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Figure 3.20: 8EXl expression in breast cancer 
(A) Grade 2 ductal cancer NST with strong 8EXI expression (xlOO) 
(8) Grade 3 ductal cancer NST with negative 8EXl expression (x200) 
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3.7.3.1 Correlation between BEXI expression and other 
clinicopathological variables 
The expression of BEX1 was associated with low tumour grade (p=O.008), 
good NPI group (p=O.002) and absence of DM (p=O.008) and tumour 
recurrence (p=O.007). No significant associations were found between BEX1 
protein expression and patient's age, tumour size, vascular invasion or 
menopausal status (Table 3.27). In the ER-positive luminal-like sUbtype was 
not associated with any of the studied variables (p>O.1) (Table 3.28). 
3.7.3.1 Correlation between BEXI expression and other 
biomarkers 
In the whole patient series, BEX1 was positively associated with CK18 
(p=O.002) and PgR (p=O.OOl) (Table 3.29). 
In the ER-positive cohort, no significant associations were found between 
BEX1 and the studied biomarkers (Table 3.30). 
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Table 3.27: Relation of BE Xl expression to other clinicopathological variables 
in the whole series 
REX) expression 
Variable Low High Total .j p-value 
Patients' age 7.535 0.057 
<40 31(41.3) 44(58.7) 75 
40-50 83(25.8) 239(74.2) 322 
51-60 112(31) 249(69) 36 1 
>60 106(30.5) 242(69.5) 348 
Tumour size 
< 1.5 em 101(27.4) 267(72.6) 368 
> 1.5 em 23 1 (31.3) 507(68.7) 
Lymph node stage 2.742 0.254 
I (Negative) 194(28.2) 493(71.8) 687 
2(1-3 LN) 106(33.1) 2 14(66.9) 320 
3(>3 LN) 31 (32 .3) 65(67.7) 96 
Tumour Grade 9.674 0.008 
I 43(21.9) 153(78.1) 196 
2 105(29) 257(7 1) 362 
3 184(33.6) 363(66.4) 547 
NP) 12.946 0.002 
Good 71(22.3) 248(77.7) 3 19 
Moderate 200(32.9) 408(67.11 608 
Poor 61 (34.1) 118(65.9) 179 
OM 7.266 0.008 
No 209(27.4) 553(72.6) 762 
Positive I 18(35.5) 214(64.5) 332 
Recurrence 7.534 0.007 
No 164(26.2) 463(73 .8) 627 
Positive 155(33 .8) 303(66.2) 458 
VI 0.191 0.909 
No 185(29.8) 436(70.2) 621 
Probable 37(28.9) 91(71.1) 128 
Definite 109(30.8) 245(69.2) 354 
Histologic tumour type 14.750 0.011 
DuctallNST 208(32} 44 1(68) 649 
Lobular 40(35.4) 73(64.6) 113 
Tubular and Tubular 47(20.6) 181(79.4) 228 
mixed 
Medullary 8(24.2) 25(75.8) 33 
Other special types* 9(42.9) 12(57.1) 2 1 
Mixed** 20(32.3) 42(67.7) 62 
Mitosis 8.292 0.016 
I 100(26.4) 279(73.6) 379 
2 51(26.7) 140(73.3) 191 
3 172(34.6) 325(65.4) 497 
Menopausal status 0.699 0.417 
Premenopausal 119(28.5) 298(71.5) 417 
Postmenopausal 213(30.9) 476(69.1) 689 
*Includes Mucoid, invasive cribriform and invasive papillary carcinoma, ** 
Include ductallNST mixed with lobular or special type 
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Table 3.28: Relation of BEX 1 expression to other clinicopathological variables 
in the ER-positive cohort 
BEX 1 express ion 
Low High Tota l 
·l Va riable p-va lue 
Pa tients' age 3.395 0.335 
<40 7(22.6) 24{77·41 3 1 
40-50 50(24) 158(76) 208 
5 1-60 72(28.9) 177{7l. l 249 
>60 82(3 1.1 ) 182(68.9) 264 
T umour size 0.575 0.498 
< 1.5 cm 71(26.4) I 98{73 .61 269 
> 1.5 cm 140(29) 343(7 1) 483 
Ly mph node stage 4.552 0. 103 
I (Negative) 11 7(25.3) 345(74.7) 462 
2( 1-3 LN) 74(3 1.9) 158(68. 1 ) 232 
3(>3 LN) 19(34.5) 36(65.5) 55 
Tumour Grade 3.430 0. 180 
I 38(22.5) 13 li77 .5) 169 
2 94(30) 219(70) 3 13 
3 79(29.4) 1 9 0 D O . ~ ~ 269 
NPI 5.877 0.053 
Good 62(22.8) 2 10(77.2) 272 
Moderate 11 7(30.9) 262(69.1) 379 
Poor 32(3 1.7) 69(68.3) 10 1 
DM 6.569 0.0 12 
No 135(25.4) 3 9 ~ 7 7 . ~ ~ 53 1 
Positive 75(34.7) 14 1(65.3) 2 16 
Recurrence 4.124 0.046 
No 108(24 .8) 32K75·21 435 
Positive 97(3 1.6) 2 10(68.4) 307 
VI 00401 0.818 
No 11 4(27.8) 296(72.2) 4 10 
Probable 27(26) 77(74) 104 
Defini te 69(29.2) 167(70.8) 236 
Histologic type 9.887 0.079 
DuctallNST 11 2(29.6) 266(70.4) 378 
Lobular 36(36) 64(64) 100 
Tubular and Tubular 40(20.2) 158(79.8) 198 
mixed 
Medullary 1J25) 3(75) 4 
Other special types · 5(3 1.2) I 1(68.8) 16 
Mixed" 17(30.4) 39(69.6) 56 
Mitosis 0.63 1 0.730 
I 9 I (27.5) 240(72.5) 33 1 
2 4 1(27) 111 (73) 152 
"' 72(30.1) 167(69.9) 239 .) 
Menopausal status 6.573 0.0 12 
Premenopausal 55(22. 1 ) 194(77.9) 249 
Postmenopausal 156(3 1) 34K69) 503 
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Table 3.29: Relation of BEXl expression to other biomarkers in the whole 
senes 
BEXI expression 
Low High Total 
·i Variable p-va lue 
CKS/6 
Negative 265(29.9) 622(70.1) 887 0.109 0.789 
Positive 56(31.1) 124(68.9) 180 
CK I4 
Negative 280(30.6) 635(69.4) 915 0.278 0.687 
Positive 38(28.4) 96(71.6) 134 
CK I8 
Negative 55(42) 76(58) 13 1 9.842 0.002 
Positive 24 1(28.5) 606(71.5) 847 
CK I9 
Negative 36(38.3) 58(61.7) 94 3.234 0.078 
Positive 285(29.4) 685(70.6) 970 
ER 
N ~ a t i v e e 105(36.3) 184(63.7) 289 6.760 0.010 
Positive 21 1(28. 1) 54 1 (71.9) 752 
PgR 
Negative 162(35.8) 29 1(64.2) 453 11.515 0.001 
Positive 151(26) 430(74) 58 1 
AR 
Negative 127(34.7) 239(65.3) 366 4. 156 0.045 
Positive 174(28.5) 437(7 1.5) 6 11 
p53 
Negative 242(3 1.6) 524(68.4) 766 2.39 1 0. 128 
Positive 74(26.6) 204(73.4) 278 
MIBI 
Low 64(26.2) 180(73.8) 244 1.200 0.315 
High 180(30) 420(70) 600 
P-cadherin 
Negati ve 128(3 1.6) 277(68.4) 405 0.498 0.507 
Positive 137(29.4) 329(70.6) 406 
E-cadherin 
Negative 138(34.8) 259(65 .2) 397 5.444 0.022 
Positive 180(27.9) 465(72. 1) 645 
HER2 
Negative 289(31.4) 632(68.6) 92 1 1.580 0.235 
Positive 36(26.1) 102(73.9) 138 
EGFR 
Negative 222(30.1) 515(69.9) 737 0.001 1.000 
Positive 52(30.2) 120(69.8) 172 
BcI-2 
Negative III (32.4) 232(67.6) 343 4.20 1 0.045 
Positive 134(25.9) 383(74. 1) 5 17 
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Table 3.30: Relation of BEX1 expression to other biomarkers in the ER-
positive cohort 
REX I expression 
Variable Low High Total X2 p-value 
CKS/6 3. 138 0.080 
Negative 198(28.7) 491 (71.3) 689 
Positive 9(17.3) 43(82.7) 52 
CKI4 
Negative 196(29.2) 476(70.8) 672 1.696 0.223 
Positive 12(21. 1 ) 45(78.9) 57 
CKI8 
Negative 13(46.4) 15(53 .6) 28 4.848 0.033 
Positive 184(27.3) 489(72 .7) 673 
CKI9 
Negative 13(33.3) 26(66.7) 39 0.599 0.464 
Positive 195(27.6) 511 (72.4) 706 
PgR 
Negative 62(34. 1) 120(65.9) 182 4.984 0.028 
Positive 142(25.5) 414(74.5) 556 
AR 
Negative 56(33.3) 11 2(66.7) 168 2.596 0.116 
Positive 142(26.9) 386(73.1) 528 
pS3 
Negative 184(30.2) 426(69.8) 610 6.538 0.070 
Positive 25(19.1) 106(80.6) 131 
MIBI 
low 54(27.3) 144(72.7) 198 0.001 1.000 
High 103(27.2) 275(72.8) 378 
E-cad herin 
Negative 89(32.4) 186(67.6) 275 3.803 0.053 
Positive 120(25.7) 347(74.3) 467 
P-cadherin 
Negative 11 2(30.5) 255(69.5) 367 3.803 0.058 
Positive 62(23 .5) 202(76.5) 264 
HER2 
Negative 196(29) 481(71) 677 1.440 0.295 
Positive 13(21.7) 47(78.3) 60 
EGFR 
Negative 164(28.8) 406(7 1.2) 570 
Positive 19(21.1 ) 71(78.9) 90 2.276 0. 163 
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3.7.3.1 Correlation between BEXI expression and patient outcome 
In the whole series, BEXI was associated with longer BCSS (LR=8.807& 
p=0.003) (Fig 3.21A) and longer DMFI (LR=7.926& p=0.005) (Fig 3.21B). 
This association with longer survival was also demonstrated in the ER-positive 
luminal-like patient cohort regarding BCSS (LR=8.040& p=O.005) (Fig 3.2IC) 
and DMFI (LR=6.497& p=O.OII) (Fig 3.2ID). 
Multivariate Cox regression analyses including tumour size, tumour grade, 
lymph node stage and systemic therapy groups showed that BEX 1 expression 
was an independent prognostic marker for longer BCSS in the whole series 
(HR=0.725, p=0.015, 95% CI=O.559-0.940) and in the ER-positive luminal-
like cohort (HR =0.694, p=0.033, 95% CI=0.496-0.971) (Table 3.31). 
BEXI expression was also an independent prognostic marker for longer DMFI 
in the whole series (HR=O.740, p=O.017, 95% CI=0.577-0.948) and in the ER-
positive luminal-like cohort (HR =0.748,p=O.033, 95% CI=O.545-1.027). 
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Table 3.31: COX analysis model of BEX 1 protein expression, tumour grade, 
LN stage, tumour size and adjuvant therapies in the ER-positive cohort in 
relation to BCSS 
Variable p value HR 95% CI 
Lower Upper 
BEXI expression 0.033 0.694 0.496 0.971 
Endocrine Therapy 0.060 0.668 0.439 1.0 17 
Chemotherapy 0.022 0.502 0.278 0.905 
Tumour size <0.001 2. 178 1.528 3.105 
Tumour stage (2) vs. (1) 0.001 1.998 1.350 2.958 
Tumour stage (3) vs. (1) <0.001 3.6 17 2. 118 6.178 
Tumour grade (2) vs. (1) 0.016 1.958 1.134 3.38 1 
Tumour grade(3) vs. (1) <0.001 4.822 2.720 8.550 
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Figure 3.21: Kaplan Meier plots of BE Xl expression 
(A)Kaplan Meier plot of BEXl protein expression in relation to BeSS in the 
whole series. (B) Kaplan Meier plot of BEXl protein expression in relation to 
DMFI in the whole series. (e) Kaplan Meier plot of BEX1 protein expression 
in relation to BeSS in the ER-positive cohort. (D) Kaplan Meier plot of BEXl 
protein expression in relation to DMFI in the ER-positive cohort. 
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3.8 Discussion 
Oestrogen receptor positive breast cancers fonn a large proportion of breast 
cancer patients and within this group much effort is being applied to discover 
reliable markers that can be used in patient prognosis and in determining 
response to various methods of postoperative therapies. In this chapter, we 
reported on biomarkers that have been previously identified using gene 
expression studies; to study if that was able to consistently classify the luminal 
cancer into patho-biological subgroup. We investigated the protein expression 
of FOXAl, IFFl, IFF3, BEXl, RERG, XBPI and GAIA3 using high 
throughput IMAs with IHC to detennine their association with a number of 
clinical parameters including age, tumour size, tumour grade, lymph node 
stage, development of distant metastases, local recurrence, expression of ER 
and progesterone and HER2, in addition to luminal and basal cytokeratins. 
3.8.1 FOXAI 
FOXAI has recently received a lot of attention because it mediates the 
expression of 50% of ER-regulated genes (Holmqvist et aI., 2005, Laganiere et 
aI., 2005) through its important functional activity on chromatin and the 
histones H3 and H4 (Cirillo and Zaret, 2007). By opening chromatin, FOXAI 
is thought to facilitate the expression of ERa associated genes (Carroll et aI., 
2005) and it has been speculated that survival and proliferation of breast cancer 
epithelial cells may be under the control of a pathway that involves ER and 
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FOXA1. Previous studies of FOXA1 in breast cancer have shown conflicting 
roles with both growth repression and stimulation effects. 
In the present study, we investigated the expression of FOXAI protein, using 
immunohistochemistry in a large and well characterised cohort of breast cancer 
cases using IMAs, to evaluate its biologic and prognostic role in unselected 
and ER-defined breast cancer subsets. In particular, we investigated whether 
FOXA1 could be used to subclassify luminal tumours. In unselected breast 
cancer patients, we found that FOXAI expression was associated with lower 
histologic grade, lower mitotic counts, smaller tumour size, and positive 
expression of hormone receptor positivity (ERa, PgR and AR) and other 
luminal markers. In addition, FOXA 1 expression was positively associated 
with BRCA1, consistent with previous reports proposing that FOXAI can 
block metastatic progression via influencing the BRCAI associated cell cycle 
inhibitor p27 expression and regulating E-cadherin expression (Williamson et 
al., 2006, Liu et al., 2005). In support of this hypothesis, although we found 
that FOXA 1 expression did not show a significant association with the 
development of distant metastasis there was an inverse relationship trend. 
Furthermore, FOXAI expression showed a lack of association with other 
markers of aggressive tumour phenotype including epidermal growth factor 
receptors and p53. Moreover, FOXAI protein expression showed a significant 
inverse association with the basal phenotype (CK5/6 & CK14 positivity) which 
is reported to have high proliferative activity and poor prognosis (Rakha et aI., 
2006). 
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Studies in MCF-7 cells suggested downregulation of FOXAI mRNA levels 
following oestrogen stimulation (Frasor et aI., 2003). Interestingly we have 
observed that positive FOXA 1 expression is associated with good survival in 
patients who did not receive hormonal treatment. These patients are mostly ER 
negative where the ER-dependent downregulation involving FOXAI is absent 
and this might lead to activation of FOXAI growth inhibitory function. 
Collectively, these results support a tumour suppressor function for FOXAI 
achieved through a growth inhibitory effect. Our findings are in agreement 
with previous studies showing association of FOXA 1 with less-aggressive 
tumour characteristics (Badve et aI., 2007, Wolf et aI., 2007). 
An important finding of this study is the lack of prognostic significance of 
FOXAI expression as assessed by immunohistochemistry in ER-positive 
tumours, thus contrasting previous results global gene expression profiling 
studies, which showed that FOXA 1 expression is a feature of Luminal A 
tumours. Our results support the growth inhibitory role of FOXA 1 in breast 
cancer and emphasized its potentially important biological role and the strong 
association between FOXAI and ER. 
3.8.2 RERG 
It is thought that novel approaches may be more appropriate for biomarkers 
discovery in breast cancer. Among the machine learning based methods, 
Artificial Neural Networks (ANNs) are emerging as valuable tools for this 
purpose. In this study, we used a transcript expression profiling of 128 frozen 
breast cancer cases and analysed the normalised expression values using 
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ANNs. Additionally, a cross-validation analysis in combination with a 
majority-vote ensemble sample classification was applied in order to obtain a 
more robust selection and ranking of genes to characterise the ER-positive 
breast cancer samples. We identified Ras-related, oestrogen-regulated growth 
inhibitor (RERG) as a candidate marker for differentiating between luminal 
and non-luminal classes among other genes including GAIA3, CA12 and 
ESRI which have been reported previously for characterising luminal class 
membership. 
RERG is a GIP-binding protein with intrinsic GTPase activity (Finlin et aI., 
2001) and was initially identified as one of the genes that characterise Luminal 
A tumours using gene expression arrays. The expression of RERG has been 
reported to be decreased in the aggressive ER negative subtypes (Sorlie et aI., 
2001). 
In our analysis of BC gene expression data, RERG correlated with high ER 
expression status using an ANN model and clearly belonged to the best-ranked 
genes for differentiating between luminal and non-luminal cases, being 
selected in each cycle a leave-one-out external cross-validation analysis that 
provided an average classification accuracy of 88.3%. Although RERG gene 
expression has been reported to be associated with ER-positive breast cancer in 
our analysis and previous studies, its protein expression has not been studied in 
breast cancer. To validate the gene expression findings, we studied RERG 
protein expression in invasive breast cancer using TMAs and 
immunohistochemistry. We found good agreement between protein and gene 
expression results, highlighting the importance of RERG as a candidate 
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luminal marker. RERG protein expression showed significant associations with 
luminal CKs (CKI8), FOXA1, E-cadherin, steroid receptors and p27 which are 
all markers associated with good prognosis and luminal phenotype. In vitro 
studies also lend support to its association with good-prognostic phenotypes 
because RERG mRNA expression is induced rapidly in ER-responsive MCF-7 
cells stimulated by oestradiol and repressed by ER-antagonist tamoxifen 
treatment (Finlin et aI., 200 l). 
In contrast, we found an inverse relation between RERG protein expression 
and indicators of cell proliferation such as tumour grade, mitosis and MIB 1 
expression and this observation of altered cellular proliferation has been 
proposed as an explanation for the difference in prognosis seen within luminal 
tumours. In agreement with this observation, our protein expression results 
confirmed that RERG expression is associated with tumours displaying low 
MIBl expression supporting the growth inhibitory function of RERG. The 
association of RERG with low tumour grade was also seen on mRNA level. 
For these reasons, we propose that within the luminal classes, expression of 
ER, RERG and MIB 1 could be used to define biological subgroups with 
different prognoses. ER+ RERG+ MIB low could represent a luminal subgroup 
with good prognosis while those with an ER+ RERG- MIB 1 high phenotype 
could define a luminal subclass with poor prognosis. 
A key aim of this study was to assess the prognostic ability of RERG protein 
expression in ER-positive luminal-like BC patients. In this important group of 
patients, we found that RERG expression was significantly associated with 
154 
Chapter 3 
longer BCSS and longer DMFI which implies its role in subclassification of 
ER-positive groups into prognostic subgroups. 
3.8.3 GATA3 
In breast cancer, GAT A3 has emerged as a strong predictor of tumour 
differentiation, oestrogen-receptor status, and clinical outcome. Supporting the 
important prognostic role of GA TA3, Dolled-Filhart and colleagues have 
shown in their clustering study that the minimal discovered set of tissue 
biomarkers with maximal prognostic or predictive value applied to 
conventional formalin-fixed, paraffin-embedded tissue sections was GAT A3, 
NATI, and oestrogen receptor (Dolled-Filhart et aI., 2006). 
Gene expression studies have shown that Luminal A breast cancers show the 
highest expression of GAT A3 in comparison to Luminal B. In our gene 
expression study, GATA3 was significantly associated with the luminal-like 
ER-positive breast cancer. To validate these findings, we have performed 
protein expression analysis in 1,045 breast tissue samples using high 
throughput immunohistochemistry on TMAs. The results of this study showed 
a statistical positive correlation between GA TA3 and markers of good 
prognosis including steroid receptor positivity, luminal CKs, BRCAl, Bcl-2 
and FOXA 1 in agreement with others (Mehra et aI., 2005). These associations 
provide further evidence that GAT A3 could be used as a marker of the ER-
positive luminal-like breast cancer. Confirming the association between 
GATA3 and ER, we found that 97.3% of GATA3 positive tumours were also 
ER positive. In the ER-positive group, 33.3% of cases were GATA3 positive. 
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This number is close to the results of Voduc et ai. who found that 39% of ER 
positive casa were also GATA3 positive (Voduc et aI., 2008). 
Tumour grade is a good indicator of breast cancer progression and 
differentiation status. It has been shown that high expression of GA T A3 
correlates with low tumour grade by cDNA microarray studies. Similarly, 
Mehra and co-workers showed that loss of GA T A3 expression is associated 
with higher histological grade (Mehra et aI., 2005). Supporting this, we found a 
strong correlation between GAT A3 protein expression and low tumour grade 
with the more differentiated breast carcinomas expressing lower levels of 
GAT A3 protein. 
Previous studies have shown an important role of GAT A3 in inhibiting tumour 
metastasis through its association with E-cadherin expression in which GAT A3 
acts as a predominant factor to induce E-cadherin and have presented an 
evidence of the association of GAT A3 with the reversal of EMT in the 
inhibition of tumour metastasis (Yan et aI.). Recently, Kouros-Mehr and 
colleagues have found that restoration of GAT A3 in advanced mammary 
carcinoma of transgenic animals triggered cancer cell differentiation and 
subsequently suppressed cancer metastasis (Kouros-Mehr et aI., 2008). 
Supporting these studies, we found a highly significant association between 
GATA3 and E-cadherin expression with a significant reduction in OM 
formation in GAT A3 expressing tumours. 
A key aim of this study was to assess the prognostic role of GAT A3 protein 
expression in ER-positive luminal-like BC patients. In this important group of 
patients, we found that GAT A3 expression was significantly associated with 
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longer BeSS and longer DMFI which implies its role in subclassification of 
ER-positive groups into prognostic subgroups. 
3.8.4 Trefoil factors 
IFFI has been reported to be correlated with hormonal status but its value, 
either at the protein or mRNA level, has shown contradictory results. IFF 1 
protein expression is induced by oestrogen through oestrogen receptors (ER), 
and is known to be inhibited by antiestrogen in the breast cancer (Ribieras et 
aI., 1998). 
We found that IFFI is significantly and positively related to ER and 
progesterone protein expression, in agreement with the findings of other 
investigators (Henry et aI., 1991). Contrasting with our results Amiry and 
colleagues demonstrated an oncogenic role for IFFI and showed that forced 
expression of IFF 1 in mammary carcinoma cells promotes mammary tumour 
progression in vitro and in vivo and functional inhibition of IFFI by RNA 
interference decreased the oncogenic properties of breast carcinoma cells 
(Amiry et aI., 2009). 
In this study, there was a non-significant correlation between IFFI expression 
and overall survival and the disease free interval. On the other hand, IFFI was 
reported as an independent prognostic factor in primary breast cancer and 
lymph node-negative patients (Foe kens et aI., 1993). 
In our study, we showed that IFFI was more expressed in low grade tumours, 
in accordance with other investigators (Joachim et aI., 2003, Speiser et aI., 
1994). 
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An important finding of this study was the lack of prognostic significance of 
TFFI expression as assessed immunohistochemistry in ER-positive tumours, 
thus contrasting with previous results from global gene expression profiling 
studies, which showed that TFFI expression is a feature of Luminal A tumours. 
Our data have shown that TFF3 expression was associated with markers of 
luminal differentiation including luminal CKs, steroid receptors, 8cl-2 
confirming its association with luminal phenotype. Although TFF3 was 
previously reported to be associated with the good prognosis Luminal A 
molecular class, our data showed that TFF3 expression is associated with poor 
outcome in luminal-like cancer and was not related to patients' survival in the 
whole series. The strong association between TFF3 and HER2 may explain the 
poor prognosis of ER+ TFF3+ phenotype although TFF3 was reported to be a 
characterising marker of Luminal A sUbtype. TFF3 could characterise a 
subgroup of ER-positive with increased HER2 expression. Supporting our 
findings, Wilson and co-workers reported that TFF3 was overexpressed in 
HER2- positive breast cancer cells in vitro and was not expressed in HER2-
negative cell lines (Wilson et aI., 2002). These finding are in agreement with 
ours that showed a strong association with HER2 protein expression in both 
ER-positive luminal-like cohort and in the whole series. 
Previously, TFF3 expression has been linked to metastatic potential in an 
animal model of colon cancer and contributed to the malignant behaviour of 
colon cancer cells (8abyatsky et aI., 2009). An in vivo animal study has shown 
that both endogenous and constitutive expression of TFF3 correlates with an 
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aggressive phenotype (Yio et aI., 2005). The expression of TFF3 was 
associated with metastasis in ER-positive patient group despite its association 
with good prognostic markers. This could be explained by its association with 
the HER2 oncogene. 
3.8.5 XBPI 
X-box-binding protein-l (XBP-l) is a key transcriptional factor of the UPR 
that activates genes required for protein folding and degradation to restore 
endoplasmic reticulum function (Hetz et aI., 2008). 
XBPI is stimulated by endoplasmic reticulum stress as part of the unfolded 
protein response (UPR), which can promote apoptosis or cell survival. Gene 
expression profiling of breast cancer tissue has previously shown an 
association between ER and XBP-l expression because of its association with 
Luminal A breast cancer (Rzymski and Harris, 2007). The XBP-l mRNA 
expression in ER-positive breast cancers was 2.7-fold as much as that in ER-
negative breast cancers (Bertucci et aI., 2000). Contrary to this, our results 
demonstrated a lack of significant association between ER and XBP I. 
Scriven and co-workers showed for the first time that oestrogenic stimulation is 
also sufficient to induce downstream effectors ofUPR activation such as XBPI 
(Scriven et aI., 2009). 
In a previous study XBPI was found to be expressed in 90% of breast cancer 
(Scriven et aI., 2009). In this study, about 15 percent showed complete loss of 
XBPI protein. Our results showed that strong XBPI expression was associated 
with shorter survival in ER-positive luminal-like breast cancer which could be 
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explained by a possible ER coactivator function of XBPI as previously shown 
(Ding et aI., 2003) or by its role in the regulation of chromatin unfolding 
which may be responsible for the enhancement of ER transcriptional function 
and promoting the growth of tumour cells (Fang et aI., 2004). 
Furthermore, our results showed important associations between increased C-
MYC expression, mutant p53 expression and increased XBPI expression 
which further explain the poor prognosis seen in ER + XBP 1 + phenotype. 
3.8.6 BEXt 
Our gene expression data has shown that BEXl shows a great variation in the 
normalised expression value within the ER-positive cohort indicating an 
important role in the biology of luminal-like breast cancer. The results of this 
study showed for the first time the association of SEXI with markers of good 
prognosis including lower tumour grade, PgR and luminal CKl8, supporting 
other studies that BEXl has a tumour suppressor function in other cancers 
(Foltz et aI., 2006). 
Furthermore, we found increased expreSSiOn BEXl in tubular and tubular 
mixed histologic tumour type which forms with the lobular cancer the low 
nuclear grade neoplasia family that mainly fall in the good prognosis luminal-
like ER-positive breast cancer (Abdel-Fatah et aI., 2008) . 
In the whole series and ER-positive luminal-like breast cancer, BEXl 
expression was significantly associated with longer survival which implies a 
potential role in subclassification of ER-positive groups into prognostic 
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subgroups. BEXl could be used as a characterising marker of ER-positive 
breast cancer. 
Our data regarding BEX 1 are novel and we are the first to report on this marker 
and its prognostic and biological role in breast cancer using a large well 
characterised series of patients with long term follow-up. 
In conclusion, using novel bioinformatics approaches to analyse high 
dimension datasets is of value to identify candidate genes to characterise the 
ER-positive/luminal like breast cancer. Subsequently, these can be used to 
subclassify these cancers in terms of biology and prognosis. 
GATA3, BEXI and RERG were able to differentiate between luminal-like 
tumours associated with poor and good prognosis and as such they could be 
useful markers for the definition of the luminal phenotype. 
Although TFF3 and XBP 1 are associated with good prognosis Luminal A 
SUbtype in the published gene expression studies, they showed associations 
with shorter BCSS while TFFl and FOXAI was not associated with survival in 
the ER-positive subtype. This could be attributed to the difference in the 
downstream technique used (RNA in expression profiling as opposed to protein 
in immunohistochemistry studies) or a post translational modification of the 
protein product of the gene. 
These results may support the view that translation of gene expression profiling 
studies into clinical practice should be interpreted with care and individual 
markers may not show the same significance when studied in isolation and not 
as part of the expression signature. 
161 
4 Role of some ER coregulators in the biology and outcome of 
ER-positive breast cancer 
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4.1 Introduction 
It is known that oestrogen plays an important role in the development and 
progression of breast cancer mediated through the oestrogens receptor (ER) in 
ER positive breast cancer. 
Ligand binding to ER produces a specific change in the receptor structure, 
which releases it from the inhibitory effect of several chaperone proteins and 
produces receptor dimerization to initiate transcription (Klinge et aI., 2004). 
Apart from ligand binding to ER, the biologic functions of nuclear receptors, 
induding the ER, are also regulated by a group of proteins known as 
transcriptional coactivators, as well as by another group of proteins known as 
transcriptional corepressors (Nair and Vadlamudi, 2007). 
Coactivators are recruited to the target gene promoters through protein-protein 
interactions with the ER rather than by DNA binding and function as linker 
molecules between DNA binding proteins and DNA protein-modifying 
enzymes, which facilitate local structural alterations (Ma et aI., 1999). It is 
important to examine the status of the steroid receptor co-regulators to identify 
their biological and clinical significance in breast cancer. 
In this chapter we studied the biological and prognostic role of two ER 
coactivators including CARMI and PELPI with respect to patient outcome and 
biological associations. 
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4.2 CARMI 
4.2.1 Introduction 
Initially CARMI (coactivator-associated arginine methyltransferase 1) was 
described as a factor that interacts with and further stimulates the transcription 
enhancing function of the p 160 family of nuclear receptor coactivators that 
comprise other members such as SRC-IINCoAl, GRIPIITIF2/SRC-2INCoA2, 
and RAC31 ACTRI AlB lISRC-3INCoA3 (Leo and Chen, 2000, Onate et aI., 
1998). CARMI can enhance the transcriptional activation by nuclear receptors 
through methylation of histone H3 at arginine 17 (Miao et aI., 2006, Schurter et 
aI.,2001). 
Confirming its important role in chromatin remodelling, Lee and co-workers 
reported on a transient-transfection assay under which the activity of various 
nuclear receptors is highly dependent on the synergistic action between 
CARMI, and other protein acetyltransferases, p300, CBP, or p/CAF. This 
synergy was observed when low levels of nuclear receptors were expressed and 
was highly dependent on the methyl transferase activity of CARM 1 and the 
acetyltransferase activity of p/CAF, but not the acetyltransferase activity of 
p300 (Lee et aI., 2002). This also suggests that the activation of gene 
transcription involves chromatin remodelling action of CARMI which could 
be recruited by DNA-bound transcription factors. 
More recently, CARMI was also found to associate with p53, suggesting that 
this enzyme plays important roles in cell proliferation and survival (An et aI., 
2004). CARMI knocked out cells showed impaired expression of a subset of 
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NF-kappaB- dependent genes (Covic et aI., 2005) which implies that CARMI 
can act as a coactivator of transcription factors other than nuclear receptors, 
like NF-kappaB (Covic et aI., 2005, Miao et aI., 2006). 
CARM I is a critical factor in the pathway of oestrogen-stimulated breast 
cancer growth downstream of ER alpha and upstream of the cell cycle 
regulatory transcription factor E2FI and its target genes which include 
CDC25A, CCNAI, CCNEI, and CCNE2 (Stallcup et aI., 2003, Frietze et aI., 
2008). Thus, CARM I plays a critical role in breast cancer cell proliferation 
through the positive regulation ofE2FI expression. 
The expression of CARMI has been linked to the development of other human 
malignancy especially prostate cancer (Hong et aI., 2004). 
The value of CARMI as a prognostic biomarker in the context of defining 
adverse, proliferative breast cancer phenotypes remains largely unexplored. 
This particularly applies to the ER-positive / luminal-like breast cancer where 
there is a pressing and important need to identify prognostic biomarkers for 
determining clinical outcome. 
4.2.2 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed usmg the streptavidin-biotin complex method using 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) (see 
General Material and Methods Chapter). Rabbit polyclonal antibody to 
CARMI (NBIOO-I8I7; Novus Biologicals Inc., Littleton, CO, USA) was 
optimized at a working dilution of 1 :300 using full-face sections of breast 
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cancer excision tissue and TMAs to assess the heterogeneity and staining 
distribution. Negative controls were perfonned by omitting the primary 
antibody and substitution with diluent. Positive breast cancer cases were used 
as positive controls. To unmask the antigens, the sections were microwaved in 
citrate buffer pH 6 for 23 minutes. 
X-tile bioinfonnatics software was used to define optimal cut off points of the 
H-score values «30= negative/low, ~ 3 0 0 and <150= moderate and ~ 1 5 0 = =
strong expression). The X-tile program randomly divides the total patient 
cohort into two separate training and validation sets ranked by patient follow 
up time. Statistical significance was tested by validating the obtained cut points 
to the validation set. 
4.2.3 CARMI expression results 
After excluding the uninfonnative TMA cores from the study, 1130 tumours 
were available for assessment. The median age of the patients was 54 years 
(range 27-70 ±ST=9.897). Fifty one percent of patients had large tumours 
greater than or equal to 2 cm in size. Fifty eight percent of the tumours were 
ductal with no special type, 17% of the tumours were grade 1 and 26.7% 
showed good NPI. Thirty one percent of the patients developed metastatic 
disease during the period of follow-up and 41.7% developed tumour 
recurrence. The CARM 1 staining pattern was mainly nuclear with homogenous 
distribution (Fig 4.1) being detected in the nuclei of the malignant cells and 
showed decreased expression in nonnal acini. 
In the whole series, 30.5% of the tumours showed negative or low expression, 
51.3% showed moderate expression while 18.2% showed strong expression. In 
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ER-positive group, 34% of case showed negative and low expression, 51.4% 
showed moderate expression and 13.4% showed strong expression. 
4.2.3.1 Correlation between CARMI expression and other 
clinicopathological variables 
In the whole series of unselected breast cancer patients, increased CARMI 
expression was associated with young age, premenopausal status, high grade 
tumours, raised mitotic counts (p<O.OOI) and poor NPI group (Table 4.1). No 
association was found between CARMI and lymph node stage or vascular 
invasion. 
In the ER-positive group, CARMI expression was positively associated with 
higher tumour grade (p=O.004), DM (p=O.OOI), tumour recurrence (p<O.OOI). 
higher mitotic counts (p=O.OOI) and menopausal status (p=O.OOI). We found 
no associations between CARM I and LN stage, NPI groups, vascular invasion 
or histologic tumour types (Table 4.2). 
4.2.3.2 Correlation between CARMI expression and other 
biomarkers 
An inverse association was found between CARM I expression and ER, PgR, 
AR, and luminal CKI8 expression. Our results showed a positive association 
between CARMI expression and basal CKs, MIBI (p<O.OOI) expression, p53, 
HER2 and EGFR. No association was found between CARMI and CKI9, 
BRCAI or E-cadherin (Table 4.3). 
In the ER-positive group, CARMI expression was positively associated with 
p53 (p<O.OOI) and P-cadherin (p<O.OOI) (Table 4.4). 
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Figure 4.1: CARMI protein expression in breast cancer 
(A) Positive expression (full section) (x200) (B) Positive expression in a grade 
2 ductal cancer (TMA core) (xlOO) 
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Table 4.1: Relation of CARMI expression to other clinicopathological 
variables in whole series 
CARM I nuclear expression 
Variable 
low Moderate Strong 
X2 p -va lue 
A ~ e e 24.606 <0.001 
<40 19 42 23 
40-50 90 156 81 
5 1-60 117 206 56 
>60 119 175 46 
Size 7.027 0.030 
$2 cm 187 286 88 
>2 cm 1157 293 118 
LN Stage 5.537 0.236 
I (Negative) 220 340 123 
2( 1-3 LN) 95 185 57 
3(>3 LN) 28 54 26 
Grade 5 1.608 <0.001 
I 88 91 14 
2 114 194 50 
3 142 294 142 
NPI 31 .235 <0.001 
Good 122 149 3 1 
Moderate 167 34 1 128 
Poor 56 89 47 
OM 12.648 0.002 
No 261 386 128 
Positive 81 187 75 
Recurrence 10.145 0.006 
No 220 318 105 
Positive 117 25 1 92 
VI 3.181 0.528 
No 187 335 117 
Probable 32 60 24 
Definite 126 181 65 
Tumour type 19.987 0.029 
DuctallNST 170 337 149 
Lobular 51 57 13 
Tubular and Tubular mixed 77 133 28 
Medullary 7 20 9 
Other special types· II 8 I 
Mixed" 29 24 6 
Mitosis 55 .033 <0.001 
I 154 188 36 
2 55 103 30 
3 123 269 136 
Menopause 24.800 <0.001 
Premenopausal 108 2 16 108 
Postmenopausal 237 363 98 
*Includes Mucoid, invasive cribriform and invasive papillary carcinoma, 
** Include ductallNST mixed with lobular or special types 
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Table 4.2: Relation of CARM 1 expressIon to other clinicopathological 
. bl . th ER h vana es In e -pOSI Ive co ort 
CARM I expression 
Variable low Moderate Strong ·l p-value 
Age 14.343 0.026 
<40 II 24 6 
40-50 64 98 4 1 
5 1-60 93 139 29 
>60 103 133 26 
Size 1.220 0.543 
:::; 1.5 em 151 208 51 
> 1.5 cm 119 186 51 
LN Stage 3.688 0.450 
I (N egati ve ) 173 225 63 
2( 1-3 LN) 75 135 3 1 
~ 3 L N ) ) 2 1 34 8 
Grade 15.357 0.004 
I 77 77 12 
2 100 169 43 
3 93 148 47 
NPI 8.478 0.076 
Good 108 131 26 
Moderate 123 2 10 60 
Poor 40 53 16 
DM 14.200 0.001 
No 2 12 262 64 
Positive 57 129 38 
Recurrence 16.583 <0.001 
No 183 2 12 5 1 
Positive 82 175 49 
VI 4.285 0.369 
No 150 22 1 55 
Probable 28 46 18 
Definite 93 125 29 
Tumour type 15.287 0.122 
DuctallNST 127 195 60 
Lobular 46 52 II 
Tubular and Tubular mixed 68 115 25 
Medullary 0 5 0 
Other special types 7 5 I 
Mixed 23 22 5 
Mitosis 17.677 0.001 
1 137 163 29 
2 45 83 27 
3 78 132 45 
Menopause 15.189 0.001 
Premenopausal 75 131 50 
Postmenopausal 196 263 52 
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Table 4.3: Relation of CARMI expression to other biomarkers in the whole 
senes 
CARMI expression 
Variable Low Moderate Strong "t p-va lue 
CKS/6 
Negative 294 470 141 33 .175 <0.00 1 
Positive 33 94 59 
CKI4 
Ne_gative 303 472 156 21.190 <0.001 
Positive 22 77 40 
CKI8 
Negative 32 73 39 11.519 0.003 
Positive 278 439 143 
CK19 
Negative 30 49 27 3.916 0.141 
Positive 299 508 173 
ER 
Negative 67 164 95 46. 195 <0.001 
Positive 258 383 99 
P ~ R R
Negative 125 226 11 2 19.182 <0.001 
Positive 194 318 82 
AR 
Negative 104 174 94 21.951 <0.001 
Positive 209 345 87 
pS3 
Negative 271 398 106 52.109 <0.001 
Positive 51 153 87 
ORCAI 
Negative 45 60 32 4.400 0.111 
Positive 237 390 126 
MIBI 
low 91 125 21 20.554 <0.001 
High 81 162 68 
P-eadherin 
Negative 169 193 51 40.8 15 <0.001 
Positive 110 265 11 2 
E-cadherin 
Negative 132 222 72 0.777 0.678 
Positive 193 322 121 
HER2 
Negative 305 481 154 18.803 <0.001 
Positive 26 75 41 
EGFR 
Negative 254 38 1 120 16.106 <0.001 
Positive 39 98 48 
Cyelin E 
Negative 97 159 50 9.304 0.010 
Positive 4 15 II 
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Table 4.4: Relation of CARM 1 expression to other biomarkers in the ER-
positive cohort 
CARMI expression 
Variable Low Moderate Strong 'l p-value 
CKS/6 
Negative 25 1 360 87 9.383 0.015 
Positive 13 30 14 
CKI4 
Negative 252 349 88 4.660 0.097 
Positive 12 31 10 
CKI8 
Negative 12 16 3 0.34 1 0.843 
Positive 243 353 89 
CKI9 
Negative 17 18 6 0.972 0.615 
Positive 250 370 96 
PgR 
Negative 74 85 25 3.612 0.164 
Positive 186 303 77 
AR 
Negative 66 72 22 3.40 1 0.183 
Positive 192 297 70 
pS3 
Negative 232 315 68 21.084 <0.001 
Positive 30 72 32 
BRCAI 
Negative 29 27 6 3.295 0.193 
Positive 205 390 76 
MIBI 
low 82 107 16 6.902 0.032 
High 60 90 29 
P-cadherin 
Negative 157 175 41 15 .5 16 <0.001 
Positive 75 155 44 
E-cadherin 
Negative 101 152 34 1.054 0.590 
Positive 164 232 66 
HER2 
Negative 247 350 85 5.447 0.066 
Positive 17 33 14 
EGFR 
Negative 219 289 71 7.163 0.028 
Positive 24 58 17 
Cyelin E 
Negative 82 116 27 3.535 0.171 
Positive I 2 2 
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4.2.3.3 Correlation between CARMI expresion and patient 
outcome 
Breast cancer specific survival (BCSS) 
In the whole patient series, an association between CARM 1 expression and 
shorter BCSS was found (Log Rank (LR)=28.786, p<O.OOI) (Fig 4.2a). 
Multivariate Cox hazard analysis including tumour size, histologic grade, 
lymph node stage, vascular invasion, systemic therapy groups and CARM 1 
expression showed that CARM I expression was an independent predictor of 
shorter BCSS (Hazard ratio (HR)=2.l79, p<O.OOI, 95%CI=1.465-3.242) 
(Table 4.5). 
In the ER-positive cohort, CARMI expression also showed an association with 
shorter BCSS (LR=17.994, p<O.OOI) in univariate analysis (Fig 4.2C). In 
multivariate analysis of ER-positive cohort, strong CARMI expression was an 
independent predictor of shorter BCSS (HR=3.084, p<O.OOI, 95% CI=1.768-
5.381) (Table 4.6) 
Disease free interval (DFI) 
In the whole patient series, an association between CARM I expression and 
shorter DFI was found (LR=12.919, p=O.002) (Fig 4.2B). Multivariate Cox 
hazard analysis showed that CARM 1 expression was an independent predictor 
of shorter DFI (HR=1.6, p=O.004, 95% CI=1.116-2.205) (Table 4.5). In the 
ER-positive cohort, CARMI expression showed an association with shorter 
DFI (LR=15.004, p=O.OOI) in univariate analysis (Fig 4.20) as well as in 
multivariate analysis (HR=2.267, p<O.OOI, 95% CI=1.491-3.447) (Table 4.6). 
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4.2.3.4 Outcome according to systemic therapy groups 
Significant associations with shorter BCSS and DFI were maintained when we 
analysed our data according to the systemic therapy groups. 
In the group of patient that did not receive adjuvant therapy (n=387), CARMI 
expression showed an association with shorter BCSS (LR=21.200, p<O.OOI) 
(Fig 4.3A) and DFI (LR=II.697, p=O.003) (Fig 4.38). 
In the group of ER-positive honnonal therapy treated patients (n=367), 
CARMI expression showed an association with shorter BCSS (LR=I1.266, 
p=O.004) (Fig 4.3C). 
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Figure 4.2: Kaplan Meier plots of CARMI expression 
(A) Kaplan Meier plot of CARM 1 expression in relation to BCSS in the 
whole series. (B) Kaplan Meier plot of CARM I expression in relation 
to OFI in the whole series. (C) Kaplan Meier plot of CARMI 
expression in relation to BCSS in the ER-positive patient cohort. (D) 
Kaplan Meier plot of CARMI expression in relation to OF! the ER-
positive patient cohort. 
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Figure 4.3: Kaplan Meier plots of CARM 1 expressIOn In systemic therapy 
groups 
(A) Kaplan Meier plot of CARM 1 expression in relation to BCSS in the 
untreated patient group. (B) Kaplan Meier plot of CARM I expression in 
relation to DFI in the untreated patient group. (C) Kaplan Meier plot of 
CARMI expression in relation to BCSS in the ER-positive tamoxifen only 
treated patient group 
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Table 4.5: Multivariate COX regression model for predictors of BCSS and 
DFI in the whole patient series 
Variable 
BeSS DFI 
P value HR 95%CI P value HR 95%CI 
Lower Upper Lower Up per 
CARMI (Low) 0.00 1 0.009 
CA RMI (Modera te vs.low) 0.01 1 1.537 1.105 2.136 0.015 1.348 1.059 1.717 
CA RMI Strong vs. low) <0.00 1 2.179 1.465 3.242 0.004 1.600 1.160 2.205 
Chemotherapy 0.006 0.556 0.368 0.842 <0.00 1 0.544 0.387 0.766 
Endocrine Therapy 0.259 0.819 0.578 1.159 0.005 0.675 0.513 0.889 
Tumour size 0.004 1.614 1.1 64 2.238 0.0 14 1.344 1.06 1 1.702 
LN stage (I) <0.00 1 <0.00 1 
LN stage (2) vs. (I) 0.00 1 1.700 1.226 2.359 0.008 1.432 1.1 00 1.863 
LN stage (3) vs. (I) <0.00 1 3.679 2.496 5.424 <0.00 1 3.643 2.625 5.055 
Tumour grade (I) <0.00 1 0.005 
Tumour grade (2) vs. (I) 0.010 2.134 1.197 3.807 0.264 1.208 0.867 1.683 
Tumour grade (3) vs. (I) <0.00 1 4.035 2.27 1 7.170 0.004 1.667 1.182 2.35 1 
Vascular invasion (Definite 0.00 1 1.598 1.198 2. 133 0.00 1 1.502 1.1 89 1.897 
vs. no) 
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Table 4.6: Multivariate COX regression model for predictors of BCSS and 
OFI in the ER-positive Iluminal like subgroup 
Variable 
BCSS OFf 
P value HR 95%Cf P value HR 95%Cf 
Lower Upper Lower Upper 
CARMI (Low) <0.00 1 <0.00 1 
CA RMI (Moderate vs.low) 0.001 2.02 1 1.330 3.073 <0.00 1 1.700 1.270 2.276 
CARM I Strong vs. low) <0.00 1 3.084 1.768 5.381 <0.00 1 2.267 1.49 1 3.447 
Chemotherapy 0.0 18 0.467 0.248 0.880 0.004 0.49 1 0.30 1 0.799 
Endocrine Therapy 0.338 0.793 0.494 1.274 0.006 0.609 0.427 0.868 
Tumour size 0.003 1.923 1.248 2.962 0.0 14 1.437 1.076 1.9 17 
LN stage (I) <0.00 1 <0.00 1 
LN stage (2) vs. (I) 0.006 1.805 1.184 2.753 0.009 1.54 1 1.112 2.135 
LN stage (3) vs. (I) <0.00 1 4.931 2.9 15 8.340 <0.001 4.455 2.897 6.850 
Tumour grade (I) <0.00 1 0.004 
Tumour grade (2) vs. (I) 0.Q28 2.034 1.080 3.83 1 0.138 1.320 0.915 1.905 
Tumour grade (3) vs. (I) <0.00 1 4.255 2.190 8.267 0.00 1 1.960 1.296 2.965 
Vascular invasion (Definite 0.008 1.645 1.138 2.378 0.0 14 1.430 1.076 1.902 
vs. no) 
178 
Chapter 4 
4.3 PELP! 
4.3.1 Introduction 
PELP I (proline, glutamate and leucine rich protein I) consists of 1,282 amino 
acids and is located on chromosome 17 (Vadlamudi et al., 2001). It improves 
17ft-oestradiol (E2) dependent transcriptional activation from the oestrogen 
response element in a dose-dependent fashion and shows high expression in 
various tissues especially in the testes, breast, and brain. Importantly, PELPI 
may add to the oncogenic properties of cancer cells by acting as a scaffolding 
protein that relates many signalling processes with ER through its interaction 
with other oncogenes including SRC, PI3K, STAT3 and EGFR (Vadlamudi et 
al.,2001). 
Previous gene knock down studies of PELP I have shown reduced E2 
activation of Akt signalling pathway significantly, and inhibited E2 genomic 
transcriptional effects on gene expression in breast cancer cells (Brann et aI., 
2008). Regulation of aromatase by PELP I represents a novel mechanism for 
autocrine oestrogen synthesis which may lead to tumour proliferation (Raj hans 
et al., 2008). These findings suggest an important tumourigenic role of PELPI 
and may open a new targeted therapeutic approach by its inhibition (Nagpal et 
aI., 2008). 
Other studies suggest a different mechanism for the oncogenic properties of 
PELPI through its involvement in histone remodelling. PELPI maintains the 
balanced hypoacetylated state of histones, while ER binding reverses its role 
through hyperacetylation of histones through an unknown mechanism (Choi et 
179 
Chapter 4 
aI., 2004). In addition, it has been suggested that PELPI contributes to 
chromatin remodelling by affecting certain types of histone in cancer cells 
(Nair et al., 2004). In a small previous breast cancer study, PELPI expression 
was reported to be up-regulated in higher grade lymph node positive invasive 
tumours (Rajhans et aI., 2008, Rajhans et aI., 2007) but the study did not 
specifically focus on PELPI expression in ER-positive/luminal cancers. 
The value of PELP I as a prognostic biomarker in defining breast cancer 
phenotypes remains undetermined. Therefore, our aim was to investigate the 
clinical relevance and biological relations of PELPI protein expression in a 
large series of consecutive patients with invasive breast cancers using high-
throughput tissue microarrays (TMAs) and immunohistochemistry and to test 
its association with other clinically and biologically relevant biomarkers. In 
addition, PELPI protein expression was investigated in the ER-positve 
patients' cohort. 
4.3.2 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed using the streptavidin-biotin complex method using 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
(General Material and Methods Chapter). 
Rabbit polyclonal antibody to PELPI (NBIOO-1749; Novus Biologicals Inc., 
Littleton, CO, USA) was optimized at a working dilution of I: I 00 using full-
face sections of breast cancer tissue to assess the staining distribution. Negative 
controls were performed by omitting the primary antibody and substitution 
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with diluent. Peptide blocking with PELPI antigen (Novus Biologicals, 
NBlOO-1749PEP) was performed to verify the antibody specificity. Positive 
breast cancer cases were used as positive controls. 
The H-score (histochemical score) was used for assessment. The X-tile (Camp 
et aI., 2004) program was used to define optimal cut off points of PELPI H-
score values «5=negative/low, ~ 5 a n d < 1 7 0 = m o d e r a t e e and ~ 1 7 0 = s t r o n g g
expression). 
4.3.3 PELP! expression results 
After excluding the uninformative TMA cores from the study, 1,162 tumours 
were available for assessment. The median age of the patients was 55 years 
(range 27-70). Sixty eight percent of patients had tumours greater than or equal 
to 1.5 cm in size. Fifty nine percent of the tumours were ductal of no special 
type, 17% of the tumours were grade 1 and 27.8% showed good NPI. Thirty 
percent of the patients developed metastatic disease during the period of 
follow-up and 41.7% developed tumour recurrence. 
PELP I staining was detected in the nuclei of the malignant cells as well as in 
some luminal ductal epithelial cells of associated normal tissues in the cores. 
Applying the peptide blocking successfully abrogated staining (Fig 4.4B). The 
In the whole series, 17.2% of the tumours showed negative or low expression, 
69.3% showed moderate expression (Fig 4.4CID) while 13.5% showed strong 
expression (Fig 4.4A). No cytoplasmic staining was observed. 
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4.3.3.1 Correlation between PELPI expression and other 
clinicopathological variables 
In the whole series of un selected breast cancer patients, increased PELP I 
expression was associated with markers of poor prognosis such as large 
primary tumour size, raised mitotic counts (p=O.004), recurrence and poor NPI 
group. 
No associations were found between PELPI and patients' age, lymph node 
stage, vascular invasion and menopausal status (Table 4.7). When the analysis 
was repeated on ER-positive/luminal-like group of tumours (n=768), PELPI 
expression showed border line associations with large tumour size and 
development of tumour recurrence (p=O.027) (Table 4.8). 
4.3.3.1 Correlation between PELPI expression and other 
biomarkers 
In the whole series, we found significant positive associations between PELP I 
expression and biomarkers of poor prognosis including P-cadherin, p53, and 
CARMI (p<O.OOI). An inverse association was found between PELPI 
expression and ERa, PgR, AR. and CK18 expression. No associations were 
found between PELPI and other biomarkers included in the study (Table 4.9). 
In the ER-positive group of tumours, PELPI expression was associated with 
CARMI expression (p<O.OOI). 
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Figure 4.4: PELPI expression in breast cancer 
(A&B) PELPI nuclear staining was lost with application of the peptide 
blocking, used as a negative control.(Ax200 & Bx200). (C&D) TMA core of a 
grade 3 ductal carcinoma showing strong positive PELPI nuclear expression 
(C xlOO & D x400). 
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Table 4.7 : Relation of PELPI expressIOn to other clinicopathological 
parameters in the whole series 
PELPI Expression 
Variable low Moderate Strong Xl p-value 
Patients' age 3.069 0.8 
<40 14 61 12 
40-50 55 23 1 45 
51-60 78 264 52 
>60 53 249 48 
Tumour size 11 .098 0.004 
<1.5 em 80 254 37 
>1.5 em 120 551 120 
Lymph node sta2e 0.930 0.920 
I (Negative) 118 49 1 92 
2( 1-3 LN) 63 238 52 
3(>3 LN) 18 73 13 
Tumour 2rade 10.045 0.040 
I 44 128 26 
2 73 247 46 
3 83 428 85 
NPI 14.045 0.007 
Poor 35 137 30 
Moderate 91 45 1 95 
Good 74 217 32 
DM 6.873 0.032 
No 145 554 97 
Positive 49 244 60 
Recurrence 11.895 0.003 
No 133 45 1 78 
Positive 62 336 76 
VI 0.593 0.964 
No III 450 83 
Probable 23 85 17 
Definite 66 268 56 
Histolo2ic tumour type 19.987 0.029 
DuetallNST 109 482 97 
Lobular 33 89 13 
Tubular and Tubular mixed 42 156 32 
Medullary 1 22 7 
Other special types . 7 10 I 
Mixed*· 8 46 7 
Mitosis 15.465 0.004 
1 88 257 48 
2 37 137 27 
3 68 388 79 
Menopausal status 1.598 0.450 
Premenopausal 67 308 60 
Postmenopausal 133 497 97 
*Includes mucOId, InvaSIve cnbnform and InvaSIve papIllary carCInoma, ** 
Includes ductallNST mixed with lobular or special types 
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Table 4.8: Relation of PELP 1 expression to other clinicopathological variab les 
in the ER-positive cohort 
PELPl Expression 
Variable low Moderate Strong ·l p-value 
Patients' age 8.354 0.2 13 
<40 5 31 3 
40-50 34 139 24 
51-60 63 175 27 
>60 45 184 38 
Tumour size 6.945 0.031 
:S1.5 em 63 189 24 
> 1.5 em 84 340 68 
Lymph node stage 1.109 0.893 
I(Negative) 89 322 51 
2( 1-3 LN) 46 167 33 
3(>3 LN) II 38 8 
Tumour Grade 4.362 0.359 
I 37 III 22 
2 67 2 17 35 
3 43 200 35 
NPI 6.379 0.173 
Poor 19 69 16 
Moderate 64 267 50 
Good 64 193 26 
OM 2.624 0.269 
No 108 375 60 
Positive 36 151 32 
Recurrence 7.222 0.027 
No 100 305 47 
Positive 45 2 16 42 
VI 4.109 0.392 
No 82 298 43 
Probable 19 60 16 
Definite 46 169 33 
Histologic tumour type 10.585 0.39 1 
DuetallNST 69 269 49 
Lobular 29 82 11 
Tubular 38 129 26 
Medullary 0 3 0 
Other special types 5 8 0 
Mixed 6 38 6 
Mitosis 8. 124 0.087 
I 80 229 38 
2 29 108 19 
3 33 175 32 
Menopausal status 3.488 0.175 
Premenopausal 38 178 27 
Postmenopausal 109 351 65 
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Table 4.9: Relation of PELP 1 expression to other biomarkers in the whole 
series 
PELPI Expression 
Variable Low Moderate Strong 'i p-value 
CKS/6 
Ne_gative 168 653 119 7.090 0.029 
Positive 23 128 35 
CKt4 
Negative 174 669 121 8.090 0.0 18 
Positive 16 97 58 
CKI8 
Negative 15 109 25 6.262 0.044 
Positive 163 619 121 
CKt9 
Negative 16 76 20 2.393 0.302 
Positive 175 705 131 
ER 
Negative 40 236 58 12. 108 0.002 
Positive 147 529 92 
P ~ R R
Negative 58 343 70 11.009 0.004 
Positive 123 420 79 
AR 
Negative 42 279 60 16.078 <0.001 
Positive 136 449 81 
~ 5 3 3
Negative 150 545 106 9.372 0.009 
Positive 33 2 17 47 
BRCAI 
Negative 21 110 12 4.882 0.087 
Positive 142 552 11 4 
BcI-2 
Negative 28 134 26 
Weak 18 11 3 20 10.961 0.090 
Moderate 53 162 20 
Strong 13 46 6 
MIBt 
low 53 163 20 8.033 0.018 
High 47 218 45 
P-cadherin 
Negative 96 295 53 12.588 0.002 
Positive 68 362 80 
E-cadherin 
Negative 69 312 57 1.240 0.538 
Positive 120 455 92 
Negative 88 425 71 
Positive 29 161 38 
CARMt 
Low 75 200 21 60.987 <0.001 
Moderate 49 366 70 
Strong 20 105 45 
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4.3.3.2 Correlation between PELP! expression and patient 
outcome 
(A) Breast cancer specific survival (BCSS) 
In the whole patient series, an association between PELP 1 expression and 
shorter BCSS was found (Log Rank (LR) =12.168, p=0.002) (Fig 4.5A). 
Multivariate Cox hazard analysis including tumour size, histologic grade, 
lymph node stage, vascular invasion, ER expression showed that PELP 1 
expression was an independent predictor of shorter BCSS (llazard ratio (HR) 
=1.349, p=0.006, 95%CI=1.091-1.668). 
In the ER-positive cohort, PELPI expression also showed an association with 
shorter BCSS (LR=7.029, p=0.030) in univariate analysis (Fig 4.5C). 
However, in multivariate Cox analysis of ER-positive cohort, PELPI was not 
an independent predictor ofBCSS (HR=1.302,p =0.061,95% CI=0.987-1.717) 
(Table 4.10). 
(A) Disease free interval (OFf) 
In the whole patient series, an association between PELP I expression and 
shorter DFI was found (LR=IO.336, p=O.006) (Fig 4.58). Multivariate Cox 
hazard analysis showed that PELPI expression was an independent predictor of 
shorter DFI (HR=1.255, p=0.01l, 95% CI=l.053-1.495). 
In the ER-positive cohort, PELPI expression showed an association with 
shorter DFI (LR=6.805, p=O.033) in univariate analysis (Fig 4.50) as well as 
in multivariate analysis (HR=1.256,p=O.036, 95% CI=l.OI5-1.553). 
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Figure 4.5: Kaplan Meier plots of PELP I expression 
(A) Kaplan Meier plot of PELPI expression in the whole series in relation to 
BCSS. (B) Kaplan Meier plot of PELPI expression in the whole series in 
relation to DFI. (C) Kaplan Meier plot of PELP 1 expression in the ER-positive 
cohort in relation to BCSS. (D) Kaplan Meier plot of PELP 1 expression in the 
ER-positive cohort in relation to OF!. 
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Table 4.10: Multivariate COX regression model for predictors ofBCSS 
(A) The whole patient cohort and (B) ER-positive patient cohort 
Variable p value HR 95%CI 
Lower Upper 
(A) Whole patient cohort 
PELPI 
0.006 1.349 1.091 1.668 express ion 
ER expression 0.104 0.808 0.625 1.045 
Tumour size 0.005 1.602 1.1 55 2.223 
Tumour stage <0.00 1 1.893 1.592 2.25 1 
Tumour grade <0.001 1.724 1.386 2. 145 
Vascular 
0.002 1.240 1.084 1.420 invas ion 
(8) ER-positive patient cohort 
PELPI 
0.061 1.3 02 0.987 1.717 expression 
Tumour size 0.009 1.718 1.144 2.58 1 
Tumour stage <0.001 1.775 1.413 2.229 
Tumour grade <0.001 1.885 1.474 2.4 12 
Vascular 
0.001 1.339 1.1 25 1.594 invasion 
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4.4 The effect of combined expression of PELP! and 
CARMI on patient survival 
The combined expression of CARMI and PELPI was investigated. The group 
of patients showing combined positive expression of both (Moderate and 
strong vs. low and negative groups) showed a significant shorter breast cancer 
specific survival (LR=14.428 and p=O.002) (Fig 4.6) and this effect was 
maintained in the ER-positive luminal-like subgroup (LR=13.797 and 
p=0.003) . 
Survival Functions 
P = = . o o ~ ~
o 50 100 150 200 
Bess In months 
250 
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Figure 4.6: Kaplan Meier plots of combined CARM 1/PELP 1 expression in the 
whole series in relation to BCSS 
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4.5 Discussion 
4.5.1 CARMI 
CARMI was originally identified because of its ability to interact with p160 
family of nuclear receptor coactivators to methylate histone H3 and activates 
transcription via chromatin remodelling. 
We found significant positive associations between CARMI and known 
features of poor prognosis including large tumour size, high tumour grade and 
frequent development of distant metastasis, tumour recurrence in the whole 
patient series as well as in the ER-positive cohort. These findings support the 
novel data by Frietze and colleagues who found that CARMI regulates 
oestrogen-stimulated breast cancer growth through up-regulation of E2F I by 
subjecting its promoter to CARM I-dependent dimethylation on histone 113 
arginine 17 (Frietze et aI., 2008). 
Supporting this further, our data showed the involvement of CARM 1 in tumour 
proliferation as elevated expression in highly proliferative tumours, assessed by 
MIB I and mitotic count was identified. 
Supporting its poor prognostic role, we found a significant positive association 
between CARMI and expression of basal CKs and p53. In contrast, we found 
an inverse relation between luminal CKs and steroid receptor expression which 
are markers of good prognosis in breast cancer. 
We found a positive correlation between cyclin E and CARMI protein 
expression in breast cancer in agreement with others (El Messaoudi et aI., 
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2006) who found CARMI is required for proper activation of endogenous 
CCNE I mRNA expression in mammalian cells. 
Our results showed a positive association between CAMRI protein expression 
and HER family members, EGFRI and HER2 suggesting a crosstalk between 
this important growth signalling pathway and ER coregulators. 
Furthermore, we have assessed the prognostic ability of CARMI In ER-
positive/luminal-like breast cancer patients. In this important group of patients, 
we found that CARMI expression was significantly associated with shorter 
BCSS and shorter DFI which implies its role in subclassification of ER-
positive groups into prognostic subgroups. These findings are also found in the 
patient group that did not receive systemic therapy to overcome the 
confounding effect of treatment on our survival analysis. 
In conclusion, this study demonstrated the biological and prognostic role of 
CARM I in breast cancer. CARM I expression was an independent prognostic 
factor of shorter survival in breast cancer and the ER-positive luminal-like 
subtype. Overexpression of CARMI is involved in the progression of breast 
cancer suggesting that targeting its expression in high proliferative breast 
cancer could be of potential in developing novel treatments for breast cancer. 
4.5.2 PELPl 
To date PELPI has not been identified as a discriminating marker in the 
luminal subclasses of breast cancer. Our results, as discussed below imply that 
192 
Chapter 4 
PELPI has the potential to stratify patients with ER positive breast cancer into 
biological subclasses with differing prognoses. 
In this study, the status of the steroid ER co-regulator PELPI was also 
investigated in a large cohort of patients with breast cancer to better understand 
its clinical and biological significance. We found a positive association 
between PELPI and markers of poor prognosis and aggressive tumour 
behaviour including larger tumour size, higher histological grade, frequent 
development of tumour recurrence in the whole patient series. These findings 
support the emerging data that PELP 1 interacts with many proteins and 
activates several oncogenes that are related to the aggressive tumour 
characteristics and metastatic behaviour, including SRC, phosphotidyl inositol 
3 kinase (PI3K), and signal transducers and activators of transcription 3 
(STAT3) (Nair and Vadlamudi, 2007). 
In this study, we found a significant positive correlation between PELPI and 
CARMI which is necessary for the E2-induced proliferation of breast cancer 
cells via E2FI and its target genes (Stallcup et aI., 2003, Frietze et aI., 2008). 
This positive correlation at the protein level suggests a possible synergistic 
action between PELPI and CARMI, being both ER coactivators, in oestrogen 
induced proliferation of ER-positive breast cancer cells. This effect was 
confirmed by studying the effect of combined expression of PELPI/CARMI 
on patient outcome indicating a significant reduction of survival. 
The significance of non-genomic ER activity in mediating oestrogen signalling 
to promote cell proliferation and survival in breast cancer cells has been 
documented (Schiff et aI., 2005). Many studies have highlighted the 
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importance of PELP 1 in tumour progression through increasing oestrogen 
mediated cell proliferation possibly through its requirement to ER alpha 
interaction with SRC which leads to activation of MAPK pathway (Cheskis et 
aI., 2008). Our data implicates the involvement of PELPI in tumour 
proliferation as we identified elevated expressions in highly proliferative 
tumours, assessed by MIB 1 and mitotic counts. 
Supporting its poor prognostic role, we found significant positive associations 
between PELPI and expression of P-cadherin and p53 which are more 
frequently expressed in basal-like breast cancer and are associated with poor 
prognosis. 
The potential prognostic role of PELPI in ER-positive/luminal-like breast 
cancer patients was investigated. PELPI expression was significantly 
associated with shorter BeSS and shorter DFI which implies its role in 
subclassification ofER-positive groups into prognostic subgroups. 
In conclusion, the results of this study demonstrated the biological and 
prognostic role of PELPI in breast cancer which cannot be considered as a 
mere reflection of ER expression as evidenced by its role in the whole series of 
breast cancer as well as in the ER-positive/luminallike subclass. 
CARMI and PELPI protein expression in breast cancer could have a role in 
clinical decision making and assessment of prognosis, particularly in the ER-
positive group. Furthermore, improved understanding of their functional role 
and their mechanism of action in breast may reveal a role as therapeutic targets. 
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5 The protein expression of biomarkers with potential 
therapeutic implication and endocrine therapy response in 
ER-positive breast cancer 
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5.1 Introduction 
ER-positive/luminal-like tumours are clearly not a homogenous group; some 
tumours respond to therapy and others do not. They are mostly low grade and 
more sensitive to endocrine therapy because of their ER-positive status 
especially in the Luminal A subclass. A proportion of ER-positive BC relapse 
after tamoxifen treatment, which is an important problem seen in clinical 
practice (Han et aI., 2006). 
To improve available therapies for ER-positive breast cancer, a better 
understanding of the mechanisms contributing to response and resistance to 
therapy is needed. It is a challenging task to discover new biomarkers that 
could be used to predict the honnonal therapy response or to be used as 
potential new therapeutic targets. 
5.2 CD71 
5.2.1 Introduction 
In this study, in collaboration with Dr Julia Gee and Prof R Nicholson (Cardiff 
School of Phannacy), it was proposed that assessment of CD71 expression 
could be used to stratify ER-positive patients to define subgroups with poor 
prognosis, high proliferation and resistance to hormonal therapy. 
The transferrin receptor (TiR, CD71) is a type II transmembrane homodimer 
glycoprotein (180 kDa) involved in the cellular uptake of iron via 
internalization of iron-loaded transferrin (Ponka and Lok, 1999, Daniels et aI., 
2006a). Transferrin (Tf) is therefore an essential component of cell growth and 
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iron-requiring metabolic processes including DNA synthesis, electron 
transport, mitogenic signalling pathways and in tum, proliferation and cell 
survival. Consequently, rapidly growing cells require more iron for their 
growth than resting cells (Daniels et aI., 2006a, Daniels et aI., 2006b). 
Not surprisingly, transferrin receptor is expressed at greater levels on cells with 
a high proliferation rate (Sutherland et aI., 1981). Over-expression of 
endogenous transferrin receptor has also been described for various cancers 
including those of lung (Dowlati et aI., 1997, Carbognani et aI., 1996), and 
pancreas (Ryschich et aI., 2004), reflecting increased cell proliferation. This 
observation can in part be attributed to the increased need for iron as a cofactor 
for the ribonucleotide reductase enzyme involved in DNA synthesis of rapidly 
dividing cells (Daniels et aI., 2006a, Daniels et aI., 2006b). 
In breast cancer, transferrin receptor expression has been shown to be up to 
five times higher in the malignant component compared to normal tissue 
(Tonik et aI., 1986), with expression relating closely to proliferative capacity in 
these tumours (Wrba et aI., 1986). Moreover, within endocrine responsive 
breast cancer cell models such as MCF-7 (representative of the ER-positive 
luminal clinical phenotype) there is believed to be a possible association 
between CD71 and oestrogen receptor signalling. Studies have revealed 17P-
estradiol (E2) can up-regulate CD71 expression in a dose-dependent manner, 
with E2 and iron showing synergistic effects in promoting proliferation (Dai et 
aI., 2008). However, it remains unknown if transferrinlCD71 signalling is a 
prominent contributor to endocrine resistant breast cancer growth, and 
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therefore if it could provide a therapeutic target specifically for this undesirable 
disease state. 
Previously, CD71 immunostaining (Wrba et al., 1986) showed elevated 
expression in poorly differentiated tumours, and a relationship with metastatic 
potential in animal mammary adenocarcinoma models (Cavanaugh et al., 
1999). 
The value of CD71 as a prognostic biomarker and a predictor of response to 
adjuvant treatment in the ER-positive/luminal-like breast cancer phenotype 
remain largely unexplored. 
Therefore, in this study we assessed the biological and prognostic role of CD71 
in breast cancer by: 1) Determining CD71 levels of expression in the endocrine 
responsive MCF-7 human breast cancer cell line as well as various sub-lines 
representative of acquired resistance to current endocrine agents (Le. 
Tamoxifen, Faslodex or severe oestrogen deprivation). 2) Examining 
transferrin effects on in vitro tumour growth and its inhibition, by evaluating 
ER blockade, phosphoinositide-3 kinase (PI3K) inhibitor L Y294002 and 
MAPK pathway inhibitor PD98059 treatment as discussed in(llabashy et al., 
2010). 3) StUdying the clinical relevance of CD71 protein expression in a large 
series of consecutive patients with invasive breast cancers using high 
throughput tissue microarrays (TMAs) and immunohistochemistry. In addition, 
we investigated if CD71 expression could be used to sub-classify ER-positive/ 
luminal-like cancers and its prognostic role in a subset of tamoxifen-only 
treated patients. 
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5.3 Material and Methods 
5.3.1 Cell culture, PCR studies and Cell growth studies 
These methods were performed by Dr Julia Gee's group and were described in 
(Habashy et al., 2010). 
5.3.2 CD7. immunohistochemistry 
The expression of CD71 was examined at the protein level using 
immunohistochemistry in various patient groups to assess its prognostic 
significance, as well as comparing staining across all the endocrine responsive 
and resistant in vitro breast cancer cell models. 
The study population was derived from the Nottingham Tenovus Primary 
Breast Carcinoma Series of women aged 70 years or less, who presented with 
primary operable invasive breast carcinomas (with tumours of less than 5 em 
diameter on clinical/pre-operative measurement, stage I and II) between 1988 
and 1998. Tissue microarrays (TMAs) were used containing a series of 853 
informative cases of un selected invasive breast carcinoma. 
Tissue microarray and immunostaining of the cell pellets and clinical 
breast cancer samples 
For paraffin-embedded pellet preparation, the methods were performed by Dr 
Julia Gee's group and were described in (Habashy et al., 2010). 
For clinical material, arrayed samples comprised single representative 0.6mm 
tissue cores taken from each tumour block, sectioned at 4 11m thickness 
(Kononen et aI., 1998). 
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Immunohistochemical staining of transferrin receptor (CD71) (clone 10Fll, 
ab49517; Abeam, Cambridge, UK) using. signal localization (plasma 
membrane, cytoplasmic) and the staining intensity was quantified using H-
score (histochemical score) analysis considering the invasive tumour 
component only (McCarty et aI., 1985). 
Statistical analysis 
Statistical analysis was perfonned using SPSS statistical software (SPSS Inc., 
Chicago, USA). Cell line growth data obtained were log-transfonned to 
compare growth rate at day 15, using ANOV A followed by a Bonferroni post-
hoc test for analysis. H-scores were compared statistically between MCF-7 and 
the resistant models using Student's t-test with post-hoc testing. Association 
between the CD71 expression (categorised by the median of the II-score ~ 5 ) )
and different clinicopathological parameters and biomarkers was evaluated 
using chi-square test. Survival curves were estimated by the Kaplan-Meier 
method with a log rank test to assess significance. Multivariate Cox regression 
analysis was used to evaluate any independent prognostic effect of the 
variables using 95% confidence intervalCD71 expression results 
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5.3.3 Endocrine responsive and resistant breast cancer cell line studies 
Immunocytochemistry on the cell pellets revealed CD71 expression was 
increased in all cell lines derived from the luminal ER-positive MCF-7 model 
that had undergone progression to endocrine resistance (Fig.S.1 C&D), with 
increased immunoreactivity localised at the plasma membrane and cytoplasm. 
Of these models, total CD71 expression was most elevated for the MCF-7X 
line with -5 fold increase versus MCF-7 (mean H-scores=144 versus 28.5). 
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Figure 5.1 : CD71 expression in cell lines and clinical samples 
(A&B) Grade 3 ductal carcinoma with positive membranous staining (Ax 1 00, 
Bx200) 
(C&D) Paraffin-embedded cell pellets: total CD71 expression was most 
elevated in the MCF-7X (C) (x200) in comparison to MCF-7 cells (D) (x200). 
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5.3.4 CD71 PCR and Growth Studies 
The results of these experiments were described previously in (Habashy et aI., 
2010) 
5.3.5 CD71 immunohistochemical results in clinical breast cancer 
5.3.5.1 Correlation between CD71 expression and other variables 
The observed CD7. staining pattern in tumour tissues was both membranous 
and cytoplasmic (Fig 5.1 A&B). 
The level and extent of staining varied from very weak focal to extensive 
strong overexpression (H-score range=5-300). CD7l overexpression was 
associated with larger tumour size, higher histologic grade and poorer NPI 
group and distant metastases. It was associated with the proliferative activity of 
tumours as assessed by mitotic counts and MIB-I expression (p<O.OOl). CD71 
expression was positively associated with other markers of aggressive tumour 
phenotype including basal CKs (CK14 and CKS/6), pS3, EGFR, and HER2. In 
contrast, CD7l expression was inversely related to ER, progesterone receptor 
(PgR), androgen receptor (AR) and Bcl-2 expression. We found higher levels 
of expression of CD7. in medullary type cancer compared with others (89%, 
p<O.OOl) (Tables 5.1 and 5.2). 
In the ER-positive/luminal-like tumours, CD7! expression showed a positive 
association with higher grade (p<0.001) and poorer NPI (p=O.004), distant 
metastasis (p=0.002) and high mitotic counts (p<O.OOl). CD71 expression was 
positively associated with pS3 (p<O.OOl) and EGFR (p<O.OOl). 
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Table 5.1: Relation of CD7 1 protein expression to other clinicopathological 
variables in the whole series 
Variable Negative Positive CD71 Total X2 p value 
CD71 N(%) 
N (%) 
Age 
<40 23(36.5) 40(63.5) 63 
40-50 78(32.2) 164(65.6) 242 0.634 0.888 
51-60 104(35) 198(65) 302 
>60 86(34.1 ) 160(65.9) 246 
Size 
<1.5 em 11 5(40.5) 169(59.5) 284 7.706 0.006 
> 1.5cm 176(30.9) 393(69. 1) 569 
LN Stage 
I (Negative) 192(35.5) 35 1(64.5) 543 1.238 0.539 
2( 1-3 LN) 73(3 1.5) 158(68.5) 23 1 
3(>3 LN) 24(3 1.6) 52(68.4) 76 
Grade 
I 81(50.3) 8Qf.49.71 16 1 78.847 <0.001 
2 128(47.1) 144(52.9) 273 
3 82( 19.5) 338(80.5) 420 
NPI 
Poor 28(23) 95(77) 123 38.912 <0.001 
Moderate 144(29) 348(7 1 ) 492 
Good 11 9(50) 1 1 ~ 5 Q l l 238 
DM 
No 220(37.7) 363(62.3) 583 10.439 0.001 
Positive 69(26.3) 193(73 .7) 262 
Recurrence 
No 172(36) 306(63) 478 1.855 0.173 
Positive 11 3(31.5) 246(68.5) 359 
VI 
No 179(35.9) 3 1 ~ 6 6 . ' l l 498 1.787 0.409 
Probable 27(3 1.8) 58(68.2) 85 
Definite 84(31.5) 183(68.5) 267 
Mitotic count 
I 153(55.6) 122(44.4) 275 98.89 <0.001 
2 52(35. 1) 96(64.9) 148 
3 72( 18.5) 317{81.5) 389 
Tumour type 
DuctallNST 121(24.9) 364(75. 1 ) 485 
Lobular 56(60) 38(40) 94 65 .803 <0.00 1 
Tubular and Tubu lar 84(44.7) 104(55.3) 188 mixed 
Medullary 3( 10.7) 25(89.3) 28 
Other special types. 8(53.3) 7(46.7) 15 
Mixed·· 19(44.2) 2 i l l l . ~ ~ 43 
*Includes MUCOId, invasive cnbnform and InvaSIve papIllary carCInoma, ** 
Include ductallNST mixed with lobular or special types 
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Table 5.2: Relation of the CD7l protein expression to other biomarkers in the 
whole series 
Variable CD71 expression 
Negative Positive 
CD71 CD71 Total X2 p value 
N(%) N(%) 
CKS/6 
Negative 247(3 7.8) 407(62.2) 654 20.527 <0.001 
Positive 32(19.2) 135(80.8) 167 
CKI4 
Negative 239(35.8) 428 (64.2) 667 10.694 0.001 
Positive 29(2 1.3) 107(78.7) 136 
CKI8 
Negative 142(33.8) 278(66.2) 420 0.280 0.579 
Positive 111(35.5) 200(64.5) 311 
HER2 
Negative 259(37.2) 437(62.8) 696 23.084 <0.001 
Positive 15(13.8) 94(86.2) 109 
pS3 
Negative 24 1{4 1.9) 334(58.1 ) 575 51.014 <0.001 
Positive 32( 14.8) 184(85.2) 2 16 
EGFR 
Negative 191 (37.2) 323(62.8) 514 16.3 16 <0.001 
Positive 29( 19.5) 120(80.5) 149 
ER 
Negative 50(18.7) 217(81.3) 267 46.012 <0.001 
Positive 229(43) 304(57) 533 
AR 
N ~ a t i v e e 78(25.6) 227(74.4) 305 18.196 <0.001 
Positive 179(40.7) 261(59.3) 440 
PgR 
Negative 90(25.6) 26 1(74.4) 351 24.011 <0.001 
Positive 186(42.4) 253(57.6) 439 
MIBI 
Low 75(42 .1) 107(58.8) 182 12.289 <0.001 
High 58(25) 174(75) 232 
Bcl-2 
Negative 29(2 1.8) 104(78.2) 133 
Weak 37(36.6) 64(63.4) 101 16.373 0.001 
Moderate 69(44.2) 87(55 .8) 156 
Strong 2 1(38.2) 34(61.8) 55 
205 
Chapter 5 
5.3.5.2 Correlation between CD7. protein expression and patient 
outcome 
In the whole series, a significant correlation between C071 expression and 
poorer BCSS was identified (Log Rank (LR)=14.833, p<0.001). In the ER-
positive/luminal-like cohort, we also found a significant association 
(LR=14.044, p<0.001) (Fig 5.2A) However, no associations were found 
between C071 expression and OFI neither in the whole series (LR=3.132, 
p=0.077) nor in the ER-positive patient group (LR=2.121,p=0.145). 
In the group ofER-positive Tamoxifen only treated patients (n=180), we found 
that C071 expression was associated with shorter Bess (LR=1O.345, 
p=O.OOI) (Fig 5.2B) and shorter OFI (LR=4.056, p=0.044) (Fig 5.2C) which 
may indicates poor response of CD7l expressing tumours to hormonal 
treatment. To support this finding, we examined the outcome in ER+C071 + 
patients that received or did not receive tamoxifen, the group of patients who 
received tamoxifen showed a significant lower BCSS (LR=5.571, p=0.018) 
(Fig 5.20) and shorter time to develop distant metastasis (LR=5.360,p=0.021). 
5.3.5.3 Multivariate analysis 
A multivariate Cox hazard model analysis for predictors of BCSS was 
performed including CD71 expression, tumour size, histologic grade and 
lymph node stage. This analysis demonstrated that C071 expression is an 
independent prognostic factor in the ER-positive/luminal-like patient group 
(HR =1.614, p =0.016, 95% CI =1.092-2.384). 
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Importantly, in ER-positive patient who received tamoxifen only, C07l was 
shown to be an independent prognostic factor of BCSS (HR=2.624, 95%CI 
=1.309-5.259 and p=O.007) (Table 5.3), where patients with C07l positive 
tumours showed shorter BCSS. 
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Figure 5.2: Kaplan Meier plots of CD71 expreSSlOn groups In relation to 
BCSS and DFI 
Kaplan Meier plots of CD7! expression and BCSS in (A) ER-positive cohort 
of unselected breast cancer patients, (B) ER-positive tamoxifen only treated 
patients. (C) Kaplan Meier plot of CD71 expression and DFI in ER-positive 
tamoxifen only treated patients. (D) Kaplan Meier plot of BCSS of patients 
received and did not receive tamoxifen in CD71 +ER+ cohort. 
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Table 5.3: Cox proportional hazards analysis for predictors of BCSS: effects of 
tumour grade, size, lymph node stage, and C07l expression in (A) ER-positive 
cohort and (B) ER-positive tamoxifen only treated patients 
Variable Hazard ratio 95% CI p value 
(A) ER-positive cohort 
Tumour Grade 2.182 1.659-2.87 1 <0.001 
Tumour size 2: 1.5 em 1.803 1.167-2.786 0.008 
Lymph node status 1.911 1.335-2.735 0.001 
CD71 expression 1.614 1.092-2.384 0.016 
(B) ER-positive tamoxifen only treated patients 
Tumour Grade 2.470 1.329-3.261 0.001 
Tumour size 2:1.5 em 1.335 0.909-2.703 0.393 
Lymph node status 2.034 1.484-2.592 0.019 
CD71 expression 2.624 1.309-5.259 0.007 
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5.4 FOX03a expression in breast cancer as a downstream 
target ofPIK3/Akt pathway 
5.4.1 Introduction 
Previous studies have highlighted the important role of AktIPI3K pathway and 
its upstream and downstream targets in the biology and prognosis of luminal-
like breast cancer (Zou et al., 2008) and this prompted us to study FOX03a as 
one of the important downstream targets of this pathway. Zou and co-workers 
have reported that FOX03a can suppress ER-dependent breast cancer cell 
proliferation and tumourigenesis in the MCF-7 breast cancer cell line, 
suggesting a crosstalk between FOX03a and ER signalling pathways (Zou et 
al.,2008). 
FOX03a (FKHRLl) gene belongs to the forkhead family of transcription 
factors (Yang and Hung, 2009) and their activity is regulated by several post-
translational modifications, including phosphorylation and acetylation (Tsai et 
al.,2007). 
Other studies demonstrated FOX03a as an important intracellular mediator of 
ER expression, suggesting possible therapeutic intervention (Guo and 
Sonenshein, 2004). Importantly, FOX03a is a downstream target in the 
AktIPI3K pathway and when phosphorylated, is prevented from translocating 
to the nucleus resulting in its loss of functional activity. In contrast, FOX03a 
dephosphorylation leads to nuclear localisation and subsequent target gene 
activation (Brunet et aI., 1999, Vara et al., 2004, Huang and Tindall, 2007, 
Yang et aI., 2008). Therefore, as a target within the AktIPI3K signalling 
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pathway FOX03a regulates the expression of proapoptotic genes, cell cycle 
regulated genes, and genes that control cellular homeostasis (Brunet et aI., 
1999, Burgering and Kops, 2002). However, there is also evidence that an Akt-
independent mechanism of FOX03a regulation exists. In vitro co-transfection 
of FOX03a and IKK resulted in strong inhibition of FOX03a activity 
independent of Akt (Hu et aI., 2004). 
It was suggested that an efficient mitotic programme depends on 
downregulation of AktlPI3K and consequent induction of FOX03a 
transcriptional activity (Alvarez et aI., 2001). 
In breast cancer, FOX03a activity has been shown to elevate p27 expression 
resulting in cell cycle arrest ( A c ~ i l i i and Arden, 2004). Furthermore, nuclear 
FOX03a can induce cellular apoptosis through upregulation of Fas ligand 
(Fas-L) (Brunet et aI., 1999) and Bim (Burgering and Kops, 2002, Stahl et aI., 
2002) and has been implicated in resistance to oxidative stress and longevity 
(Kops et aI., 2002). Other studies have highlighted the importance of FOX03a 
for maintenance of the hematopoietic stem cell pool (Miyamoto et aI., 2007, 
Tothova et aI., 2007). Moreover, it has been reported that activation of 
FOX03a could induce p53-dependent apoptosis even in cells with a 
transcriptionally inactive p53 (You et aI., 2006). 
FOX03a may have therapeutic implications because some clinical anticancer 
treatments target FOX03a through three main oncogenic kinases (Akt, IKK, 
and ERK) (Yang and Hung, 2009, Myatt and Lam, 2007). For instance, nuclear 
localization of FOX03a could potentially improve the effectiveness of anti-
EGFR agents such as gefitinib by mediating proliferative arrest (Krol et aI., 
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2007). Gefitinib treatment causes cell cycle arrest and induces apoptosis due to 
the effects of FOX03a dephosphorylation and nuclear translocation at Akt 
sites. In contrast, resistant cells show inactive phosphorylated FOX03a 
restricted to the cytoplasm (Krol et aI., 2007). Furthermore, up-regulation of 
FOX03a by paclitaxel has been reported to increase Bim mRNA and protein 
level with subsequent induction of apoptosis in breast cancer cells (Sunters et 
al.,2003). 
The value of FOX03a as a prognostic biomarker for ER-positive luminal-like 
breast cancer remains unclear. Therefore, in this study, we have investigated 
the clinical relevance and biological associations of FOX03a protein 
expression in a large series of patients and in a subgroup of luminal-like ER-
positive invasive breast cancers using high-throughput tissue microarrays 
(TMAs) and immunohistochemistry. 
5.5 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed usmg the streptavidin-biotin complex method using 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) (see 
general material and methods chapter). To unmask the antigens, the sections 
were microwaved in citrate buffer pH 6 for 23 minutes. Rabbit polyclonal 
antibody to FOX03a (Antibody 9467, Cell Signalling Technology, Danvers, 
MA, USA) was optimized at a working dilution of 1 :50 using TMA sections 
and full-face sections of breast cancer tissue to assess the staining distribution. 
Negative controls were performed by omitting the primary antibody and 
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substitution with a diluent. Positive breast cancer cases were used as positive 
controls. 
Western blotting was performed on breast cancer cell lysates of the human 
breast cancer cell line MCF-7 to confirm the specificity of the FOX03a 
antibody used in immunohistochemistry. The specificity of the FOX03a 
antibody was confirmed using Western blotting (Fig 5.7) (See General 
Material and Methods chapter). In normal breast tissue, FOX03a expression 
was detected mainly in the nuclei of mammary epithelial cells. In the malignant 
tissues, FOX03a showed both nuclear and cytoplasmic staining patterns but 
one pattern were obviously dominant. Examination of the TMAs has shown 
that some cases showed nuclear pattern and others were mainly cytoplasmic. 
Since the expression pattern and localisation of FOX03a protein expression 
show variable biological functions, we categorised the positive cases according 
to whether they showed predominant nuclear (N) or predominant cytoplasmic 
(C) localisation. Both patterns scored separately using the percentage of the 
positive cells in each TMA core. Cases were categorised as showing a nuclear 
or cytoplasmic pattern in 50% or more of the informative TMA core provided 
that there is more than 20 % variation between both patterns. We have defined 
the cases with obvious overlap (less than 20 % variation, n=31) and were 
excluded to ensure a clear separation in their patterns of expression. The cases 
were scored without the knowledge of patient outcome. 
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5.6 FOX03a expression results 
The median age of the patients was 56 years (range 27-70). At the time of the 
primary diagnosis, Forty seven percent (47%) of patients had tumours less than 
2 cm in size and 31.5% had grade 2 tumours. During follow-up, 30.6% of the 
patients developed metastatic disease. 
100KD 
75KD 
50KD 
37KD -
A B 
Figure 5.3: Western blotting analysis of MCF -7 cell lysates using the FOX03a 
rabbit polyclonal antibody. 
Enhanced chemiluminescence was used to visualize the membrane. The 
expected band size ranges from 82 -97 KD. Lane (A) is FOX03a and lane (8) 
is p-actin. 
In whole series, about 23 % showed predominant nuclear expression pattern 
and 34 % cytoplasmic pattern while 3 % showed both with less 20% difference 
in the predominant pattern. In ER-positive patient cohort, 26 % showed nuclear 
expression pattern (Fig 5.4A) and 31 showed % cytoplasmic pattern (Fig 
5.4B). 
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Figure 5.4: FOX03a expression in breast cancer 
(A) Predominant FOX03a nuclear expression (x200) 
(B) Predominant FOX03a cytoplasmic expression (x200) 
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5.6.1.1 Correlation between FOX03a expression and other 
clinicopathological variables 
The tumour-specific FOX03a IHC staining characteristics were initially 
categorised into negative and positive expression (showing either nuclear or 
cytoplasmic expression), regardless of FOX03a localisation. FOX03a 
expression status did not show significant associations with the other 
clinicopathological variables including tumour grade, size, stage, NPI and 
vascular invasion. 
Subsequently, the cases were categorised according to the pattern of expression 
into nuclear and non-nuclear, the latter included cytoplasmic predominant 
localisation and negative expression. Analysis of whole patient series revealed 
that FOX03a nuclear localisation is positively associated with low mitotic 
counts, lower grade tumour, less frequent development of distant metastasis 
(p<O.OOI) and tumour recurrence (p=O.002) (Table 5.4). 
In the ER-positive, FOX03a nuclear expression pattern was associated with 
low mitotic counts (p=O.008) and less frequent development of distant 
metastasis (p<O.OOl) (Table 5.5). 
5.6.1.2 Correlation between FOX03a expression and other 
biomarkers 
In the whole series, the nuclear pattern showed significant positive associations 
with molecular biomarkers associated with good prognosis including PgR 
(p<O.OOI), FOXAI (p<O.OOI) and p27 (p=O.OOl) expression. It also showed an 
inverse correlation with PIK3CA (p=O.OOl) (Table 5.6). 
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In ER-positive cohort, the nuclear pattern showed significant positive 
associations with molecular biomarkers associated with good prognosis 
including PgR (p=O.004), FOXAI (p<O.OOI) and p27 (p=O.004) expression. It 
also showed an inverse relation with PIK3CA (p=O.006) (Table 5.7). 
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Table 5.4: Relation of FOX03a immunostaining to other clinicopathological 
variables in the whole series 
Non-Nuclear Predominant 
Variable localisation Nuclear Total l p-value localisation 
~ e e
<40 59(85.5) IQ(l 4.51 69 
40-50 2 15(78.2) 60(21.8) 275 5.276 0.153 51-60 235(79.2) 61(20.6) 295 
>60 194(73.8) 69(26.6) 263 
Tumour size 
:s2 em 335(78. 1) 94(21.9) 429 0.032 0.873 >2 em 367(77.6) IOlK22.4) 473 
L.ymph node stage 
I (Negative) 4 13(76.6) 12«23·41 539 
2( 1-3 LN) 2 19(79. \) 58(20.9) 277 1.169 0.557 
3(>3 LN) 69(8 1) 1 6 ( 1 ~ ~ 84 
Tumour grade 
I 97(71.3) 39(28.7) 136 
2 2 14(74.6) 7 ~ ~ 2 5 . 4 ) ) 287 9. 11 5 0.010 
3 391 (81.6) 88( 18.4) 479 
Vascular invasion 
No/Probable 457(77.9} 130(22. 10 587 0.003 1.000 Definite 244(77.7) 70(22.3) 3 14 
NPI 
Good 164(73.5) 59(26.5) 223 
Moderate 408(78.3) 113(2 1.7) 52 1 4.364 0. 11 3 
Poor 131(82.4) 28(17.6) 159 
Mitotic counts 
I 204(73 .6) 73(26.4) 277 
2 109(67.7) 52(32.2) 161 20.308 <0.001 
3 365(83.5) 72(16.5) 437 
OM 
No 45 1(73.5) 163(26.5) 614 2 1.375 <0.001 Positive 242(87.4) 35(12.6) 277 
Recurrence 
No 374(73.9) 132(26.1) 506 10.000 0.002 Positive 3 14(82.8) 65(17.2) 379 
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Table 5.5: Relation of FOX03a immunostaining to other clinicopathological 
variables in the ER-positive cohort 
Variable 
Non-N uclea r Predomi na nt 
loca lisation Nuclea r Tota l .j p-value localisation N (%) N (%) 
Age 
<40 24(72.7) 9(27.3) 33 
40-50 135(73 .81 48{26.2) 183 1.535 0.674 5 1-60 159(78·71 43(2 1.31 202 
>60 147(75.4) 48(24.61 195 
Tumour size 
S2em 23 1(75.2) 76(24.8) 307 0.126 0.777 
>2 em 234(76.5) 72{23.5) 306 
Lymph node stage 
I (Negative) 269(73.9) 95(26.1) 364 
2(1-3 LN) I 53(77.7} 44(22.3) 197 2. 135 0.344 
3(>3 LN) 4 1 (82) 9(18} 50 
Tumour g rade 
I 88(7 1.51 35(28.5) 123 
2 185(73.5) 6 7 J 2 6 . ~ ~ 253 4.905 0.086 
3 19 1(80.6) 4 4 1 9 . 3 4 ) ) 237 
Vascula r invasion 
No/Probable 302(76. 1) 95(23.9) 397 0.040 0.844 Definite 162(75.3) 53124.'2 2 15 
NPI 
Good 142(72.4) 5 4 ( 2 7 . ~ ~ 196 
Moderate 247(75.5) 80(24.5) 327 5.078 0.079 
Poor 77(84.6) 14( 15.40 9 1 
Mitotic counts 
I 184(73.3) 67126.'2 25 1 
2 90(68.2) 4 2 ( ( ) . ~ ~ 132 9.643 0.008 
3 172(82.31 37( 17.7) 209 
OM 
No 3 0 6 ( ( ) . ~ ~ 122(28.5) 428 13.825 <0.001 Positive 155(85.6) 26JI 4·41 18 1 
Recurrence 
No 25 1(72.3) 96J27.71 347 I 4.627 0.035 Positive 207(79.9) 52(20. 1) 259 
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Table 5.6: Relation of FOX03a immunostaining to other biomarkers in the 
whole series 
Variable Non-Nuclear Predominant Total 
Xl p-value 
localisation Nuclear Localisation 
ER 
Negative 202(83 .8) 39(16.2) 24 1 6.356 0 .013 
Positive 466(75.9) 148(24. 1) 614 
PgR 
N e ~ a t i v e e 319(84.4) 59(15 .6) 378 16.878 <0.001 
Positive 345(72.6) 130(27.4) 475 
AR 
Negative 259(82.5) 55(17.5) 3 14 1.925 0. 191 
Positive 242(78.1) 68(21.9) 310 
FOXAI 
Ne_gative 319(85.1) 56(14.9) 375 15.1 45 <0.001 
Positive 234(73 . 1) 86(26.9) 320 
CARMI 
Negative/ low 159(80.7) 38( 19.30) 197 1.806 0.405 
Moderate 281(81.2) 65(18.8) 346 
Strong 97(75.8) 3 1 (24.20 128 
PELPI 
Negative/ low 76(74.5) 26(25.5) 102 2.652 0.266 
Moderated 4 13(80.7) 99(19.3) 512 
Strong 69(75.8) 22(24.2) 91 
p53 
Negative 474(77.8) 135(22.2) 609 0.080 0.856 
Positive 196(78.8) 53(21.3) 249 
MIBI 
Low 126(71 .2) 5 1(28.8) 177 5.180 0.028 
High 407(79.5) 105(20.5) 512 
PIK3CA 
Negative 176(71) 72(29) 248 11.01 7 0.001 
Positive 444(8 1.5) 101 (18.5) 545 
p27 
Negative 319(83.9) 61(16. 1) 380 11.35 1 0.001 
Positive 272(73.9) 96(26.1) 368 
C-MYC 
Negative 88(88.9) II (11.1) 99 
Low 203(80.6) 49( 19.4) 252 8.298 0.040 
Moderate 203(75.5) 66(24.5) 269 
Strong 11 3(80.10 28(19.9) 14 1 
Bcl-2 
Negative 236(80.8) 56( 19.2) 292 1.896 0.193 
Positive 3 12(76.5) 96(23.5) 408 
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Table 5.7: Relation of FOX03a immunostaining to other biomarkers in the 
ER-positive cohort 
Variable 
Non-Nuclear Predominant Total 
Xl p-value 
localisation Nuclear localisation N(%) N(%) 
PgR 
Negative 123(84.2) 23(15 .8) 146 7.968 0.004 
Positive 333(72.7) 125(27.3) 458 
AR 
Negative 110(79.1) 29(20.9) 140 0.860 0.423 
Positive 326(75.3) 60(24.7) 433 
FOXAI 
Negative 183(84.7) 33( 15.3) 216 14.177 <0.001 
Positive 180(70) 77(30) 257 
CARMI 
Negative/low 121(78.1) 34(21.9) 155 2. 128 0.345 
Moderate 191(79.6) 49(20.4) 240 
Strong 44(7 1) 18(29) 62 
PELPI 
Negative/low 57(74) 20(26) 77 2.136 0.344 
Moderated 278(79) 74(2 1) 352 
Strong 40(71.4) 16(28.6) 56 
~ 5 3 3
Negative 374(76.8) 113(23.2) 487 0.036 0.545 
Positive 86(74.1) 30(25.9) 116 
MIDI 
Low 102(68.9) 46(31.1 ) 148 4.580 0.039 
High 253(78.1) 71(21.9) 324 
PIK3CA 
Negative 136(69.4) 60(30.6) 196 8.120 0.006 
Positive 276(80.2) 68(19.8) 344 
p27 
Negative 162(83.9) 31(16.1) 193 8.438 0.004 
Positive 22 1(72.7) 83(27.3) 304 
C-MYC 
NeAative 56(88.9) 7(11.1) 63 
Low 137(78.3) 38(2 1.7) 175 6.756 0.080 
Moderate 138(73.4) 50(26.60 188 
Strong 69(79.3) 18(20.7) 87 
BCL2 
Negative 92(78.6) 25(21.4) 117 0.351 0.1 2 1 
Positive 275(76) 87(24) 362 
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5.6.1.3 Correlation between FOX03a expression and patient 
outcome 
Univariate analysis 
In the whole patient series, initial univariate analysis of FOX03a expression 
status (as positive versus negative) was not associated with BCSS (Log Rank 
(LR)=O.005, p=O.942) nor DMFI (LR=O.015, p=O.904) but when the 
localisation of expression was considered FOX03a nuclear expression was 
associated with better outcome in terms of longer BCSS (LR=24.079,p<O.OOl) 
and longer DMFI (LR =15.996,p<O.OOI). 
In the luminal-like ER-positive subgroup (n=633), (median follow up 
time=126 months), univariate analysis of survival showed no associations 
between FOX03a expression status (as positive versus negative) and patient 
outcome in terms of breast cancer specific survival [BCSS] (LR=O.234, 
p=O.628) or distant metastasis free interval [DMFI] (LR=O.198, p=O.656). 
However, FOX03a nuclear localisation showed a significant association with 
both longer BCSS (LR=15.813, p<O.OOl) (Fig 5.5) and longer DMFI 
(LR=11.836,p=O.OOI) (Fig 5.6). 
Analysis of patient survival using categorisation of the cohort into three 
groups: predominant nuclear, predominant cytoplasmic and negative, our 
results showed that subcellular localisation differences of FOX03a are 
associated with striking survival differences. Specifically there is a contrast 
between nuclear and cytoplasmic expression localisation where nuclear pattern 
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showed the most favourable BCSS (LR =18.279, p<O.OOl) (Fig 5.7) and DMFI 
(LR=14.775, p=O.OOI) (Fig 5.82) in ER-positive luminal-like cancer. 
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Figure 5.5: Kaplan Meier plot of FOX03a nuclear verse non-nuclear protein 
expression in relation to BCSS in the ER-positive cohort 
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Figure 5.6: Kaplan Meier plot of FOX03a nuclear expression in relation to 
DMFI in the ER-positive cohort 
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Figure 5.7: Kaplan Meier plot of FOX03a expression patterns in relation to 
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Figure 5.8: Kaplan Meier plot of FOX03a expression patterns in relation to 
DMFI 
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According to systemic therapy groups 
When systemic therapy was considered, similar associations of longer survival 
were found in the subgroup of ER-positive patients who did not receive 
adjuvant systemic therapy (n=222) with regards DMFI (LR= lO.llO, p=O.OOI) 
(Fig 5.9) and in the subgroup of patients who received tarnoxifen monotherapy 
(n=221) with regards BCSS (LR=5.201,p=O.023). 
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Figure 5.9: Kaplan Meier plot of FOX03a nuclear expression in non-treated 
cohort in relation to BCSS. 
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Multivariate analysis 
Since many potential prognostic factors may interact with specific therapies 
and therefore are compounded by the effect of adjuvant hormone therapy and 
chemotherapy, we have included the systemic therapy groups (given versus not 
given) in the multivariate analysis together with the other well established 
prognostic variables such as MIB 1, PgR, tumour size, stage, grade to assess the 
prognostic independence of nuclear FOX03a expression in the ER-positive 
patient cohort. 
FOX03a nuclear expression was an independent prognostic factor for 
predicting better outcome in terms of longer BCSS (Hazard ratio (HR)=O.392, 
p=O.006, 95% CI=O.202-0.760) (Table 5.8) and longer DMFI (HR=O.530, 
p=O.020, 95% CI=O.310-0.906) (Table 5.9) in ER-positive / luminal-like breast 
cancer. 
Table 5.8: Cox model of predictors ofBCSS in the luminal-like breast cancer 
Variable P value HR 95% CI 
Lower Upper 
FOX03a nuclear localisation 0.006 0.392 0.202 0.760 
PgR expression 0.049 0.642 0.413 0.997 
MmI expression 0.011 2.105 1.184 3.742 
Tumour size 0.001 2.228 1.41 1 3.520 
LN stage 0.000 1.746 1.290 2.363 
Tumour grade 0.006 1.629 1.152 2.302 
Endocrine therapy 0.502 0.846 0.519 1.3 79 
Chemotherapy 0.305 0.715 0.377 1.358 
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Table 5.9: Cox model of predictors of OM in the luminal-like breast cancer 
Variable p value HR 95%CI 
Lower Upper 
FOX03a nuclear localisation 0.020 0.530 0.3 10 0.906 
PgR expression 0.035 0.64 1 0.424 0.970 
MIDI expression 0.008 1.989 1.194 3.3 11 
Tumour size 0.001 2.094 1.380 3. 177 
LN stage <0.001 1.836 1.380 2.442 
Tumour grade 0.048 1.375 1.003 1.887 
Endocrine therapy 0.889 0.967 0.604 1.548 
Chemotherapy 0.938 0.977 0.536 1.779 
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5.7 AGTRI 
5.7.1 Introduction 
Angiotensin II is a pleiotropic honnone which could act as a neurotransmitter, 
growth factor, angiogenic factor, vasoconstrictor, and cytokine (Ladd et aI., 
2007). Via ligand-induced activity through the angiotensin II type 1 receptor 
(AGTRl), angiotensin II is converted from its precursor by the action of 
angiotensin I-converting enzyme (ACE) (Koh et aI., 2005). Angiotensinogen 
has anti-proliferative properties while, angiotensin II is a potent growth factor 
and it mediates its actions through AGTRI (Ladd et aI., 2007). 
AGTRI was found to be one of the most highly overexpressed genes in 10-
20% of breast cancers across independent breast cancer microarray studies 
(Rhodes et aI., 2009). It has been shown that AGTRI overexpression defines a 
subset of ER-positive breast cancer that can benefit from AGTRI antagonists. 
Specifically, AGTRI was overexpressed only in tumours that were HER2-
negative and ER-positive (Rhodes et aI., 2009). 
Angiotensin II has a carcinogenic effect via the AGTRI which increases the 
risk of cancer development possibly via different mechanism. The first one is 
by promoting cell division and proliferation through the activation of mitogenic 
pathways especially EGFR (Greco et aI., 2003). Another mechanism by which 
AGTRI could induce its carcinogenic effect is the angiogenesis and promoting 
arterial smooth muscle cell proliferation via vascular endothelial growth factor 
in animal models (Egami et aI., 2003). 
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Koh and co-workers investigated the genetic polymorphisms in ACE and 
AGTRI genes by SNPs. Breast cancer patients possessing the low risk 
polymorphisms of AGTRI and ACE had a lower breast cancer risk. This 
observation lends further support to the argument that gene variations within 
the renin angiotensin system may playa role in breast carcinogenesis (Koh et 
aI.,2005). 
This has a potential clinical importance because AGTRI can be blocked by 
commonly prescribed antihypertensive agents especially those used for ACE 
inhibition. Inhibition of the angiotensin II effect by blockade of ACE and/or 
AGTRI could be potential targets for the prevention and treatment of cancer 
especially breast cancer. 
5.7.2 Material and Methods 
5.7.2.1 Identification of AGTRI as a candidate luminal marker by 
gene expression analysis 
The ANN methodology was discussed in details in general material and 
methods chapter. The luminal versus non-luminal data was used to divide the 
gene expression data into two groups to identify genes that can characterise the 
luminal phenotype. These data were bioinfomatically analysed in collaboration 
with Dr Graham Ball from Nottingham Trent University. 
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5.7.2.2 AGTRI immunohistochemistry 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed using the streptavidin-biotin complex method (LSAB) using 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
(general material and methods chapter). Mouse monoclonal antibody [lEIO-
lA9] to Angiotensin II Type 1 Receptor (ab9391, Abeam, UK) was optimised 
at a working dilution of 1: 1 00 with 6 hour primary antibody incubation time. 
Negative controls were performed by omitting the primary antibody and 
substitution with diluent. Positive breast cancer cases and kidney tissue were 
used as positive controls. The H-score (histochemical score) was used to assess 
the intensity of staining and the percentage of stained cells following 
immunohistochemistry (McCarty et aI., 1985). 
The X-tile (Camp et aI., 2004) program was used to define optimal cut off 
points of AGTRI H-score values «30=negative/low, ~ 3 0 a n d < I O O = m o d e r a t e e
and ~ 1 1OO=strong expression). 
5.7.3 AGTRI expression results 
At mRNA level, AGTRI gene was identified as a characterizing gene of ER-
positive luminal like subgroup using ANN analysis (Table 5.10). 
(Fig 5.10) shows AGTRI gene expression in luminal and non-luminal samples. 
Of the whole series 1002 tumour cores were available for assessment. The 
expression was detected in the cytoplasm of tumour cells (Fig 5.11) with 
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decreased expression in normal acini. In the whole patient seri es, 23.3% of 
cases showed negative and low expression, 38% showed moderate expression 
and 38.7% of cases showed strong expression. 
Table 5.10: ANN genes rank, summary of the first step 
Rank Gene 10 Name Selection error 
I G1 4885330-S GPR42 0.3844000 19 
2 GU4043065-A AGTRI 0.395 1066 1 
3 Gl_29728071-S TBC ID9 0.397092733 
4 GI_22202636-A MM- I 0.39841089 
5 Gl_ 4507456-S CD7 1 0.4011911 55 
6 Gl 4758297-S HER2 0.404675377 
7 Hs.499488-S Hs.499488-S 0.405384429 
8 GI 4503602-S ESR I 0.4068704 
9 Hs.466852-S Hs.466852-S 0.40740 I 035 
10 GI 503 1906-S MEF2A 0.410688739 
II Gl 47592 15-S TCEAL I 0.4133543 17 
12 GI 2 136 1616-S FLJ20 15 1 0.41 39392 
13 Gl 4885496-S v-MYB 0.4 15354654 
14 hmm23409-S hmm23409-S 0.4 1714708 
15 Hs.179 11 5-S Hs. 179 1 15-S 0.4 17 177662 
16 Gl 42658625-S KIAAI 549 0.4 1759 1627 
17 Gl 3 1377840-S FLJ 11280 0.418409403 
18 hmm20201-S hmm20201 -S 0.419244839 
19 GI_ 42658619-S NUP205 0.419958 11 5 
20 GI_ 199 13405-S TOP2A 0.420003738 
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Figure 5.10: Boxplot of the AGTRI nonnalised expression values in luminal 
vs. non-luminal samples 
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Figure 5.11: Grade 2 invasive ductal carcinoma with high expression of 
AGTRI (A xlOO & B x200) 
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5.7.3.1 Correlation between AGTRI protein expression and other 
clinicopathological variables 
AGTRI immunohistochemistry revealed significant association with the 
histological tumour type (p=O.007) (Table 5.11). In ER-positive luminal-like 
patients' cohort, AGTRI showed a border line association with increased 
mitotic counts (Table 5.12). 
5.7.3.2 Correlation between AGTRI protein expression and other 
biomarkers 
In the whole series, high AGTRI expression was associated with reduced 
nuclear BRCAI expression. We found no association between AGTRI 
expression and other biomarkers (Table 5.13). 
In ER-positive cohort, increased AGTRI expression was positively associated 
with EGFR (p=O.OOI). In contrast, AGTRI high expression was associated 
with reduced nuclear BRCAI expression (p<O.OOl). No associations between 
AGTRI expression and other biomarkers were found (Table 5.14). 
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Table 5.11: Relation of AGTR l immunostaining to other clinicopathological 
variables in the whole series 
AGTRI expression 
Variable low Modera te Strong 
·l p-value 
Age 13 .995 0.030 
<40 13( 18.8) 33(47.8) 23(33.31 
40-50 85(29) 106(36.21 102(34.8) 
5 1-60 80(24) 12 1(36.3) 132(39·62 
>60 55(17.9) 12 1(39.4) 13 1(42.7) 
Size 0.059 0.97 1 
:S1.5cm 113(23) 186(37.9) I 92{39. 10 
> 1.5 cm 120(23.5) 194(38) 196(38·41 
LN Stage 4.285 0.369 
I (Negative) 145(24) 233(38.6) 225(37.3) 
2( 1-3 LN) 74(24.21 109(35.6) 123(40·21 
3(>3 LN) 14( 15.6) 37(4 1.1 ) 39(43.31 
G rade 5.592 0.232 
I 34(20·41 73(43 .7) 60(35.91 
2 87(26.5) 1 2 1 ( 3 6 . ~ ~ 120136.62 
3 11 2(22. 1) 1 8 ~ 3 6 . 1 ! l l 208(41. 1) 
NPI 3.205 0.524 
Good 66(23.8) 11 4{4 1.21 971351 
Moderate 132(23.71 201 (36. 1) 224(40·21 
Poor 35(20.8) 66(39.3) 67(39.91 
DM 5.875 0.05 
No 168(24. 1) 2 7 5 ( 3 9 . ~ ~ 254{36.'!2, 
Positive 60(20.6) 101 (34.7) 130(44.'Z} 
Recurrence 1.358 0.507 
No 140(24.4) 2 18(38) 2 15(37.5} 
Positive 87(2 1.4) I 56(38.'!2, 163140. 1) 
VI 7.343 0. 11 9 
No 133(24.6) 217{40. 1) 19 1 (35.3) 
Probable 25(2 1.4) 46(39.3) 46(39.3) 
Definite 73(2 1.4) 11 7(34.4) 15 1(44.31 
Tumour type 24.302 0.007 
DuctallNST 129(21.8) 209(35.3) 2 5 4 ( 4 4 . ~ ~
Lobular 27(27.3} 51(5 1.51 2 I{2 1.21 
Tubular and Tubular mixed 53(25.6) 82(39.6) 72(34.81 
Medullary 9(32. 11 8(28.6) 11 (39.3) 
Other special types· 6(35.3) 6(35.3} 5(29·41 
Mixed" 9( 15.3) 25(42.4) 25(42.4) 
Mitosis 8.957 0.062 
I 8 1(241 I 38{40.91 I 18(35) 
2 50(28.2) 67(37.9) 60(33.9) 
3 98(2 1.3) I 63 (35.4) I 99{43.31 
*Includes Mucoid, invasive cribriform and InvaSive papillary carCInoma, ** 
Include ductaJINST mixed with lobular or special type 
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Table 5.12: Relation of AGTRI immunostaining to other clinicopathological 
variables in the ER-positive cohort 
AGTRt expression 
Variable low Moderate Strong X2 p-value 
Age 5.445 0.488 
<40 5(17.9) 13(46.4) 10(35.7) 
40-50 54(28) 74[38.3) 65(33.7) 
51-60 54(23.9) 85(37.6) 87{38.51 
>60 47(20) 9 1(38.7) 97(41.3) 
Size 1.074 0.584 
:51.5 cm 88(24.9) I 37(38.'Q 129136·41 
> 1.5cm 72(220 126(38·41 1 3 0 Q 9 . ~ ~
LN Stage 5.65 1 0.227 
I (Negative) 98(24.4) 161(40) 143{35.61 
2( 1-3 LN) 54(23.8) 77(33.91 96(42.3) 
3(>3 LN) 8(15.7) 24(47.1.0 19(37.31 
Grade 8.476 0.076 
I 29( 19.7) 63(42.9) 55(37.4) 
2 83(28.7) 104(36) 102(35·31 
3 48(19.5) 96(39) 102(41.5) 
NPI 3.356 0.500 
Poor 62(25.6) 97(40. 10 83134·31 
Moderate 79(23.1) 125(36.5) 138(40.4) 
Good 19( 19.4) 41(41.8} 3 ~ 3 8 . ~ ~
DM 4.372 0. 11 2 
No 11 9(24. 1) 1 9 ~ ( 4 4 . ~ ~ 1 7 ~ 3 3 · 7 1 1
Positive 38(20.9) 63(34.6) 81(44.5) 
Recurrence 0.870 0.647 
No 99(24.60 152(37.7) 152(37.7) 
Positive 58(21.6) 108(40.3) 102(38.1) 
VI 6.170 0.187 
No 90(25.5) 1 4 2 { 4 0 . ~ ~ 12 L(34.31 
Probable 19( 19.8) 4Q(41.7) 3 ~ ( 3 3 . ~ ~
Definite 49(2 1.2) 81(35.1) 101(43.7) 
Tumour type 16.933 0.076 
DuctallNST 73(21.3) 126(36.7) 144(42) 
Lobular 26(28.3) 45(48.90 21(22.80 
Tubular and Tubular 47(26.3) 66(36.9) 66(36.9) 
mixed 
Medullary 1(25) 1(25) 2(50) 
Other special types 5(41.7) 4(33.3) 3(25) 
Mixed 8(15.4) 21(40.41 23(44.2) 
Mitosis 10.821 0.029 
I 74(24.6) 123(40.90 104(34.6} 
2 43(29.7) 5 3 { 3 6 . ~ ~ 49(33 .8) 
3 39( 18.1 ) 78(36.3) 98145.9) 
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Table 5.13: Relation of AGTR I expression to other biomarkers in the whole 
series 
AGTR) express ion 
Variable Low Moderate Strong l p-value 
C KS/6 2.463 0.292 
Negative 177(22.2) 302(37.9) 3 17(39.8) 
Positive 47(27.2) 66(38.2J 6Q(34.'Q 
CK14 0.868 0.648 
Negative 197(23 .7) 306(36.91 327139.4) 
Posit ive 30(25) 48(40) 42(35) 
CK )9 5.3 19 0.070 
N ~ a a i v e e 29(3 1.9) 26(28.6) 36(39.6) 
Positive 198(22.6) 340(38.80 338(38.6) 
CK )8 5.168 0.075 
Negative 38(30.2) 39(3 1 ) 49{38.9) 
Positive 166(21.7) 297(38.81 302(39.5) 
ER 
Negative 62(22.90 99(36.5) 11 0(40.6) 0.58 1 0.748 
Positive 160(23.5) 263(38 .6) 259{38} 
Pj!R 2.0 12 0.366 
Negative 94(22. 10 156136.7) 175(4 1.2) 
Positive 130(24.70 203(38.5) 1 9 ' ! ( 3 3 . ~ ~
AR 0.745 0.689 
Negative 77(22 .6) 125(36.8) 138(40.6) 
Positive 140(25) 206(36.7} 2 15(38.3) 
pS3 1.225 0.542 
Negati ve 16 1(23 .2) 2 6 8 f 3 3 . ~ ~ 266(38.3) 
Positive 62(23 .9) 90(34.7) I 07(4 I.:!} 
BRCA) 15.282 <0.00 1 
Negative 18(14.4) 40(32) 67(53 .6) 
Positive 173(25 .2) 2 6 8 ( 3 ~ ~ 246(35 .8) 
MIB) 5.869 0.053 
low 56(25. 1) 94(42.2) 73(32.7) 
High 128(22.9) 196(35. I) 2 3 ' ! ( ( 1 1 ~ ~
P-cadherin 2.052 0.358 
Negati ve 85(23.4) 146(40. 1) 133(36.5) 
Positive 107(24) I 58(35.4} 18L(40.61 
E-cadherin 3.500 0. 174 
Negati ve 79(22. 1) I 49{4 1.61 130136.31 
Positive 146(24.4) 2 13(35.6) 240(40. 1 ) 
HER2 8.630 0.0 13 
Negative 201(24) 320(38. 1) 3 18(37.9) 
Positive 18(14.6) 43{351 62150·41 
EGFR 8.805 0.0 12 
Negati ve 163(24.1) 267(39.5) 246(36.4) 
Pos itive 34(20.2) 521311 8 ~ 4 4 . ~ ~
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Table 5.14: Relation of AGTRI expression to other biomarkers in the ER-
positive cohort 
ACTR l expression 
Variable Low Moderate . Strong X 
2 p-value 
CKS/6 0.195 0.907 
Negative 143(23) 240(38·61 2 3 ~ 3 8 . 4 ) )
Positive 12(25) 19(39.6) 17(35.4) 
CKl4 1.238 0.539 
Negative 148(24.4) 229(37.7) 23QQ7.91 
Positive 9(18) 19(38) 22(44) 
CKl9 1.603 0.449 
Negative 10(28.6) lQ(28.6) 15{42.9) 
Positive 148(23.2) 250(39. 1) 241Q7.-zl 
CKl8 2.8 13 0.245 
Negative 6(24) 6(24) I 3 (52J 
Positive 138(22.6) 242(39.7J 230(37.7) 
P ~ R R 1.073 0.585 
Negative 36(21.4) 63(37.5) 69(41.1 ) 
Positive 123(24.3) 197(38.9) 187(36.9) 
AR 4.737 0.094 
Negative 27( 17.6) 63(4 1.2J 36(41.2) 
Positive 127(26.3) 177(36.6) 179(37.1) 
pS3 0.577 0.757 
Negative 126(22.7) 2 1I(39) 2 13(38.30 
Positive 30(25.9) 43(37. 1) 4Ji37.1} 
BRCAl 17.027 <0.001 
Negative 1(1.8) 24(43·61 3 Q . { 5 4 . ~ ~
Positive 135(25.5) 206(38.9) 189f35.-zl 
MlBl 6.343 0.042 
low 48(25.7) 79(42.2) 60(32.1) 
High 79(22.7) 11 9(34.2) 15Q.{43 . 11 
P-cadherin 2.175 0.337 
Negative 77(23.1) 137(41.11 1 1 1 3 5 · 7 1 1
Positive 60(24. 1) 88(35·31 10 1140.6) 
E-cadherin 6.895 0.032 
Negative 50(20.4) 11 1(45.3) 84(34.3) 
Positive 108«25. 1 ) 151(35. 1) 17IQ9.8) 
HER2 3.598 0.165 
Negative 146(23.7) 237(38.5) 233137.8) 
Positive 6(12) 22(441 22(44) 
ECFR 10.821 0.001 
Negative 124(23.9) 2 13(41.1) 181(34.9) 
Positive 15(17.4) 25(29. 1) 46(53.5) 
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5.7.3.3 Correlation between AGTR1 protein expression and 
patient outcome 
In the whole series, AGTR I expression was associated with shorter breast 
cancer specific survival (BeSS) (LR=14.S24, p=O.OOI ) and shorter di stant 
metastasis free interval (DMFI) (LR=9.558, p=O.008). In ER-positive luminal 
like patient cohort, strong AGTRI expression was associated with shorter 
Bess (LR= 12.71 3, p=O.002) (Fig 5.12) and shorter di stant metastasis free 
interval DMFI (LR=6.84 I , p=O.039) (Fig 5.13). 
Multivariate e o x analysis model including tumour grade, size and LN stage 
showed that strong AGTRI expression can independently predict increased 
breast cancer specific death risk (HR= 1.788, p=O.008) (Table 5.15). 
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Figure 5.12: Kaplan Meier plot of AGTRI expression in relation to Be SS in 
ER-positive luminal-like cohort 
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Figure 5.13: Kaplan Meier plot of AGTRI expression in relation to DMFI in 
ER-positive luminal-like cohort 
Table 5.15: Multivariate COX analysis of predictor of BCSS in ER-positive 
cohort 
Variable P value HR 95%CI 
Lower Upper 
AGTRI expression 0.01 
AGTRI moderate vs. low 0.460 1. 190 0.750 1.887 
AGTRI strong vs.low 0.008 1.788 1.160 12.755 
Tumour size <0.001 2.081 1.448 2.991 
LN staee <0.001 
LN (2) vs. (1) 0.001 1.869 1.305 2.678 
LN (3) vs. (1) <0.001 3.803 2.353 6.145 
Tumour erade <0.001 
Tumour grade (2) vs. (1) 0.117 1.1.574 0.893 2.773 
Tumour grade (3) vs. (1) <0.001 3.196 1.846 5.535 
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5.8 Discussion 
5.S.1 CD71 
Transferrin acting via CD71 has been shown to alter during disease progression 
and may promote aggressive tumour growth (Inoue et aI., 1993). Because of 
these associations and presence of CD71 gene expression in luminal group C 
(Sorlie et aI., 2001), we propose that assessment of CD71 expression might 
equally be used to stratify ER-positive patients to define subgroups with poor 
prognosis, high proliferation and resistance to hormonal therapy. The present 
study has shown for the first time that elevated CD71 is a feature of endocrine 
resistant breast cancer, as evidenced by immunostaining of acquired endocrine 
resistant sub-lines derived from luminal-like MCF-7 cells. Furthermore, we 
showed that the model for resistance to severe oestrogen deprivation, MCF-7X, 
over-expresses CD71 at the gene and protein level in the presence of 
exogenous transferrin, leading to increased growth and this could represent a 
prominent mitogenic mechanism for endocrine resistant cells in the presence of 
circulating transferrin. Studies in breast cancer models are promising with 
antisense inhibition of CD71 or selective antibodies to this receptor, where 
these inhibit cell survival and proliferation confirming a fundamental growth 
importance of CD71 to such cells (Yang et aI., 2001a, Yang et aI., 2001 b). 
Peng and colleagues (Peng et aI., 2007) suggested the use of intracellular 
antibody technology targeted against CD71 in CD71-overexpressing cancer. 
The use of monoclonal antibodies against transferrin receptor and ascorbate to 
inhibit both cell proliferation and the pro-angiogenic hypoxia inducible factor 
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HIF-la may also be of therapeutic use glvmg them a selective growth 
advantage (Jones et aI., 2006). Transferrin/CD71 trafficking has been closely 
associated with PI3K where inhibitors of this intracellular kinase appear able to 
deplete cell surface CD71 level (Jess et aI., 1996). Our finding that Faslodex 
and the phosphoinositide-3 kinase inhibitor (L Y294002) can partially deplete 
transferrin-induced growth of MCF-7X cells implies mechanistic cross-talk 
between transferrin/CD71 mitogenic signalling, ER and PI3K (in contrast to an 
apparent lack of CD71 interplay with MAP kinase) in ER-positive endocrine 
resistant cells. 
Our retrospective tissue studies supported the concept that there is a need for 
increased iron uptake mediated through elevated CD71 protein levels in high 
grade breast tumours, characterised by poor NPI, large size and, as predicted, 
high mitotic activity. Consequently, CD71 expression was more frequently 
increased in medullary carcinoma and basal-like tumours (CKS/6+ & CK14+) 
that show these features (Rakha et aI., 2006). Furthermore, CD71 expression 
was also significantly associated with other markers of aggressive phenotype 
and endocrine treatment resistance including pS3, HER2 and EGFR (Tsutsui et 
aI.,2002). 
Tumours with elevated CD71 expression had a shorter BCSS in the whole 
patient series and in the ER-positive/luminal-like patient cohort. These results 
confirmed that CD71 expression can define poor clinical outcome in the ER-
positive patient group. Supporting this, CD71 expression was found to be an 
independent prognostic marker in ER-positive cohort. In considering ER-
positive tamoxifen-only treated patients, increased CD71 expression was 
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associated with shorter BCSS and DFI suggestive that there might (as in vitro) 
be a relationship between CD71 expression and adverse endocrine response. 
We found that CD71 positive patients who were given tamoxifen, In 
comparison to those who did not take treatment have poorer prognosis. A 
possible explanation of this might be related to the function of 
transferrin/CD71 as a transporter for iron, needed for enzyme function and 
hence potentially mitogenic pathways. One would envisage that this would be 
beneficial in tumour cells and thus contribute to resistance, whether to 
oestrogen deprivation or tamoxifen. CD71 has been shown previously to 
interact with PI3 Kinase signalling, and this is certainly a prominent 
contributor in tamoxifen resistant cell growth experimentally. It is feasible that 
CD71 crosstalks with such growth factor signalling (e.g. EGFR, HER2, 
MAPK, PI3K) (Knowlden et al., 2003, Nicholson and Gee, 2000, Nicholson et 
al., 2005, Nicholson et al., 2004a, Nicholson et al., 2004b) which is prevalent 
in tamoxifen resistance, and actively permits adverse agonistic behaviour of the 
endocrine agent and thus adverse growth and invasion promotion in the 
presence of the antihormones. 
In conclusion, the present study demonstrated that prominent expression of 
CD71 protein is a feature of breast cancers with poor prognosis and as such, we 
propose that transferrin receptor expression may have implications for 
diagnosis and prognosis. CD71 protein expression could be of value in 
characterizing a subset of ER-positivelluminal-like tumours with poor 
prognosis in clinical practice, as well as defining patients less likely to respond 
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to endocrine therapy. Therapies of current interest in breast cancer (e.g. 
Faslodex, PI3K-inhibitors) appear able to partially impact on transferrinlCD71-
promoted growth, but further investigation of this important mitogenic 
mechanism may assist in designing new therapeutic strategies to target highly 
proliferative, endocrine resistant breast cancers. Therapies targeting iron 
delivery or CD71 itself, may have therapeutic benefits in treating CD71 + ER-
positive breast cancer phenotype in the clinic. 
5.8.2 FOX03a 
AktlPI3K pathway regulates the sub-cellular localization of FOX03a by 
phosphorylation and prevents the protein from translocating to the nucleus to 
regulate transcription (Brunet et aI., 1999). This indicates that absence of 
nuclear FOX03a expression, with either complete absence or cytoplasmic 
localisation due to its phosphorylation by Akt, may represent an important 
biological mechanism responsible in part for poor prognosis in ER-positive 
breast cancer, thus removing a constraint to cellular proliferation and 
potentially to tumourigenesis through an active AktIPI3K pathway. This 
proposal is supported by our findings showing that absence of nuclear 
expression of FOX03a was associated with poorer outcome and showed a 
significant association with PIK3CA as a marker strongly related to Akt. Other 
breast cancer studies confirmed the association between AktlPI3K activation 
and cytoplasmic FOX03a expression pattern with decreased patient survival, 
in agreement with our findings (Hu et aI., 2004). 
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In this study we did not find a significant association with survival when 
patients were categorised into either negative or positive FOX03a expressers 
per se. Instead, we found that subcellular localisation indicates functional 
relevance as evidenced here by more favourable outcome in patients with 
predominant nuclear expression. Supporting these findings, previous studies 
have shown that nuclear FOX03a induces the expression of genes that inhibit 
cell cycle progression such as the CDK inhibitors (Brunet et aI., 1999, Zou et 
aI., 2008). Subsequently, we found a significant positive association between 
nuclear FOX03a and the expression of the cell cycle inhibitor p27 implying a 
role in the induction of cell cycle arrest. 
In this patient series including ER-positive/luminal-like subtype, nuclear 
localisation of FOX03a was associated with markers of good prognosis such 
as PgR (Bardou et aI., 2003), and FOXAI expression which is required for the 
expression of 50% of ER-regulated genes (Thorat et aI., 2008). Furthermore, 
we have also shown that nuclear FOX03a expression is significantly 
associated with longer BCSS and DMFI which implies its role in stratification 
of ER-positive groups into prognostic subgroups, possibly explained by a 
tumour suppressor function associated with cell cycle arrest. 
Previous studies have shown that loss of FOX03a function by its absence or by 
cytoplasmic localisation is positively associated with proliferation (Accili and 
Arden, 2004). We have found that Be especially luminal-like cases expressing 
nuclear FOX03a are characterised by low proliferation as indicated by 
negative correlation with mitosis. Taken together, our findings support the 
interaction of FOX03a as a downstream target of AktlPI3K pathway with 
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markers related to proliferation and cell cycle, a role which is independent of 
the systemic therapy as shown here by our multivariate analysis results. Our 
results demonstrated the biological and prognostic role of FOX03a protein 
expression and its subcellular localization in BC. Promoting FOX03a nuclear 
localisation could be a potential therapeutic target. Loss of nuclear FOX03a 
expression could tilt the balance in favour of proliferation and poor outcome in 
luminal-like breast cancers through active AktlPI3K pathway highlighting the 
importance of cellular proliferation in their biological stratification. 
5.8.3 AGTRI 
Recently, it has been shown that AGTRI overexpression defines a subset of 
ER-positive breast cancer that can benefit from AGTRI antagonists (Ateeq et 
aI., 2009, Rhodes et aI., 2009). In this study, AGTRI gene expression was 
associated with the luminal phenotype at mRNA level while our protein 
expression study has shown that increased AGTRI expression characterised an 
aggressive ER-positive phenotype with shorter survival. 
The poor prognosis of AGTRI +ER+ phenotype could be explained in part by 
loss of BRCA 1 tumour suppressor function that we have shown in the current 
study. 
Our results showed a positive correlation between AGTRI and EGFR implying 
that AGTRI can perform its function through the activation of mitogenic 
signalling pathways supporting the results of a previous study that showed 
AGTRI possible regulation of mitogenic signalling pathways by two 
simultaneous mechanisms, one involved conventional PKCs and the other 
involved EGFR transactivation (Greco et aI., 2003). 
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This study demonstrated an increase of OM with AGTR 1 overexpression 
which could be explained by the role played by AGTRI through angiotensin II 
in promoting tumour cell invasion. A previous study (Rhodes et aI., 2009) has 
shown that overexpression of AGTRI due to angiotensin stimulation 
significantly promoted cell invasion in a AGTRI transfected breast carcinoma 
cells in comparison to the negative control. Importantly, AGTR 1 and 
angiotensin mediated invasion was decreased in a dose-dependent manner with 
addition of the AGTRI blocker, losartan (An ACE inhibitor). 
The non-significant association between ER and AGTR I protein expression 
could be attributed to a post translational modification event that could alter the 
protein product of the gene, further study are warranted to clarify this point. 
In conclusion, AGTR 1 expression in the luminal-like breast cancer 
characterises an aggressive phenotype with shorter survival. Evaluation the 
potential application of AGTRI blockade as a novel targeted therapy in breast 
cancer is warranted. 
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6 Prognostic and biological significance of cellular 
proliferation and its role in oestrogen receptor positive 
breast cancer subgrouping 
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6.1 Introduction 
The importance of cellular proliferation in subclassifying luminal cancer is 
recognised. Many studies have demonstrated a strong relationship between 
cellular proliferation and poor prognosis in breast cancer particularly in the 
oestrogen receptor (ER)-positive/luminal-like molecular sUbtype (Cheang et 
al.,2009). 
Several proliferation markers have been proposed to be of clinical importance 
for assessing prognosis in breast cancer, among them is the pan proliferation 
marker Ki67 (MIB 1), cyclins, PCNA, S-phase fraction, thymidine kinase and 
others (Stuart-Harris et aI., 2008, Colozza et aI., 2005). 
In this chapter, we studied the biological and prognostic implication of 
proliferation using cell cycle phase specific proteins and compared their 
association with the pan proliferation marker MIB I. 
In addition, we have studied the protein expression of p27 and Bcl-2 and their 
roles in the biology and outcome of breast cancer with particular emphasis on 
the ER-positive subgroup. 
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6.2 Prognostic and biological significance of the cell-cycle 
associated proteins, cyclin Bl and thymidine kinase 1 
(TKl) in breast cancer and luminal-like subtype 
6.2.1 Introduction 
TKI is an enzyme involved in the synthesis of thymidine triphosphate needed 
by the proliferating cells to enter S phase (Gasparri et al., 2009). Structurally, 
human TKI has a molecular mass of25.4 kDa, and consists of234 amino acids 
(WeI in et al., 2004). Phosphorylation of thymidine is catalyzed by two 
thymidine kinases: the cytoplasmic TKI which is absent in non-dividing cells 
and the mitochondrial TK2 (Munch-Petersen et al., 1995). TKI is activated in 
the G liS phase of the cell cycle to perform its function, and this activity has 
been shown to correlate with the proliferative activity of tumour cell (Hallek et 
al., 1992). 
TKI usually increases earlier than Ki67 and represents a unique marker of G 1 
phase in the cell cycle while Ki67 on the other hand is expressed maximally in 
mid and late S-phase (Gasparri et aI., 2009). 
Previous studies have shown that serum TK I appears to have some clinical 
value in solid tumours as prostate cancer, breast cancer, and small-cell lung 
cancer (Hallek et aI., 1992). 
TK 1 serum level could be used with success in predicting increased risk of 
recurrence after surgery in patients with early breast cancer (He et aI., 2006). 
These findings highlight the importance of proliferation related genes in ER-
positive luminal-like breast cancer. 
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Cyclin Bl is the regulatory subunit of cyclin-dependent kinase 1 (Cdkl). It is 
virtually undetectable in cells from GO/G 1 phase to mid S phase, but became 
visible in the cytoplasm in late S phase. As cells proceed within 02 phase, the 
level of cYclin B 1 rapidly increased in the perinuclear region of the cytoplasm 
then appears in the nucleus at the mitotic phase (Kakino et aI., 1996, Winters et 
aI., 2001). In other words, cyclin B 1 is translocated to the nucleus from the 
cytoplasm, and plays an essential role in cell proliferation through promotion 
of mitosis. Breast epithelial cells express cyclin B 1 in their cytoplasm in the 02 
phase and in their nuclei in the M phase (Kawamoto et aI., 1997). 
Proper regulation of cyclin B 1 is essential for the initiation of mitosis as it 
regulates the 02-M transition of the cell cycle and its expression is higher in 
premalignant and malignant than normal breast lesions (Aaltonen et at, 2009, 
Yuan et aI., 2004). Previous cell line studies have demonstrated that 
downregulation of cyclin B1 with small interfering RNA (siRNA) inhibited 
proliferation of several breast and cervical cancer cell lines including MCF-7, 
BT-474, SK-BR-3, MDA-MB-231 and HeLa cells (Androic et aI., 2008, Yuan 
et aI., 2004). 
Cyclin B 1 protein has been found to be expressed in many cancers and shown 
to be associated with high grade tumours and advanced stage, as well as poor 
prognosis, including oesophageal squamous cell carcinoma (Take no et aI., 
2002), small cell lung cancer (Yoshida et aI., 2004, Cooper et aI., 2009) and B-
cell lymphoma (Obermann et aI., 2005). 
Clinical in vivo studies showed that cyclin B 1 was an independent predictor of 
poor overall survival among premenopausal (Kiihling et aI., 2003). Previously, 
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it has been demonstrated that CCNB 1 gene clustered in Luminal B subtype 
which is characterised by low ER expreSSIon and high expression of 
proliferation related genes (Hu et aI., 2006). 
Cyclin B 1 expression tends to increase in tumours with co-occurrence of TP53 
mutations and MYC amplification, a combination that seems to characterize 
basal-like and poor prognosis Luminal B tumours (Agarwal et aI., 2009). 
Confirming the clinical importance of both TK 1 and cyclin B 1, several 
prognostic gene signatures were previously developed for ER-positive/luminal-
like breast cancer composed of many cell-cycle and proliferation associated 
genes including both TKI and cyclin Bl (Chanrion et aI., 2008). 
In this study, we assessed the biological and clinical relevance of these cell-
cycle stage specific markers, both individually and in combination, and 
compared their expression to the pan-proliferation marker MIB 1 in the whole 
patient series and in the ER-positive breast luminal-like cohort. 
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6.2.2 Material and Methods 
Mouse monoclonal antibodies to TKI (ab57757; Abeam, Cambridge, UK) and 
cyclin Bl (ab72; Abeam, Cambridge, UK) were optimized at a working 
dilution of 5J..lglml and O.3J..lglml respectively using optimisation tumour TMAs 
and full-face sections of breast carcinoma; tonsil tissue was used as positive 
control tissue. To unmask the antigens, the sections were microwaved in citrate 
buffer pH 6 for 23 minutes at 700W. An indirect labelled streptavidin avidin 
biotin technique (LSAB) technique with DAB chromogen was performed using 
a DakoCytomation Techmate 500 Plus (DakoCytomation, Cambridge, UK) 
automatic immunostainer as previously discussed in the Material and methods 
chapter. Negative controls were performed by omitting the primary antibody 
and substitution with diluent. 
For TK1, the informative cores were scored using the percentage of positive 
cells stained in each core. The data was categorised using the median of the 
TKI percentage (8%). 
For cyclin Bl H-score was used for assessment. The median of the H score> 0 
cutoff was used to categorise the data of cyclin B 1. 
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6.2.3 Results 
In breast cancer tissue, protein expression was detected in the cytoplasm of 
malignant cells for TK 1 and cyelin B 1 (Fig 6.1). 
Figure 6.1 : Expression ofTKl and cyclin B 1 in breast cancer 
(A) TKI expression in high grade invasive ductal carcinoma (x200). (8) Cyclin 
B 1 expression in high grade invasive ductal carcinoma (x400). 
TK1 
In the whole series, high TKI expression (2: median 8%) was found in 51.5% 
of patients and was positively associated with younger age group (p=O.OO 1), 
large tumour size (p=O.OOl), high tumour grade (p<O.OOI), rai sed mitotic 
counts (p<O.OOI), poor NPI group, DM and recurrence. The positive expression 
was noted in medullary type cancer and ductal NST with very low expression 
in lobular cancer (p<O.OOl). 
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In the ER-positive grouP. TKI was associated with younger age group 
(p<O.OOI). high tumour grade (p<O.OOI). LN stage (p=0.004). mitotic counts 
(p<O.OO 1). poor NPI group (p<0.00 1) and vascular invasion (p=0.0 10). 
In the whole series. there was an inverse association between TKI expression 
and ER. PgR. AR, Bcl-2. CKl8 and CKI9. In contrast. positive associations 
between TKI expression and basal CKs expression (CK5/6; (p<0.001). P-
cadherin (p<0.001). p53. HER2. EGFR and MIBI expression were found 
(Table 6.1). 
In the ER-positive patients. TKI expression was positively associated with 
MIBI. p53. P-cadherin. E-cadherin. HER2 and EGFR (Table 6.2). 
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Table 6.1: Relation ofTKl expression to other biomarkers in the whole seri es 
of breast cancer patients 
TKJ expression 
Variable Negative Positive Total l p-value 
CKS/6 
Negative 398(51) 383(49) 781 18.751 <0.001 
Positive 40(30.5) 91(69.5) 131 
CKJ4 
Negative 398(49.2) 411(50.8) 809 3.882 0.049 
Positive 34(38.2) 55(61.8) 89 
CK18 
Negative 31 (25.8) 89(74.2) 120 26.81 4 <0.001 
Positive 382(51 .3) 363(48.7) 745 
CKI9 
Negative 29(31 .5) 63(68.5) 92 11 .608 0.001 
Positive 411(50.2) 407(49.8) 818 
ER 
Negative 69(28 .3) 175(71.7) 244 51 .343 <0.001 
Positive 359(55.1) 292(44.9) 651 
PgR 
Negative 139(36.5) 242(63.5) 381 37.090 <0.001 
Positive 288(57. 1) 2 16(42.9) 504 
AR 
Negative 107(36) 190(64) 297 28.793 <0.001 
Positive 308(55.3) 249(44.7) 557 
~ _ S 3 3
Negative 351(54) 299(46) 650 34.504 <0.001 
Positive 78(32) 166(68) 244 
BcI-2 
Negative 100(37.2) 169(62.8) 269 28.207 <0.001 
Positive 254(57.7) 186(42.3 440 
MIBI 
low 149(76.4) 46(23.6) 195 91.57 <0.001 
High 203(36.6) 351(63.4) 554 
P-cadherin 
Negative 217(32.4 77) 166(43.3) 383 32.477 <0.001 
Positive 152(36.5) 264(63.5) 416 
E-cadherin 
N!lgative 182(54.3) 153(45.7) 335 7.680 0.006 
Positive 253(44.8) 3 12(55.2) 565 
HER2 
Negative 425(52.3) 388(47.7) 81 3 38.779 <0.001 
Positive 21(20) 84(80) 105 
EGFR 
Negative 353(52.2) 323(47.8) 676 37. 198 <0.001 
Positive 40(25.3) 118(74.7) 158 
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Table 6.2: Relation of TKI expression to other biomarkers in ER-positive 
cohort 
TKI expression 
Variable Negative Positive Total X2 p -va lue 
CKS/6 
Negative 333(55. 1 ) 27 1 (44.9) 604 0.024 0.607 
Positive 18(50) 18(50) 36 
CK14 
Negative 327(54.9) 269(45. 1) 596 0.015 1.000 
Positive 2 1(53.8) 18(46.21 39 
CK18 
Negative 10(4 1.7) 14(58.3) 24 1.658 0.215 
Positive 329(55) 269(45} 598 
CKI9 
Negative 17(45.9) 20(54. I) 37 1.383 0.307 
Positive 339(55.80 268(44.2) 607 
PgR 
Negative 81(51.3) 77948.'Q 158 1.193 OJ II 
Positive 270(56.20 2 10(43.8) 480 
AR 
N ~ a t i v e e 65(52.4) 5 ~ 4 7 . ~ ~ 124 0.717 0.419 
Positive 277(56.6) 2 12(43.3) 489 
p53 
Negative 304(58 .1) 2 19(41.9) 523 13.220 <0.001 
Positive 44(39.3) 6!K60.7) 11 2 
Bcl-2 
N ~ a t i v e e 56(47.5) 62(52.5) 118 4.96 1 0.033 
Weak 224(59. 1) 155(40.9) 379 
MIB) 
low 131(78) 37(22) 176 56.292 <0.001 
High 154(43) 204(57) 355 
P-cadherin 
Negative 203(58) 147(42) 350 6.798 0.009 
Positive 105(46.9) 1 I ~ 5 5 . 1 ) ) 224 
E-cadherin 
N ~ a t i v e e 150(64.9) 81(35. 1) 23 1 14.4 16 <0.001 
Positive 202(49.4) 207(50.6) 409 
HER2 
Negative 347(58.7) 244(4 1.3J 59 1 39.5 15 <0.001 
Positive 5( 10.9) 41(89. 1) 49 
EGFR 
Negative 302(58.2) 2 17(41.8) 5 19 23.032 <0.001 
Positive 24(29.6) 57(70.4) 81 
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Cyelin Bl 
The invasive breast cancer tissue showed expression of cyclin B 1 in cytoplasm 
and with perinuclear localisation (Fig 6.1).42.7% of the tumours were positive 
for cyclin B 1 expression. 
Correlation with the clinicopathological variables 
There was a positive association between cyelin Bland P-cadherin expression 
(p=O.Ol). 
In the ER-positive subtype, cyelin B 1 expression was positively associated 
with mitotic counts and distant metastasis. Positive expression was noted in 
medullary type cancer and NST. We found significant positive associations 
between cyelin B 1 expression and P-cadherin and p53 (Tables 6.3 and 6.4). 
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Table 6.3: Relation of cyclin B 1 expression to other clinicopathologic 
variables in the ER-positive cohort 
cyclin BI expression 
Variable Negative Positive Total X2 p-value 
Patients' age 1.743 0.627 
<40 26(63.4) 15(36.6) 4 1 
40-50 117(59.4) 80(40) 197 
51-60 127(58.8) 89(41.2) 2 16 
>60 128(54.7) 106(45.3) 234 
Tumour size 2.693 0.109 
< 1.5 em 155(62) 95(38) 250 
> 1.5cm 244(55 .6) 195(44.4) 439 
Lymph node stage 0.338 0.844 
I (Negative) 246(58.3) 176(41.7) 422 
2(1-3 LN) 125(57.9) 91(42.1) 2 16 
3(>3 LN) 27(54) 23(46) 50 
Tumour Grade 7.7 13 0.021 
I 77(56.6) 59(43.4) 136 
2 186(63 .7) 106(36.3) 292 
3 399(57.9) 290(42. 1) 26 1 
NPI 6.353 0.042 
Good 152(63.9) 86(36.1) 238 
Moderate 190(53.5) 165(46.5) 355 
Poor 57(59.4) 39(40.6) 96 
DM 6.321 0.012 
No 296(60.8) 191 (39.2) 487 
Positive 98(50.3) 97(49.7) 195 
Recurrence 7.685 0.007 
No 250(61.9) 154(38. 1) 404 
Positive 138(51.1) 132(48.9) 270 
VI 2.886 0.236 
No 213(59.3) 146(40.7) 359 
Probable 48(50) 48(50) 96 
Definite 137(59.1) 95(40.9) 232 
Histologic tumour type 7.701 0.173 
DuctalfNST 204(55.4) 164(44.6) 368 
Lobular 58(69.9) 25(30. 1) 83 
Tubular and Tubular mixed 101(59.4) 69(40.6) 170 
Medullary 3(75) 1(25) 4 
Other special types* 5(52.8) 6(47.2) II 
Mixed*'" 28(52.8) 25(47.2) 53 
Mitosis 10.073 0.006 
I 191(64.7) 104(35.3) 295 
2 85(56.3) 66(43.7) 151 
3 \1 5(51.1) 110(48.9) 225 
Menopausal status 1.1 35 0.294 
Premenopausal 146(60.6) 95(39.4) 24 1 
Postmenopausal 250(56.4) 290(42.2) 447 
*Inc\udes MucOld, invasive crIbrIform and mvaslve papillary carcinoma, ** 
Include ductallNST mixed with lobular or special type 
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Table 6.4: Relation of cyclin B 1 expression to other biomarkers in the ER-
positive cohort 
cyclin BI Expression 
Variable Negative Positive Total l p-va lue 
CKS/6 
Negative 369(58.2) 265(41.8) 634 0.866 0.352 
Positive 23(5 1.1 ) 22(48 .9) 45 
CKI4 
Negative 368(59.1) 255(40.9) 623 4.888 0.027 
Positive 19(42.2) 26(57.8) 45 
CKI8 
Negative 16(53.3) 14(46.7) 30 0.294 0.705 
Positive 364(58.3) 260(41.7) 624 
CKI9 
Negative 22(62.9) 13(37.1) 35 0.373 0.601 
Positive 374(57.4) 275(42.4) 649 
~ R R
Negative 97(57.7) 71(42.3) 168 0.008 0.928 
Positive 297(58. 1) 2 14(4 1.9) 511 
AR 
Negative 87(58.8) 6 1(4 1.2) 148 0.01 4 0.924 
Positive 296(59.3) 203(40.7) 499 
pS3 
Negative 330(60.1) 2 19(39.9) 549 7.035 0.010 
Positive 6 1(47.3) 68(52.7) 129 
BcI-2 
Negative 67(52.3) 61 (47.7) 128 
Positi ve 235(58.6) 166(4 1.4) 40 1 1.552 0.220 
MIBI 
Low 110(62.9) 65(37.1) 175 3.752 0.050 
High 205(54. 1) 174(45.9) 379 
P-cadherin 
Negative 23 1 (63.5) 133(36.5) 364 14.283 <0.001 
Positive 11 5(47.9) 125(52 .1) 240 
E-cadherin 
Negative 13 1 (56.2» 102(43.8) 233 004 17 0.567 
Posi ti ve 264(58.8) 185(4 1.2) 449 
HER2 
Negative 356(57.8) 260(42.2) 616 0.230 0.680 
Positive 36(6 1) 23(39) 59 
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6.2.4 Survival analysis 
Univariate analysis 
TKI 
In the whole series, a significant correlation between TK 1 expression and 
poorer BeSS was identified (Log Rank (LR)=11.623, p=0.001). In the ER-
positive/luminal-like cohort, we also found a significant association between 
TKI and shorter BeSS (LR=11.835,p=0.001) (Fig 6.2A). 
A significant relation between TKI expression and shorter DMFI in the whole 
series (LR=7.225, p=0.007) and in the ER-positive patient group (LR=9.518, 
p=O.002) was found (Fig 6.2B). 
DMFI according to systemic therapy group 
Tamoxifen only treated patients in ER-positive patient group (n=237) 
Patients with tumours expressing high TKI protein showed a significant 
shorterDMFI (LR= 6.58 1, p=O.OlO). 
Chemotherapy only treated patients in ER- patient group (n=JJ9) 
We found no significant relation between TKI expression and DMFI in ER 
negative chemotherapy treated patients (LR= 0.271. p=0.603). 
Cyelin HI 
We found no significant association between cyclin B 1 expression and BCSS 
in the whole series (LR= 2.399,p=O.l21). In contrast, the ER-positive/luminal-
like cohort showed a significant association with shorter Bess (LR=7.606, 
p=0.004) (Fig 6.2C). 
No significant association was found between cyclin B 1 expression and DMFI 
in the whole series (LR= 2.059, p=O.l51). In contrast, the ER-positive/luminal-
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like cohort showed a significant association with shorter DMFI (LR= 6.694, 
p=O.021) (Fig.6.2D). 
DMFI according to systemic therapy group 
Tamoxifen only treated patients in ER-positive patient group (n=217) 
Patients with tumours expressing high cyclin B 1 protein showed a significant 
shorter DMFI (LR= 5.438,p=O.OlO). 
Chemotherapy only treated patients in ER- patient group (n=127) 
We found a significant relation between cyclin B 1 expression and longer 
DMFI in ER negative chemotherapy treated patients (LR= 4.128, p=O.042) 
(Fig.6.2E). 
The effect of combined expression of both proteins on the DMFI in luminal-
like ER-positive cohort was tested and we found significantly shorter DMFI in 
patients expressing both markers (LR=8.194, p=O.017) than patients expressing 
only one marker in univariate analysis (Fig.6.2F). 
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(A) Kaplan Meier plot of TKI expression in relation to BCSS in ER-positive 
luminal like cohort. (B) Kaplan Meier plot of TK 1 expression in relat ion to 
DMFI in ER-positive luminal like cohort. (C) Kaplan Meier plot of cyclin B 1 
expression in relation to BCSS in ER-positive luminal like cohort. (D) Kaplan 
Meier plot of cyclin B 1 expression in relation to DMFI in ER-positive luminal 
like cohort. (E) Kaplan Meier plot of cyclin B I expression in relation to BeSS 
in ER negative chemotherapy treated patients. (F) Kaplan Meier plot of TKI 
and cyclin B 1 combined expression in relation to DMFI in ER-positive luminal 
like cohort. 
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Survival analysis in relation to MIBt expression 
To compare the combined expression ofMIBI and TKI or cyclin HI, we have 
studied the clinical outcome of patients expressing both markers (MID IITK 1) 
or (MIBI/cyclin BI). 
Our results showed that MID I in term of risk stratification, is superior to cycIin 
BI (LR=21.817, p<O.OOl) (Fig 6.3A) and TKI (LR=27.900, p<0.00l) (Fig 
6.3B) in univariate analysis. 
Multivariate analysis 
Multivariate analyses including the tumour stage, grade, size and endocrine 
therapy with regards to BCSS or DMFI showed that neither TK 1 nor cycIin B 1 
expression was found to be an independent prognostic marker in ER-positive 
subgroup (Table 6.5). 
The effect of combined expression of both proteins on the DMFI in luminal-
like ER-positive cohort was tested and we found that patients expressed both 
markers had a significantly shorter DMFI (LR=8.194, p=0.017) than patients 
expressing only one marker, in univariate (Fig.6.2F) and multivariate analysis 
(HR= 1.1738, p= 0.040, 95% CI=1.025-2.946) (Table 6.6). 
264 
Chapter 6 
1.0 
(ij 0.8 
> ~ ~
:::J 
(I) 0.6 
II> 
> ;:: 
~ 0 . 4 4
E 
:l 
uo. 
0.0 
1.0 
0.8 
ta 
> ~ ~ . 6 6
~ ~
> ~ ~
"3 0.4 
e ;:, 
u 
0.2 
o 50 
o 50 
Survival Functions 
100 150 200 
Bess In months 
100 150 200 
Bess In months 
A 
250 
B 
MIB1_CCNBl 
.Jl tllBl -CCr..I31 • 
.Jl tllBl -CCr..I31 + 
tllB+CCr..I31· 
.Jl tllBl +CCr..13 1 + 
-+- tllBl ·CCr..I31.-censored 
-+- IIIB1·CCr..I31 +-censored 
tiIB+CCr..I31 - censored 
-+- tllBl +CCr..I31 +-censored 
TK1 _MIBl 
..J""1MlBl .TK1 • 
..J""1MlBl .TK1+ 
MlBl +TK1 • 
..J""1MlBl+TK1+ 
-+- MIll . TKl.-<;enSored 
-+- MIll . TKl +·cens ored 
MIIIl + TK1·-cens ored 
-+- MlBl + TKl +-censo<ed 
250 
265 
Chapter 6 
Figure 6.3: Kaplan Meier plots of the combined expression of (A) cyclin B I 
and (B) TK 1 with MIB 1 in relation to BCSS 
Table 6.5: COX model of predictors of BCSS and DMFI In ER-positive 
patients 
BCSS DMFI 
Variable 95% CI 95%CI HR 
P value HR Lower Upper P value Lower Upper 
TKI expression 0.399 1.207 0.779 1.871 0.090 1.435 0.945 2. 180 
eyclin Bl expression 0.193 1.320 0.869 2.006 0.330 1.216 0.82 1 1. 80 1 
Tumour size <0.001 <0.001 2.503 1.580 3.966 2.469 1.607 3.792 
LN stage <0.001 0.061 
LN stage 2 vs.l 0.050 1.591 1.001 2.529 0.049 1.563 1.002 2.437 
LN stage 3 vs.l 0.053 1.949 0.992 3.830 <0.001 3.614 2.025 6.449 
Tumour grade 0.010 0.044 
Tumour grade 2 vs. 1 0.071 1.901 0.946 3.820 0.102 1.702 .899 3.22 1 
Tumour grade 3 vs. 1 0.003 2.876 1.424 5.808 0.014 2.248 1.180 4.282 
Endocrine Therapy 0.198 0.754 0.491 1.159 0.197 0.769 .516 1.146 
266 
Chapter 6 
Table 6.6: COX model of the combined expression of TK 1/cyc lin B 1 with 
regards DMFI in whole series and ER-positive patients 
Whole series ER-positive patients 
Variable 
P value IIR 95%CI P value I I I ~ ~ 95%CI 
Lower Upper Lower Upper 
Tumour size <0_001 2.030 1.437 2.868 <0.001 20435 1.586 3.738 
LN stage <0.001 <0.001 
LN stal!:e 2 vs.\ 0.040 1.442 1.016 2.047 .048 1.564 1.004 2.436 
LN stage 3 vs.\ <0.001 4.620 3.015 7.080 <0.001 3.580 2.019 6.347 
Tumour grade 0.038 0.039 
Tumour grade 2 vs. I 0.139 1.583 0.861 2.908 0. 102 1.702 0.900 3.2 18 
Tumour grade 3 vs. I 0.015 2.047 1.149 3.648 0.01 2 2.26 1 1.194 4.282 
Endocrine Therapy 1.000 1.000 0.728 1.373 0.246 0.788 0.527 1.178 
TKIICCNBI(double -v e) 00408 0.096 
TKIICCNBI(single +ve vs. 
0. 180 1.306 0.884 1.931 0.080 1.526 0.951 20450 
double - vel 
TKIICCNBI(double +ve vs. 
double -vel 
0.416 1.207 0.767 1.901 0.040 1.738 1.025 2.946 
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6.2.5 Discussion 
Many studies showed the clinical importance of TKI and cyclin BI (Chen et 
aI., Chanrion et aI., 2008) among gene signatures that can predict the disease 
relapse in breast cancer patients. Cyclin B 1 is included in the 21 gene 
commercially available recurrence signature for predicting the relapse in ER-
positive lymph node negative patients (Oncotype OX) (Paik et aI., 2004). 
Some authors have previously reported that TKI is a more useful proliferation 
marker than Ki-67 and PCNA in breast, lung and colorectal carcinoma (Guan 
et aI., 2009). 
In this study, we found a highly significant positive association between TKI 
and high proliferation as assessed by MID 1 protein expression, high mitosis 
and higher tumour grades indicating a high reliability of TK I in assessing the 
activated G 1 state in the cell cycle (Gasparri et aI., 2009, Zhang et aI., 2001, lIe 
et aI., 2006, Broet et aI., 2001). 
TKI usually increases earlier than Ki67 and represents a unique marker for the 
activated G 1 phase in the cell cycle (Gasparri et aI., 2009). The results of this 
study showed that MIBI expression is more powerful than TKI or cyctin BI in 
assessing the patient outcome contrasting with the results of another 
investigator who previously reported that TKI was a more useful proliferation 
marker than Ki-67 and PCNA in breast, lung and colorectal carcinoma (Guan 
et aI., 2009). 
Our results showed that ER-positive tumours expressing high levels of TKI 
and cyclin B 1 proteins are liable to metastasize. Oai and colleagues identified a 
subset of patients characterized by relatively high oestrogen receptor 
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expression for their age, the occurrence of metastases was strongly predicted 
by a homogeneous gene expression pattern almost entirely consisting of cell 
cycle genes among which TKI gene was included (Dai et aI., 2005). Others 
have shown that serum TKI concentration was higher in patients developing 
distant and/or loco-regional recurrence within 3 months after surgery (He et aI., 
2006). 
Supporting its role as a marker of poor prognosis in breast cancer, we found 
significant positive associations between TKI and other clinicopathological 
variables of unfavourable outcome including younger age group, high tumour 
grade, high mitotic counts and poor NPI group in agreement with others 
(Gasparri et aI., 2009, Zhang et aI., 2001, He et aI., 2006, Broet et aI., 2001). 
Our results showed that high cyclin B 1 expression was associated with mutated 
p53 protein expression in luminal-like breast cancer. Previous study has shown 
that in case of expression of the mutated p53, the cells tend to express cyclin 
B 1 more than those with wild type (Taylor and Stark, 200 I). Cyclin B 1 
expression tends to increase in tumours with co-occurrence of TP53 mutations 
and MYC amplification, a combination that seems to characterize basal-like 
and Luminal B tumours (Agarwal et aI., 2009). 
Clinical in vivo studies showed that cyclin B 1 was an independent predictor of 
poor overall survival among premenopausal (Kiihling et aI., 2003). In this 
study, although cyclin B 1 protein expression was found to be associated with 
shorter BCSS and DMFI in univariate analysis in ER-positive cohort, it was 
not an independent prognostic marker. However, interestingly cyclin B 1 was 
found to be associated with longer BeSS in chemotherapy only treated ER 
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negative patients indicating its potential role in assessing the chemotherapy 
response, especially in ER negative patients. 
There are suggestions that the difference between different luminal subclasses 
is due to its variable expression of proliferation associated genes (Sotiriou et 
aI., 2003). Our results are consistent with these findings and showed that 
increased cellular proliferation, as assessed by high TK 1 and cyclin B I 
expression, was associated with poor outcome in the ER-positive cohort. 
Although TKI is a predictor of outcome and not cyclin B I in the whole series, 
using both markers in combination produced better stratification in tenus of 
DMFI than each one separately. 
In conclusion, overexpression of cyclin Bl and TKI is involved in the 
progression of ER-positive breast cancer suggesting that targeting their 
expression in high proliferative breast cancer could offer novel treatment of 
breast cancer. Using both markers in combination produced better stratification 
in tenus of outcome than each one separately. Increased cellular proliferation 
occurs in some luminal cancers and appears to form a biological and clinically 
distinct subclass ofER-positive breast cancer patients. 
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6.3 The prognostic and biological significance of p27 and 
BcI-2 expression in breast cancer and ER-positive 
subtype 
6.3.1 Introduction 
Cellular proliferation has a significant impact on ER-positive breast cancer 
biology. The cell cycle is regulated by many mechanisms and is affected by the 
interaction of multiple pathways that either enhance or delay its progression. 
In addition to its control by cyclins and cyclin dependant kinases and cell cycle 
regulators, many studies have highlighted the role of Bcl-2 in controlling the 
cell cycle independent of its antiapoptotic function by causing retarded entry 
into the cell cycle (Vairo et al., 2000, Huang et al., 1997). In Bcl-2 transgenic 
cells, delayed cycle entry correlated with increased expressionofp27 (Vairo et 
al., 2000). Elevated Bcl-2 levels are associated with decreased proliferation and 
a favourable prognosis in many malignancies, including breast and colorectal 
cancer (Maze I et al., 1996). Further evidence that Bcl-2 can regulate cell cycle, 
was provided by Deng et el (Deng et aI., 2003) who found that Bcl2 may 
regulate GIl S transition by a novel signalling mechanism that couples 
regulation of intracellular reactive oxygen species (ROS) with p27 and Cdk2. 
Phosphorylation of Bcl2 may functionally link its antiapoptotic, cell cycle 
retardation, and antioxidant properties(Deng et al., 2003, Maddika et al., 2007). 
Also, Greider and co-workers suggested that one possible mechanism by which 
BCL2 can delay cell cycle entry may be the inhibition of C-MYC activity 
through the elevation of p27 (Greider et al., 2002). These observations have 
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also been found in other organs where Bcl-2 delays hepatocyte cell cycle 
progression during liver regeneration (Vail et al., 2002). Furthermore, Bcl-2-
induced inhibition of hormonal dependent apoptosis was associated with an 
inhibition of Rb protein downregulation, a constant level of p21 protein, and a 
inhibition of cell cycle (Truchet et aI., 2000). 
6.3.2 p27 (kipl) 
p27 is a cell cycle inhibitor involved in G 1 arrest of cell cycle due to its potent 
inhibition of cyclin E and cyclin A-CDK2 complexes. In addition, it is a 
positive regulator of cyclin D-dependent kinases such as CDK4 (Han et al., 
2003). Low expression of p27 and its degradation correlate with increased 
cellular proliferation and poor prognosis in many cancers including lung, 
breast, colon, ovary, oesophagus, thyroid and prostate cancer (Han et al., 
2003). p27 gene transfection in malignant human brain tumour cells blocked 
cellular proliferation in G 1 phase of the cell cycle (Chen et al., 1996). In 
addition, subcellular localization of p27 has an important role in p27 
regulation. p27 needs to be translocated to the nucleus to function in G I and its 
degradation is linked to nuclear export (Tomoda et al., 1999). 
6.3.3 BcI-2 
Bcl-2 is an antiapoptotic protein that promotes cell survival, but also may block 
cellular proliferation, and contrary to expectation, its expression is associated 
with good prognosis oestrogen receptor (ER) positivity in breast cancer 
patients (Callagy et al., 2008). 
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Deregulation of normal programmed cell death mechanisms plays an important 
role in the pathogenesis of breast cancer by two major pathways. The intrinsic 
pathway (mitochondrial) involves changes in mitochondrial membrane 
permeability, release of cytochrome c, exposure of phosphatidylserine on the 
outer part of the plasma membrane, and loss of plasma membrane integrity. 
The other mechanism, the extrinsic pathway is dependent on extracellular 
signals including tissue necrosis factor-alpha (TNF), Fas ligand, and TNF-
related ligand TRAIL. The intrinsic and extrinsic pathways activate caspases, 
which cleave DNA and catabolise the cytoskeleton (Zhivotovsky and Kroemer, 
2004, Brown and Attardi, 2005, Youle and Strasser, 2008) (Fig 6.4). 
Bcl-2 inhibits most kinds of programmed cell death and provides a selective 
growth advantage to various cell types. This function is achieved by controlling 
the mitochondrial membrane permeability and suppressing apoptosis by 
inhibiting caspase activity either by preventing the release of cytochrome C 
from the mitochondria or by binding to the apoptosis-activating factor (APAF-
1) (Y oule and Strasser, 2008). 
Supporting its clinical applications, Bcl-2 was included as one of a panel of 
sixteen genes whose expression can predict tumour recurrence in tamoxifen-
treated node-negative breast cancer (Paik et al., 2004). 
Many studies have demonstrated the relation between Bcl-2 and p27. 
Overexpression of Bcl-2 may lead to retardation of the GOIS transition by 
sustaining the expression level of cyclin-dependent kinase inhibitor p27 
(Linette et al., 1996). Others have demonstrated that p27 may mediate the 
effects of Bcl-2 on cellular proliferation (Cheng et al., 2008). 
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In this study, we hypothesized that the interaction between 8c1-2 and p27 can 
significantly retard the cell proliferation and enhance the cell cycle arrest 
which could possibly reflect on patient prognosis and tumour biology. 
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Figure 6.4: Intrinsic and extrinsic pathways of apoptosis. 
Adapted from (Youle and Strasser, 2008) 
6.3.4 Material and Methods 
Tissue microarrays were prepared and the immunohistochemical staining was 
performed usmg the streptavidin-biotin complex method usmg 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
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(general material and methods chapter). To unmask the antigens, the sections 
were microwaved in citrate buffer pH 6 for 23 minutes. p27 mouse monoclonal 
antibody (clone SX53G8, Dako, UK) was optimized at a working dilution of 
1 :40 using full face sections and TMAs on DakoCytomation Techmate 500 
plus (DakoCytomation, Cambridge, UK) automatic immunostainer with a 
labelled streptavidin biotin technique (LSAB) in accordance with the 
manufacturer's instructions. Negative controls were performed by omitting the 
primary antibody and substitution with diluent. Positive breast cancer cases 
were used as positive controls. The H-score (histochemical score) was used to 
assess the intensity of staining and the percentage of stained cells following 
immunohistochemistry (McCarty et aI., 1985). 
Mouse monoclonal antibody to Bcl2 (clone 124, Dako, UK) was optimised at a 
working dilution of 1: 1 00 using full face sections and TMAs on 
DakoCytomation Techmate 500 plus (DakoCytomation, Cambridge, UK) 
automatic immunostainer with a labelled streptavidin biotin technique (LSAH) 
in accordance with the manufacturer's instructions. Negative controls were 
performed by omitting the primary antibody and substitution with diluent. 
Positive breast cancer cases were used as positive controls. 
Cut-offs were chosen using ( ~ 1 0 % ) ) positive cells (Abdel-Fatah et al.). 
6.3.5 p27 expression results 
The optimization, scoring and staining process have been discussed in details 
in the general material and methods chapter. 
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The pattern of staining in breast carcinoma was nuclear (Fig 6.5), with 
increased expression in the normal breast acini. After exc luding the 
uninformative TMA cores from the study, 1029 tumours were avai lable for 
assessment. 
Figure 6.5: TMA core with positive p27 expression (x200) 
6.3.5.1 Correlation between p27 expression and other 
clinicopathological variables 
p27 expression was associated with small tumour size (p=O.003), low grade 
tumours (p<O.OOl), good NPI group (p<O.OOI), lower mitotic index (p<O.OOJ) 
and less frequent development of distant metastasis. No associations were 
found between p27 expression and LN stage or vascular invasion. A significant 
decrease of p27 expression was found in medullary cancer (Table 6.7). 
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In the ER-positive luminal-like patient cohort, p27 retained its associations 
with low grade tumours, good NPI group and lower mitotic index (Table 6.8). 
6.3.5.2 Correlation between p27 expression and other biomarkers 
In the whole series, we found significant positive associations between p27 and 
luminal associated markers including CKs (CKI9 and CKI8), ER, PgR and 
AR. In contrast, p27 expression was inversely associated with markers of basal 
differentiation (CKSI6), MIB 1 and HER2 (Table 6.9). In the ER-positive 
luminal-like patient cohort, p27 showed no significant associations with the 
studied markers (Table 6.10). 
6.3.5.1 Correlation between p27 and patient outcome 
In the whole series, p27 was associated with longer BCSS (LR= 10.991, p= 
0.001) (Fig 6.6) and longer DMFI (LR=8.404,p=O.004) (Fig 6.7). 
In the ER-positive cohort, p27 retained its associations with longer BeSS (LR= 
5.959 and p= 0.015) (Fig 6.8) and longer DMFI (LR=4.72S and p=0.030) (Fig 
6.9). 
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Table 6.7: Relation of p27 expression to other cl inicopathological variab les in 
the whole series 
p27 Expression 
Variab le Low High Tota l l p-va lue 
Patien ts' age 3.350 0.34 1 
<40 58(79.5) 15(20.5) 73 
40-50 2 14(69.7) 93(30.3) 307 
5 1-60 241(70.5) 10 1(29.5) 342 
>60 2 11 (68.7) 96(31.3) 307 
Tumour size 8.989 0.003 
<1.5cm 2 11(64. 1) 11 8(35.9) 329 
> 1.5 cm 5 13(73.3) 187(26.7) 700 
I...ymph node s t ~ e e 3.625 0.163 
I (Negative) 431(68.6) 197(3 1.4) 628 
2( 1-3 LNl 220(7 1.4) 88(28.6) 308 
3(>3 LN) 7 1 (78) 20(22) 92 
Tumour Grade 63 .33 1 <0.001 
I 9 1(53.5) 79(46.5) 170 
2 207(62) 127(38) 334 
3 425(8 1.1 ) 99( 18.9) 524 
NPI 45.73 1 <0.001 
Good 154(54.8) 127(45.2) 281 
Moderate 434(75.3) 142(24.7) 576 
Poor 136(79. 1) 36(20.9) 172 
DM 8.042 0.005 
No 474(67.6) 227(32.4) 70 1 
Positive 248(76.3) 77(23.7) 325 
Recurrence 4.288 0.039 
No 397(67.9) 188(32. 1) 585 
Positive 327(73 .8) 11 6(26.2) 443 
VI 0.776 0.678 
No 393(69.3) 174(30.7) 567 
Probable 86(7 1.7) 34(28.3) 120 
Defini te 243(7 1.9) 95(28. 1) 338 
Histologic tumour type 50.402 <0.001 
Ductal/NST 480(76.8) 145(23.2) 625 
Lobular 55(58.5) 39(4 1.5) 94 
Tubular and Tubular mixed 11 0(55.3) 89(44.7) 199 
Medullary 28(93.3) 2(6.7) 30 
Other ~ e c i i l l types* 13(59.1) 9(40.9) 22 
Mixed** 38(64.4) 2 1(35.6) 59 
Mitosis 66.247 <0.00 1 
I 178(54.8) 147(45.2) 325 
2 11 7(66.5) 59(33.5) 176 
3 398(8 1.2) 92( 18.8) 490 
Menopausal sta tus 0.026 0.889 
Premenopausal 28 1(70.1) 120(29.9) 40 1 
Postmenopausal 443(70.5) 185(29.5) 628 
*Includes MucoId, inVaSIVe cnbnform and inVaSIVe papillary carcinoma, ** 
Include ductallNST mixed with lobular or special type 
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Table 6.8: Relation of p27 expression to other clinicopathological variables in 
the ER-positive cohort 
p27 Expression 
Low High Tota l 
-l Variable p-value 
Patients' age 0.305 0.959 
<40 20(64.5) II (35.5) 3 1 
40-50 120(60.91 77(39.1) 197 
5 1-60 151 (63.2) 88(36.8) 239 
>60 142(62.3) 86(37.7) 228 
Tumour size 2.343 0. 138 
<1.5 cm 139(58.4) 99(41.6) 238 
> 1.5 em 294(64.3) 163(35.7) 457 
Lymph node stage 4.566 0.102 
I (Negative) 248(59.2) 171 (40.8) 4 19 
2( 1-3 LN) 144(65·tn 75(34.2) 2 19 
3(>3 LN) 39(70.9) 16(29. 1) 55 
Tumour Grade 14.465 0.00 1 
I 80(53) 71 (47) 15 1 
2 172(59.5) 117140.5} 289 
3 180(70.9) 74(29.1) 254 
NPI 13.498 0.001 
Poor 132(53.7) 11 4{46.3) 246 
Moderate 23 1(65.6) 12 1(34.4) 352 
Good 70(72.2) 27(27.8) 97 
DM 3.76 1 0.060 
No 29 1(60) 194(40) 485 
Positive 141(67.8) 67(32.2) 208 
Recurrence 1.907 0.177 
No 244(60.2) 1 6 t t 3 9 . ~ ~ 405 
Positive I 89(65 .4} 100(34.6) 289 
V I 2. 12 1 0.346 
No 222(60} 148(40) 370 
Probable 64(66.7) 32(33.3) 96 
Definite 146(64.6) 80(35.4) 226 
Histologic tumour type 12.906 0.024 
Ducta1fNST 24 1(67.1 ) I 18{32.91 359 
Lobu lar 50(60.21 33(39.8) 83 
Tubular and Tubular 96(53 .6) 83(46.4) 184 
mixed 
Medullary 4( 1001 0(0) 4 
Other special types 8(50) 8{501 16 
Mixed 34(63) 20(37) 54 
Mitosis 16.820 <0.001 
I 153(53.3) 134(46.7) 287 
2 92(63) 54(37) 146 
3 165(70.8) 68{29.2) 233 
Menopausal status 1.796 0.189 
Premenopausal 142(58.9) 99(41.1 ) 24 1 
Postmenopausal 29 1(64·11 I 63Q5 .91 454 
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Table 6.9: Relation ofp27 expression to other biomarkers in the whole series 
p27 Expression 
Variable Low High Total .j p-value 
CKS/6 
Negative 555(67.8) 264(32.2) 819 12.3 16 <0.001 
Positive 142(8\, 1) 33( 18.9) 175 
CKt4 
Negative 577(69) 259(3 1) 836 4.109 0.045 
Positive 107(77.5) 3 1(22.5) 138 
CKt8 
N ~ ~ t i v e e 114(88.4) 15( I \.6) 129 23.522 <0.001 
Positive 525(67.3) 255(32.7) 780 
CKt9 
N e ~ a t i v e e 76(85.4) 13( 14.6) 89 10.629 <0.001 
Positive 62 1(68.8) 28 1 (31.2) 902 
ER 
N ~ a a i v e e 251(90.3) 27(9.7) 278 74.483 <0.001 
Positive 433(62.3) 262(3 7.7) 695 
IXR 
Negative 360(82.6) 76( 17.4) 436 58. 170 <0.00 1 
Positive 320(60) 2 13(40) 533 
~ S 3 3
Negative 474(67.4) 229(32.6) 703 8.460 0.004 
Positive 2 10(76.9) 63(23.1) 273 
AR 
N ~ a a i v e e 282(79.2) 74(20.8) 356 23 .144 <0.001 
Positive 366(64.3) 203(35.7J 569 
MIBI 
low 138(63.9) 78(36.1) 216 9.353 0.003 
H!&h 429(74.9) 144(25. 1) 573 
P-cadherin 
Negative 234(64.5) 129(35.5) 363 9.906 0.002 
Positive 338(74.6) 11 5(25.4) 453 
E-cadherin 
Negative 267(70.8) 110(29.2) 377 0.320 0.6 16 
Positive 4 14(69.1) 185(30.2) 599 
HER2 
N ~ a a i i e e 587(68.62 269(3 1.4) 856 8.274 0.004 
Positive 106(80.9) 25( 19. 1) 131 
EGFR 0.8 18 0.406 
Negative 467(68.7) 2 11 (31. 1) 678 
Positive 126(72.4) 48(27.6) 174 
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Table 6.10: Relation of p27 expression to other biomarkers in the ER-posi tive 
cohort 
p27 expression 
Variable Low High Total 
, 
1.- p-value 
CKS/6 
Negative 394(62.3) 238(37.7) 632 0.371 0.548 
Positive 29(58) 2 1(42) 50 
CKI4 
Negative 380(62.3) 230(37.7) 6 10 0.037 0.889 
Positive 36(61) 23(39) 59 
CKI8 
Negative 2 1(75) 7(25) 28 1.946 0.230 
Positive 38 1 (62) 234(38) 6 15 
CKI9 
Negative 26(76.5) 8(23.5) 34 3.022 0. 102 
Positive 402(61.7) 250(38.3) 652 
Pg R 
Negative 11 5(68.9) 52(3 1.1 ) 167 3.968 0.054 
Positive 3 11 (60.3) 205(39.7) 5 16 
AR 
Negative 109(65 .7) 57(34.3) 166 1.054 0.354 
Positive 298(6 1.2) 189(38.8) 487 
J!.53 
Negative 343(6 1.8) 2 12(38.2) 555 0.270 0.684 
Positive 81(64.3) 45(35.7) 126 
MIBI 
low 110(60.8) 71(39.2) 181 1.950 0. 182 
High 240(66.9) 11 9(33. 1) 359 
E-cadherin 
Negative 158(62.9) 93(37. 1) 25 1 0.083 0.806 
Positive 269(6 1.8) 166(38.2) 435 
P-cadherin 
Negative 2 11 (63.4) I 22(36.6J 333 0.178 0.730 
Positive 156(61. 7) 97(38.3) 253 
HER2 
Negative 384(6 1.3) 242(38.7) 626 1.721 0.242 
Positive 38(70.4) 16(29.6) 54 
EGFR 
N ~ ~ t i i e e 333(63.8) 189(36.2) 522 
Positive 49(53.8) 42(46.2) 9 1 3.265 0.079 
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Figure 6.6: Kaplan Meier plot of p27 expression in relation to BCSS in the 
whole series 
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Figure 6.7: Kaplan Meier plot of p27 expression in relation to DMFl in the 
whole series 
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Figure 6.8 Kaplan Meier plot of p27 expression in relation to BCSS in the ER-
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Figure 6.9: Kaplan Meier plot of p27 expression in relation to DM Fl in the 
ER-positive luminal-like cohort 
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6.3.6 BcI-2 expression results 
The pattern of staining in breast carcinoma was cytoplasmic (Fig 6.10), with 
increased expression in the normal acini. After excluding the uninformative 
TMA cores from the study, 1190 tumours were available for assessment. 
Figure 6.10: TMA core of grade 2 ductal cancer with positive Bcl-2 
expression (x 1 00) 
6.3.6.1 Correlation between BcI-2 expression and other 
clinicopathological variables 
In the whole patient series, BcI-2 was associated with postmenopausal status 
and older age group, small tumour size, LN negativity, low grade tumours, 
lobular and tubular histologic type (Table 6.11). 
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In the ER-positive cohort, Bcl-2 was significantly associated with low tumour 
grade, low mitotic index, good NPI group, absence of DM and more frequent 
expression in lobular and lobular histological types with decreased expression 
in medullary cancer (Table 6.12). 
6.3.6.2 Correlation between BcI-2 expression and other 
biomarkers 
On studying the correlation between Bc1-2 and other biomarkers, we found that 
its expression is positively associated with markers of good prognosis 
including ER, PgR, AR and p27. Bc1-2 expression was positively associated 
with markers of luminal differentiation such as CK 18, PgR and AR. On the 
other hand, Bcl-2 was inversely associated with basal CKs, IIER2, p53 and P-
cadherin expression. In the ER-positive group, Bcl-2 expression showed 
similar results (Tables 6.13&14). 
6.3.6.1 Correlation between Bcl-2 expression and patient outcome 
In the whole series, Bc1-2 was associated with longer BCSS (LR= 32.911 and 
p< 0.001) (Fig 6.11) and longer DMFI (LR=25.150 andp< 0.001) (Fig 6.12). 
In the ER-positive breast cancer, Bcl-2 retained its associations with longer 
BCSS (LR= 12.220 andp<O.OOI) (Fig 6.13) and longer DMFI (LR=12.167 and 
p< 0.001) (Fig 6.14). 
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Table 6.11: Relation of Bcl-2 expression to other clinicopathological vari ables 
in the whole series 
BcI-2 Express ion 
Negative Positive Tota l 
'l Variable p-va lue 
Patients' a2e 29.095 <0.001 
<40 49(55.71 39(44.31 88 
40-50 93(26.9) 253(71 .3) 253 
51-60 128(31.41 28Q(68 .61 408 
>60 98(28.2) 249(71 .8) 347 
Tumour size 18.729 <0.001 
<1.5 em 94(22.9) 316(77.1) 410 
> 1.5cm 274(35 .1) 5 0 6 ( 6 4 . ~ ~ 780 
Lymph node stage 14.299 0.001 
I (Negative) 229(301 535{70) 764 
2(1-3 LN) 93(28.4) 235(71.6) 328 
3(>3 LN) 46(47.9) 50(52·11 96 
Tumour Grade 183.9 <0.001 
I 20(8.5) 214(91.5) 234 
2 62( 16.5) 3 14(83.5) 376 
3 286(49·41 293(50.6) 579 
NPI 107.3 <0.001 
Good 38(10.6) 322(89.4) 360 
Moderate 246(37.6) 409(62.4) 655 
Poor 84(48) 91f52) 175 
DM 26.429 <0.001 
No 225(26.5) 624(73.5) 849 
Positive 139(41.91 193(58.1) 332 
Recurrence 17.746 <0.001 
No 187(26.3) 525i73.'Q 71 2 
Positive 174(37·41 285(62. 1) 459 
VI 2. 165 0.339 
No 199(29.4) 478(70.6) 677 
Probable 43(30.9) 96(69.1) 139 
Definite 126(33.8) 2 4 K 6 6 . ~ ~ 373 
Histologic tumour 130.9 <0.001 
!YJ:!e 
DuctallNST 282(4 1.2} 4 0 ~ 5 5 . 8 1 1 684 
Lobular 27(22.3) 94(77.7) 12 1 
Tubular and Tubular 22(8.4) 24 1 (91.6) 263 
mixed 
Medullary 21(70) 9{301 30 
Other special types* 6(241 1 ~ 7 6 1 1 25 
Mixed** 10(14.9) 57(85.1 ) 67 
Mitos is 186.5 <0.001 
I 50(1 1.8) 373(88.2) 423 
2 40(19.6) 164(80.4) 204 
., 
269(5 1.4) 254(48.61 523 oJ 
Menopausal status 1.291 0.256 
Premenopausal 149(32.9) 304i67.1) 453 
Postmenopausal 2 19(29.8) 5 17(70.2) 736 
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Table 6.12 : Relation of Bcl-2 expreSSlOn to other biomarkers In the ER-
positive cohort 
8c1-2 Expression 
Variable Negative Positive Total X2 p-value 
Patients' age 4.744 0. 19 1 
<40 7(19.4) 29(80.6) 36 
40-50 24( 10.7) 20 1(89.3) 225 
51-60 49(16.7) 244(83.3) 293 
>60 35( 13.6) 223(86.41 258 
Tumour size 4.929 0.026 
< I.Scm 33(10.7) 276(89.3) 309 
> 1.5 cm 82(16.3) 422(83 .7) 504 
Lymph node stage 6.443 0.040 
Jillegative) 71(13.7) 447(86.3) 5 18 
2( 1-3 LN) 29(12.4) 204(87.6) 233 
3(>3 LN) 15(25) 45(75) 60 
Tumour Grade 20.305 <0.00 1 
I 14(6.8) 193(93 .2) 207 
2 43(13.1) 286(86.9) 329 
3 58f211 2 18(79) 276 
NPI 11.870 0.003 
Poor 30(9.4) 290(90.6) 320 
Moderate 63( 16.1) 328(83.9) 39 1 
Good 22(21 .6) 80(78.4) 102 
DM 9.06 1 0.004 
No 172( 12) 526(88) 598 
Positive 43 (20.5) 167(79.5) 2 10 
Recurrence 6.283 0.0 16 
No 60( 11.9) 443(88.1 ) 503 
Positive 55(18.3) 245(8 1.7) 300 
VI 4.685 0.096 
No 55( 12.4) 390(87.6) 445 
Probable 18(16.5) 91 (83 .5) 109 
Definite 42(16.3) 2 16(83.7) 258 
Histolol!ic tumour type 23 .037 <0.00 1 
DuctalfNST 69(17.7) 320(82.3) 389 
Lobular 22(20.8) 84(79.2) 106 
Tubular and Tubular mixed 15(6.3) 222(93.7) 237 
Medullary 1(50) 1(50) 2 
Other special types. 2( 10) 18(90) 20 
Mixed" 6( 10.2) 53 (89.8) 59 
Mitosis 23.349 <0.00 1 
1 37(9.9) 336(90. 1) 373 
2 18(10.8) 149(89.2) 167 
3 56(23.2) 185(76.8) 24 1 
Menopausal status 4.909 0.032 
Premenopausal 28(10.3) 243(89.7) 27 1 
Postmenopausal 87(16. 1) 454(83 .9) 25 1 
*Includes Mucoid, invasive cnbnform and invaSive papIllary carCinoma, ** 
Include ductallNST mixed with lobular or special type 
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Table 6.13: Relation of BcI-2 expression to other biomarkers in the whole 
series of breast cancer patients 
8c1-2 Expression 
Variable Negative Positive Total X2 p-value 
CKS/6 
Negative 235(24.7) 716(75.3) 951 105.4 <0.001 
Positive 12 1(62. 1) 74(37.9) 195 
CK14 
Negative 270(27.6) 710(72.4) 980 37.93 1 <0.001 
Positive 80(52.3) 73(47.7) 153 
CK18 
Negative 95(66.4) 48(33.6) 143 99.302 <0.001 
Positive 226(25. 1 ) 676(74.9) 902 
CKI9 
Negative 40(40) 60(60) 100 3.999 0.046 
Positive 3 17(30.3) 729(69.7) 1046 
ER 
Negative 234(74.3) 81(25.7) 3 15 384.3 <0.00 1 
Positive 115(14. 1) 698(85.9) 813 
PgR 
Negative 276(57.4) 205(42.6) 48 1 278.2 <0.00 1 
Positive 67( 10.7) 561(89.3) 628 
jJS3 
Negative 175(2 1.5) 638(78 .5) 813 118.6 <0.00 1 
Positive 169(55.2) 137(44.8) 306 
AR 
Negative 202(51.1 ) 193(48.9) 395 120.2 <0.001 
Positive 126( 18.9) 539(81.1) 665 
MIBI 
low 44(15.9) 233(84. 1) 277 4 1.64 1 <0.001 
High 234(37.4) 392(62.6) 626 
P-cadherin 
Negative 55(12.9) 373(87. 1) 428 116.3 <0.001 
Positive 230(45.5) 276(54.5) 506 
E-cadherin 
Negative 142(34.5) 270(65.5) 4 12 5. 125 0.024 
Positive 196(28) 504(72) 700 
HER2 
Negative 258(26) 735(74) 993 89.083 <0.001 
Positive 90(65.7) 47(34.3) 137 
EGFR 
Negative 206(26) 585(74) 79 1 36.275 <0.001 
Positive 92(48.4) 98(51 .6) 190 
..Q27 
Negative 209(41.8) 291(58.2) 500 47.890 <0.001 
Positive 37(15.9) 196(84. 1) 233 
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Table 6.14: Relation of Bcl-2 expreSSlOn to other biomarkers In the ER-
positive cohort 
8c1-2 Expression 
Variable Negative Positive Total X2 p-value 
CKS/6 
Negative 98(13.2) 642(86.8) 740 8.601 0.006 
Positive 16(27. 1) 43(72.9) 59 
CKI4 
Negative 95( 13) 636(87) 731 6.674 0.018 
Positive 15(25) 45(75) 60 
CKl8 
Negative 9(33.3) 18(66.7) 27 9.174 0.007 
Positive 93(12.9) 626(87.1) 719 
CKI9 
Negative 5(13.2) 33{86.8) 38 0.037 1.000 
Positive 109(14.3) 655(85 .7) 764 
PgR 
Negative 51(27.1) 137(72.9) 188 36.495 <0.001 
Positive 58(9.7) 541(90.3) 599 
AR 
Negative 38(22.2) 133(77.8) 171 11.841 0.001 
Positive 69(11.8) 516(88.2) 585 
JlS3 
Negative 75( 11.5) 579(88.5) 654 18.779 <0.001 
Positive 34(25.8) 98(74.2) 132 
MlBl 
low 24(10) 2 15(90) 239 3.936 0.047 
High 60(15 .6) 324(84.4) 384 
P-cadherin 
Negative 36(9.2) 355(90.8) 39 1 15.906 <0.001 
Positive 56(19.9) 255(80.1) 28 1 
E-cadherin 
Negative 47(17.4) 223(82.6) 270 4.109 0.05 1 
Positive 63(12.1) 456(87.9) 519 
HER2 
Negative 89(12.2) 640(87.8) 729 19.905 <0.001 
Positive 19(33.3) 3S{66.7) 57 
EGFR 
Negative 79(13) 529(87) 608 5.058 0.032 
Positive 22(21.4) 81(78.6) 103 
J!27 
Negative 54(18.1) 245(8 1.9) 299 3.778 0.05 
Positive 23(11.6) 175(88.4) 198 
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Figure 6.11: Kaplan Meier plot of Bcl-2 expression in relation to BCS in the 
whole series. 
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Figure 6.12: Kaplan Meier plot of Bcl-2 expression in relation to DMFI in the 
whole series 
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Figure 6.13 Kaplan Meier plot of BC\-2 expression in relation to BCS in the 
ER-positive luminal-like cohort 
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Figure 6.14: Kaplan Meier plot of BC\-2 expression in relation to DMFI in the 
ER-positive luminal-like cohort 
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6.3.6.2 The effect of combined BcI-2 and p27 expression on breast 
cancer spesific survival 
We have found that combined positive expression of Bcl-2 and p27 in the Bcl-
2+p27+ cancer phenotype is associated with significant longer breast cancer 
specific survival when compared to their single phenotype. ER+Bcl-2+p27+ 
phenotype was associated with a significant longer BCSS in the whole patient 
series (LR=33.657, p<O.OOl) (Fig 6.15) and in the ER-positive luminal-like 
patient cohort (LR=29.244, p <O.OOl) (Fig 6.16). 
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Figure 6.15 Kaplan Meier plot of Bcl-2+p27+ expression in relation to BCSS 
in the whole patients series 
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Figure 6.16: Kaplan Meier plot of Bcl-2+p27+ expression in relation to BCSS 
in the ER-positive luminal-like cohort 
Multivariate analysis 
Multivariate COX proportional hazard analysis model including the tumour 
grade, LN stage, tumour size and the systemic therapy groups has shown that 
Bcl-2 was an independent prognostic maker of longer BCSS in the ER-positive 
luminal-like cohort (HR=0.473, p <O.OOl , 95% CI=O.339-0.659) (Table 6.15). 
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Table 6.15: COX multivariate analysis of predictors of BCSS in lum inal-li ke 
cohort 
Variable p value HR 95% CI 
Lower Upper 
p27 expression 0.335 0.84 1 0.59 1 1.196 
BcI-2 expression <0.001 0.473 0.339 0.659 
Tumour size <0.001 1.961 1.367 2.8 13 
LN staee <0.001 
LN staee (2) vs. (1) 0.011 1.67 1 1.124 2.483 
LN staee (3) vs. 0) <0.001 3.002 1.835 4.9 11 
Tumour erade <0.001 
Tumour ~ r a d e e (2) vs. (1) 0.239 1.369 0.8 11 2.3 10 
Tumour erade (3) vs. (1) <0.001 3.296 1.9 11 5.684 
Endocrine therapy 0.165 0.745 0.492 1. 129 
Chemotherapy 0.084 0.604 0.34 1 1.070 
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6.3.7 Discussion 
Many authors have repeatedly implied a strong relationship between cellular 
proliferation and poor prognosis in breast cancer with particular emphasis on 
ER-positive luminal subtypes (Cheang et at, 2009). 
The effect of Bcl-2 on tumour formation is complex and its high expression 
may either delay or increase tumour formation (Pietenpol et at, 1994). The 
oncogenic activity is due to its anti-apoptotic function while the growth 
inhibitory function has been attributed to its inhibition of cellular proliferation. 
In the ER-positive subgroup, we found that Bcl-2 was significantly associated 
with LN negativity, low grade, low mitotic index, good NPI group and absence 
of tumour recurrence. In addition, Bcl-2 was positively associated with markers 
of good prognosis including steroid receptors and CK18 and was inversely 
associated with proliferation as assessed by mitotic counts. Supporting this, in 
vitro experiments have revealed that high levels of Bcl-2 can result in dramatic 
growth inhibition in different cell types (Pietenpol et at, 1994) (Oreilly et at, 
1996). These findings are supported also by the association of Bcl-2 with 
longer breast cancer specific survival as demonstrated by other investigators 
(Callagy et at, 2006). 
To further support its growth inhibitory role in breast cancer, we have found a 
significant association between Bc1-2 and the cell cycle inhibitor p27. These 
results collectively, support that the dominant role of Bcl-2 in breast cancer is 
related to growth inhibition via decreasing cellular proliferation and inducing 
cell cycle delay. 
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In this study, we have shown that Bcl-2 and p27 are positively associated with 
luminal phenotype and inversely associated with mutated p53, basal CKs and 
EGF family members which provide more evidences for their biological role is 
characterising the luminal-like breast cancer subclass. 
p27 (kip!) is an important negative regulator of cell cycle progression and 
plays an important role in the pathogenesis of many tumours including breast 
cancer. In breast cancer cells, the level of p27 (kip 1) expression usually 
decreases during tumour development and progression. Low p27 expression 
appears to be associated with poor prognosis, especially among patients with 
steroid receptor positive tumours (Porter et aI., 2006, Traub et aI., 2006) in 
agreement with our findings. 
Recent studies demonstrated that p27 may mediate the effects of Ilcl-2 on 
cellular proliferation in tumour development (Cheng et aI., 2008). We have 
found that combined positive expression of Bcl-2 and p27 in the Ilcl-2+p27+ 
cancer phenotype is associated with significant longer breast cancer specific 
survival when compared to their single phenotype. So, we propose that the 
luminal phenotype expressing double markers is highly characterised with 
lower rate of proliferation and in a state of growth arrest which may explain the 
good prognosis associated with their combined expression. 
In conclusion, Bcl-2 is associated with luminal phenotype and has a growth 
inhibitory function in breast cancer possibly via its effect on p27 expression. 
Bcl-2+p27+ phenotype is associated with good prognosis in luminal-like breast 
cancer. 
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7 The use of cluster analysis of protein expression to identify 
prognostic and biological ER positive breast cancer 
subclasses 
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7.1 Introduction 
In common with other cancers, the development of breast cancer is a complex 
process involving genetic, epigenetic and environmental factors. There is now 
general acceptance that the histological criteria used for classifying breast 
cancer reflect molecular events occurring only at the cellular level. For this 
reason, recent studies have focused on the development of a 'molecular 
classification' system to profile the genetic and protein expression of an 
individuals' tumour (Perou et aI., 2000, Sorlie et aI., 2001). Subsequently, a 
number of different patient groups have been identified, with group 
membership reflecting similarities in the tumour biological characteristics. 
Oestrogen receptor positive breast cancers form a large proportion of breast 
cancer patients and within this group; much effort is being applied to discover 
reliable markers that can be used in patient prognosis. Our study aimed at 
subclassifying ER-positive luminal-like cancers into prognostic patho-
biological subgroups using their protein expression characteristics to identify 
the biological and behavioural characteristics seen in this heterogeneous group 
of tumours. 
This might lead to a sub-classification of luminal breast cancer patients into 
discrete entities that represent clinically relevant groups and when possible, 
Identification of unique sets of genes whose expression best identify subgroups 
of luminal ER positive tumours. 
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An alternative approach to gene expression profiling is to use established 
laboratory method, such as immunohistochemistry on formalin fixed paraffin 
embedded clinical patient tumour samples with follow-up data. We have 
applied protein biomarker panels with known relevance to breast cancer, to 
large numbers of cases using tissue microarrays, exploring the existence and 
clinical significance of distinct ER-positive breast cancer classes. We studied 
these markers in patients with breast cancer treated by a uniform drug regimen 
so that treatment was not associated with variability in outcome. 
7.2 Material and methods 
7.2.1 Patient selections 
In this analysis, we have used different clustering methods to analyze the 
protein expression data for identification of biological classes in the ER-
positive patient subgroup. 583 immunohistochemically confirmed ER-positive 
cases with data available on the selected biomarkers (FOXA 1, RERG, GAT A3, 
TFFI, TFF3, XBPI, BEXl, CARMI, PELPI, CD71, FOX03a, AGTRl, p27, 
Bcl-2, TKI, and cyclin Bl) in addition to other 9 important markers that are 
available from the database (ER, PgR, MIB I, HER2, CK516, C-MYC, EGFR, 
CK18 and p53) and have been used previously in immunohistochemical 
definition of the breast cancer subtypes or has a strong relevance to breast 
cancer development, were used in the analysis. 
Levels of immunohistochemical reactivity were determined by microscopic 
analysis using the modified H-score (values between 0 and 300), giving a semi 
quantitative assessment of both the intensity of staining and the percentage of 
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positive cells. For the intensity, a score of 0-3, corresponding to negative, 
weak, moderate and strong positivity, was recorded. For MIB1, TK1, FOX03a 
and Bcl-2, we used the percentage of the positive cells normalised to a scale of 
0-300 to prevent the bias that may result from including different scales in the 
same analysis. For RERG and XBP1, we rescored the available TMAs slides 
using the H-score. 
K-nearest neighbor algorithm (KNN) was used to adapt for missing values 
(Troyanskaya et al., 2001) which provides a more robust and sensitive method 
for missing value estimation in comparison to other methods over the range of 
1-20% missing values (Mehra et al., 2005). Table 7.1 shows the biomarkers 
used in the analysis. 
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Table 7.1: Markers used in the clustering analysis 
Antibody supplier Cat number/clone Dilution Pretreat ment 
FOXA I Abcam Ab40868/2F83 1:2000 Microwave 
TFFI Abcam Ab l7829 1:2000 Microwave 
CD7 1 Abcam Ab495 17110F II 1:30 Microwave 
PELP I Novus NB100-1749 1:100 No 
CARM I Novus NB 100- 1817 1:300 Microwave 
BcI-2 Dako M0887/124 1:100 Microwave 
BEXI Abcam Ab69032 1:3500 Microwave 
TK I Abcam Ab57757 5).lg/ml Microwave 
AGTR I Abeam Ab939 1 ( IEI0- IA9) 1:100 No 
XBP I Novus NB I 00-8086 1 0.5 ).lg/ml Microwave 
Cycl in B I Abcam Ab72 0 . 3 ~ ~ g g m l l Microwave 
TFF3 Abcam Ab57752 3 ).lg/ml Microwave 
FOX03a Cell Signalling 9467 1:50 Microwave 
RERG Proteintech 10687- I-AP 1:20 Microwave 
p27 Dako SX53G8 1:40 Microwave 
GATA3 Santa Cruz sc-268/HG3-3 I 1:80 Microwave 
C-Myc Abcam Ab32/9A 10 1:100 Microwave 
ER Dako ID5 1:80 Microwavc 
PgR Dako PgR636 1:100 Microwave 
EGFR Novocastra EGFR.11 3 1:10 Microwave 
p53 Dako D07 1:50 Microwave 
Ki67 Dako MIBI 1:100 Microwave 
HER2 Dako cerbB-2 1:250 No 
CK5/6 Boehringer D5116 134 1:100 Microwave 
CK I8 Dako DC 10 1:50 Microwave 
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7.2.2 Clustering algorithms 
7.2.2.1 K-means clustering of the protien expression data 
The K-means (KM) technique aims to partition the data into K clusters so that 
the sum of squares from points to the assigned cluster centres is minimised. 
The algorithm repeatedly moves all cluster centres to the mean of their Voronoi 
sets which is the set of data points which are nearest to the cluster centre. K· 
means clustering is dependent on the initial cluster centres setting which, in 
tum, determines the initial cluster assignment. For this study, we used a fixed 
initialization obtained with hierarchical clustering. The number of clusters is an 
explicit input parameter to the K-means algorithm (Jain et aI., 1999, Soria et 
aI., 2010). 
7.2.2.2 Partitioning around medoids clustring of the protien 
expression data 
The partitioning around medoids (PAM) algorithm is a technique which 
attempts to minimise the distance between points labelled to be in a cluster and 
a point designated as the centre of that cluster. In contrast to the K-means 
algorithm, PAM chooses data points as centres (medoids) and then assigns 
each point to its nearest medoid. A medoid is defined as the object within a 
cluster for which the average dissimilarity to all other objects in the cluster is 
minimal, i.e. it is the most centrally located data point in the given cluster. 
Dissimilarities are nonnegative numbers that are small and close to zero when 
two data points are near to each other and become large when the points are 
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very different usually, an Euclidean metric is used for calculating 
dissimilarities between observations. 
The algorithm consists of two phases: the build phase in which an initial set of 
k representative medoids is selected and the swap phase in which a search is 
carried out to improve the choice of me do ids (and hence the cluster allocations) 
(Jain et al., 1999, Soria et al., 2010). 
Biplots are generated by firstly transforming the original data space using 
principal component analysis and then plotting the points at their projected 
position on axes of the first and second principal components. 
All clustering statistical analysis was done in collaboration with Dr Daniele 
Soria (University of Nottingham-School of Computer Science) using R, a free 
software environment for statistical computing and graphics. The methodology 
was applied to a 583 ER-positive cases of breast cancer patients in order to 
obtain core classes in the ER-positive positve disease. Once these core classes 
were obtained, the clinical relevance of the corresponding patient groups were 
investigated by means of associations with related patient data. 
Consensus clustering 
The idea of combining and companng the results of different clustering 
algorithms is particularly important in order to evaluate the stability of a 
proposed classification. Monti and colleagues (Monti et aI., 2003) used a new 
methodology of class discovery and clustering validation tailored to the task of 
analysing gene expression data. The new methodology, termed 'consensus 
clustering', provides a method to represent the consensus across multiple 
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analyses of a clustering algorithm and to assess the stability of the discovered 
clusters (Monti et aI., 2003). 
7.2.2.3 Validity indices 
Two different algorithms were used for cluster analysis: the K-means and the 
partitioning around medoids methods. They were both run for between 2 and 
20 clusters. Six validity indices were calculated and recorded to determine the 
best number of clusters. The indices are Calinski and Harabasz, Ilartigan, Scott 
and Symons, Marriot, Trace W, and Trace W-IB. For each index, the number 
of groups to be considered was chosen according to the rules reported by 
(Dimitriadou et aI., 2002). 
7.3 Results 
7.3.1 Optimal number of clusters 
After application of the six validity indices of the kmeans (Fig 7.1) and PAM 
(Fig 7.2) clustering algorithms, three clusters were identified as the most 
appropriate number which could represent the true core classes of the data. 
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Figure 7.1: Kmeans validity indices 
5 indices agreed on 3 clusters solution 
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Initially we have used 16 markers to cluster the 583 cases USIng the same 
methodology and we found that the optimal cluster number is three. rn order to 
make sure that the number does not change when using a different set of 
biomarkers, we have added 9 important biomarkers which proved previously to 
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have a defining role in breast cancer subtypes characterisation and those with 
strong relevance to breast cancer biology including (ER, PgR, MIB I, HER2, 
CK5/6, EGFR, C-MYC, CK18 and p53). 
Next to identification of the optimal cluster number using the different indices, 
is to identify the cases that have been clustered in the same group by the two 
clustering methods. Seventy eight percent of cases (454 out of 583) were 
clustered in the same group using the 25 markers panel (Table 7.2). 
Table 7.2: The distribution of the clusters of the consensus algorithms 
Cluster Frequency Percent Valid Percent 
Valid 1 208 35.7 45 .8 
2 127 21.8 28.0 
3 119 20.4 26.2 
Total 454 77.9 100.0 
unclassified 129 22.1 
Total 583 100.0 
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Figure 7.3: A diagram showing the flow of methods used in the clustering 
process 
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7.3.2.2 Histopathological criteria of the clusters 
Examination of the histopathologic characteristics of the clusters has shown a 
wide variation between the clusters identified especially cluster 2. Cluster 1 
and cluster three were not significantly variable. Table 7.3 summaries the 
clusters characterisation with regards to the conventional histopathological 
variables. Cluster 1 and cluster 3 patients were mainly of lower grade, lower 
LN stage, and lower NPI group and decreased incidences of DM and tumour 
recurrence. Cluster 2 patients were mostly of grade 2 and grade 3, higher LN 
stage, and poor NPI group with increased incidence of DM and tumour 
recurrence. 
309 
Chapter 7 
Table 7.3 : Histopathological criteria of the three clusters identified 
Clusters 
Variable Cluster I Cluster 2 Cluster 3 .j p-value 
Patients' age 23. 134 0.001 
<40 8(38.1 ) 7(33.3) 6(28.6) 
40-50 5 ~ 3 7 . 7 1 1 30(21. 7) 56(40.6) 
51-60 73148} 48(31.6) 31(20.4) 
>60 75152·41 42(29.4) 26( 18 .2) 
Tumour size 7.998 0.018 
~ 1 . 5 5 cm 104{46.8} 50(22.5) 68(30.61 
> 1.5 cm 103(44.6) 77(33 .3) 51(22.1) 
yrmph node s t a ~ e e 12.144 0.016 
I (Negative) 122(46.9) 63(24.2) 75(28.8) 
2(1-3 LN) 7L(47J 44(29. 1) 36(23.8) 
3(>3 LN) 121301 20(50) 8(20) 
Tumour Grade 14.635 0.006 
I 44(48.9) 13(14.4) 33(36.7) 
2 8L(43·81 54(29.2) 50(27) 
3 82(46.1) 60(33.7) 36(20.2) 
NPI 19.585 0.001 
Good 71(49.3) 23( 16) 50(34.7) 
Moderate 105{43 .8} 77(32.1) 58(24.21 
Poor 32(45.7) 27(38.6) II (15.7) 
DM 2 1.627 <0.001 
No I 58{50.6) 67(21.5) 87(27.9) 
Positive 4'2.{35.51 59(42.8) 30(2 1.7) 
Recurrence 13.5 17 0.001 
No 1 3 ! l 5 ~ ~ 54(21.4) 67(26.6) 
Positive 74(37.6) 71 (36) 52(26.4) 
VI 9.896 0.042 
No 1 1 4 { 4 4 . ~ ~ 56(23.8) 65(27.7) 
Probable 32{56. 1 15(26.3) 10(17.5) 
Definite 61(38.6) 56(35.4) 41(25.9) 
Histologic tumour 22.954 0.011 
type 
DuctallNST 115(47.1) 77(3 1.6) 52(21.3) 
Lobular 2 4 { 3 9 . ~ ~ 23(37.7) 14(23) 
Tubular and Tubular 
46(45.1) 18(17.6) 38(37.3) mixed 
Medullary L(501 1(50) O(O} 
Other special types* 2(33.3) 0 4(66.7) 
Mixedu 20(55.61 8(22.2) 8(22.2} 
M e n ~ a u s a l l status 28.242 <0.001 
Premenopausal 60(37.3) 35(21.7) 66(41) 
Postmen®ausal 1 4 8 { 5 0 . ~ ~ 92(3 1.4) 53( 18. 1) 
*Includes Mucoid, invasive cribrIform and invaSIve papIllary carCinoma, ** 
Include ductallNST mixed with lobular or special type 
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Figure 7.4: Boxplots of the biomarkers expression of the consensus clu ters 
using the two clustering methods 
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Figure 7.S: Biplots of the 3 common clusters identified using the 25 marker 
panel. 
Biplots are generated by transforming the original data space using principal 
component analysis and then plotting the points at their projected position on 
axes of the first and second principal components. 
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7.3.3 Decision tree analysis ofthe common clusters 
'C4.5 decision tree' is a supervised classifier to get a set of rules to see which 
are the most important markers involved in the classification process and 
which are the most important markers that playa relevant role in the decision 
of the 3 common classes. Decision tree learning is a common method used in 
data mining. The goal is to create a model that predicts the value of a target 
variable based on several input variables. 
The decision tree and the boxplots have shown that Bcl-2, PgR, and p27 are the 
most important factors that differentiate between the three clusters identified. 
The results also showed that BEXt is overexpressed in cluster 3. 
The boxplots of the common clusters identified (Fig 7.4) showed that cluster 1 
is characterised by high expression of Bcl-2 and moderate expression of PgR 
and p27. Cluster 2 showed a low expression of Bcl-2, PgR and p27. Cluster 3 
showed a high expression of Bcl-2 but was lower than the expression noted in 
cluster 1, a high expression of PgR, p27 and BEXt with relative increase of 
CARMI and TFF3 expression in comparison to the other clusters. 
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7.3.4 Univariate analysis 
Univariate analysis of the common clusters identified has shown a significant 
association with survival. Cluster two was associated with shorter breast cancer 
specific survival (LR= 28.185 & p<O.OOl) (Fig 7.6) and DFS (LR= 14.900 & 
p=O.OOI) (Fig 7.7). This relation was also maintained in the untreated patient 
group (n= 161) where cluster two showed the worth BCSS (LR= 10.776 & 
p=0.005) (Fig 7.8). 
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Figure 7.6: Kaplan Meier plot of the three clusters in relation to BCSS 
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Figure 7.8: Kaplan Meier plot of the three clusters in relation to BCS in the 
untreated patient group. 
7.3.5 Multivariate analysis 
To further test the prognostic significance of the luminal clusters identified, we 
have developed a COX model including the clusters and the standards 
prognostic factors such as tumour size, grade and LN stage. Our results showed 
that the ER-positive clusters identified is independent on the other fac tors in 
the model (p<O.OOI ) (Table 7.4). 
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Table 7.4: COX model of the predictors of breast cancer specific surv ival 
using the cluster assignment identified by the K-means and PAM clustering 
methods 
HR 95% CI 
Variable p value Lower 
upper 
ER-positive clusters <0.001 
ER-positive cluster 2 vs.1 <0.001 2.090 1.404 3. 111 
ER-positive cluster 3 vs. 1 0.755 1.080 0.667 1.748 
Tumour stage <0.001 
Tumour stage 2 vs.1 0.046 1.507 1.007 2.254 
Tumour stage 3 vs. I <0.001 3. 185 1.919 5.284 
Tumour grade <0.001 
Tumour grade 2 vs. 1 0.226 1.479 0.784 2.789 
Tumour grade 3 vs. 1 <0.001 2.998 1.621 5.546 
Tumour size 0.004 1.808 1.215 2.691 
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7.4 Discussion 
Tumour formation is widely accepted as an evolution that incorporates the 
harmonised action of a set of genes, instead of a single one. The alteration in 
biomarker expression patterns may provide a unique molecular feature of each 
tumour. In order to study the coordinated action of a group of biomarkers 
rather than studying each biomarker separately, we need a powerful and 
reliable statistical method for this purpose. Single clustering methods have 
often been used to interpret clusters in high dimensional datasets, however 
depending on a single algorithm is known to be questionable (Soria et aI., 
2010) . The principle of combining the results of different clustering methods 
is particularly important in order to evaluate the robustness of a clustering 
classification. The two clustering methods that we have used here have been 
successfully used before to identify biological subclasses within certain groups 
of breast cancer patients (Elsheikh et aI., 2009). 
In this study, we have shown that a classification of ER-positive breast cancer 
can be done based on clustering analysis of the immunohistochemical profiles 
of selected important biomarkers on tissue microarray slides. The methodology 
we have used for clusters identification from our complex dataset was done 
using a variety of clustering algorithms and the most appropriate number of 
clusters was investigated by means of cluster validity indices to ensure that the 
identified optimal cluster number is based on a statistical base and not 
randomly selected. 
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Our data showed that the expression of certain biomarkers was associated with 
specific tumour groups when used in combination. Furthermore, our data also 
suggest that correlations can be made with immunohistochemical profiles of 
highly discriminatory panel of related biomarkers in breast tumours as we have 
shown in the previous chapters. The clusters we have identified showed a wide 
variation in the histopathological criteria. Cluster 2 patients were mostly of 
grade 2 and grade 3, higher LN stage, and poor NPI group with increased 
incidence of DM and tumour recurrence. 
Our panel of markers as identified by the boxplots and the decision tree 
analysis indicates that Bcl-2, PgR, p27 are the most important biomarkers for 
ER-positive biological class identification in this study. BEXl, also showed a 
defining role in characterisation between cluster 1 and cluster 3 where cluster 
three showed the highest level of BEXt expression. We would propose that 
within the ER-positive breast cancer, three distinct biological classes that show 
a wide variation in their biological features with emphasis on cell cycle 
regulators and apoptosis related genes as evidenced in our study by the strong 
differentiating role of p27 as a cell cycle inhibitor or Bcl-2 as an antiapoptotic 
factors with a cell cycle regulatory role (Vairo et aI., 2000). 
Many studies have previously used HER2 to characterise luminal subclasses 
with poor prognosis. The clustering approach that we have used here did not 
show any association with HER2 in agreement with others (Natrajan et aI., 
2009, Bhargava and Dabbs, 2008). Regarding HER2 expression, although GEP 
studies have shown that some luminal tumours express HER2 and some 
authors include HER2 positivity as a feature of Luminal B tumours , others 
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argue against that and include HER2-positive tumours, regardless of the 
expression of ER, with the HER2-positive subgroup and argue against this 
definition of Luminal B tumours (Bhargava and Dabbs, 2008). In addition, it 
has been reported that prognostic factors, to be of clinical use, must show a 
wide separation in the outcome of the groups identified and select adequate 
numbers in each group. However, most studies have shown that the number of 
HER2-positive ER-positive tumours is usually too small to constitute a 
meaningful prognostic subgroup. ER-positive HER2 positive tumours are 
currently receive specific systemic therapy which may be different to those of 
other ER-positive HER2 negative tumours. 
Cheang and colleagues have used MIB 1 to characterise poor luminal 
subclasses within the luminal group (Cheang et al., 2009). We found a strong 
role of cellular proliferation in characterising luminal subclasses, although 
MIB 1 was not a strong characterising marker of the three clusters identified 
here, p27 loss was seen in the poor prognosis cluster identified in our study 
supported by the Bcl-2 growth inhibitory role. Estimation of cell proliferation 
pathways could have significant clinical benefit in predicting behaviour and 
subclassification of the luminal-like subclasses, and their potential for response 
to systemic therapy. 
ER+PgR+ phenotype has previously shown to be associated with better 
outcome in comparison to ER+PgR- group (Rakha et al., 2007). Our clustering 
result have identified that PgR has a powerful characterising role in ER-
positive breast cancer subclassification and its loss proved to be more reliable 
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than HER2 and MIB 1 in identification of poor prognostic subclasses in ER-
positive breast cancer. 
In conclusion, the value to study the proteomics of hundreds of tumours by 
TMA makes it a powerful tool for the molecular classification of breast cancer. 
Furthermore, the results of this study indicate that a powerful clustering 
algorithm using protein expression TMA data could be used as a simple 
method for better characterization and refinement of large tumour series for 
identification of biological subgroups with homogenous distribution. Molecular 
profiling of breast cancer using protein biomarkers on TMAs can sub-classify 
ER-positive tumours into clinically and biologically relevant subgroups. 
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Human breast cancer (BC) represents a heterogeneous group of tumours 
differing in their morphology, biologic behaviour, outcome, and response to 
therapy (Gusterson et al., 2005). Currently, pathological diagnosis and 
classification of BC is mainly based on well-established traditional 
histopathologic morphological features. However, morphological features 
alone do not adequately reveal the molecular heterogeneity and complexity of 
BC. 
Immunohistochemistry (IHC) was developed prior to gene expression profiling 
and currently remains the preferred technique for biomarker profiling in routine 
pathology laboratories. In situ hybridization was introduced after that and is 
now also routinely used to classify breast cancer into HER-2 gene amplified or 
non-amplified groups. Recently, high throughput proteomic and gene-
expression profiling methods are being studied as diagnostic tools (Pusztai et 
al.,2006). 
The identification of subgroups within ER-positive breast cancer based on 
biological characterisation of tumours could be used to better predict therapy of 
clinical outcome. 
8.1 The ER-positive/luminal-like subtype 
ER plays a crucial role in the progression of breast cancer by regulating genes 
and signalling pathways mostly related to cellular proliferation. Regulation of 
gene transcription by ER requires the activity of ligand binding and other 
protein interactions. However, the intracellular signalling pathways that control 
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these events and regulate ER alpha transcriptional activity are not fully 
understood and need further refinement. 
The ER-positive luminal-like breast cancer subtype has recently attracted a lot 
of attention due to its association with more than 70% of breast cancer patients 
Seminal studies have identified more than one luminal class with different 
prognoses implying heterogeneous biological variation within the ER-positive 
breast cancer subtype (West et al., 2001). Despite its importance, there is no 
standard definition of this important class in routine clinical practice. 
Moreover, there is an immediate need for well-defined biomarker panels for 
clinical diagnostic use as currently there is no gold standard for what defines 
these tumours. 
Three luminal-like subclasses (Luminal A, B and C) have been proposed but 
differ in terms of their prognosis. Luminal Band C have been described as 
having a worse prognosis in comparison to Luminal A cancers (Sorlie et al., 
2001). The reasons for this difference in prognosis are still unknown but a 
possible explanation relates to ER function and signalling differences, which 
could be attributed to the influence of transcription factors, coactivators, and 
corepressors that modulate ERa activity. In addition, overexpression of 
proliferation and cell cycle genes in breast cancer is well recognised to be 
associated with poor outcome suggesting that these genes may contribute to the 
poor prognosis in some luminal cancers. Also, it has been proposed that 
abnormal apoptosis function, DNA damage response and PI3KJAKT pathways 
may be additional factors influencing prognosis (Bertucci et al., 2009). 
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Subclassification of ER-positive luminal-like cancer using gene expression 
studies and microarray analysis can be expensive and time-consuming and 
generally requires fresh frozen tissue. Our study aimed to subclassifying ER-
positive luminal-like cancers into prognostic and biological subgroups using 
their protein expression with routinely processed FFPE tissue. Furthermore, 
the biological phenotype characteristics and the associations between these 
subgroups and survival outcome were investigated. 
8.2 The value of TMAs in subclassification of ER-positive 
breast cancer 
We have used protein expression profiling using a large panel of biomarkers 
with strong relevance to breast cancer, by immunohistochemistry on tissue 
microarrays for refining the classification and prognostication in ER-positive 
breast cancer. 
We proposed that an alternative approach to gene expression profiling is to use 
established robust laboratory technology, such as immunohistochemistry on 
formalin fixed paraffin embedded patient tumour samples on a high throughput 
proteomic platform such as TMAs to explore the existence and clinical 
significance of distinct breast cancer classes. In this study, we have studied the 
protein expression of 25 biomarkers to investigate if it was possible to classify 
the luminal cancer into biological subgroup. 
TMAs allow large populations of patients' tumours to be rapidly screened to 
detect overall protein expression in large patient groups, overcoming the 
weakness of IHC results when using smaller cohorts. The validity of TMA 
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analysis has been shown by comparisons with full section examination in 
breast (Camp et aI., 2000, Gillett et aI., 2000), prostate (Mucci et aI., 2000), 
and bone marrow (Zimpfer et aI., 2007). All studies reported >90% 
concordance for common breast cancer biomarkers such as oestrogen and 
progesterone receptors and the HER-2 oncoprotein. Moreover, prognostic 
associations for these markers could be reproduced with the TMAs. 
It is arguable that whether these specimens are representative of their donor 
tumours. Some alterations may not be detected if the analysis of heterogeneous 
tumours is restricted to samples measuring 0.6 mm in diameter. However, it is 
important to mention that the TMA technique has been developed to examine 
large tumour populations and not to study individual tumours. This suggests 
that TMA studies will provide consequential data, even if only one sample is 
analyzed per tumour (Moch et aI., 2001). The assessment ofTMA sections is, 
when possible, to be carried out by more than one assessor to overcome inter-
observer variability, to achieve the maximum level of concordance and to 
strengthen the accuracy of the study. Alternatively, the assessment could be 
done by one observer on two separate occasions and the results could be 
compared by kappa statistics. 
The value of studying the proteomics of hundreds of tumours by TMA makes it 
a powerful tool for the molecular classification of breast cancer. Furthermore, 
the results of this study indicate that a powerful clustering algorithm using 
protein expression TMA data could be used as a simple method for better 
characterization and refinement of large tumour series for identification of 
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biological subgroups with homogenous distribution as reported previously 
(Abd EI-Rehim et aI., 2005). 
By this high throughput approach, we have been able to identify three 
biological clusters with unique characteristics and variable biological and 
prognostic features. 
8.3 The prognostic and biological roles of the studied 
markers 
We aimed to identify potential candidate markers for inclusion in the study by 
applying novel bioinformatics methods including artificial neural networks, 
Ensemble cross validation analysis to our gene expression data. In addition to 
a literature search for genes with strong relevance in ER-positive breast cancer 
or have been the subject of recently published studies and strongly suggest an 
important role in the biology and molecular classification of ER-positive breast 
cancer. The selection criteria was based on the published literature 
concentrating mainly on ER related pathways such as ER coregulators, cellular 
proliferation, apoptosis, AKTIPIK3 pathway and endocrine resistance. 
We have characterised a number of biomarkers that have not been 
characterised before in breast cancer and luminal-like subtype using a large 
number of patients including RERG, CARMI, PELPI, CD71, BEXI, XBPI, 
AGTRI and TFF3 producing novel data. Some of these markers were 
previously identified as characteristics markers of the Luminal A subclass in 
the seminal gene expression studies. GATA3, BEXI and RERG were able to 
differentiate between luminal-like tumours associated with poor and good 
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prognosis and as such they could be useful markers for the definition of the 
luminal phenotype as reported by others (Sorlie et aI., 2001). 
Although TFF3 and XBPI are associated with the good prognosis Luminal A 
subtype in the published gene expression studies, they showed associations 
with shorter BCSS while TFFI and FOXAI were not associated with survival 
in the ER-positive subtype in this study. 
This could be attributed to the difference in the downstream technique used 
(RNA in expression profiling as opposed to protein in immunohistochemistry 
studies) and sensitivity of the detection system, or a post-translation 
modification of the protein product of the gene. These results may support the 
view that translation of gene expression profiling studies into clinical practice 
should be interpreted with care and individual markers may not show the same 
significance when studied in isolation rather than as part of an expression 
signature. 
Apart from ligand binding to ER, the biologic functions of nuclear receptors, 
including ER, are also regulated by a group of proteins known as 
transcriptional coactivators, as well as by another group of proteins known as 
transcriptional corepressors (Nair and Vadlamudi, 2007). Subsequently, we 
aimed to study PELPI and CARMI as two of the novel ER coactivators to 
characterise their biological associations within ER-positive breast cancer. This 
study showed that CARM I and PELP I protein expression is associated with 
features of poor prognosis in breast cancer particularly in the ER-positive 
luminal class implying a potential role in their biological stratifications. 
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In this study, in collaboration with Dr Julia Gee and Prof R Nicholson (Cardiff 
School of Pharmacy), it was proposed that assessment of CD71 expression 
might equally be used to stratify ER-positive patients to define subgroups with 
poor prognosis, high proliferation and resistance to hormonal therapy. We 
demonstrated that prominent expression of CD71 protein is a feature of breast 
cancers with poor prognosis and as such, we proposed that transferrin receptor 
expression may have implications for diagnosis and prognosis. CD71 protein 
expression could be of value in characterizing a subset ofER-positive/luminal-
like tumours with poor prognosis in clinical practice, as well as defining 
patients less likely to respond to endocrine therapy. Therapies targeting iron 
delivery or CD71 itself, may have therapeutic benefits in treating ER+ CD71 + 
breast cancers in the clinic. 
Previous studies have highlighted the important role of PTEN/AktlPI3K 
pathway and its upstream and downstream targets in the biology and prognosis 
of breast cancer (lou et aI., 2008). PI3K dependent Akt activation can be 
regulated PTEN, which works essentially as the opposite of PI3K. PTEN is a 
tumour suppressor gene involved in the biology of breast cancer and its loss is 
associated with high grade tumour and inversely correlated with the pAkt 
activation (Bose et aI., 2005). 
Upregulation of Akt was found to inhibit cell cycle arrest in Gland G2 phases. 
The activated Aktmay enhance proliferation and survival of cells which may 
lead to mutations in other genes (Ramaswamy et aI., 1999). Akt I has also been 
shown to playa role in angiogenesis and tumour development. AKTI deficient 
mice showed enhanced pathological angiogenesis and tumour growth (Chen et 
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aI., 2005). Given these facts, it would be of interest to study the biological 
correlation of PTEN and AKT to the other biomarkers included in this thesis. 
Our results demonstrated the biological and prognostic role of FOX03a 
protein expression and its subcellular localization in breast cancer. Loss of 
nuclear FOX03a expression could tilt the growth balance in favour of 
proliferation and poor outcome in luminal-like breast cancers through active 
AktIPI3K pathway, highlighting the importance of cellular proliferation in their 
biological stratification as reported by other investigators (Zou et aI., 2008). 
In the future, it is important to study the relation between PTEN as an upstream 
target to AktlPI3K pathway to the FOX03a expression. 
Recently, it has been shown that AGTRI overexpression defines a subset of 
ER-positive breast cancer that can benefit from AGTRI antagonists. 
Specifically, AGTRI was overexpressed only in tumours that were ERBI32· 
negative and ER-positive (Rhodes et aI., 2009). In this study, AGTRI 
expression in the luminal-like breast cancer characterised an aggressive 
phenotype with high proliferation and shorter survival which provides further 
evidence of its importance in the biology of ER-positive breast cancer. A 
finding that warrants the evaluation of its potential application as a novel 
targeted therapy in breast cancer. 
Many studies have demonstrated a strong relationship between cellular 
proliferation and poor prognosis in breast cancer particularly in the oestrogen 
receptor (ER)-positive/luminal-like molecular subtype (Cheang et aI., 2009). 
This prompted us to study the biological and prognostic implication of 
proliferation in the ER-positive breast cancer using cell cycle phase specific 
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proteins. Our findings showed that overexpression of the proliferation related 
markers cyclin B I and TKI is involved in the progression of breast cancer. 
This is also confirmed when using both markers in combination to produce 
better stratification in terms of outcome. Increased cellular proliferation occurs 
in some luminal cancers and appears to form a biological and clinically distinct 
subclass of ER-positive breast cancer patient as previously reported by others 
(Sotiriou et aI., 2003). 
The cell cycle is regulated by many mechanisms and is affected by the 
interaction of multiple pathways that either enhance or delay its progression. In 
addition to its control by cyclins and cyclin dependant kinases and cell cycle 
regulators, many studies have highlighted the role of Bcl-2 in controlling the 
cell cycle independent of its antiapoptotic function by causing retarded entry 
into the cell cycle (Vairo et aI., 2000). Our finding has shown that Bcl-2 is 
associated with the luminal phenotype and has a growth inhibitory function in 
breast cancer possibly via its effect on p27 expression. In this study, the Bcl-
2+p27+ phenotype was associated with good prognosis in luminal-like breast 
cancer due to cell cycle arrest as reported by others (Vairo et aI., 2000). 
Estimation of subcellular localisation of p27 has been shown to correlate with 
patient's prognosis in other cancers. Cytoplasmic localisation of p27 indicates 
an inactive form. As expected, Rosen and co-workers have found that 
cytoplasmic localization of p27 predicts poorer prognosis in advanced ovarian 
carcinomas (Rosen et aI., 2005) due to its loss of cell cycle inhibitory function. 
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8.4 Biological classes within the ER-positive breast cancer 
Combining all the studied markers in a clustering analysis has revealed the 
presence of three biological clusters. The characteristics of the luminal-like 
clusters identified here reflect the biological heterogeneity of the ER-positive 
breast cancer. For instance, Cluster 1 and Cluster 3 patients were mainly of 
lower grade, lower LN stage, and lower NPI group and showed decreased 
incidence of OM and tumour recurrence. Although Cluster 3 was not 
prognostic ally different from cluster 1 it showed a lower Bc1-2 expression than 
Cluster 1, a high expression of PgR, p27 and BEXl which reflects different 
biological characteristics. 
Although Cluster 1 and Cluster 3 have different biological features, their 
prognostic characteristics were similar. Together they may represent a large 
luminal-like subclass with close similarity to the Luminal A subclass (Sorlie et 
aI., 2006). In contrast, Cluster 2 patients were mostly of high grade, higher LN 
stage, poor NPI group and increased incidence of OM and tumour recurrence. 
Those patients are more likely to be resistant to hormonal therapy due to low 
expression ofPgR and Bcl-2 and this may explain their poor prognosis. Cluster 
1 is characterised by high expression of BcI-2 and moderate expression of PgR 
and p27. These criteria could explain the longer BCSS seen in this group. The 
high expression of Bcl-2 in good prognosis luminal subclasses was also 
reported by other investigators (Ihemelandu et al., 2009). 
The survival analyses revealed significant differences in BCSS among clusters. 
Cluster 2 represents a distinct group with poor prognosis and was associated 
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with loss of Bcl-2, PgR and p27. All of these variables are known to be 
associated with good prognosis in breast cancer. The significant prognostic 
independence of the three clusters identified in multivariate analysis further 
supports the relevance of the clustering methods used in this study. This 
indicates that the classification of ER-positive breast cancer using such 
methods is of a great value in the evaluation of outcome in patients with ER 
positive disease. 
We would propose that within ER-positive breast cancer three distinct 
biological classes exist that show a wide variation in their biological features 
with emphasis on PgR, cell cycle regulators and apoptosis related genes. This 
is evidenced in our study by the strong differentiating role of p27 as a cell 
cycle inhibitor or Bcl-2 as an antiapoptotic factors with a cell cycle regulatory 
role. We recommend the use of an external validation cohort to confirm the 
results of the current study as used previously in other studies of the 
Nottingham Breast Cancer Research Group (Abdel-Fatah et aI., 2010). 
8.5 Summary and Conclusions 
It appears increasingly evident that the ER-positive subclasses with good 
prognosis, as shown here in Cluster 1 and Cluster 3, have distinct 
characteristics, defined by high expression of ER, PgR, and Bcl-2 and cell 
cycle inhibitors. The remaining poor prognostic cases in Cluster 2 comprise a 
heterogeneous collection that can be recognised by additional genetic lesions 
particularly those which result in clinical behavioural characteristics of poor 
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outcome and lack of dominant ER related pathway especially those related to 
PgR, apoptosis and cell cycle regulation. 
In conclusion, our results emphasised the biological and behavioural 
heterogeneity of ER-positive luminal-like breast cancer. More importantly, we 
have identified a novel panel for ER-positive luminal-like breast cancer and the 
existence of luminal subclasses that differ with respect to patient outcome. 
Identification of biologically and clinically distinct breast cancer subtypes 
could improve prognostic assessment of the ER-positive breast cancer. 
The use of novel bioinformatic approaches to analyse high dimension datascts 
is of value in identifying candidate genes to characterise ER-positive/luminal 
like breast cancer. Subsequently, these can be used to subclassify these cancers 
in terms of biology and prognosis. Molecular profiling of breast cancer using 
protein biomarkers on TMAs can sub-classify ER-positive tumours into 
clinically and biologically relevant subgroups. 
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8.6 Future directions 
1-We have been able to identify novel genes that showed expression 
differences between ER-positive luminal-like and ER negative breast cancer; 
further validation of more genes using either QPCR or TMAs and the I1IC 
protein expression platform might strengthen the current findings that we have 
shown in this study. Also it would be of interest to perform in vitro functional 
studies on some of these novel genes identified (Summarised in tables 5.10, 
3.6,3.7) using breast cancer cell lines that exhibit luminal ER+ features. These 
would include apoptosis, proliferation assays in cells that overexpress certain 
genes and their siRNA knocked out subsets. 
2-0ur results support the prognostic and biological importance of Dcl-2, RERG 
and GAT A3 protein expression which could be used in routine clinical 
diagnosis of luminal-like breast cancer and patient follow-up. 
3-Evaluation of the potential application of AGTRI blockade as a novel 
targeted therapy in ER-positive breast cancer is warranted in clinical trial 
settings. 
4-This study highlighted the prognostic role of CARMI and PELPI as novel 
ER coregulators in breast cancer. Improved understanding of the functional 
role and mechanism of action of ER coregulators in breast cancer may reveal 
new therapeutic targets. 
5- We would need to explore the nature of CD71 interplay with growth factor 
signalling and ER in the future (e.g. using immunioprecipitation studies), 
although the data in the paper (Habashy et aI., 2010) with Faslodex or PI3K 
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blockade already suggests there can be productive interplay with 
transferrinlCD71 signalling. 
6- We recommend the use of external validation cohort to confirm the results 
of the current study. 
7- Study the amplification of certain genes related to oestrogen receptor 
pathways such as ESRI and Progesterone by Chromogenic in Situ 
Hybridization (CISH) or Fluorescent in situ Hybridization (FISH) using the 
available probes. 
8- Study chromosome lq gain and 16q loss which might associate with steroid 
receptors in breast tumours. Gains of the long arm of chromosome 1 and losses 
of chromosome 16q are often the result of unbalanced translocations between 
these two chromosomes. These genetic changes and the resulting chromosome 
imbalances have been thought to playa pathogenic role in breast carcinoma 
development and steroid hormone pathway. 
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